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Abstract 
Acety1cholinesterase (AChE) is the serine hydrolase that catalyses hydrolysis of the 
neurotransmitter acetylcholine to efficiently control neurotransmission at cholinergic 
synapses. Current Alzheimer's disease drugs include AChE inhibitors designed to 
maximise acetylcholine levels, and inhibitors bind either the active site or a distinct 
C peripheral anionic site' (PAS). A number of observations and studies suggest that 
AChE has a much broader influence on cell behaviour and morphology than the purely 
enzymatic. It has been suggested that AChE may participate in neuronal development, 
differentiation, and pathogenic processes such as Alzheimer's disease and 
tumorigenesis. The mechanism by which AChE influences neuronal morphology, and 
the extent to which this property extends to other cells, remains unclear and is the 
subject of this thesis. 
Characterisation of the expression, localisation and activity of AChE in both neuronal 
and non-neuronal cells reveals equivalent levels of expression in primary cerebellar 
neurons, the neuronal PC12 cell line, astrocytes and fibroblasts, but disparate levels of 
activity. Although under normal culture conditions fibroblasts show low levels of AChE 
activity, induction of apoptosis significantly increases AChE protein and activity in a 
JNK dependent manner. However, inhibiting AChE upregulation with a JNK inhibitor 
does not prevent cell death, indicating that AChE is unlikely to be required for 
apoptosis. On the cell surface of both neuronal and non-neuronal cells, AChE localises 
to regions of membrane protrusion; the growth cones of neurones and the leading edge 
of migrating fibroblasts and astrocytes in discrete patches at sites confirmed by TfRF 
microscopy to be close to the substratum. At these sites AChE precisely colocalises with 
amyloid precursor protein, a known mediator of outgrowth and migration. Partial 
colocalisation was also observed with the heparan sulphate proteoglycan perlecan, 
which was found to redistribute with AChE upon clustering and with sites of tyrosine 
phosphorylation. Increasing AChE levels in fibroblasts by overexpression increases in 
vitro wound healing, while this is reduced by perturbation of AChE function using an 
antibody. In the analogous process in neurones, increased AChE mediated increases in 
outgrowth while this is reduced by selected AChE ligands and an AChE antibody. 
These results indicate a coordinated role for AChE together with APP and perlecan in 
polarised cell migration at the leading edge of both neuronal and non-neuronal cells. 
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I Introduction 
1.1 What is Acety Ic ho lin este rase? 
Acety1cholinesterase (ACK) is one of the most studied enzymes in the world, with over 
20,000 relevant articles available on Pubmed. Since the first postulation of the existence 
of cholinesterases by Dale in 1914, and their naming by Stedman in 1932 (upon 
observing a "splitting" activity on the neurotransmitter acetylcholine (ACh)) (Stedman 
and Easson, 1932), cholinesterases have enthralled and confounded researchers in equal 
measure. Later studies showed that, in fact, the serum contained 2 enzymes capable of 
hydrolyzing acetylcholine (ACh), both of which belong to the enzyme class of serine 
hydrolases but are distinguished by their specificities toward substrates and inhibitors 
(Mendel et al., 1943; Mendel and Rudney, 1943). These two molecules were denoted 
acety1cholinesterase (AChE; EC 3.1.1.7), the subject of this thesis, which specifically 
hydrolyses ACh and the less specific butyry1cholinesterase (BChE; EC 3.1.1.8) which 
are now known to be encoded by separate genes in mammals. Over the ensuing ninety 
years, the structure and function of AChE has been extensively studied and fascinated 
neuroscientists, biochemists and clinicians alike. However, despite the wealth of 
information provided by such studies, particularly in the structural arena, the most 
recent work of the past two decades has suggested that AChE may have additional 
functions, both in the nervous system and beyond. 
Although the principal function of AChE at central synapses and the neuromuscular 
junction is to hydrolyse ACh and thus inactivate cholinergic neurotransmission, a 
growing body of evidence has revealed that in addition, AChE possesses a number of 
further functions, including possible morphogenic, trophic and adhesive roles. This PhD 
thesis will aim to gain a greater understanding of these morphoregulatory functions and 
the underlying mechanisms in both neuronal and non-neuronal cells. 
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1.2 Genetics and primary structure of AChE. 
Gene structure. 
The first AChE sequence was cloned in 1986 from Torpedo californica (a electric ray) 
electric organ (Schumacher et al., 1986b). Now cDNAs for Torpedo marmorata, 
Drosophila, Anopheles stephensi, Caenorhabditis elegans, mouse, rat, human and 
chicken have been cloned. In Drosophila, as in vertebrates, AChE is encoded by a 
single gene (Hall and Spierer, 1986). In contrast, the nematode Caenohabditis elegans 
(Celegans), has four AChE genes: ace-1, ace-2, ace-3, and ace-4 (Johnson et al., 1988, 
Johnson and Russell, 1983; Kolson and Russell, 1985; Selkirk et al., 2005a; Selkirk et 
al., 2005b). 
In humans the AChE gene is located on the long arm of chromosome 7, at position 7q22 
(Ehrlich et al., 1992; Getman et al., 1992), while it is on chromosome 5 in mouse 
(Rachinsky et al., 1992). The duality of AChE and BChE is specific to vertebrates and is 
suggested to have originated by duplication of one cholinesterase gene, in an ancestor of 
the gnathostomes Oawed vertebrates). This hypothesis is supported by the closer 
sequence similarity of AChE and BChE in lower vertebrates such as Torpedo than in 
higher vertebrates further along the evolutionary scale (Toutant et al., 1985). The 
genomic regions containing the coding sequences of cholinesterases differ markedly in 
their lengths; over 25kb for Torpedo AChE (Maulet et al., 1990), 34kb for Drosophila 
AChE, but only 6 kb for humans (Getman et al., 1995), depending mostly on the size of 
the introns. 
AChE is a highly polymorphic molecule resulting from use of alternative promoters, 
alternative splicing and differential protein associations. Regulation of expression of the 
gene occurs at 3 levels; transcriptional through alternative promoters, translational by 
affecting mRNA stability and processing of distinct mRNAs, and post-translationally by 
modifications such as glycosylation, all giving rise to distinct peptide chains which are 
processed differently. 
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1.2.2 Genetic control of AChE expression. 
The AChE gene is subject to complex tissue- and cell type-specific concerted control. 
The human AChE distal promoter, proximal promoter and the intron- I enhancer domain 
contain consensus motifs for numerous transcription factors. Among these are motifs for 
the leukemia-associated factor AML I /Runx. I, and c-fos, a transcription factor known to 
regulate ACHE gene expression under stress (Kaufer et al., 1998). Furthermore, the 
distal enhancer domain of the human ACHE promoter, located 17 Kb upstream from the 
ACHE transcription start site, includes functional binding sites for osteogenic factors 
including 17-estradiol and 1,25-dihydroxy vitamin D3 (Grisaru et al., 1999a), and two 
adjacent functional binding sites for Hepatocyte nuclear factor-3, and a glucocorticoid- 
response-element (Shapira et al., 2000). There is also an internal enhancer positioned in 
the first intron, which can influence AChE production as it contains consensus-binding 
sites for the transcription factors AP2, SPI, NF-KB and GATAI (Getman et al., 1995). 
ACHE gene expression in neuronal and glial cells has also been shown to be modulated 
by a variety of growth factors and cytokines, including epidermal growth factor (EGF), 
nerve growth factor (NGF) and interleukin- I (IL- 1) (Li et al., 2000b; Wu and Bradshaw, 
1993). 
1.2.3 AChE alternative splicing. 
Though AChE is encoded by a single gene, it achieves complexity by the use of 
alternative promoters, transcription initiation sites, and N- and C-terminal splicing 
(Meshorer et al., 2004; Sikorav et al., 1987). The mammalian AChE gene contains six 
exons. Exon I contains the 5' untranslated region and the open reading frame begins in 
exon 2. Splicing after exon 4 regulates the assembly of the different molecular isoforms 
of AChE (Li et al., 1993). The mature catalytic subunit consists of a major common 
domain of approximately 500 amino acids followed by variable C-terminal peptides of 
less than 50 residues (Massoulie. 2002). The common domain is highly homologous in 
all cholinesterases from invertebrates to vertebrates. Indeed, the mouse muscle ACK 
sequence shares approximately 88% and 61% amino acid identity with bovine and 
tot-pe4lo AChE. respectively, but onl\- 52% identity with mouse BChE (Rachinsky et al.. 
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1990). The specific C-terminal sequence of each AChE variant detennines their 
oligomeric assembly and membrane interactions, which in turn directs distinct 
subcellular and intercellular localisation of the corresponding proteins. 
1.2.4 The AChE C-terminal splice variants. 
AChE possesses an N-terminal secretory signal peptide directing it into the endoplasmic 
reticulum (ER) during biosynthesis. In the ER, AChE undergoes various post- 
translational modifications in the secretory pathway, including N-glycosylation and 
oligomerization. Though several elements contribute to the complexity of AChE forms, 
the best characterised is alternative C-terminal acceptor sites of the AChE mRNA 
transcript. 
The common region of all isoforms, including the catalytic domain is encoded by exons 
2-4. The different isoforms result from C-terminal splicing which is denoted by 
different groups in slightly different ways. Traditionally the regions after exon 4 have 
been denoted the intronic 4' region, followed by exon 5 and exon 6 (as shown). 
However, it has been suggested that these coding sequences not be considered proper 
exons as they simply arise from the choice of alternative acceptor sites, following the 
last exon encoding the catalytic domain (exon 4). Thus, the absence of splicing at this 
site generates "readthrough" (R) transcripts, use of the first acceptor site generates 
"hydrophobic" (H) transcripts, and a downstream acceptor site generates "tailed" (T) 
transcripts (Massoulie et al 2005). This results in three major C-terminal AChE mRNA 
transcripts; AChE-T, AChE-H and AChE-R as described and depicted in Figure I. I. 
The amino acid sequences for the different C-termini are depicted in Table 1.1. 
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Figure U: Schematic representation of the mammalian AChE gene and possible splice 
variants. All AChE mRNA transcripts contain exons 2,3 and 4, which produce the common 
domain. Depending on the choice of splice acceptor site downstream of exon 4, three different 
regions may be placed in a coding position, in transcripts R, H and T. 
1.2.4.1 AChE-T "tailed" variant. 
The most abundant AChE form in brain and muscle is known as the AChE tailed 
(AChE-T) variant (also known as AChE-S for the synaptic form particularly by 
Hermona Soreq's group in Israel), which contains the common exons 2-4 as well as a 
tailed extension. This variant is found expressed in all vertebrate species and its specific 
40 amino acid C-ten-ninal peptide is strongly conserved and evolutionarily related in 
both vertebrates and invertebrates (Massoulie et al., 2005). The t-peptide contains a 
cysteine at position -4 from the C-terminus, seven aromatic residues, (including three 
evenly spaced tryptophans), and can be organized as an amphiphilic alpha helix 
(Massoulie et al., 2005). This peptide is responsible for much of the polymorphism of 
AChE as it mediates interactions both with other AChE subunits and with anchoring 
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proteins and indeed can actually function as an autonomous interaction domain which 
has been denoted WAT for Tryptophan (W) Amphiphilic (A) Tetramerization (T) 
domain (Simon et al., 1998). 
There are two anchoring proteins thus far known in vertebrates; the collagen like tail 
known as CoIQ (Krejci et al., 1991), and the 20kDa transmembrane protein PRiMA 
(denoting Proline Rich Membrane Anchor) identified in 2002 (Perrier et al., 2002). By 
attaching to the strands of the collagen ColQ, AChE-T tetramers form collagen-tailed 
forms. Three such forms have been found; A4, A8 and A12, which contain one, two or 
three tetramers respectively. These forms are best characterised at the neuromuscular 
junction, where they constitute the major AChE form. Alternatively, AChE can be 
tethered to the membrane by attaching to the small transmembrane 20kDa anchor 
PRiMA and this form constitutes the major AChE species in the mammalian brain 
(Perrier et al., 2003). The associations of AChE-T and its anchoring proteins are further 
discussed in later sections. 
1.24.2 AChE-H "hydrophobic" variant. 
The hydrophobic (H) splice variant produces AChE-H subunits that generally become 
glycolipid-anchored dimers. This splice variant originates from the splicing of the 
common exons 2-4 with the first acceptor site (exon 5). This variant has been found in 
insects, nematodes, and some vertebrates including Torpedo and mammals (Li et al., 
1993). In mammals, this form has mainly been found associated with the membrane of 
blood cells, including erythrocyte and platelet membrane surfaces, but is not 
significantly expressed in the brain (Li et al., 1993). The role of AChE-H on blood cells 
is not entirely clear, proposed roles include regulation of membrane permeability, or 
scavenging of any ACh that diffuses into the bloodstream (Massoulie et al., 1993). In 
torpedo, AChE-H exists in the brain and in electric organs, and is the sole AChE form 
in dorsal muscles (Bon and Massoulie, 1980). 
The H peptide contains 1-2 cysteine residues (one in human and two in rat) which allow 
dimerization by the formation of disulfide bonds. It also has a hydrophobic C-terminal 
region, which serves as a signal for cleavage and glycosylphosphatidyl inositol (GPI)- 
addition (Massoulie et al., 2005). Immediately after completion of the polypeptide chain 
in the ER, the H peptide is cleaved after amino acid 14 of the open reading frame in H 
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region (rat numbering) and linked to GPI, and thus anchored to the membrane. The 
cleavage addition site is known as the (o-site and mutagenesis studies have revealed that 
GPI addition is dependent upon the residues preceding the cleavage addition site 
(Coussen et al., 2001). 
1.2.4.3 A ChE-R "readthrough " variant. 
AChE subunits of the "readthrough", AChE-R type result from a lack of splicing in the 
3' alternative region, and produces a C-terminus of 26-residues (in humans) devoid of 
cysteines, and thus disulphide bonding, so that AChE-R is considered to be a soluble 
monomer (Seidman et al., 1995). These forms have been found in both Torpedo 
(Sikorav et al., 1988) and mammals (Li et al., 1991). The proportion of AChE-R 
transcripts in adults is normally relatively low and their function unclear. However 
higher AChE-R levels are found in embryonic tissue, tumour cells, as well as after acute 
stress, exposure to AChE inhibitors or heat shock in cultured cells (Kaufer et al., 1998; 
Perrier et al.,, 2005). In adults, trauma and acute stress has been shown to induce 
changes in AChE splicing resulting in the overexpression of AChE-R (Kaufer et al., 
1998). Indeed, in adults the normally rare AChE-R variant is reported to be highly 
upregulated in brain, intestine, and spermatocytes after stress (Kaufer et al., 1998; Mor 
et al., 2001a), though the relative increase in AChE-R appears to show some variation 
between studies (Perrier et al., 2005). In addition, the 26 amino acid C-terminal peptide 
has been reported to have growth promoting effects on haernatopoietic cells (Grisaru et 
al., 2001). How these actions are mediated is still under investigation (see section 1.7.7 
for further detail), particularly since the AChE-R C-terminus shows little conservation 
between different mammalian species, as shown in Table 1.1 
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Table I. I: Sequences of the C-terminal peptides: 
Splice 
Variant 
Species Sequence 
R Torpedo GNVFAFHMQKVRTPAKTYHFGVIVAHLLLLSRPTASDVPRLAS 
SKWWAHSDPLCSRRCWESWGRIL 
Rat GRRGVGKQGMHKAARVGRTGERKGGKHRM 
Human GMQGPAGSGWEEGSGSPPGVTPLPSP 
H Torpedo ACDGELSSSGTSSSKGIIFYVLFSILYLIFY 
Rat ATEVPCTCPSPAHGEAAPRPGPALSLSLLFFLFLLHSGLRWL 
Human ASEAPSTCPGFTHGEAARRPGLPLPLLLLHQLLLLFLSHLRRL 
T Torpedo ETIDEAERQWKTEFHRWSSYMMHWKNQFDGYSRHENCEAL 
Rat DTLDEAERQWREAFHRWSSYMVHWKNQFDHYSKQDRCSDL 
Human DTLDEAERQWKEAFHRWSSYMVHWKNQFDHYSKQDRCSDL 
The R sequences of Torpedo, rodents and humans do not show any significant 
homology. The H sequences of rodents and humans are homologous, but differ 
significantly from that of Torpedo (the underlined regions are cleaved during processing 
and red C denotes cystemes). The T sequences are very strongly conserved in the 
AChEs of Torpedo, rat and human as shown by the highlighted blue residues. Adapted 
from Massoulie et al 2005 
1.2.4.4 AChE-S variant 
In the Elapid snake Bungarus multicinctus a fuither AChE subunit has been identified 
and denoted type S (AChE-S) and results from use of an acceptor site after that of the T 
site (exon 6) (Cousin et al., 1996a; Cousin et al., 1996b; Cousin et al., 1998). This 
variant has a short 15 residue C-terminal extension that is very basic (Cousin et al., 
1998). It is secreted by the venom glands as a soluble monomer, however it does not 
appear to contribute to the toxicity of the venom, making its function unclear (Cousin et 
al., 1998). 
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The various oligomeric forms that can arise from AChE C-terminal splicing are 
depicted schematically below: 
AChE-R 
0 
Soluble monomer GPI anchored dimer 
teý4ý 
ÄOW& 0%, d9% ? Wý4, oN 
Soluble globular 
monomers, dimers and 
tetramers 
PRiMA tethered CoIQ tethered asymmetric tetramer forms 
Figure 1.2 Schematic representation of the potential oligomeric forms that can result from 
alternative C-terminal splicing and association with anchoring proteins. Adapted from 
Massoulie 2002. 
1.2.5 N-terminal AChE splice variants: 
A recent study analysing the genomic regions flanking the human and mouse ACHE 
genes revealed evolutionarily conserved alternate exons at their 5' end. These newly 
identified exons appear to be regulated by stress- and glucocorticolds (Meshorer et al 
2004). Five alternative exons were identified in mouse (denoted Ela-e) and three in 
humans (denoted Ela, c and e). The expression profiles of these N-terminally spliced 
variants were distinct from those of the 3' acceptor sites, suggesting that first exons use 
does not dictate a given 3' usage (Meshorer et al 2004). The first 31 amino acids of 
AChE constitute a hydrophobic signal peptide that functions to dock AChE to the ER 
reticulurn membrane and is cleaved off during maturation. Most of the recently 
identified 5'-encoded exons produce alternative untranslated regions; however, exon 
Ele gives rise to a protein that has an extended N-terminus, designated N-AChE. This 
extension been postulated by Meshorer et al to prevent cleavage of AChE's signal 
peptide creating an N-terminally extended protein with a hydrophobic region which 
AChE-T 
AChE-H 
I. 
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could then serve as a transmembrane domain, enabling AChE to anchor itself to the 
synaptic membrane (though the catalytic activity is still proposed to be extracellularly 
located) (Meshorer et al 2004). This would be particularly interesting for AChE-R, 
which is a soluble monomeric isoform, as it would allow it to anchor to membranes. 
The different 5'versus 3' alternative combinations can potentially give rise to 15 and 12 
different AChE transcripts in mice and humans, respectively (Meshorer et al 2004) and 
these are depicted schematically below: 
AChE gene 
Mouse 
L0U Ifll 2 
Ele Eld Ela 
Elc Elb 
2 
"2 
12 
2 
2 
Human.,,,, 
I. ,,.,,,., 
2 
Ele Elc Ela 
mRNA 
iwmý 
owl 
our_, 
2 
2 
34 
34 
34 
Putative membrane docking 
through the extended N terminus 
(N-AChE, pink) transcribed by 
the alternative exon Ele 
Figure 1.3 Schematic diagram of mouse and human ACHE genes showing potential N- 
terminal splicing options. N-ten-ninal splicing (lines above genes denote splicing options) 
could produce an N-terminally extending AChE with a transmembrane domain. Adapted from 
Meshorer et al 2004. 
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1.2.6 AChE forms during development and aging: 
Studies in both the mouse and quail nervous systems have noted that during 
embryogenesis there is a shift from the monomeric isoforms to tetrameric AChE 
isoforms, the significance of which is not clear (Anselmet et al.. 1994-, Inestrosa et al., 
1994). In comparison, during dementia there is a reduction in the proportion of 
tetramers to monomers, mimicking the pattern seen during embryogenesis (Arendt et 
al.,, 1992). During normal aging in rodents a decrease in tetrameric forms in the frontal 
cortex, striatum and hypothalamus, is also observed, with little change in the level of 
monomeric fon-ns, though this is not as marked as in the demented brain (Das et al., 
2001). 
1.3 Three-Dimensional structure of AChE: 
1.3.1 AChE subunit domains. 
The first AChE crystallised was the catalytic subunit of the dirneric GPI-linked form in 
1991 at a resolution of 2.8A (Sussman et al., 199 1). Catalytically AChE is defined as a 
serine hydrolase as it has a characteristic serine in its catalytic active site. However its 
crystallisation revealed that unlike classical serine hydrolases such as subtilisin, AChE 
has a different 3D-fold. The fold of AChE is known as the (x/P hydrolase fold, since the 
outer layer of the structure is composed of alpha helices packing against a central core 
of parallel beta sheets (Ollis et al., 1992). Other proteins with this characteristic fold 
include the fungal triacylglycerol lipases from Candida rugosa (Cygler et al., 1993) and 
dienlacetone from Pseudomonas (Ollis et al., 1992). The AChE subunit consists of a 12- 
stranded mixed P sheet, surrounded by 14 cc helices, and is ellipsoid in shape (45 x 60 x 
65 A) (Sussman et al., 1991). 
Each AChE subunit is composed of several domains. Most important for its enzymatic 
activity is the catalytic active site, which is located within a gorge which penetrates 
halfway into the protein. This gorge is 20A deep and the catalytic active site lies 4A 
above its base (Sussman et al., 1991). Forty percent of the gorge lining is composed of 
14 aromatic amino acids, which are highly conserved between cholinesterases of 
different species and located at the loops which lie between the beta sheets. The active 
site contains two subsites; the esteratic subsite, which contains the catalytic triad of 
serine, glutamate and histidine and the anionic subsite that accommodates the positive 
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ammonium pole of ACh (Ordentlich et al., 1993). The quartemary ammonium of ACh 
interacts with the n-electrons of these aromatic groups lining the active site gorge. In 
Torpedo AChE, the catalytic triad consists of serine-200, histidine-440 and glutamate- 
327 (Sussman et al. 9 1991). This 
differs from the catalytic triad of true serine proteases, 
which classically consists of a catalytic triad of Aspartate-Histidine-Serine but is highly 
conserved between AChE's of different species, as is the disulphide bonding pattern 
(MacPhee-Quigley et al., 1986). 
One of the characteristics of AChEs three dimensional structure is its asymmetric 
distribution of charged residues that are divided into a negative hemisphere at the top of 
the protein (including the mouth of the gorge) and a positive one located at its bottom 
(Ripoll et al., 1993). This pattern gives rise to a large dipole moment, which is 
orientated along the axis of the active site gorge (Porschke et al., 1996). Surprisingly, 
this asymmetric distribution of charge is not essential for hydrolysis, as neutralisation of 
up to seven residues at the entrance of the active-site gorge did not have any major 
effect on catalysis (Shafferman et al., 1994). 
One of the most interesting aspects of this enzyme is the peripheral anionic site (PAS), 
which has been localised by site-directed labelling and mutagenesis studies at 
approximately 14A froin the active site near the entrance of the aromatic gorge. The 
PAS is composed of the residues Tyrosine 72, Aspartate 74, Tyrosine 124, Tryptophan 
286, and Tyrosine 341 (human numbering), (Tyrosine 70, Aspartate 72, Tyrosine 121, 
Tryptophan 279 and Tyrosine 334; Torpedo numbering) (Barak et al., 1994). The PAS 
is distinct from the catalytic active site, but has been shown to be able to modulate the 
confonnation of the residues within the aromatic gorge and active site (Barak et al., 
1994; Berman et al., 198 1). The PAS can bind to many different types of ligands, and 
several roles have been proposed for it, including: a landing site for charged ligands, an 
ionic strength sensor, and the site of excess substrate inhibition (see enzymatic activity 
for further explanation) (Radic et al., 1991). The three dimensional structure of AChE 
with the catalytic triad and residues of the PAS are shown overleaf in Figure 1.4. 
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Figure 1.4 Three dimensional structure of Torpedo Californica AChE-T. 
The folded AChE is shown with the catalytic triad highlighted in red and the five residues of the 
PAS shown in blue. Shown in yellow is the potential N-terminal extension (PDB I GQS; Taken 
from Zimmerman and Soreq 2006). 
Recent work has suggested that the PAS may also play a significant role in the so called 
non-enzymatic or non-classical actions of AChE, in particular since it is important in the 
forination of oligomers and is within a conserved region found in a number of cell 
adhesion molecules (further described in section 1.6 on homology to cell adhesion 
molecules) (Botti et al., 1998). Indeed, crystallographic studies have revealed two 
potential distinct structures of the AChE tetramer, both involving a dimer of dimers 
(Bourne et al., 1999). In the first conformation, known as the compact square non- 
planar tetramer, the two AChE dimers are close with the four C-terminal sequences 
aligned in the same direction. In the second conformation, known as the loose pseudo 
square planar tetramer, there is a larger distance between two dimers and the four C- 
terminal sequences are aligned antiparallel to each other (Bourne et al., 1999). 
Crystallographic studies suggest that in the dimers interacting to form tetramers, a 
short loop of conserved hydrophobic residues from one subunit of each dimer (a 
cysteine bridged loop of residues 257-272 in mouse, containing conserved proline- 
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proline-glycine-glycine-alanine-glycine-glycine sequence) associates with the PAS of 
the facing subunit, occluding access to the active site. This leaves the two PAS of the 
two loop-donor subunits accessible (Bourne et al., 1999). Such interactions potentially 
suggest that the PAS could act as a site for association both of neighbouring subunits 
and potentially heterologous proteins with interactive surface loops (Bourne et al.. 
1999). 
1.3.2 Enzymatic activity: 
As mentioned, AChE along with BChE are classified as serine hydrolases as they use a 
serine residue at the active site to initiate binding of the substrate, though the AChE fold 
and the presence of a glutarnate in the catalytic triad distinguishes it from classical 
serine hydrolases. AChE cleaves ACh most actively and is less potent at hydrolysing 
other alkyl esters such as butyrylcholine. The function of BChE remains a puzzle. It has 
no known specific natural substrate, although it is capable of hydrolysing ACh as well 
as other alky esters. Mutations in BChE in humans do not result in anýr significant 
physiological consequence, indeed in rare individuals the BChE gene has been found to 
be completely missing. There is one clinical consequence of BChE mutations; the 
inability to hydrolyse the muscle relaxant succinyl choline, commonIv used to aid in the 
administration of inhalation anaesthetics during tracheal intubation. In such cases. 
BChE mutations can induce prolonged apnea (Surina et al.. -1004). 
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AChE enzyme catalysis is an acid-base reaction that involves a two-step reaction 
(Rosenberry, 1975). Firstly, there is the formation of an acyl inten-nediate between the 
serine residue and the substrate. Then in the second step there is deacylation with 
nucleophilic attack upon the acyl intermediate by a molecule of water. 
A 
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Figure 1.5 Schematic representation of monomeric AChE and its catalysis reaction. (A) 
Schematic representation of the structure of monomeric AChE showing the active site at the 
bottom of a hydrophobic gorge, and composed of serine (S), glutamate (E) and histidine (H), 
mammalian numbering. Also highlighted is the peripheral anionic site, identified by site- 
directed mutagenesis. (B) The AChE acetylcholine reaction, which occurs in two steps, 
fon-nation of an acetyl-AChE intermediate with release of choline, and the subsequent 
hydrolysis of the intermediate to release acetate. Adapted from Soreq and Seidman 2001. 
This reaction occurs extremely quickly, indeed AChE is among the fastest enzymes 
known with a turnover rate of 108 M-1 s-1, approaching the maximal theoretical limit set 
by molecular diffusion of the substrate. Interestingly, AChE does not display Michaelis- 
Menten kinetics; rather it has been shown to be inhibited at high substrate 
concentrations, known as substrate inhibition (Marcel et al., 1998; Szegletes et al., 
1999). At high concentrations of ACh, its binding at the PAS is thought to impair 
choline exit from the active site, thereby inhibiting catalysis (Shafferman et al., 1992). 
Indeed, binding of PAS ligands is reduced at high ACh concentrations, supporting this 
hypothesis (Radic et al., 1991). Another intriguing aspect of AChE's enzymatic activity 
it how its enzyme products are cleared out of the active site gorge. This is not entirely 
understood, in particular since the active site is located at the bottom of a narrow gorge 
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and yet AChE is a supremely efficient enzyme. One theory to explain this is the so- 
called "backdoor" hypothesis, whereby there is a transient opening of a short channel to 
allow products to escape (Gilson et al., 1994). Experimental proof for this theory is still 
missing, though molecular docking studies support such a hypothesis (Alisaraie and 
Fels, 2006). Surprisingly since AChE shows significant polymorphism, the different 
AChE forms do not differ significantly in activity. 
AChE can be inhibited by a broad range of chemicals, which can be roughly divided 
into three groups; those that interact with the active site of the enzyme and can thus be 
classified as competitive inhibitors, those that interact with the peripheral anionic site 
and are therefore non-competitive inhibitors, and those that interact with both sites and 
therefore show mixed competitive/non-competitive inhibition. One class of AChE 
inhibitors which is well known in health and agriculture are organophosphates. These 
agents are very potent inhibitors ol'AChE and are used as agricLiltUral IIISCCUCICICS Or as 
nerve gases in chemical warfare. These compounds react with the active site serine 
forming a very stable covalent phosphoryl-enzynic conij)Ie\. Aniong, the most widely 
used organophosphates are parathion, malathion, chlorpyrifos and diazinon. 
1.3.3 Inactive AChE forms 
There have been several reports of both AChE and BChE forms with negligible enzyme 
activity and of largely unknown function (Chatel et al., 1994; Chatel et al., 1993a; 
Rotundo, 1988; Thullbery et al., 2005; Weikert et al., 1994; Weikert and Layer, 1994). 
Inactive BChE strongly expresses a glycoepitope known as the HNK-l epitope, which 
is not expressed by the active form (Weikert and Layer, 1994). Such inactive forms 
have been postulated to play non-enzymatic, potentially morphoregulatory roles (Layer 
and Willbold, 1995). 
1.3.4 Enzymatic side activities of AChE: 
Several previous studies suggested that AChE possessed enzymatic activities in addition 
to ACh hydrolysis. Previous work at one time suggested that AChE could act as a 
protease. This was particularly interesting since this trypsin-like protease activity was 
suggested to play a role in Alzheimer's disease (AD). AChE was reported to possess 
amyloid precursor protein (APP) secretase activity since it was able to release a soluble 
anti-amyloidogenic I OOkDa form of APP from transfected HeLa cells and cleave 
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peptide fragments of APP (Small et al., 1992). In AD, which is characterised by 
increased cleavage and production the amyloidogenic AP peptide from APP and loss of 
AChE, there would more amylodogenic cleavage (Small et al., 1991). Further 
investigation then indicated that this activity appeared to result from a contamination of 
the AChE preparation (Campos et al., 1998). However, some groups still suggest that a 
protease activity may be associated with AChE (Zhang et al., 2002). 
Another enzymatic activity ascribed to AChE is arylacylamidase activity. This activity 
has been confirmed to be intrinsic and not due to the presence of contaminating 
enzymes (Checler et al., 1994). This enzyme activity can cleave the artificial substrate 
o-nitrocetanilide, but the endogenous substrate if any is unknown. This activity is 
inhibited by AChE inhibitors and by 5-hydroxy-tryptamine (5-HT). The physiological 
role of the arylacylamidase activity on AChE is unclear. However, since 5-HT is 
involved in the release of pain, AChE may be implicated in pain relief mechanisms 
(Balasubramanian and Bhanumathy, 1993). 
1.3.5 Allefic Variants: 
The most well known allelic variation for human AChE is a single nucleotide 
polymorphism (SNP) where histidine 322 is changed to an asparagine (Asn). This 
variation is found in 5% of AChE alleles of European and American populations and 
has no effect on the catalytic properties of the enzyme. The His322-Asn variation is 
associated with the blood group YT (Spring et al., 1992), which maps at the genetic 
locus 7q22 like the AChE gene (Zelinski et al., 1991) meaning that the YT blood group 
antigen is located on the AChE of red blood cells (Bartels et al., 1993). Anti-YT 
antibodies and therefore anti-AChE antibodies are found in people who have undergone 
multiple blood transfusions and have been suggested to have potential deleterious 
neurological effects or cause agglutination of donor red blood cells following later 
transfusions. Recent studies have also found two additional polymorphisms, one in the 
distal promoter of AChE which affects the interaction of the glucocorticoid response 
element (GRE) and one on a4 base pair deletion in the promoter region in the 
hepatocyte nuclear factor 3 binding site (Shapira et al., 2000). Both these 
polymorphisms have been shown to induce hypersensitivity to AChE inhibitors 
(Shapira et al., 2000). While the ACHE gene exhibits little polymorphism, BCHE has 
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been found to have abundant mutations. Such differences have been interpreted as a 
reflection of the absolute necessity of a functional AChE. 
1.4 AChE Anchoring: 
AChE molecules are divided into two main classifications; globular and asymmetric 
forms. The globular classes of AChE include monomers (Gl), dimers (G2) and 
tetramers (G4) of the catalytic subunit. The globular forms can further be divided 
depending on their amphiphilicity; they are either attached to the cell membrane by a 
GPI anchor, as earlier indicated for the AChE-H splice variants, or by the hydrophobic 
20kDa PRiMA subunit. As mentioned, AChE-T subunits constitute the major AChE 
isoform expressed in mammals. These subunits are anchored at specific sites by two 
proteins, CoIQ and PRiMA. CoIQ targets the enzymes in the basal lamina, while 
PRiMA targets the enzymes to the plasma membrane. AChE associates with both 
PRiMA and CoIQ in the Golgi apparatus. In mammalian brain, most AChE is found as 
tetrameric subunits (Muller et al., 1985) membrane anchored via PRiMA (Perrier et al.. ) 
2002). Asymmetric AChE is found at the skeletal neuromuscular junction anchored to 
the basal lamina of the synaptic cleft by the collagen-like ColQ. Both PRiMA and CoIQ 
have a proline-rich anchoring domain (PRAD) at their N-terminus which mediates their 
interactions with the WAT domain of AChE-T. Four parallel alpha-helical WAT chains 
associate around one antiparallel PRAD helix, which has a left handed polyproline 11 
conformation. The WAT chains each form a helix with a coiled-coil conformation and 
the four of them form a left-handed supercoil around the PRAD, producing very tightly 
interacting PRAD-WAT complexes. 
1.4.1 AChE and PRiMA: 
The proline rich membrane anchor (PRiMA) of AChE-T on cell membranes was first 
cloned in 2002 (Perrier et al., 2002). Since then PRiMA has been shown to exist as two 
alternative splice variants, designated variant I and 11 which differ in their cytoplasmic 
regions (Perrier et al., 2003). PRiMA I has an intracellular domain of 40 amino acids, 
while PRiMA 11 has an intracellular domain of II residues (Perrier et al., 2003), the 
cytosolic interactions of which are currently under investigation. Analysis of PRiMA 
expression using RT-PCR and in situ hybridisation revealed that its expression mainly 
correlates with other elements of the cholinergic system (Perrier et aL, 2003), since it 
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largely coincides with the ACh synthesising enzyme choline acetyltransferase (ChAT). 
All PRiMA expressing cells expressed AChE, however not all AChE expressing cells 
appear to express PRiMA, suggesting other modes of attachment in these cells. In vitro 
experiments have shown that anchoring of AChE to cell membranes by PRiMA 
represents a limiting factor for production of the AChE-T: PRiMA complex (Perrier et 
al., 2003). 
1.4.2 AChE and CoIQ: 
CoIQ was first cloned from torpedo in 1991 (Krejci et al., 1991), and subsequently 
cloned from rat muscles in 1997 (Krejci et al., 1997) and humans in 1998 (Ohno et al., 
1998). CoIQ is a non-fibrous collagen in which a central collagen domain is flanked by 
N- and C-terminal domains. Three strands of CoIQ associate in a triple helix and the N- 
, C-, and central collagen domains all have specific interactions which contribute to 
orientate AChE correctly at the NMJ (Krejci et al., 1991). The N-ten-ninal region of 
CoIQ contains the PRAD, which interacts with the WAT domain in the C-terminus of 
the AChE T subunit. Four t-peptides form a tight interaction with the N-terminal PRAD 
to recruit AChE subunits and stabilise them through disulphide bonds (Bon and 
Massoulie, 1997). Crystallography studies have revealed that four alpha helical t- 
peptides can form a staggered coiled-coil around the PRAD in the form of an elongated 
polyproline 11 helix (Dvir et al., 2004). Within this helix, all the aromatic residues are 
orientated towards the interior, with the tryptophans apposed to the rings of the proline 
residues (Dvir et al., 2004). The central collagen domain of CoIQ contains two different 
heparin binding domains, both of which have a BBXB motif (where B is a basic residue 
and Xa non-basic residue) and interact with heparan sulphate proteoglycans (Deprez 
and Inestrosa, 1995). The two binding sites have different affinities for heparin, 
mutagenesis studies revealing that the C-terminal binding site has a stronger interaction 
with heparin which may have a role in coordinating the position of asymmetric AChE at 
the basal lamina of the NMJ (Deprez and Inestrosa, 1995). The C-terminal non- 
collagenous domain contains many charged residues which help initiate triple helix 
formation and has recently been shown to have other interactions as discussed below 
(Cartaud et al., 2004). The CoIQ sequence and conformation is highly conserved in 
those vertebrate CoIQ's that have been described (Krejci et al.. 1991; Krejci et al., 1999; 
Krejci et al.. 1997). 
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Though encoded by one gene, CoIQ achieves complexity by utilising alternative 
promoters denoted pCoIQ- I and pCoIQ- I a, to produce two CoIQ transcripts, ColQ I and 
CoIQ IA (Cartaud et al., 2004). These two CoIQ isoforms differ only by a few amino 
acids in their mature N-terminus, which has no effect on their association with AChE 
catalytic subunits, but does confer differences in distribution. CoIQ anchors AChE at the 
NMJ of skeletal muscle which is divided into several subtypes including oxidative slow 
twitch muscle, which sustains aerobic activity and fast twitch muscles which contract 
more quickly, with greater force and generally sustain anaerobic activity. The promoter 
pCoIQ-1 drives the expression of the ColQ-1 transcript in slow-twitch muscles to 
assemble predominately A8 and A4 forms in both extra-junctional regions of muscle 
fibres, and at these NMJs. In fast-twitch muscles, the promoter pColQ-1a drives 
expression of the CoIQ-1a transcript which produces only A12 AChE at the NMJ 
(Cartaud et al., 2004; Krejci et al., 1999). Interestingly, rat heart ventricles only 
contained a low level of collagen-tailed AChE forms, but the heart has been shown to 
have the highest level of CoIQ transcripts. This suggests that CoIQ could have 
additional roles, independent of AChE tethering, (though the authors acknowledge that 
this may also simply result from inefficient detection of AChE in this region (Krejci et 
al., 1997)). 
Mutations in CoIQ have highlighted its importance in AChE anchoring. Disruption of 
the PRAD domain revealed that in the absence of interactions with its anchoring 
protein, no clusters of AChE can be detected at the NMJ (Feng et al., 1999). 
Interestingly, not only did these mice lack AChE asymmetric forms, but they were also 
found to be deficient in asymmetric BChE forms and globular ACK tetramers at the 
NMJ. This would appear to indicate that the Co1Q gene also has a role in the assembly 
or stabilization of AChE forms that do not themselves contain a collagenous subunit. In 
humans, mutations in CoIQ result in end-plate AChE deficiency. Such mutations can 
occur in several regions, but still perturb AChE localisation. Mutations in the proline- 
rich attachment domain abrogate attachment of catalytic subunits; mutations in the 
CoIQ collagen domain prevent the assembly of asymmetric AChE, while hydrophobic 
mutations in the C-terminal domain prevent triple helical assembly of the CoIQ collagen 
domain (Cartaud et al., 2004; Donger et al., 1998; Engel et al., 2003a; Engel et al., 
2003b; Engel et al., 2003c; Ohno and Engel, 2003). 
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1.4.3 AChE and molecular interactions at the NMJ: 
The localisation and organisation of AChE has been most well studied at the NMJ. 
Indeed, while PRiMA was only identified as the AChE anchor on brain membranes in 
2002, the study of the action of AChE at the NMJ dates back to the 1930s, when high 
concentrations of AChE were noted by Mamay and Nachmansohn at the sites of nerve- 
muscle contact (Marnay and Nachmansohn, 1937; Marnay and Nachmansohn, 1938; 
Nachmansohn,, 1939). Many studies since then have investigated the specific 
localisation and genetic control of AChE in this area. Though skeletal muscle fibres and 
motorneurons in all vertebrate species so far examined express both the globular and 
collagen-tailed forms of AChE, the asymmetric CoIQ tethered form is the unique form 
of the enzyme at the NMJ (Brandan and Inestrosa, 1984; Brandan et al., 1985; Hall and 
Kelly, 1971; Rossi and Rotundo, 1993). 
At the NMJ synapse, AChE is clustered in discrete regions. However, the mechanism 
governing this clustering is only now coming to light, as its location in the ECM means 
it cannot on its own associate with the cytoskeleton for clustering. During development, 
myotubes initially express asymmetric AChE over their entire surface before then 
accumulating it at the newly formed synapses (Ziskind-Conhaim et al., 1984). In the last 
15 years, several key components important for controlling AChE distribution at the 
NMJ have been revealed, namely perlecan, a heparan sulphate proteoglycan (HSPG), a- 
dystroglycan (aDG), a component of the dystrophin complex, and a tyrosine kinase 
receptor called muscle-specific kinase (MuSK). ccDG knockout mice display aberrantly 
developed neuromuscular junctions, with perturbed AChE distributions (Peng et al., 
1999). aDG has previously been shown to bind to and colocalise perlecan, a major 
HSPG at the NMJ which interacts and colocalises with asymmetric forms of AChE via 
interactions with ColQ. Perlecan interacts with aDG via globular G-domain motifs in its 
core protein (Talts et al., 1999). Perlecan knockout mice have normal skeletal muscle 
development, and AChE expression (Arikawa-Hirasawa et al., 2002). However, in these 
mice CoIQ and AChE subunits are absent from the NMJ. Thus, proper localisation of 
AChE and CoIQ to the NMJ appears to be perlecan dependent (Arikawa-Hirasawa et 
al., 2002). Indeed ColQ-AChE are thought to associate with perlecan intracellularly and 
then be secreted to interact with the other components such as CCDG (Rotundo et al., 
2005). Immunoprecipitations and biocore binding studies have revealed that only CoIQ 
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tethered AChE can bind to perlecan, while globular forms cannot (Peng et al., 1998; 
Peng et al., 1999). 
A third component important for AChE distribution in the NMJ was revealed in 2004: 
MuSK, a tyrosine kinase receptor already known to be important for ACh clustering 
(Cartaud et al., 2004). This tyrosine kinase receptor is specifically concentrated at the 
postsynaptic membrane and upon its activation by agrin it induces a cascade of signal 
transduction events through rapsyn leading to the formation of AChR clusters (Apel et 
al.,, 1997). Crosslinking, co-immunoprecipitation and co-immunofluorescence 
experiments revealed that MuSK can bind to the C-terminus of CoIQ to help anchor 
AChE in the basal lamina (Cartaud et al., 2004). However, other C-terminal CoIQ 
binding partners may also exist since at the NMJ, MuSK is mostly observed at the crests 
of the postsynaptic membrane folds, while AChE is distributed at both the crests and the 
depths of the folds (Cartaud et al., 2004). The current model for AChE anchoring at the 
NMJ is depicted in Figure 1.6. 
Figure 1.6 Interactions anchoring AChE at the NMJ. 
At the NMJ AChE is anchored by its CoIQ in the basal lamina by interactions with three 
components. MuSK binds the C-terminus of ColQ, while Perlecan interacts with the central 
collagen core of CoIQ and ccDG to cluster AChE at the NMJ. Adapted from Cartaud et al 2004. 
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However, though the scheme depicted in Figure 1.6 places MuSK directly interacting 
with the C-terminus of Co1Q, it is not yet clear whether this is the case or whether other 
proteins are involved in a complex. Indeed a direct role for MuSK in AChE clustering at 
the NMJ is met with some hesitation (Rotundo et al., 2005) since in perlecan or cCDG 
(Arikawa-Hirasawa et al., 2002; Peng et al., 1999) deficient mice MuSK is still present 
but unable to cluster AChE, though this may reflect a need for multiple interaction in 
AChE clustering. 
1.5 Glycosylation of AChE: 
AChE is a glycoprotein, containing about 10-15% carbohydrate. The primary sequence 
of Torpedo AChE contains 4 potential N-Glycosylation sites, all of which are utilised 
(Schumacher et al., 1986a), while human AChE has 3 potential N-glycosylation sites, 
all located at the surface of the molecule. Studies have revealed that these are important 
in AChE secretion, since their removal by mutagenesis reduced secretion to 20% of the 
wildtype when one site was mutated and to 1% when all three sites were mutated. 
However, mutation had no effect on the activity of the secreted enzyme (Velan et al., 
1993). 
The glycan chains of AChE are matured in a complex manner, which differs according 
to the tissue. For example in humans the erythrocyte globular dimeric form has more 
carbohydrate than the globular tetrameric form in brain (Liao et al., 1992). In each 
tissue, the various molecular forms are glycosylated differently, in depending on their 
distinct subcellular localisation (Meflah et al., 1984). AChE molecules are also 
recognised by the antibody HNK-I, which binds a glycanic epitope containing 
sulphated glucuronic acid. Its precise function is unknown, however it has been 
suggested to be able to act as an independent mediator of adhesive function (Riopelle et 
al., 1986) and is a common motif of many cell adhesion molecules including Neural 
Cell Adhesion Molecule (NCAM), Ll and members of the tenascin family. This has 
resulted in the presence of this epitope on a glycoprotein being taken as indicative that 
the protein has an adhesive nature. An HNK-1 carbohydrate epitope was discovered on 
AChE from electric organs of Electrophorus electricus and Torpedo marmorata (Bon et 
al., 1987), and human neuroblastoma cells (Johnson and Moore. 2001). 
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Although mutating the glycosylation sites of AChE does not affect its activity, previous 
work has shown that activity may be modulated by different types of glycosylation. For 
example, after removal of sialic acids from neuronal and glial cells in culture, AChE 
activity increased (Stefanovic et al., 1975). This system resembles the modification of 
NCAM adhesivity by sialic acid during embryogenesis (Franceschini et al., 2001). 
1.6 Structural homologies to adhesion proteins: 
In recent years, several proteins have been found to share significant homology with 
AChE. Currently five different proteins; thyroglobulin, glutactin, neurotactin, gliotactin 
and neuroligins have been shown to have domains homologous to AChE but without 
conservation of the catalytic triad meaning that they lack catalytic activity. All five 
proteins contain a single cholinesterase domain, which shares 25-32% amino acid 
identity with rat AChE (Scholl and Scheiffele, 2003). Though neuroligin, gliotactin and 
neurotactin function as transmembrane receptors, the cholinesterase homologous region 
in all the proteins is extracellularly located. AChE, gliotactin, neurotactin and neuroligin 
show a characteristic ring-shaped electrostatic motif of negative potential around the 
zone homologous to the active-site gorge of the cholinesterases. This has lead to the 
classification of these proteins as members of the "electrotactins" class of adhesion 
proteins (Botti et al., 1998). This motif overlaps with the PAS and its presence in 
cholinesterase-domain proteins that lack enzymatic function suggests that this motif 
might also contribute to alternative ftinctions beyond that of substrate inhibition. The 
homologous regions are illustrated overleaf as shown in figure 1.7: 
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Figure 1.7 Structural organisation of cholinesterase homologous proteins. 
The cholinesterase homologous electrotactin family all contain a single extracellular 
cholinesterase domain (blue), which shares 25-32% amino acid identity with rat 
acety1cholinesterase (AChE). Thyroglobulin is a much larger protein than the other family 
members, containing ten additional thyroglobulin repeats and is therefore not shown. 
Neuroligin, gliotactin, and neurotactin all contain transmembrane domains. Adapted from Scholl 
and Schieffele 2003. 
Neurotactin is a Drosophila transmembrane glycoprotein encoded by the gene Nrt. In a 
similar manner to AChE (described later in section 1.7.1), neurotactin is initially widely 
expressed during neurogenesis, unlike AChE though it becomes restricted to points of 
cell-cell contact as development continues. Neurotactin mediates heterophilic adhesion, 
and a binding partner known as amalgam has recently been characterised (Fremion et 
al., 2000). Interestingly, neurotactin contains three copies of the tripeptide leucyl- 
arginyl-glutamyl sequence (LRE), which is known to be involved in S-laminin binding 
(Hunter et al., 1991) and which is also present at residues 266-268 in Torpedo AChE, 
suggesting they may share common binding partner. Gliotactin like neurotactin is 
another Drosophila membrane bound cholinesterase domain containing protein and is 
expressed in peripheral glia and in epithelial cells where it mediates heterophilic cell 
adhesion with an as yet unknown ligand (Auld et al., 1995). Neuroligins in mammals 
use their cholinesterase domain to bind to their transmembrane receptors, the P-neurexin 
transmembrane family (Ichtchenko et al., 1995; Ichtchenko et al., 1996). Neuroligin-1 is 
concentrated in the postsynaptic membrane of excitatory synapses and is suggested to 
play a role in synapse formation (Scheiffele et al., 2000) since addition of purified 
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neuroligin-I can recruit its ligand P-neurexin to cell-cell contact sites and trigger the 
formation of presynaptic specialisations (Dean et al., 2003). All these cholinesterase 
homologous proteins are involved in extracellular protein-protein interactions, 
suggesting that AChE may function in a similar manner. 
1.7 Morphoregulation by AChE: 
The structure of AChE and its interactions at the NMJ are generally accepted. However, 
the ability of AChE to have additional, possible morphoregulatory actions in both 
neuronal and non-neuronal cells still causes much debate. In particular, serious doubts 
were raised as to whether AChE's actions were specific, when the ascribed protease 
activity of AChE was found to be due to a contaminant (as mentioned previously). To 
distinguish these additional effects from the classical enzymatic function of AChE at 
synapses, various different terms such as non-cholinergic, non-classical and non- 
enzymatic have been used, further complicating classification. However, since the 
extent to which the enzymatic action is responsible for these effects is still not clear, 
defining the range of actions of AChE is admittedly difficult. While there are significant 
bodies of work describing the potential involvement of AChE in many cellular 
processes in many cases there is a distinct lack of a cohesive mechanism which would 
explain how AChE may be mediating such effects. This introductory section will aim to 
present some of the most relevant evidence available on the potential morphoregulatory 
action of AChE within the nervous system and beyond. 
1.7.1 Distribution of AChE: 
Initial indications that AChE may play a wider role than previously thought came from 
examining its distribution. Indeed, early on neurochernists are taught that AChE cannot 
be relied upon as a marker of the cholinergic system, since its localisation does not 
always correlate with the topology of cholinergic synapses. AChE is very broadly 
expressed in many species including parasites and has even been detected in the pea 
(Muralidharan et al., 2005). Indeed, AChE is present in organisms with a primitive 
nervous system such as Aplysia (Srivatsan and Peretz, 1997). It is present in all 
helminthic invertebrates including trematodes and nematodes and has been detected in 
Caenorhabditis elegans (Johnson et al., 1988), Steinernema carpocapsae (Arpagaus et 
al., 1992), and Necator americanus (Pritchard et al., 1994; Pritchard et al.. ) 
1991). In 
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trematodes AChE is associated with the surface and the internal subcellular structures, 
while in nematodes a substantial fraction of AChE is secreted. In parasites such as 
Schistosoma mansoni and Nippostrongy1us brasiliensis, the function of AChE is not 
fully characterised (Amon et al., 1999; Hussein et al., 2000). 
Within the mammalian central nervous system, there are several areas of the brain that 
express high levels of AChE but which receive little cholinergic input, including the 
lateral hypothalamus, dorsal raphe nucleus, substantia nigra and cerebellum (Brimijoin 
and Hammond, 1996; Gorenstein et al., 1991). Transient peaks in AChE expression 
have been noted for years in postmitotic neurons preceding neurite formation (Geula et 
al., 1995). While traditionally the majority of AChE is thought to be expressed in 
neurons, it is also known to be expressed in some glial cells, with variable levels of 
protein and activity being detected (Bond et al., 2006; Keller et al., 2001b). 
In addition, recent studies have revealed that AChE is widely expressed outside the 
nervous system. Several studies have shown that high levels of AChE are found in the 
haernatopoietic system, in plasma, erythrocytes, lymphocytes, thymocytes, 
megakaryocytes and platelets (Lev-Lehman et al., 1997; Lev-Lehman et al., 1994; 
Patinkin et al., 1994; Patinkin et al., 1990). In addition, multiple forms of AChE are 
found on the surface of the chrornaffin cells of the adrenal medulla, where it is difficult 
to imagine the need for two different forms if their sole function is to hydrolyse ACh, 
since the different forms differ little in their catalytic activity (Bon et al., 1990). AChE 
has also recently been shown to be expressed in osteoblasts (Genever et al., 1999; 
Inkson et al., 2004) and mesenchymal stem cells (Hoogduijn et al., 2006). 
AChE distribution is often determined by detection of its characteristic enzymatic 
activity. Determining AChE distribution in normal and malignant human cell lines by 
histochernical methods, such as that described by Karnovnsky and Roots (Karnovsky 
and Roots, 1964), revealed that in normal human fibroblasts, no AChE activity could be 
demonstrated,, but enzymatic activity was observed in HT-1080 human fibrosarcoma 
cells, RD 2 human rhabdomyosarcoma cells, and SW 311 human colon carcinoma cells 
(Falugi et al., 1986). AChE has also been found expressed in human brain endothelial 
cells where its activity levels were increased by coculture with astroglial cells (Pakaski 
and Kasa, 1992). Intriguingly, a recent study found comparable levels of AChE protein 
expression in both neuronal and non-neuronal cells including cerebellar neurons, 
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astrocytes and fibroblasts, while only low levels of enzymatic activity were detected in 
the non-neuronal cells, suggesting the AChE had a ftinction other than hydrolysis in 
these cells (Thullbery et al., 2005). 
1.7.2 AChE and neural development: 
The nervous system develops via a regulated system of neural induction, neurulation 
differentiation, neuronal proliferation, migration, axon elongation, survival, synapse 
formation and synapse rearrangement. Several in vivo and in vitro studies have 
suggested that AChE has a significant role during this process. AChE is expressed in 
Drosophila (Wolfgang and Forte, 1989), mammals, and even ascidians (sea squirts) 
(Whittaker et al., 1977) at early stages of development, prior to the formation of 
functional synapses and therefore cholinergic signalling. Experiments using the P19 
embryonic carcinoma cell line revealed that the level of AChE mRNA increased 
dramatically and at a very early stage during differentiation (Coleman and Taylor, 
1996). Indeed, since the nineteen seventies there have been correlations noted between 
the occurrence of embryonic cholinesterases in many tissues of the chick embryo with 
morphogenetic events in particular in cell migration and aggregation (Drews, 1975). 
In the nervous system, AChE is expressed transiently by neurons during developmental 
periods of migration and axonal outgrowth, regardless of their eventual neurotransmitter 
system (Anderson and Key, 1999). Indeed, up to 90% of all migrating neural crest are 
postulated to express AChE (Cochard and Coltey, 1983; Drews, 1975). During 
development of cranial nerves of the avian hindbrain, the neural crest cells transiently 
express AChE during their emigration, with expression declining once the target is 
reached, suggestive of a role in pathfinding (Layer and Alber, 1990). Cells that express 
AChE in the developing brain are generally those that then establish connections with 
distant targets (Robertson, 1987). Transient AChE expression is often found on both the 
origin and the target side of long ranged projections, such as in both the developing 
visual and auditory cortex of the rat and thalamocortical neurons during growth into the 
cerebral cortex. This expression pattern is specific for AChE since other elements of the 
cholinergic system such as ChAT do not show this transient expression pattern 
(Robertson, 1987; Robertson et al., 1989; Robertson et al., 1991). In the developing 
chick brain, the expression of AChE correlates with the cessation of mitosis and the 
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beginning of differentiation (Robitzki et al., 1997). The expression of AChE is thus 
considered one of the earliest postmitotic events in the life of neurons. 
In those neurons that retain AChE. it is suggested to play a role in synaptogenesis. 
There is growth related shift from monomeric and dimeric forms in the developing brain 
to membrane anchored tetramers during and after synapse formation (Layer and 
Willbold, 1994). Thus, AChE expression has been suggested to occur in two distinct 
phases; firstly a pathfinding and morphogenic period involving monomers and dimers, 
which then switches to the formation of tetramers which have a synaptogenic role on the 
cell membrane (Layer and Willbold, 1995). Thus, Layer and Willbold have proposed 
that during the inital morphogenetic period neuronal precursors may assemble 
monomeric AChE into tetramers and secrete them,, after which, concomitant with 
neurite extension, the tetrameric forms become localised to the neuronal cell surface 
(Layer and Willbold, 1995). This would explain the increase in the ratio of tetramers to 
monomers seen during development (Anselmet et al., 1994). Notably, embryonic forms 
of AChE show some distinct characteristics from the adult forms; including lack of 
substrate inhibition (also found in demented patients and this is discussed further in 
section 1.7.9.4 and by Arendt et al., 1992). 
The role of AChE in outgrowth implied by its striking distribution has been investigated 
in a number of in vitro studies. Modulating the interactions of AChE using enzyme 
inhibitors or antibodies has been found to retard neurite outgrowth in several neuronal 
populations. However, the enzymatic activity of the protein does not seem to be 
involved in this effect since ligands acting only at the active site of AChE do not 
modulate outgrowth (Koenigsberger et al., 1997; Olivera et al., 2003b). 1,5-bis-(4- 
allyldimethylammoniumphenyl) pentan-3-one dibromide (BW284c5 1) is a selective, 
reversible bisquarternary AChE inhibitor, which binds both the active site and the PAS. 
Application of this AChE ligand has been shown to strongly inhibit neurite outgrowth in 
cultured chick neurons, cultured rat dorsal root ganglion (DRG), neuroblastorna cells 
and Xenopus neuronal cultures (Anderson and Key, 1999; Dupree and Bigbee, 1994). 
Furthermore, cell bodies treated with BW284c5l showed a large accumulation of 
neurofilaments (Dupree and Bigbee, 1996). 
Fasciculin, a toxin found in green mamba venom, is a well characterised AChE inhibitor 
which acts by binding to the PAS with nanornolar affinity (Radic et al., 1994). 
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Application of fasciculin reduces the number of primary neurites and bifurcations in rat 
spinal cord neurons (Bataille et al., 1998). Moreover, in chick neurons, which due to 
sequence differences in the PAS are less susceptible to enzymatic inhibition by PAS 
ligands, fasciculin still reduces the size of retinal cell aggregates, which are unaffected 
by active site inhibitors (Blasina et al., 2000). A monoclonal antibody MAB304 raised 
against human AChE, which is reported not to inhibit the catalytic activity of AChE has 
also been found to modulate neurite outgrowth in vitro (Olivera et al., 2003b; Sharma 
and Bigbee, 1998). MAB304 substantially alters the pattern of neurite outgrowth in 
DRG cultures, reducing outgrowth and increasing branching (Sharma and Bigbee, 
1998). and reducing outgrowth from cultures of dissociated hippocampal neurons 
(Olivera et al., 2003b). 
The mechanism by which the ligands retarded outgrowth is suggested to be perturbation 
of an adhesive function on AChE. However, there is still debate regarding the 
specificity of the interactions of the inhibitors, in particular since the concentrations 
needed to induce effects on neurite outgrowth are higher than required to inhibit AChE 
activity and at such concentrations neurotoxicity can occur (Olivera et al., 2003b; 
Posturna et al., 1999). In addition, though application of agents that fully inhibit AChE 
catalysis by binding to the active site of AChE such as tetrahydroaminoacridine 
(tacrine), edrophonium. and physostigmine have generally not been found to affect 
neurite outgrowth (Olivera et al., 2003b), suggesting that this action is not dependent 
upon catalytic activity, there have been occasional indications that these may have some 
actions. Indeed, addition of tacrine has been shown to be able to disrupt focal adhesion 
contacts and the actin cytoskeleton of Neuro 2A and B12 glial cells (De Ferrari et al., 
1998), suggesting that there may be differences in the actions of inhibitors on different 
cell types. 
1.7.3 Actions of exogenous AChE: 
A number of studies have examined the effects of exogenous application of AChE both 
in vivo and in vitro on different neuronal populations. In vitro, application of AChE has 
been reported to have neurotrophic effects. Mouse recombinant AChE increases the 
survival and outgrowth of mid-brain doparninergic cultured neurons (Holmes et al., 
1997). Likewise, addition of soluble AChE has recently been reported to increase the 
neurite outgrowth in organotypic hippocampal neurons (Day and Greenfield, 2002). in 
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primary dissociated embryonic ventral mesencephalic neurons (Whyte and Greenfield, 
2003) and in primary dissociated hippocampal cultures (Olivera et al., 2003b), where 
the effect has been suggested to be via an adhesive mechanism. Furthermore, in support 
for a role of AChE in adhesion Small et al in 1995 showed that when dissociated chick 
brain or sympathetic neurons were grown on plates precoated with purified AChE, 
neurite outgrowth was strongly stimulated. However, this neurite outgrowth-promoting 
effect was dependent upon the presence of substratum-bound HSPG, suggesting AChE 
needs to interact with these or additional components in the extracellular matrix to 
promote neurite outgrowth (Small et al., 1995). Application of ACK to cerebellar 
Purkinje cells enhanced the synaptic responses evoked by stimulation of the climbing 
fibres (Appleyard and Jahnsen, 1992). This may be due to AChE blocking excitatory 
amino acid uptake, since the effects are sensitive to the re-uptake blockers DL-2-amino- 
4-phosphonobtyric acid, and dihydrokainate. Based on such evidence, soluble ACK 
has been proposed to act as a modulator that enhances the sensitivity of some neurons to 
synaptic input (Greenfield, 1991). Indeed in vivo microinfusion of AChE into the 
substantia nigra produces behavioural effects, such as turning and chewing movements 
(Hawkins and Greenfield, 1992). Application of AChE has also been shown to stimulate 
proliferation of the neuronal phaeochromocytoma (PC 12) cell line (Munoz et al., 1999) 
and to increase the number of Amino-3-hydroxy-5-methylisoxazolepropionate (AMPA) 
receptors in rat brain homogenates (Olivera et al., 2003a). 
However, not all the effects of AChE appear to be trophic. AChE was demonstrated to 
be neurotoxic to Neuro2A neuroblastoma cells in culture in a concentration dependent 
manner (Calderon et al., 1998). In vivo, intrahippocampal injection of AChE in rodents 
resulted in neuronal cell loss in the dentate gyrus, astrocytic hypertrophy and cognitive 
impairment (Chacon et al., 2003). 
1.7.4 Actions of secreted AChE: 
AChE secretion from many tissues has been reported, including enteric nerves 
(Appleyard and Smith, 1989), dorsal root ganglia (Gupta and Bigbee, 1992) 
neuroblastorna cells (Biagioni et al., 1995), Aplysia hemolymph (Srivatsan et al., 1992), 
the cerebellum (Appleyard et al., 1988), the striaturn (Greenfield et al., 1980), motor 
neurons (Rodriguez-lthurralde and Vincent, 1994), adrenal gland (Small et al., 1993) 
and the substantia nigra (Greenfield, 1991; Greenfield et al., 1983). 
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In areas of cholinergic innervation in muscles, the central nervous system. the peripheral 
nervous system, and neuronal cell lines, tetrameric AChE is secreted and this process 
appears to be mediated by microtubules (Lucas and Kreutzberg, 1985; Weston and 
Greenfield, 1985). Studies in neuroblastoma have shown that AChE secretion during 
neuronal differentiation is increased by depolarising stimuli (Biagioni et al., 1995), 
while in the hippocampus local AChE secretion is greatly enhanced by activation of 
muscarinic cholinergic receptors and is depressed by GABA agonists (Appleyard et al., 
1987). In the hippocampus AChE secretion is thought to have a function in 
complementing the action of membrane-bound AChE at cholinergic synapses. Indeed in 
areas with strong cholinergic components the secretion of AChE could be explained by 
a conventional cholinergic action, to aid ACh hydrolysis. However, in regions with little 
or no cholinergic transmission, such as the cerebellum (Appleyard and Jahnsen, 1992), 
the secreted AChE is likely to have another role. 
Several studies, in particular by Susan Greenfield's group in Oxford have investigated 
the role of secreted AChE in the substantia nigra. In this region, AChE is secreted from 
the dendrites of non-cholinergic, dopaminergic neurons in a manner independent of 
cholinergic neurotransmission (Heiland and Greenfield, 1999). While there is 
cholinergic input into the substantia nigra, it is meagre and there is a significant 
disparity between the levels of AChE and ChAT and ACh in this region (Emmett and 
Greenfield, 2005; Martinez-Murillo et al., 1988). Secretion of AChE in the nigra is 
linked to physiological events, stimulating guinea pigs with visual cues such as flashing 
lights, induced pulsatile AChE secretion, often associated with periods of locomotion 
(Jones and Greenfield, 1991). Since the substantia nigra has only sparse cholinergic 
innervation it is unlikely that this secreted AChE plays a role in cholinergic 
transmission. Similarly in the cerebellar cortex, it is difficult to ascribe a cholinergic 
ftinction to secreted AChE. In this region there are high levels of AChE, however there 
is little evidence for cholinergic transmission. In the cerebellum, AChE appears to be 
secreted in response to neuronal depolarisation, and not due to cholinergic transmission, 
since its secretion was not affected by application of the ACh mimetic carbachol 
(Appleyard et al., 1988). In the adrenal gland, AChE is also secreted and secretion is 
stimulated upon electrical stimulation (Small et al., 1993). 
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This widespread phenomenon of secretion of AChE in particular from areas with little 
cholinergic signalling is suggestive of additional non-cholinergic roles for AChE in the 
extracellular space. Based on these findings, Susan Greenfield has suggested that 
secreted AChE may be acting as a novel neuronal signalling molecule (Greenfield, 
1996). Such a hypothesis is supported by the observation that AChE can not only be 
secreted but can be taken up into neurons, possibly via an AChE binding site in the 
substantia nigra (Dickie et al., 1995). 
1.7.5 Adhesive activities of AChE: 
The significant homology that is shown by AChE to known cell adhesion molecules 
suggests that it may modulate cellular responses via an adhesion mechanism. The 
adhesive ability of the AChE core domains was examined by constructing chimeras, 
replacing the AChE-homologous domain of the cell-adhesion protein neurotactin with 
that of the core domain of Torpedo or Drosophila AChE. These AChE-neurotactin 
chimeras retained the adhesive properties of wildtype neurotactin in a cell-aggregation 
assay (Darboux et al., 1996). However, AChE alone is not capable of mediating cell 
aggregation, suggesting that lack of a transmembrane domain may be a critical factor. 
Recent studies have revealed that human AChE in vitro can bind to components of the 
extracellular matrix including laminin-1 and collagen IV by electrostatic interactions 
involving the PAS (Johnson and Moore, 2003) and indeed AChE can co- 
immunoprecipitate with laminin (Paraoanu and Layer, 2004; Paraoanu and Layer, 
2005). Recent work in bone has also suggested that AChE plays a role in the adhesion 
of osteoblasts, where it may function as a novel bone-matrix protein (Genever et al., 
1999; Inkson et al., 2004). 
1.7.6 Effects of manipulation of AChE levels: 
The effects of modulating AChE levels have been investigated in vitro using AChE 
overexpression and anti-sense suppression as well as in vivo with transgenic 
overexpression and knock-outs. Manipulation of AChE levels in several cell lines and 
primary cultures has been shown to alter process outgrowth. Antisense suppression of 
AChE led to a reduction in neurite production by PC 12 cells (Grifman et al., 1998). This 
decrease was accompanied with a loss of neurexin-l(x, the receptor for neuroligin. a 
member of the cholinesterase domain family and a postsynaptic cell adhesion molecule. 
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Furthen-nore the levels of neurexin- IP were lowered in transgenic mice overexpressing 
human AChE (Andres et al., 1997), supporting a link between AChE and neurexin 
expression. AChE-T transfected into glioma cells produced extension of processes, 
while overexpression of AChE-R produced cells that were small and round (Karpel et 
al.,, 1996). Moreover, Xenopus spinal neurons expressing either catalytically active or 
inactive human AChE-T forms extend longer neurites than control neurons grown in 
dispersed cultures (Sternfeld et al., 1998). Though increased outgrowth in these studies 
has been suggested to be dependent upon the presence of the AChE-T C-terminus, one 
study found that expression of a GPI-anchored form, as well as a soluble form are also 
capable of stimulating neurite outgrowth of transfected neuroblastomas (De Jaco et al., 
2002). 
Several studies have begun to investigate the effects of manipulating ACK levels. 
Transgenic mice overexpressing human AChE showed a two fold increase in ACK 
activity accompanied by show behavioural disturbances including loss of learning and 
memory capabilities, and modified anxiety responses (Erb et al., 2001). In addition, 
AChE-T overexpression in mice induces excessive neurite outgrowth, deterioration of 
their neuromuscular junctions (Lev-Lehman et al., 2000) and causes muscle exhaustion 
due to aberrant synaptic transmission (Farchi et al., 2003). 
The effects of reducing AChE levels have been examined in several systems of both 
vertebrates and invertebrates including Drosophila, Celegans, Zebrafish and mouse. 
Drosophila has a single AChE gene (Ace) (Fournier et al., 1989), which produces a 
GPI-anchored form (Incardona and Rosenberry. 1996). No functional BChE gene has 
been found in Drosophila, however the AChE form shows some characteristics of 
BChE suggesting it may be a hybrid form. Null mutations in the Ace gene are 
embryonically lethal, highlighting its importance during normal development. In order 
to overcome this. conditional temperature sensitive alletes and mosaic animals were 
generated (Hall et al., 1980, Mutero et al.. 1994). Using the temperature sensitive alleles 
(where growth can occur at a permissive temperature). AChE \\as found to be most 
critical for processes late in embryogenesis and early laval stages (Hall et al.. 1980). 
Rescue experiments showed that the Ace knockout phenotype could be rescued b,, 
expression of GPl-AChE from a minioene, and restoration of as little as 9-1 -", o of the 
wildtype actvv'ity (Hoffmann et al.. 1992). However. if a chimeric transmembrane AChl' 
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form is used during rescue the animals have behavioural defects and require highei- 
levels of enzyme activity to be viable. even though the enzyme is localised in a similar 
manner to the GPI-anchored form (Incardona and Rosenberry. 1996). In contrast 
expression of an Ace mutant that lacks the membrane attachment domain entirel\. 
completely rescues the null mutant phenotype, suggesting that AChE is unlikelý to act 
as an adhesion molecule. 
Nematodes such as Celegans have four AChE genes. acel-ace4 of \\Iiich acel and 
ace2 account for 95% of total AChE activity. The remaining 5% is due to ace3l. while 
ace4 appears to be devoid of hydrolytic activity. The products of these genes are also 
differentially localised: ace-I is expressed in muscle cells and a few neurons, whereas 
ace-2 is mainly expressed in motorneurons. ace-3 is expressed only in a few cells, and is 
resistant to cholinesterase inhibitors, while ace-4 is transcribed, but no protein has thus 
far been detected in vivo (Arpagaus et al., 1998; Grauso et al., 1998; Combes et al., 
2000; Combes et al., 2001; Combes et al., 2003). Mutations in a single Ace gene or 
mutations of either acel/ace3 or ace2/ace3 display only minor alteration of behaviour 
and no developmental defects, whilst the acel/ace2 double mutant, which retains only 
5% AChE activity, can only move slowly and are uncoordinated (Culotti et al.. 1981 '- 
Johnson et al., 1981, Johnson et al., 1988). The triple mutant strain (acel/ace2/ace3) 
dies as larva but this lethality can be suppressed bý' lowering the levels of ACh 
suggesting AChE only functions in nematodes to hydrolyse ACh (Johnson et al., 1988). 
Zebrafish has one AChE gene and no functional BChE species has been detected 
(Bertrand et al.. 2001). Several mutations in AChE have been characterised in 
Zebrafish, including mutation of the conserved Ser -226 (suggested to contact glutamate 
127 of the catalytic triad) to Asparagine which abrogates enzyme activity (Behra et al., 3 
2002). These mutant fish show impaired motility. similar to that observed upon 
antisense suppression of AChE. Initially resembling the wildtype in terms of mobility- 
the mutant embryos become progressively less mobile (Behra et al., 2002). However 
this phenotype can be rescued by mutation of the alpha subunit of nicotinic AChR 
(Behra et al., 2002-, Leonard and Salpeter. 1979), suggesting this phenotype results frorn 
excessix, e cholinergic transmission. Though in these mutant the AChE is catalyticall" 
inactiN7e it is still proposed to be folded correctly and should therefore be able to carry 
out aiiN, non-catalytic functions. However. the phenotype resulting from this mutation is 
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very similar to that seen when translation of AChE is blocked b\, an antisense 
oligonucleotide (Behra et al.. 2002). This would suggest that AChE is required for 
proper neuronal and muscular development in the zebrafish embryo. but that this is 
dependent upon the enzymatic activity and hydrolysis of ACh and not on any 
pathfinding or adhesive function. 
Both null homozygous and heterozygous mutations in AChE of mice have beeii 
generated by homologous recombination. Analysis of the heterozygous mutations 
revealed that a 50% reduction in AChE activity was still sufficient to support 
development and growth (Mesulam et al., 2002; Me et al., 2000). Surprisingly, even 
null mice without AChE activity were found to be viable, and were initially able to 
survive up to 3weeks after birth (Xie et al., 2000). At this point in rodent brain 
development there is growth of axons and dendrites, establishment of neural 
connections, synapse elimination, and beginning of myelination, which suggested that 
AChE may play a role in these processes. However, further studies revealed that the null 
homozygous animals could survive for up to a year if supplied with a liquid diet 
(Duysen et al.,, 2002). Even when compensated with a rich diet null homozygous 
animals showed significant developmental delays such as in temperature regulation and 
eye opening, and were characterised by body tremors, and seizures. However, all such 
characteristics are similar to the symptoms of organophosphate poisoning and can be 
attributed to excessive ACh stimulation (Duysen et al., 2002). This suggests that the 
mouse phenotype is attributable to loss of the catalytic activity of AChE. One surprising 
finding was that in knockout mice completely lacking AChE, the NMJs are intact, 
whilst mutations in CoIQ lead to NMJ degeneration suggesting AChE itself does not 
contribute to NMJ formation (Feng et al., 1999). 
AChE knockout mice have increased sensitivity to the toxic effects of organophosphate, 
and to the BChE inhibitor Bambuterol, which is not toxic to normal mice (Duysen et al., 
2002; Me et al., 2000). This suggests that BChE has compensatory effects in these mice 
and such effects may even have been underestimated due to the presence of Triton X- 
100 in the analysis reagents which inhibits BChE (Li et al., 2000a). Indeed, further 
compensation is afforded by reduction of surface expression of Mi. N122 and \14 
muscarinic ACh receptors in the cortex and the hippocampLIS. to dampen down the ACh 
stimulation (Duysen et al.. 2002). Such compensatorv mechanisms make determinin(u, 
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the effects of the AChE knockouts difficult. however since most of the deficits can be 
related to excess ACh stimulation. this has been suggested to indicate that the postulated 
adhesive or other non-catalytic mechanisms either do not exist or are not vital functions 
(Cousin et al., 2005). 
1.7.7 AChE and stress: 
Several studies have shown that after traumatic stress, psychological, physical or 
chemical, AChE alternative splicing is modulated, leading to increased levels of the 
AChE-R isoform. (Kaufer et al., 1998; Sternfeld et al., 2000; Mor et al., 2001a). This 
came to particular prominence in the late 1990's when Gulf war veterans who had been 
exposed to anti-cholinesterases such as organophosphates presented with 
psychopathologies that show similarities to post-traumatic stress disorder. Subsequent 
studies in mice revealed that acute stress or exposure to anti-cholinesterases both lead to 
rapid specific increases in AChE-R mRNA levels, while AChE-T and AChE-H levels 
are unchanged (Kaufer et al., 1998). This shift is dependent upon neuronal activity and 
intracellular calcium, as it can be blocked by a calcium chelator (Kaufer et al., 1998) 
and requires the splicing factor SC35 (Meshorer et al., 2005). The function of the 
increased AChE activity is suggested to be to protect the brain from hyperexcitability 
and the associated risk of seizure activity and neuronal toxicity by increased ACh levels. 
Comparison of the effects of overexpression of AChE-R and AChE-T in mice revealed 
that AChE-R transgenic mice were relatively free of stress correlates compared with 
controls, whereas AChE-T overexpressors showed increased neuronal stress responses 
including accumulation of heat-shock proteins, presence of reactive glia and curled 
neurites (Sternfeld et al., 2000). Increases in AChE-R are not only reported in the brain. 
Indeed after forced swim stress mice showed increased testicular AChE-R, while once 
again AChE-T levels were largely unaffected (Mor et al., 2001b). Though AChE-R 
upregulation is postulated to initially act as a protective mechanism, its chronic 
upregulation is thought to affect neuronal plasticity and long term potentiation, leading 
to increased anxiety and contextual fear responses (Nijholt et al., 2004). Though 
investigation is still continuing, AChE-R has been suggested to mediate its actions 
intraneuronally via interactions with the scaffold protein receptor for activated protein 
kinase CI (RACKI) and its protein kinase C betall (PKCbetall), identified by yeast- 
two hybrid systems and coirnmunoprecipitations (Birikh et al., 2003). In glial cell lines 
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AChE-R interacts with RACK and PKC-F-. suggesting its interactions are cell type 
specific (Perry et al., 2004). Though AChE-R secretion has been shown to double 
within 30mins of a stressful stimuli (Kaufer et al., 1998), recent studies call into 
question the significance of increase in AChE-R, since even after heat shock, swim 
stress or anti-cholinesterase treatment it only comprised 2% of total brain AChE (Perrier 
et al., 2005). 
1.7.8 AChE involvement in haematopoiesis: 
AChE is linked to the haematopoietic system in several ways. It is expressed by 
haematopoetic cells and has been implicated in the control and proliferation and 
differentiation of some haematopoietic cell types (Grisaru et al., 2001). Indeed there are 
three clusters of potentially active haernatopoietic transcription factors found within the 
AChE locus. These include a consensus binding site for GATA-1, a zinc finger 
transcription factor important for erythroid and megakaryocytic development, in the 
upstream regulatory regions of both rat and human AChE genes (Grisaru et al., 200 1). 
AChE is highly expressed by haernopoietic cells including eythrocytes, and 
megakaryocytes (MKs). Megakaryocyte colony-forming units express AChE when 
mitosis ends and they switch to megakaryocyte formation (Paulus et al., 1981). AChE 
inhibitors can increase the proportion of murine colony-forming units, whilst addition of 
AChE decreases the growth of megakaryocyte colony-forming units in culture (Burstein 
et al., 1980). This is suggestive of a suppressive role for AChE in the production of 
platelets which originate by budding off MKs. Indeed, anti-sense suppression of AChE 
expression in murine bone marrow cultures induced expansion of progenitors, 
proliferation of primary bone marrow cells and suppression of apoptosis in their 
progeny, an effect mimicked by the addition of carbachol (Patinkin et al., 2003; Soreq et 
al.,, 1994). 
Additionally a synthetic 26 amino acid peptide referred to as the acety1cholinesterase 
readthrough peptide (ARP as it the C-terminus of the AChE-R subunit) is as effective as 
stem cell factors in promoting the expansion and differentiation of bone marrow cells 
into myeloid and megakaryocyte lineages in vitro (Grisaru et al., 2001). This effect is 
specific since addition of the C-terminal peptide of AChE-T had no effect on cellular 
proliferation. 
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1.7.9 Role of AChE in pathology: 
There is a long list of disorders where the levels or forms of AChE are altered. These 
include neurological disorders, particularly those involving dementia such as 
Alzheimer's, Parkinson's, and Huntington's disease, but also includes neural tube 
defects, schizophrenia, mania, depression, Guillain-Barre syndrome, muscle diseases 
and turnours. Indeed, elevated concentrations of AChE in human amniotic fluid are 
considered diagnostic sign for spina bifida and anencephaly. These defects are 
associated with a dramatic increase in tetrameric AChE and a minor increase in 
monomeric AChE (Chubb et al., 1979; Smith et al., 1979). 
1.7.9.1 AChE and Neurodegenerative disorders: 
Particular neurons in the brain are especially vulnerable to neurodegeneration. Although 
Alzheimer's disease (AD), Parkinson's disease (PD), and Motor Neuron disease (MND) 
have very different clinical profiles, the underlying pathology in all cases has been 
shown to result from the death of a group of neurons known as global neurons which 
form a central hub in the brain, and extend from the basic regions of the brain to higher 
centres (Vickers et al., 2000). These include motor neurons, the raphe nuclei, the locus 
coeruleus, the substantia nigra, and the basal forebrain. The regions affected by PD, AD 
and MND; the substantia nigra, basal forebrain and motor-neurons, are all encompassed 
within these groups of neurons. These neurons have been shown to differ from others in 
the brain as they have retained their capacity for axonal regeneration and proliferation 
(Greenfield and Vaux, 2002). In light of this Susan Greenfield has suggested that 
pathologies affecting these neurons may result from their attempting to compensate for 
traumas such as head injury, toxicity, or stroke by trying to regenerate, and in doing so 
trigger a process that is potentially lethal (Greenfield and Vaux, 2002). One 
compensatory mechanism could be by the entry of calcium into the neurons, which 
would then trigger neurodegeneration since mature neurons are less able to withstand 
increased calcium levels than immature ones (Eimerl and Schramm, 1994). AChE is 
linked to these neuropathologies since all global neurons, irrespective of the transmitter 
they employ, contain AChE, where it is proposed to act in a manner independent of its 
traditional catalytic action, acting instead as a neurotrophic agent (Greenfield and Vaux. 
2002). 
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1.7.9.2 AChE and Parkinson's Disease: 
In the substantia nigra, which is the key area damaged in PD, there is a large amount of 
AChE, but only low levels of acetylcholine and its synthesizing enzyme, ChAT, as 
previously mentioned, suggesting AChE in this area has other functions. The nigral 
doparninergic neurons which are lost in PD not only contain, but secrete, AChE in 
response to physiological events, such as locomotion (Jones and Greenfield, 1991). In 
turn,, AChE can modulate these neurons, increasing their neurite outgrowth in vitro 
(Holmes et al., 1997; Whyte and Greenfield, 2003). This modulatory activity is 
independent of its normal enzymatic function,, since it is not abolished by active site 
inhibitors and heat inactivation (Greenfield et al., 1989). 
AChE inhibition has been found to exacerbate the symptoms of I'D (Duvoisin, 1967). 
Indeed, epidemiological studies reveal a correlation between chronic exposure to AChE 
inhibitors and I'D (Paolini et al., 2004). Other factors leading to increased ACh levels, 
including psychological stress (Kaufer et al., 1998) and head trauma (Shohami et al., 
2000), are also PD risk factors (Veldman et al., 1998). Recent work suggests the 
alternative splicing of AChE may also contribute to PD. An increased risk for PD has 
been found to correlate with mutations in the regulatory region of AChE which impair 
AChE-R up-regulation and mutations in the adjacent PON] gene (Benmoyal-Segal et 
al., 2005). The PON] gene produces paraoxonase, an enzyme involved in the 
degradation of organophosphate cholinesterase inhibitors (Furlong et al., 2006). 
Together,, these mutations change the dopamine-ACh balance by preventing the 
restoration of proper cholinergic levels and have been found to correlate with insecticide 
induced PD (Benmoyal-Segal et al., 2005). 
1.7.9.3 AChE and Motor Neuron Disease: 
Motor neuron disease (NIND) is characterised by the progressive death of motor 
neurons. This group of neurons secrete AChE (Rodriguez-1thurralde et al., 1998), 
respond to exogenous AChE by increasing neurite length and to PAS inhibitors by 
decreasing the number of primary neurites (Bataille et al., 1998). Interestingly, 
overexpression of human AChE in mice has been shown to enlarge the NMJs, which 
then progressively degenerate (Andres et al., 1998). Several studies have suggested that 
AChE is modulated in MND and may even play a causative role in its pathology. An 
increase in plasma AChE has been observed in a large proportion of M`ND patients, 
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while it is decreased at the degenerating NMJs (Festoff and Fernandez, 1981; Rasool et 
al., 1983). One hypothesis for the cause of MND is the production of autoinimune 
antibodies to AChE,, which travel back to the NMJ by retrograde axonal transport to 
induce the death of spinal motor neurons (Conradi and Ronnevi, 1993; Conradi and 
Ronnevi, 1994). However, immunosuppression to reduce AChE antibody levels has not 
been found to be effective in treating MND, weakening this hypothesis (Niebroj-Dobosz 
et al., 1999a; Niebroj-Dobosz et al., 1999b). 
1.7.9.4 AChE and Alzheimer's Disease. 
The strongest correlations between AChE and neurodegeneration come from work on 
AD. A role for the cholinergic system in human memory was first suggested in the early 
1970s, when cholinergic antagonists were found to impair learning, while AChE 
inhibitors could have a positive effect (Drachman and Leavitt, 1974). At this time, 
examination of post mortem AD brain tissue also showed reduction in the cholinergic 
neuronal markers ChAT and AChE in the cortex, hippocampus and nucleus basalis 
(Drachman and Leavitt, 1974). These findings led to the formulation of a "cholinergic 
hypothesis", linking abnormalities in the cholinergic system to functional and 
pathological changes in AD. Indeed, in 1984, Smith and Cuello suggested that the 
common link between the different cell groups damaged in AD was their expression of 
AChE irrespective of whether they are cholinergic. The AChE loss has more recently 
been refined to selective loss of the membrane bound tetrameric form, but upregulation 
of the monomeric form (Arendt et al., 1992). In AD patients treated with AChE 
inhibitors, an increase in monomeric forms is also observed, suggested to be the AChE- 
R variant (Darreh-Shori et al., 2002). 
In addition, cholinesterases are found in senile plaques, even at the initial stages of their 
formation (Moran et al., 1993), and in neurofibrillary tangles (Mesularn et al., 1987). In 
AD there is a reduction in AChE secretion from the adrenal gland (Appleyard and 
McDonald, 1991) and a reduction in salivary AChE, which is being considered as an 
AD biomarker (Sayer et al., 2004). Though tetrameric AChE levels decrease in AD, 
there is a high concentration of AChE found in senile plaques. Intriguingly the AChE in 
plaques is mainly monomeric and has characteristics reminiscent of embryonic AChE, 
including loss of substrate inhibition and decreased sensitivity to AChE inhibitors such 
as BW284c5l and Tacrine (Arendt et al., 1992; Mesulam et al., 1987). This has lead to 
65 
Chapter 1: Introduction 
the suggestion by Susan Greenfield that neurodegeneration in AD and potentially PD 
and MND may result from a reversion to an embryonic restoration programme. when 
neurons attempt to de-differentiate and instead proliferate, a process that is not tolerated 
in the landscape of the integrated adult brain (Greenfield and Vaux, 2002). However, 
another possibility is that the AChE associated with the arnyloid plaques may be of 
astroglial origin (Geula and Mesulam, 1995). 
In vitro studies have also demonstrated a role for AChE in AD. AChE promotes the 
aggregation of amyloid beta peptides into amyloid fibrils and can form a stable complex 
with them ( Inestrosa et al., 1996b; Alvarez et al., 1998). Moreover, the toxicity of these 
complexes is dependent upon the AChE concentration within the complex, not the beta 
amyloid content, potentially explaining why AChE expressing neurons are damaged in 
AD (Munoz et al., 2002). Similar results were obtained using the different molecular 
forms of AChE, indicating that it was the result of interactions with the domain 
common to all subunits. Studies with competitive and non-competitive inhibitors of 
AChE to determine the molecular domain of AChE involved have implicated the PAS 
in this interaction (De Ferrari et al., 2001). These in vitro AChE-amyloid complexes 
showed properties similar to those seen in AD plaques including resistance to low pH, 
lack of substrate inhibition and reduced sensitivity to AChE inhibitors. Treatment of 
neuronal and astrocyte cultures with amyloid beta peptide has been shown to increase 
AChE expression, and thus at senile plaques a pernicious cycle may occur of Ap- 
induced AChE expression and AChE-induced AP aggregation (Saez-Valero et al., 
2003). These in vitro studies were subsequently confirmed in vivo, when transgenic 
mice overexpressing AChE and APP were found to present more numerous and larger 
amyloid plaques than observed in mice expressing APP alone (Rees et al., 2003). 
Moreover, as previously mentioned, transgenic mice expressing twice as much AChE as 
normal show cognitive deficits reminiscent of AD (Beeri et al., 1995). Together these 
results suggest that increases in AChE may have a role in the neurodegeneration and 
cognitive deterioration observed in AD. 
Current therapeutic strategies for the treatment of AD aim mainly to alleviate cognitive 
deficit by maximising residual cholinergic transmission (increasing ACh levels). Work 
has mainly focused on inhibitors of AChE, which have produced limited symptomatic 
improvement for some patients. The only currently licensed drugs for the treatment of 
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AD are AChE inhibitors including Tacrine (Cognex), Galanthamine (Reminyl), 
Rivastigmine (Exelon) and E2020 (Aricept). In cortical slices, cholinesterase inhibitors 
have been shown to increase the secretion of non-amyloidogenic derivatives of APP 
(Mori et al., 1995). Thus AChE may have a modulatory effect on the metabolic 
pathways involved in APP processing. In the light of the emerging wider role of AChE, 
it is possible that AD drugs may act by positively modulating the morphogenic activity 
of AChE rather than simply increasing the availability of ACh or potentially their 
actions could be less effective due to their limiting the morphogenetic activity of AChE. 
1.7.10 AChE and tumorigenesis: 
There are several correlations between AChE and a variety of cancers. The human 
ACHE gene maps to the 7q22 chromosomal location, which is frequently subject to 
amplification, mutation or deletion in abnormal megakaryopoiesis and leukemia 
(Ehrlich et al., 1992). Indeed, a 20-100-fold amplification of both the AChE and BChE 
genes was observed in the peripheral blood cells of some leukemic patients (Lapidot- 
Lifson et al., 1989), while decreased levels of AChE activity have been found in some 
cases of chronic lymphoid leukemia (Bartha et al., 1982). In addition, changes in the 
structure and/or expression of the ACHE gene as well as the presence of AChE 
molecules with abnormal properties have been reported in brain and non-brain tumours 
(Zakut et al., 1988; Zakut et al., 1990; Zakut et al., 1992). Epidemiological studies have 
indicated correlations between exposure of farmers to AChE-inhibitory 
organophosphates and an increased risk of leukemia, while in vitro studies reveal that 
the AChE inhibitor eserine can induce carcinogenesis and potentiate the action of 
estrogen in the epithelium of rat mammary glands (Calaf et al., 2007) and exposure of 
rodents to the anti-cholinesterase pesticide malathion can induce breast turnours 
(Cabello, 2001 #29731. 
However,, changes in AChE levels appear to vary depending upon the cellular origin of 
the tumour, so that there is no clear general correlation between either increased or 
decreased levels of AChE and cancer. AChE activity increases in breast cancer (Ruiz- 
Espejo et al., 2003; Ruiz-Espejo et al., 2002), however it decreases in malignant lymph 
nodes and colon (Montenegro et al., 2006; Ruiz-Espejo et al., 2003). In lung turnours, 
AChE levels vary depending on the type of tumour, it has modified glycosylation and is 
reduced in squamous cell carcinomas and large cell carcinomas (Martinez- Moreno et al.. 
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2006). Aggressive astrocytomas show a splicing shift from the AChE-T to the AChE-R- 
mRNA, and transfection of AChE-R into glioblastorna increases proliferation (Perry et 
al., 2004). 
1.7.11 AChE and apoptosis: 
An intriguing paper in 2002 introduced the possibility that AChE could play a direct 
role in apoptosis (Zhang et al., 2002). Induction of apoptosis in a wide variety of cell 
types was shown to induce an increase in AChE specific activity (Zhang et al., 2002). In 
many cell types AChE was found to be in the cytoplasm at the initiation of apoptosis 
and then in the nucleus or apoptotic cell bodies upon commitment to cell death (Zhang 
et al., 2002). Pharmacological inhibitors of AChE, as well as antisense to AChE 
prevented cell death, implying that ACK enzyme activity was important (Zhang et al., 
2002). Later studies using SK-N-SH neuroblastorna cells revealed that upon apoptosis 
these cells show increased intranuclear ACK (Yang et al., 2002). This suggested that 
AChE could act as a marker and/or regulator of cell death. Suppression of AChE 
expression with small interfering RNA has been shown to protect colon 
adenocarcinorna cells from apoptosis and prevent formation of the apoptosome, a 
critical component in the apoptotic pathway (Park et al., 2004). Based on these results, 
AChE has been suggested to play a critical role in fon-nation of the apoptosome and 
therefore apoptosis, though the exact mechanism mediating this action is unclear (Park 
et al., 2004). Such a role for AChE would be intriguing given its localisation in senile 
plaques in AD, where if such a role is valid, AChE could drive apoptosis. Indeed 
application of AChE itself has been found to be able to reduce the survival of the 
neuronal cell line Neuro2A and glial B12 cells (Calderon et al., 1998). More recent 
studies however have contested the requirement of AChE in apoptosis since the ability 
of AChE inhibitors to prevent cell death appears variable (Huang et al., 2005). 
Therefore, the contribution of AChE and in particular its catalytic activity to cellular 
apoptosis remains unresolved and this is further discussed in the introduction to Chapter 
5. 
A peptide of the sequence AEFHRWSSYMVHWK derived from the C-terminus of 
AChF-T, with structure and sequence homology to the AP region of Amyloid precursor 
protein has recently been described by Susan Greenfield's group In Oxford and has been 
suggested to be the salient region of AChE involved in some of the non-cholinergic 
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actions of AChE (Day and Greenfield, 2003). This group has demonstrated that this 
AChE peptide has both neurotrophic and neurotoxic effects on neuronal cultures 
depending on the peptide concentration and length of treatment (Day and Greenfield, 
2003). Low concentrations of the AChE peptide appear to induce neuronal damage via a 
predominately apoptotic mechanism involving 0 nicotinic AChR activation and 
suggested attempted re-entry into the cell cycle, while high peptide concentration induce 
cell death via a necrotic pathway (Day and Greenfield, 2003). However, the existence of 
this peptide as an independent entity in vivo has not been proven and therefore its 
potential contribution to cellular morphoregulation remains speculative. 
Altogether, AChE is a fascinating molecule and has enthralled researchers for close to a 
century. As one of the most efficient enzymes known it serves a vital role in controlling 
neurotransmission, a role currently highlighted by the ongoing fears of chemical 
warfare, the components of which are AChE inhibitors. Since AChE already has such 
an established and vital function, one could question why it should serve any additional 
roles. However, evidence accumulated over the past two decades, a selection of which 
was presented in the preceding pages has implicated it in many fundamental cellular 
processes including neuronal outgrowth and pathfinding, cellular apoptosis, 
haematopoiesis and stress responses. While the involvement of AChE in these processes 
is intriguing, the mechanism underlying some of these effects, particularly those 
involving neurite outgrowth and apoptosis are unclear. Indeed, there are significant 
areas of controversy in the literature as to whether these actions are specific and in the 
relative contribution of the enzymatic activity and different protein domains. 
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1.8 Aims of this study 
AChE is widely expressed both in the nervous system and beyond, where evidence 
suggests it may be involved in neurite outgrowth, cell adhesion, apoptosis, survival and 
proliferation, in some cases acting independently from its enzymatic activity. However, 
though many intriguing results have been published, in many cases the mechanism by 
which AChE mediate its effects is unclear. Therefore, the aim of this thesis was to 
examine whether AChE could have a morphoregulatory function in both neuronal cells, 
where previous evidence favours such a role, and in non-neuronal cells, where a role for 
AChE has only recently begun to emerge. In order to achieve this, the first approach 
used was to characterise the expression levels, activity and localisation of AChE within 
a panel of neuronal and non-neuronal cells. Once information regarding possible 
functions for AChE had been obtained from its localisation, the actions of a spectrum of 
AChE ligands acting at both the active and/or PAS, and AChE itself was then 
systematically analysed in several paradigms including neurite outgrowth from different 
regions of the rodent brain and fibroblast migration. Lastly, the involvement of AChE in 
cellular apoptosis and survival was tested, all with an aim of gaining insights into the 
potential morphoregulatory function of AChE in the nervous system and beyond. 
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2 Materials and Methods 
2.1 Reagents 
2.1.1 Cell culture reagents 
Dulbecco's Modified Eagles Medium (DMEM), Fetal Calf Serum (FCS). IX trypsin- 
EDTA, 1: 1 DMEM/F 12 basal media, B27 supplement and Lipofectamine were obtained 
from Invitrogen-Gibco Life Technologies (Paisley, UK). FuGENE 6 transfection 
reagent was purchased from Roche (Welwyn Garden City, UK). CellTiter 96 AQ,, eo,, s 
One Solution Cell Proliferation Assay reagent and TUNEL detection kit were purchased 
from Promega (Southampton, UK). Laminin (Engelbreth-Ho Im- Swarm Sarcoma laminin- 
1), Collagen IV, Fibronectin and Poly-L-lysine, and JNK inhibitor SP600125 was 
purchased from Sigma Aldrich (Poole, UK). All AChE inhibitors (Fasciculin, BW284c5 1, 
Edrophonium chloride, Tacrine), and pure eel AChE were purchased from Sigma. K-blue 
was purchased from Neogen (Ayr, Scotland, UK). 
2.1.2 Antibodies 
Monoclonal AChE antibody Clone 46 was purchased from BD Biosciences (Oxford 
Science Park, UK), monoclonal AChE antibody MAB304, monoclonal APP antibody 
22CII and polyclonal GAP43 antibody were purchased from Chemicon (Hampshire 
UK). Polyclonal AChE antibodies H-134 and E-19, polyclonal PARP antibody H-250 
and secondary anti-goat-HRP antibody were purchased from Santa Cruz biotechnology 
(Wembley UK). 01-integrin monoclonal A11132 antibody was obtained from the 
Developmental Studies Hybridoma Bank, NICHD, University of Iowa. a-dystroglycan IIH6 
IgM monoclonal was a kind gift of Prof Kevin Campbell, Howard Hughes Medical 
Institute. Perlecan R63 polyclonal was a kind gift of Prof John Couchman, Imperial College 
London. NCAM16 (N16) monoclonal antibody was purchased from BD Biosciences. 
Monoclonal APP 6E10 antibody was purchased from Signet (Dedham, MA, USA) and 
polyclonal APP antibody was purchased from LabVision (Newmarket, UK). Monoclonal 
vinculin antibody Clone hVINC-1, monoclonal IgM vimentin antibody LN-6 and TRITC 
phalloidin were purchased from Sigma-Aldrich. Tubulin rat monoclonal antibody ab6161 
was purchased from Abcarn (Cambridge, UK). GFAP monoclonal antibody Clone I was 
purchased from Oncogene (Buckinghamshire, UK). HRP-conjugated anti-rabbit and anti- 
mouse secondary antibodies were from Biorad (Hertfordshire, UK), Secondary anti-mouse 
IgG/IgM and anti-rabbit IgG Alexa Fluor 488 & 595 and anti-rat Alexa Fluor 568 were 
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from Molecular Probes (Paisley, UK), FITC-conjugated anti-goat secondary antibody was 
from DAKO (Cambridgeshire, UK). Concentrations of IgG in antibody preparations used 
in functional assays were determined/confirmed on coomassie gels, or by BCA protein 
assay using purified IgG as a standard. 
2.2 Cell culture: 
2.2.1 Routine cell culture of fibroblasts and neuronal cell lines: 
N1H3T3 fibroblasts were obtained from American Type culture collection (Rockville, MD). 
Primary human fibroblasts were derived from elbow biopsy samples, kind gift of Dr Susan 
Brown,, PC12 cells were a kind gift from Dr Graham Wilkins and the N132a 
neuroblastoma cell line was a kind gift Dr Yuri Ushkaryov, all at Imperial College 
London. NIH 3T3 fibroblasts, human fibroblasts, PC12s and N132as were routinely 
cultured on 10cm. tissue culture plates (Appleton Woods, Birmingham, UK) in DMEM 
containing 10% FCS at 37C in a humidified incubator, atmosphere 92.0% air, 8%CO2- 
Tissue culture dishes used for PC12 cell culture were additionally coated with Poly-L- 
lysine (PLL) at a concentration of 16.6 ýtgml-' and then washed once with sterile water 
to allow adherence. All cells were subcultured when 70-80% confluent. Culture medium 
was removed by aspiration, cells washed once with DMEM and detached from the 
culture dish at 37'C for 10mins in the presence of 0.25% trypsin (Invitrogen Life 
Technologies). Trypsin activity was neutralised by an equal volume of 
10%FCS/DMEM and a single cells suspension achieved by repeated trituration. The 
suspension was then transferred to a 30ml Universal tube and pelleted in a centriftige at 
20OOrpm for 5mins for fibroblasts and 2800rpm for 10mins for PC12 and NB2a cells. 
Pellets were resuspended in an appropriate volume and an appropriate proportion of this 
replated in DMEM/10% FCS on 10cm plates for routine cell culture. NB2a cells were 
induced to differentiate by serum deprivation in unsupplemented DMEM. PC12 were 
differentiated by culture with nerve growth factor (NGF) at 100 ngml-1 in DMEMT12 
supplemented with 1: 50 dilution of B27 supplement. For use in experiments, a single 
cell suspension was ensured by passing the cells through a 19 gauge needle (BD 
Microlance) and the cell number determined using a haemocytometer (VWR). 
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2.2.2 Freezing and thawing cells 
Cells were frozen for long term storage by trypsinising as described above, and 
resuspension in cell culture medium. The cells were then centrifuged at 20OOrpm for 5 
minutes, and resuspended in DMEM/10%FCS/10% DMSO in Iml aliquots in cryovials 
(VWR). The cells were then gradually cooled to -700C over 12 hours, and subsequently 
stored at -1 80'C in liquid N2- 
Cells were thawed from storage rapidly by incubation in a 37C incubator for 2-3 
minutes. 9ml of cell culture media was then added slowly, dropwise to the cells, the cell 
suspension pelleted by centrifugation as described in 2.2.1, resuspended in growth 
media and grown in aI Ocm 2 culture dish. After allowing time for cell adhesion (16-24 
hours), the culture media was replaced with fresh media to remove final traces of 
DMSO. Upon reaching 70-80% confluency, the cells were passaged and maintained as 
described above. 
2.2.3 Establishment of astrocyte cultures: 
Primary astrocytes were isolated from the cortex of postnatal day 4 (PND4) Sprague 
Dawley rat pups. Rats were sacrificed by cervical dislocation, and cortices rapidly 
removed into Hanks' balanced salt solution (HBSS), the meninges and blood vessels 
were removed by rolling on ethanol sterilised filter paper. The cortices were coarsely 
chopped using two parallel razor blades and enzymatically dissociated with 0.25% 
trypsin-EDTA for 20 minutes at 37C in a shaking incubator. These cultures were 
allowed to grow for 8 days and then subjected to 24hours of vigorous shaking at 
250rpm in order to de-adhere oligodendrocytes and any remaining neurons in the 
culture. The purity of the astrocytes was confirmed using immunostaining to detect 
expression of the characteristic astrocytic marker Glial fibrillary acidic protein (GFAP). 
Astrocyte precursors of the CNS initially express vimentin as the major intermediate 
filament, with maturation being followed by a switch to GFAP expression, which is 
recognized as an astrocyte maturation marker. Astrocytes isolated in this manner were 
greater than 95% pure using the expression of GFAP as a criterion. The average 
percentage of GFAP expressing cells from 5 separate isolations and representative 
images of the astrocytic morphology of cultures immunocytochernically stained for 
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GFAP is illustrated overleaf in Figure 2.1. The rare GFAP negative cells are likely to be 
contaminating meningeal or endothelial cells. 
Table 2.1: 
Isolation 
Number 
Total 
Number of 
Cells 
counted 
Number of 
GFAP 
positive cells 
Percentage 
of GFAP 
positive cells 
1 250 250 100.0% 
2 250 239 95.6% 
3 250 234 93.6% 
4 250 237 94.8% 
5 258 247 95.7% 
Figure 2.1 Preparation of cortical astrocytic cultures. 
(A-C) Representative images of GFAP positive cells. Cells were plated after isolation and 48hrs 
post-plating, fixed in 4% paraformaldehyde, permeabilised using 0.2% Triton X- 100 and GFAP 
visualised using mouse monoclonal anti-GFAP antibody (1: 5000) and secondary antibody anti- 
mouse Alexa Fluor A488 (1: 8000). Table 2.1 shows the percentage of GFAP expressing cells 
obtained from 5 separate isolations. As can be seen on average 95% or more cells within the 
isolated population were GFAP positive. Scale bar 20ýtrn. 
2.2.4 Isolation of cerebellar, hippocampal and cortical neurones 
PND4-5 Sprague Dawley rats were sacrificed by cervical dislocation, and the 
cerebellum removed. Cerebellar meninges were detached and discarded, the cerebellum 
ically dissociated with 0.25% Trypsin-EDTA for separated with tweezers and enzymati III 
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20 minutes at 37'C. To isolate hippocampal and cortical neurones, time-mated Sprague- 
Dawley rats at gestational day 18-9 were sacrificed by cervical dislocation and embryos 
removed into HBSS. Embryos were sacrificed by decapitation, and the entire brain 
removed. Cortices were isolated, separated, meninges removed and the hippocampus 
isolated with tweezers and trimmed. Cortices and hippocampi were then put into 
separate dishes of 0.25% Trypsin-EDTA, pulled apart with tweezers and enzymatically 
dissociated for 20 minutes at 37'C. In all cases trypsin was neutralized with addition of 
an equal volume of 1: 1 DMEMM2 media supplemented with a 1: 50 dilution of B27 
supplement. Neurons were spun at 2800rpm for 10mins and resuspended and diluted to 
required density in 1: 1 DMEM/1`12 media supplemented with 1: 50 dilution of B27 
supplement. 
2.3 Cellular assays: 
2.3.1 Generation of 3T3 fibroblasts expressing AChE-T: 
3T3 fibroblasts were plated at a density of 2x 105 cells per I Ocm plate. 24hrs later I ýig 
AChE-T/pcDNA3 (further described in section 2.7.12) or pcDNA3 was combined with 
30gl Lipofectamine Reagent in DMEM at room temperature (RT) for 45mins. The 3T3 
fibroblasts were washed with DMEM, then 3mls of the DNA/Lipofectamine 
transfection mixture was incubated with the fibroblasts for Mrs at 37'C and 8%CO2- 
The transfection mixture was removed and replaced with 10%FCS/DMEM containing 
Geneticin/G418 Sulphate (G418) (Invitrogen-Gibco Life Technologies) to select for 
fibroblasts stably expressing the transgene product. AChE-T expressing clones were 
selected using 2 or 3 mgml-1 G-418. A control transfection was performed where 
DMEM was used instead of DNA. Medium was changed as necessary to remove dead 
cells, and after 4 weeks G-418 resistant clones were picked. Clones were identified on 
the plate, outlined with a marker pen, growth medium removed and a cloning ring 
placed over them. 100ýtl trypsin was added to the cloning ring for 10mins, then the 
trypsin solution containing fibroblasts was gently removed with a pipette, placed on a 
24-well plate (VWR) in Iml 10%FCS/DMEM containing 2-3 mgml-1 G-418 and 
incubated at 37 T and 8%CO2until cultures reached a density at which they could be 
passaged. 
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2.3.2 Transfection of 3T3 fibroblasts, NB2a neuroblastoma and primary 
human fibroblasts with RNAi constructs for suppression of AChE 
3T3 fibroblasts and NB2a neuroblastornas were transfected with RNAi constructs 
(further described in section 2.7-13) with sequences targeted to mouse AChE using the 
calcium phosphate precipitation method. 2x 104 3T3 fibroblasts or NB2a cells were 
plated onto 13mm coverslips in 24 well plates. 24hrs post-plating the cells were 
transfected with the mouse RNAi construct using the Calcium phosphate transfection 
method. X2 HEPES buffer saline (280mM NaCl, I OmMKCI, 1.5mM Na2HP04,, l2mM 
glucose, 50mM HEPES pH7), sterile distilled water and 2M calcium chloride solution 
were pre-warmed to 37C. 400[d containing 20ýtg plasmid DNA, 200mM calcium 
chloride and sterile distilled water was prepared per well. This DNA/calcium chloride 
mixture was added drop-wise to an equal volume of X2 HEPES buffer saline and mixed 
by gentle swirling before incubation at RT for 15 minutes. This mixture was then added 
drop-wise to the cells and the cells incubated overnight. 24hrs post-transfection, the 
media was removed by aspiration and replaced with fresh DMEM/10% FCS and the 
cells cultured until required. 
Lipofectamine and Calcium Phosphate transfection methods were not capable of 
transfecting primary human fibroblasts, therefore transfection was carried out using the 
FuGENE 6 transfection reagent according to the manufacturer's protocol. Preliminary 
experiments were carried out to determine the optimal ratio of DNA to FuGENE 6 
reagent to produce the highest transfection efficiency using ratios of FuGENE 6 reagent 
to DNA of 3: 1, and 6: 1. The number of transfected cells were determined and counted 
using a fluorescence microscope and compared between the different conditions. A ratio 
of 3: 1 was found to give the highest transfection efficiency and was therefore used for 
the RNAi construct transfection, though the percentage of transfected cells was still less 
than 5%. Primary human fibroblasts were set up at 2x 104 cells per well of a 12 well 
plate on 19mm. coverslips and prior to transfection media was replaced with lml fresh 
DMEM/10%FCS. Transfection was carried out by adding 1.5ýd FuGENE reagent to 
50ýtl DMEM, this was mixed by tapping, then 0.5ýtg of the DNA construct added and 
incubated for 30mins before being added dropwise to each well of the 12 well plate. 
77 
Chapter 2: Materials and Methods 
For all three cell types, the cells were examined for AChE knockdown at 24,48 and 
72hrs post-transfection. In order to do this,, cultures were fixed in 4% 
paraformaldehdyde for 10mins at RT, permeabilised with 0.2% Triton X-100 for 
10mins at RT and blocked in 5% BSA/PBS. Intracellular AChE expression was then 
detected using the monoclonal antibody Clone 46 at 1: 200 dilution and the goat anti- 
mouse Alexa Fluor A555- 
2.3.3 Proliferation assay for 3T3 and AChE-T expressing fibroblasts: 
Proliferation was assessed using the CeIlTiter 96 AQ,,,,,,,, One Solution Cell 
Proliferation Assay (Promega), a colorimetric method for determining the number of 
viable cells. 2x 103 fibroblasts were plated per well of a 96-well plate (Triple Red 
Laboratory Technology) in 10%FCS/DMEM. On the day after plating (Day 0) and on 
days 1-5 post-plating 20ýil Cell Titer 96 AQ,,,,,,,, One Solution Reagent (Promega) which 
contains a novel soluble tetrazolium compound [3-(4,5-dimethyl-2-yl)-5-(3- 
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, in salt (MTS)] and an 
electron coupling reagent [phenazine ethosulphate (PES)] was added to the appropriate 
wells for 3hrs. The optical density at 490rum (OD490nn0was then obtained after using a 
media only control as a blank, using a Molecular Devices Spectramax 340P plate- 
reader. MTS is bioreduced by NADPH or NADH, produced by dehydrogenase enzymes 
in metabolically active cells, into a coloured formazan product (Promega). This reading 
gives an index of relative cell number if respiration is assumed to be equal in each well. 
2.3.4 Proliferation assay of 3T3 fibroblasts: 
1.4xl 04 3T3 fibroblasts were plated per well of a 96-well plate in 0.5%FCS/DMEM. 
The following day the appropriate concentration of AChE inhibitor/ligand was added to 
the wells in DMEM in a volume of 59[d. Two hours later 20ýtl CeIlTiter 960 AQUEOUS 
One Solution Reagent (MTS) (Promega) was added to a quadruplicate of appropriate 
wells for 3 hours, the OD490nn, reading taken on a Molecular Devices Spectramax 340P 
plate-reader. This reading constituted the day 0 reading taken against a no cell, growth 
medium only blank. On day 3 MTS was added to the remaining wells and the OD490nm 
reading taken against a, growth medium only blank using a Molecular Devices 
Spectramax 340P plate-reader. 
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2.3.5 Survival assay of 3T3 fibroblasts: 
7x 103 3T3 fibroblasts were plated per well of a 96-well plate in 0.5%FCS/DMEM. The 
following day the medium was removed by aspiration and replaced by the appropriate 
concentration of AChE inhibitor/ligand diluted in DMEM in a volume of 100ý11. Two 
hours later 20ýtl CeIlTiter 960 AQUEOUS One Solution Reagent (MTS) (Promega) was 
added to a quadruplicate of appropriate wells for 3 hours, the OD490""' reading taken on 
a Molecular Devices Spectramax 340P plate-reader. On day 3 MTS was added to the 
remaining wells the OD490nmreading taken as previously. 
2.3.6 Nocodazole treatment of 3T3 fibroblasts 
Fibroblasts were plated at a density of 2x 104 cells per well of 24-well plates. After 
48hrs in culture nocodazole (Sigma Aldrich) was added to the growth medium; 
fibroblasts were incubated in the presence of 0.2ýtM nocodazole at 37 'C with 8.0%CO2 
for 15mins before being fixed and labelled for surface AChE or APP and then 
intracellular tubulin as described below in section 2.3.7. These conditions were 
optimized to achieve almost complete removal of all microtubules from most wildtype 
fibroblasts. 
2.3.7 Fixed immunocytochemistiry 
Immunocytochernistry was perfonned after the cells had been plated for 48hrs in order 
to obtain their normal morphology unless otherwise stated. IX 104 cells or 2x 1 04 cells 
were plated in 8-well chamber slides (VWR) or on 13mm 1.5 thickness coverslips 
(VWR) in 24well plates (VWR). 
For surface labelling, cells were briefly fixed in 4% paraformaldehyde for 7mins at RT, 
non-specific binding was blocked with 5% BSA/PBS, and cells incubated with 
appropriate primary and secondary antibodies as indicated in table 2.2. For subsequent 
intracellular staining, cells were then permeabilised in 0.2% triton X-100 for 10mins 
and then blocked again in 5% BSA/PBS. Between each step cells were washed three 
times for 5 minutes each in phosphate buffered saline (PBS). Cells labelled with 
2+ 2+ 
TRITC-phalloidin were fixed in 3.7% fonnaldehyde in PBS containing Mg and Ca 
Slides were mounted in mowoil containing DABCO and 4,6-diamidino-2-pheylindole 
(DAPI) at I mgml-l- 
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Table 2.2 Primary antibody names, dilutions and secondary antibody 
combinations used for fixed immunocytochemistry: 
Secondary Antibody 
Primary Antibody name Primary Antibody Dilution 
Dilution 
AChE 
Anti-rabbit IgG Alexa 
1: 75 
H-134 Fluor 
A555 
488 (1: 8000) 
AChE 
Anti-mouse IgG Alexa 
1: 200 
Clone 46 Fluor 
A556/488 (1: 8000) 
AChE 
Anti-goat IgG FITC 
1: 100 
E-19 (1: 100) 
ACK 
Anti-mouse IgG Alexa 
1: 200 
Fluor A556/488 (1: 8000) MAB304 
ccDG Anti-mouse IgM Alexa 
1: 200 
Fluor A488 (1: 8000) 
IIH6 
Perlecan 
Anti-rabbit IgG Alexa 
1: 200 
Fluor A556/488 (1: 8000) 
R63 
NCAM 
Anti-mouse IgG Alexa 
1: 10,000 
Fluor A556 (1: 8000) 
N16 
PI-integrin Anti-rat IgG Alexa Fluor A568 
1: 200 
(1: 3000) 
A11132 
APP Anti-mouse IgG Alexa 
1: 100 
Fluor A556/488 (1: 8000) 
6EIO 
APP Anti-mouse IgG Alexa 
1: 800 
Fluor A556 ý488 (1: 8000) 22C II 
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Secondary Antibody 
Primary Antibody name Primary Antibody Dilution Dilution 
APP 
Anti-rabbit IgG Alexa 
1: 100 
Fluor A556 488 (1: 8000) 
pAPP 
Tubulin 
Anti-mouse IgG Alexa 
Gift Dr D. Mann 1: 50 
Fluor A556/488 (1: 8000) 
Tubulin 
Anti-rat IgG Alexa 
1: 1000 
Ab6l6l Fluor 
A556 (1: 2000) 
TRITC-Phalloidin 1: 5000 N/A 
Vimentin 
Anti-mouse IgG Alexa 
1: 5000 
Fluor A488 (1: 8000) 
LN-6 
Anti-mouse IgG Alexa 
Vinculin 1: 400 
Fluor A488 (1: 8000) 
Anti-mouse IgG 
GFAP 1: 2000 
Alexa Fluor A488 (1: 8000) 
2.3.8 Live immunocytochernistry and coclustering: 
Several antibodies were shown to be capable of binding to their antigens on unfixed 
cultures. Surface AChE can be detected by the monoclonal antibody MAB304 and 
polyclonal E- 19, cell surface NCAM can be detected by the monoclonal antibody N 16 
and alpha dystroglycan ((xDG) can be detected by the monoclonal antibody IIH6 on live 
cell cultures. 
For live immunocytochemistry, wildtype 3T3 fibroblasts or those transfected with the 
140kDa form of NCAM (designated the N24 cell line) were plated at Ix 104 cells on 
l3mm coverslips per well of 24 well plate and left for 48hrs as for fixed 
immunocytochemistry. Cultures were washed twice 'n DMEM and ACK or NCAM 
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detected by sequential incubation with primary and then secondary antibody at 4 'C for 
lhr, with 3 washes after each step. AChE was detected by MAB304 (1: 200) and then 
anti-mouse IgG Alexa Fluor A488 (1: 8000). AChE was detected by E-19 (1: 100) and 
then anti-goat IgG FITC conjugate (1: 100). NCAM was detected by N16 (1: 5000) and 
then anti-mouse IgG Alexa Fluor A488(1: 8000). All antibody dilutions and washes were 
carried out in 2%BSA/DMEM/2OmM Hepes Cultures were then fixed in 4% 
paraformaldehyde for 7mins, permeabilised in 0.2% Triton X-100 for 10mins, blocked 
in 5% BSA for lhr and processed for (x-tubulin immunocytochemistry as described 
previously. 
For co-clustering studies wildtype 3T3 fibroblasts or N24 cells were plated at 2x 104 
cells on 13mm coverslips per well of 24 well plate and left for 48hrs. AChE, NCAM 
and aDG were clustered by sequential incubation with primary antibody; AChE 
detected by MAB304 (1: 200), NCAM detected by N16 (1: 5000) or COG detected by 
IIH6 (1: 200) for lhr at 37'C, all antibodies diluted in 2%BSA/DMEM/2OmM Hepes. 
Secondary antibodies were then also applied for lhr at 37'C in 2%BSA/DMEM/2OmM 
Hepes, MAB304 was detected with anti-mouse IgG Alexa Fluor A488 (1: 8000) and IIH6 
was detected with anti-mouse IgM Alexa Fluor A488 (1: 8000), before fixing. Cultures 
were washed three times in DMEM/Hepes between each step. Cultures clustered with 
MAB304 were then processed for Perlecan (R63), APP (pAPP) or tubulin 
immunocytochemistry. Cultures clustered with 11146 were processed for AChE (H-134) 
immunocytochemistry, and N16 clustered cultures were processes for (X-tubulin as 
described in section 2.3.7. 
2.3.9 Treatment of 3T3 fibroblasts with laminin, collagen IV and 
fibronectin 
For localisation studies following treatment with ECM components laminin, collagen 
IV and fibronectin, wildtype 3T3 and primary human fibroblasts were plated at 2x 104 
cells on 13mm coverslips in a 24 well plate. 24hrs post-plating media was removed and 
replaced with media containing Laminin at 50ýtgml-', Fibronectin at 50ýigml-' or 
Collagen IV at I OýM for a further 24hrs. Cells were then fixed in 4% paraformaldehyde 
for 7mins and processed for AChE. ocDG or Pl-integrin immunofluorescence as 
described in section 2.3.7. 
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2.3.10 Induction of apoptosis by serum starvation or staurosporine 
3 T3 fibroblasts, astrocytes, PC 12 cells and NB2a neuroblastorna were set up at a density 
of 5x 105 cells per well of 35mm dishes. 24hr hours post-plating cells were placed into 
either 1% heat inactivated FCS/DMEM, DMEM for serum starvation or treated with 
staurosporine in 1% heat inactivated FCS for designated times. Fibroblasts and 
astrocytes were treated with IýtM staurosporine, while PC12s, NB2a neuroblastomas 
were treated with lOOnM. For studies investigating the role of JNK in apoptosis, 3T3 
fibroblasts were co-treated with I ýtM staurosporine and 20gM JNK inhibitor SP600125 
for 24hrs. Media was then removed, cells washed once in DMEM and cells lysed in 
enzyme lysis buffer for Ellman enzyme assay or SDS sample buffer western blotting as 
described in section 2.6. 
2.3.11 Detection of apoptosis by TUNEL: 
3T3 fibroblasts were set up at 2x 104 cells per well of 24 well plate on 13mm coverslips 
in 10%FCS/DMEM. 24hrs post-plating cell, media was removed and replaced with 
either fresh 10%FCS/DMEM or serum free media for a further 24hrs. Control and 24hr 
serum deprived cultures were then fixed in methanol-free formaldehdye for 10mins, 
permeabilised, blocked and processed for intracellular AChE immunocytochernistry 
with monoclonal Clone as described previously. After washing in PBS, 50ýd terminal 
deoxynucleotidel transferase-mediated-dUTP nick end labelling (TUNEL) reaction 
mixture (Promega) was added and incubated for 60 min at 37'C in the dark. Cells were 
then washed in water and mounted. 
2.3.12 Detection of AChE levels in apoptosing cells by ELISA 
The change in AChE levels upon serum deprivation or staurosporine treatment of 3T3 
fibroblasts was quantified using a colorimetric ELISA. 3T3 cells were set up at 2x1 04 
cells per well of a 96-well plate in 10%FCS/DMEM. Twenty four hours later the media 
was removed and cells were either treated with I ýM Staurosporine or put into DMEM 
in order to induce apoptosis. To measure the levels of ACK, the treatments were 
carried out in triplicate and were fixed after 72hrs serum starvation or 24hrs exposure to 
staurosporine. Cells were fixed for 7minutes with 4% paraformaldehyde. In order to 
detect total AChE levels, sister cultures were fixed and then permeabilised with 0.2% 
Triton X-100 before cells were blocked with 5% BSA for Ihr. ACK levels were 
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detected with the anti-AChE polyclonal antibody H-134 (1: 500) for lhr at RT. To 
control for cell loss during apoptosis sister treated cultures were fixed, permeabilised 
and tubulin content detected with anti-tubulin antibody ab6161 for lhr at RT. After 
vigorous washing with PBS, plates were incubation with corresponding HRP- 
conjugated secondary antibody (GE Healthcare) both at 1: 3000 for 45 minutes. The 
HRI? substrate K-blue (Neogen) was then added to produce a colour reaction. The 
optical density (OD) at 650 rim was measured at 25 'C on a VersaMax microplate reader 
with Softmax Pro V. 3.0 software. After subtraction of the background reading, the 
AChE-mediated OD change was normalized against tubulin content to account for cell 
loss. 
2.3.13 In vitro wounding Assay 
Wildtype 3T3 fibroblasts and astrocytes were set up at 1.6 x 105 cells per 13mm coverslip in 
24 well tissue culture dishes. Primary fibroblasts and AChE-T transfected 3T3 fibroblasts 
were plated at a density of IX 105 per 13mm glass coverslip. 24hrs post-plating, 
subconfluent monolayers of 3T3 fibroblasts, primary fibroblasts or astrocytes were scraped 
with a blunted 21G needle. For immunocytochemistry cells were fixed and labelled 6hrs 
post-wounding. For quantitative measurements the wound width was measured 
immediately and at regular intervals up to 24h post-wounding to find the rate of reduction 
of wound size, each width being the mean of 40 measurements taken along the entire 
wound length, as illustrated on the left in Figure 2.2. Where used, antibodies (20ýtgml-') or 
AChE inhibitors were added immediately after wounding. 
*-- -- 2.2 Schematic diagram illustrating 
quantitation of wound closure. 
+- -> 
Cell 
Migratior, AO 
*- -- 301. 
-+---* 
+-+ 
Inverted microscope phase bright images 
were electronically captured using a 
Zeiss Axiovert 200M inverted 
microscope with a XIO eye piece and 
XIO objective lens and an Axiocam 
camera with Axiovision 3 and KS300 
Zeiss software. Immediately post- 
wounding and at desired time points, 40 
measurements were carried out along the 
wound length. 
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2.3.14 Cell adhesion measurements 
3x 104 wildtype 3T3 cells were plated in 10%FCS/DMEM on 35mm tissue culture dishes. 
24hrs post plating, media was removed, antibodies were diluted to required concentration in 
2% BSA/DMEM/HEPES and added for 18hrs before the single-cell adhesion was measured 
as previously described (Mycielska et al., 2006) using a single cell adhesion measurement 
apparatus. The "detachment negative pressure" (applied to single cells through the tip of a 
50 ýtrn diameter pipette) required for detachment was recorded on line and is expressed as 
DNPR/cell and used as an index of adhesion. In each independent experiments, the 
DNPRJcell of 100-200 cells were measured 
2.3.15 Neurite outgrowth assays 
Eight-chamber tissue culture slides or 13mm coverslips were placed in 24-well tissue 
culture dishes were coated with PLL, at a final concentration of 16.6 ýtgml-' in water. 
PND4 rat cerebellar neurons, E18-19 rat hippocampal neurons or E18-19 rat cortical 
neurons isolated as described earlier were added in F12/DMEM basal media 
supplemented with 1: 50 dilution of B27 supplement. 5x 103 neurones were added to the 
prepared slides/coverslips. Cultures were incubated for 16hrs to allow the neurones to 
adhere and then media was gently removed using a Gilson PION and replaced with 
F12/DMEM basal media supplemented with 1: 50 dilution of B27 supplement in the 
presence or absence of AChE, AChE ligands or controls. After 48hrs incubation, the 
neuronal cultures were fixed in 4% paraformaldehyde for 10mins at RT, permeabilised 
with 100% ice cold methanol for 10mins at RT and non-specific binding blocked with 
10% FCS/PBS for lhr. Neurones were then and labelled with PBS containing rabbit 
anti-GAP43 antibody used at a dilution of 1: 2000, then PBS containing goat anti-rabbit 
Alexa Fluor A555 (Molecular Probes) diluted 1: 8000. 
2.3.16 Establishment of fibroblast and neuron co-cultures for neurite 
outgrowth assays. 
13mm coverslips were placed in 24-well tissue culture dishes. These were coated 
sequentially with PLL followed by fibronectin. PLL was diluted to a final concentration 
of 16.6 ýigrnl-' in water and added to the coverslips in their dishes for 30mins at RT 
after which it was aspirated off and washed once with sterile water. Fibronectin was 
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diluted to a final concentration of lOmMY' in DMEM and added to the coverslips for a 
minimum of two hours at 37'C in 8%CO2 before being removed by aspiration. 
Wildtype 3T3 fibroblasts or those expressing AChE-T, APP695 or 140kDa NCAM were 
then added to the prepared coverslips. Iml of a2 X105 cells/mI suspension of control 
wildtype 3T3 fibroblasts or 140-kDa NCAM expressing fibroblasts (Doherty et al., 
1990) and Iml of a 1.6 x 105 cell/ml suspension of AChE-T, and APP695 expressing 3T3 
fibroblasts were added per well in DMEM/10% FCS and the 24-well tissue culture 
dishes were incubated overnight at 370C and 8%CO2 to allow the establishment of 
confluent monolayers. Approximately 24hrs post-plating, the medium was gently 
removed by aspiration and either PND4 rat cerebellar neurons or E18-19 rat 
hippocampal neurons isolated as described earlier, were added in F12/DMEM basal 
media supplemented with 1: 50 dilution of B27 supplement at a density of 5x 10 3 
neurons per well. Co-cultures were incubated for 16hrs to allow the neurons to extend 
neurites. The cultures were then fixed and labelled for GAP-43 as above in section 
2.3.15 
2.4 Image analysis: 
Inverted microscope fluorescent images were electronically captured using a Zeiss 
Axiovert 200M inverted microscope with a XIO eye piece and X40 or X63 objective 
lens and an Axiocam camera with Axiovision 3 and KS300 Zeiss software. Confocal 
images were captured and processed using a laser scanning module (LSM510, Zeiss) 
mounted on an upright Zeiss Axioplan 2 microscope with a XIO eye piece and a MOO 
ob . ective lens. 9 
2.4.1 Image analysis for measurement of neurite lengths: 
Mounted cultures were scanned systematically over the whole slide with X 10 eye piece 
and X40 ob ective, and the length of the longest neurite protruding from each cell body j 
was measured in random fields following electronic capture of images for 150-200 
neurites in each condition. Only the longest neurite per neuron was quantitated as 
illustrated below (Figure 2.3). Where there was no visible neurite, a measurement of 
less than I ýim was recorded. 
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Figure 2.3 Schematic diagram illustrating 
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quantitation of neurite length. Inverted microscope 
fluorescent images were electronically captured using a 
Zeiss Axiovert 200M inverted microscope with a XIO 
eye piece and XIO objective lens. The longest neurite of 
each neuron (shown in grey) per field of view was 
measured using an Axiocam, camera with Axiovision 3 
and KS300 Zeiss software. 
2.4.2 Image analysis for measurement of cell area: 
Mounted cultures were systematically scanned and the area of every cell in a random 
field was measured until 100 cells had been counted. 
2.4.3 TIRF microscopy 
Total internal reflection fluorescence microscopy imaging used Zeiss Axiovert 200 
microscope modified for objective-type TIRF microscopy (Till Photonics). TRITC 
fluorescence was excited by argon laser 514nm or 488nm line focused in the back focal 
plane of a 1200x phase contrast Zeiss Plan- Apochromat objective (1.4NA). The evanescent 
wave was produced by shifting the laser beam from the centre of objective lens to increase 
the angle of reflection, which decreases the penetration depth of the evanescent wave. The 
penetration depth was set to approximately 100 nm from the glass surface. The images were 
recorded with a PCO SensiCam D camera using custom acquisition program for Image J 
(NIH). Image acquisition was carried out in collaboration with Dr Dmitriy Ushakov and 
Professor Michael Ferenzi. 
2.5 Enzymatic analysis 
2.5.1 Ellman assays 
A modified version of the Ellman assay was carried out in microtitre 96-well plates. 
Cells were scraped Into lys's buffer and syringed vigorously with a 25G needle to obtain 
a homogeneous solution. Protein concentrations were then determined using the BCA 
assay (Pierce) and lysates diluted to required concentrations. I OPI of diluted lysates was 
then added per well. 200ýtl 0.39mM 5,5-dithiobis(2-nitrobenzoic acid) [DTNB] in 
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sodium phosphate buffer pH 7.4 was then added to the lysates and left to incubate for 
10mins (final concentration in the well is 0.3mM). Finally 50111 5.2mM 
Acetylthiocholine (ATCh) was added to the DTNB/lysates (final concentration in "'vell 
is ImM). Changes in absorbance were measured at OD 412 nm at 25'C on a VersaMax 
microplate reader with Softmax Pro V. 3.0 software. Readings were taken at Imin. 
5mins 20mins, 40mins and 60mins to allow maximum changes in absorbance for 
samples versus blanks. Data is shown as difference in OD after 60mins. 
2.5.2 Roots and Karnovsky cytochernical staining 
Cells were set up as for immunocytochemistry. Cells were then washed in PBS and 
fixed for 5 min in 1.5 % paraformaldehyde in PBS. After fixation, cells were rinsed in 
PBS and incubated for 6hrs at 37'C in staining solution [0.67 mM acetylthiocholine, 5 
mM sodium citrate, 3 mM cupric sulfate, 0.5 mM postassium ferricyanide in IOOmM 
sodium phosphate buffer (pH 6.0)] and mounted as previously. 
2.6 Protein analysis 
2.6.1 Protein extraction and concentration determination 
Cells were harvested with a cell scraper in either enzyme lysis buffer or in Sodium 
Dodecyl Sulphate (SDS)-containing lysis buffer (I OOmM Tris-HCI pH6.8 4% w/v SDS, 
20% w/v glycerol), boiled at 100'C for 5 mins, sonicated, vortexed and either used 
immediately or stored at -20'C until required. Protein concentrations between 1-2000 
ugml-l were assayed by reaction with bicinchoninic acid using the Micro BCA Protein 
Assay Reagent Kit (Pierce), according to the manufacturer's instructions. Standard 
curves were produced using Microsoft excel. 
2.6.2 Deglycosylation of N-linked glycans 
Cells were lysed in 0.5% SDS, 0.04M DTT and boiled for 5minutes before addition of 
NP-40 at a concentration of 1%. 1 unit (U) of peptide-N-glycosidase-F (PNGase) 
(Upstate) was added to lysate containing 20ýig protein and incubated for 2hr at 370C. A 
control incubation was also carried out where 50mM sodium phosphate buffer pH 7.5 
was added in place of enzymes. The proteins were then separated by western blotting as 
detailed overleaf 
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2.6.3 Subcellular fractionation 
To obtain 3T3 membrane fractions cells were lysed in hypotonic buffer (Tris/HCL ImM 
pH7.4, EDTA Im-M) for 1hr at 40C with periodic resuspension. of the lysate- Large 
debris was pelleted by centrifuging at 1000 g for 10 min and the supernatant centrifuged at 
47,000 g for 30 min at 40C to pellet membranes. After washing, membranes were 
centrifuged at 100,000 g for 30 min at 4'C, and solubilised with I% Titon X- 100 for Ih at 
4'C before pelleting insoluble material by centrifugation at 100,000 g for 30 min at 40C. 
Triton X-100 solublised proteins were resolved by non-reducing PAGE. 
2.6.4 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The protein samples in SDS lysis buffer were resolved on 7.5%, 10% or 12% SDS- 
PAGE gels using Biorad Mini-PROTEAN 3 Electrophoresis equipment. Pre-stained 
SDS-PAGE protein standards were loaded in a separate lane to determine protein 
molecular weights. SDS-PAGE gels consisted of resolving gels of 5cm height and 
stacking gels of 2cm height, both with a thickness of 1.5mm. Samples were run through 
the stacking gel at 50 volts and through the resolving gels at 100-150 volts in IX SDS 
running buffer (25mM Tris-HCI pH8.3,192mM glycine, 0.1% SDS). When the dye 
front had reached the end of the gel, the gel was removed for western blotting. 
2.6.5 Electrotransfer: 
The resolved proteins were electrotransferred from the gel to a 0.45[tm nitrocellulose 
membrane (Schleicher and Scholl) using Mini Trans-Blot cell equipment (Biorad). The 
gel and nitrocellulose membrane, whatman paper and sponges were soaked for 10mins 
in transfer buffer (25mM Tris-HCI pH8.3,192mM glycine, 20% methanol). The gel and 
nitrocellulose were then sandwiched between two sheet of whatman paper and sponges, 
placed in the tank and transferred in transfer buffer either for 90mins at I 00volts at RT 
or for 16hrs at 15 volts at 4'C. 
2.6.6 Western blotting 
The nitrocellulose membrane was incubated in 5% milk [PBS either overnight at 4'C or 
for I hr at RT to block non-specific binding sites. The membrane was then washed with 
PBS/0.1% Tween before incubating with the appropriate primary and secondary 
antibodies (Table 2-3) at RT each for lh and washed three times with 
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PBS/O. I`/`TWEEN each for 15 minutes after each antibody incubation. 
Immunoreactivity was visualised using Enhanced Chemiluminescence (ECL TM )reagent 
(GE Healthcare) according to the manufacturer's instructions for HRP-conjugated 
secondary antibodies with exposure to X-ray film (GE Healthcare) and development or 
use of a Fuji Image Analyser LS3000. Densitometric analysis was performed on Fuji 'i 
image analyser obtained images using the program Scion Image. 
Blocking condition and Primary Secondary Antibody Primary Antibody name 
Antibody Dilution Dilution 
AChE BI ocked for I hr at RT Anti-mouse HRP 1: 3000 in 
0.1 %TWEEN Clone 46 1: 2500 1% milk/O. I%TWEEN 
Blocked overnight at VC AChE 
Anti-rabbit HRP 1: 5000 in 
1: 500 in 1% 0.1 %TWEEN H-134 
milk/ I %BSA/0. I %TWEEN 
PARP Blocked overnight at 40C Anti-rabbit HRP 1: 5000 in 
0.1 %TWEEN 
H-250 1: 200 in 1% milk/0.1%TWEEN 
PrP Blocked overnight at 40C Anti-mouse HRP 1: 3000 in 
0.1 %TWEEN 
SAF84 1: 1000 in 0.1 %TWEEN 
Blocked for I hr at RT Anti-mouse HRP 1: 3000 in 
Tubulin 
0.1 %TWEEN 
1: 15 00 in 0.1 %TWEEN 
1 I 
Table 2.3 Primary and secondary antibody dilutions used for western blotting. 
2.6.7 Coomasie gels 
After SDS-PAGE separation, gels were stained for 1-2hrs with Coomassie brilliant blue 
R-250 (0.025g of Coomassie in dH20,10% methanol and 10% acetic acid) washed for 
I hr with destain (10% methanol, 10% acetic acid in 
dH20) then washed with dH20- 
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2.7 Molecular biology methods: 
2.7.1 Agarose gel electrophoresis 
Agarose gels of 0.7 to 2% were made by adding the appropriate amount of agarose to 
50ml of IXTBE buffer and heating until all the agarose had dissolved- This was cooled 
slightly before 5[d of 1000x ethidium bromide (5mg/ml) was added. The gel was cast 
in a horizontal gel electrophoresis tank (Horizon TM , Invitrogen) and immersed in 
IXTBE also containing 5pg/ml ethidium bromide. Loading buffer (Bioline, London) 
was added to the samples and these were then loaded into the wells. The gels were 
electrophoresed at I OV/cm for 30 min to an hour. 
2.7.2 Alkaline lysis plasmid miniprep 
Five ml of LB medium was inoculated with a single bacterial colony from the 
transformed plates and left at 37C for 12-16h. One ml of these cells were microfuged 
for 10minutes at 12,000 rpm, the supernatant was removed and the pellet resuspended in 
100ýtl of TE buffer containing 10ýtg/ml RNase A. This was placed at room temperature 
for 5min. 200[d of NaOH/SDS (0.2M NaOH, I %SDS) solution was added, mixed and 
left on ice for 5 min. Next, 150ýtl of 3M potassium acetate pH5.5 solution was added, 
vortexed for 2secs and left on ice for 5 min. The sample was then microfuged for 
10mins at 13,000 rpm and the supernatant was transferred to a clean eppendorf tube. 
An equal volume of phenol chloroform (1: 1) was added, vortexed and microfuged for 
10mins at 13,000 rpm. The top layer was transferred to a clean eppendorf This was 
mixed with 0.9ml of 100% ethanol,, left at room temperature for 2 min to precipitate the 
DNA and microfuged for Imin at 13,000 rpm. The DNA pellet was washed with 70% 
ethanol, dried and resuspended in 20ýtl of ultrapure water. Alternatively, the Qiagen 
Plasmid Mini-Prep kit was used according to manufacturer's instructions. 
2.7.3 Large scale plasmid purification 
Large scale plasmid purification was performed with the Qiagen Plasmid Maxi-Prep kit, 
according to manufacturer's instructions. 
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2.7.4 Preparation of electrocompetent E. coli 
A 5ml culture of bacteria was grown up in 2TY media overnight with appropriate 
antibiotics at 37'C. One ml of this culture was added to 100mls of 2TY media and 
grown until the cells were growing in the exponential phase (A600 reached 0-6). 
Subsequent steps were performed at 4'C. The cells were centrifuged at 1700g and the 
pellet resuspended in 100ml ice-cold dH20. The cells were centrifuged again at 1700g 
for 10 minutes and the pellets resuspended in 20ml ice-cold dH20. The cells were 
centrifuged again at 1700g for 10 minutes and the pellets resuspended in 5ml ice-cold 
dH20 with 10% glycerol v/v. These were aliquoted into chilled 1.5ml eppendorfs in 
volumes of 200ýil per tube, left on ice for I Omin then snap-frozen in dry-ice. Cell were 
then stored at -80'C. 
2.7.5 Electroporation of E. coli 
Electrocompetent cells (100[tl) were placed in a chilled electroporation cuvette (Bio- 
Rad) with aI mrn electrode gap. DNA in dH20was added, and the cuvette shocked in a 
GenePulser electroporator (Bio-Rad) at 25pF, 200 Ohms, and at 2.5kV. After shocking, 
Iml of warm 2TY media was added, and cells incubated at 37'C for one hour to 
recover. The cells were then centrifuged at 160OOg for 2 min, and the pellet resuspended 
in I OOpI 2TY. Cells were then spread onto LB agar plates with appropriate antibiotics 
an incubated overnight at 37'C. 
2.7.6 Purification of PCR products 
After PCR, and in some cases subsequent restriction digestion, the DNA products were 
purified using the QlAquick Gel Extraction Kit (Qiagen), according to the 
manufacturer's instructions. 
2.7.7 Restriction digests 
Digests were set up with the appropriate volumes of I Ox reaction buffer (New England 
Biolabs) DNA sample, ultrapure water and restriction enzyme (New England Biolabs) 
to give at least I unit enzyme/ýtg of DNA sample. These were mixed together and 
incubated at 370C for 2-4h. 
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2.7.8 Elution of DNA from electrophoresis gels 
DNA was eluted from electrophoresis gels using the QlAquick Gel Extraction kit 
(Qiagen) following the protocols provided by the manufacturer 
2.7.9 Ligations 
Ligation reactions were set up in a volume of 10-20[tl. These typically contained a 1: 3 
molar ratio of vector to insert, 1-2[tl of I OX ligation buffer and I pl (I unit) of T4 DNA 
ligase (Roche). Control ligations were also set up with no insert present. Reactions 
typically contained 10-100ng of DNA. Reaction mixes were left to ligate at room 
temperature for 15 min. In some cases PCR products were ligated directly into the 
pBluescript (Promega) without prior restriction digestion. 
2.7.10 DNA sequencing 
DNA samples and primers were sent to the Advanced Biotechnology Centre, Imperial 
College London, for analysis. The resulting chromatograms were analysed using 
Chromas software (C. McCarthy, Griffith University, Australia) and the Translate tool 
at www. expasy. org. 
2.7.11 Production of AChE-T construct: 
Z 7.11.1 PCR to obtain A ChE- T DNA for pEF-BOSIA ChE- T 
The rat coding sequence of the AChE-T splice variant was kindly provided by Professor 
Massoulie in the expression vector pEF-BOS. This expression vector does not contain 
any mammalian selection, therefore in order to produce fibroblasts stably expressing 
AChE-T, the full length coding sequence of Rattus norvegicus AChE-T was subcloned 
into a linear pCDNA3 with BamHI and XbaI ends. In order to obtain AChE-T with ends 
complementary to BamH1 and XbaI, a three step procedure was carried out. Firstly, 
primers were designed to introduce a Bg1H site at the front of AChE to allow ligation 
into the complementary BamHI site of pcDNA3. In order to reduce the probability of 
errors being introduced into sequence, only 357bp was amplified by PCR using Taq 
polymerase, terminating with a primer to amplify an endogenous KpNI site. This 
fragment was then cloned into pBluescript, from which it was subsequently excised 
with BgIII and KpNI. The remainder of the AChE-T sequence was excised from pEF- 
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BOS using KpNI and A'bal. These two fragments were then ligated together into 
pcDNA3 in a three-way ligation. This sequence of steps is illustrated in Figure 2-4: 
PCR to introduce N- 
terminal Bglll site 
L k\ \,,,, Bgffl 
Ligation of PCR product 
bhh, 
into pBluescript 
Bg111 
pBluescript 
KpNI 
BamHl KPNI 
pCDNA3 
Xbal Xbal 
+ 
I 
Bg111 
4 %Vi W; 
Figure 2.4 Schematic diagram of steps involved in cloning AChE-T from pEF-BOS into 
pCDN3. A 5' BgIII site was introduced into AChE-T by PCR. This PCR fragment was cloned 
into pBluscript before release with BgIII and KpNI. The remainder of AChE-T was released 
from pEF-BOS by digestion with KpNI and XhaI. The two AChE-T fragments were then ligated 
into the BaniHI and XbaI sites of pCDNA3. 
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The pEF-BOS/AChE-T vector was subject to Taq polymerase PCR with an N-terminal 
BgI H primer (5'AGATCTATGAGGCCTCCCTGGTATCCCCTGC 3') and a C- 
terminal KpNI primer (5' GTTCCACATCTCGGTACCCTCAA-ACCCAGG 3'). This 
resulted in a PCR product of 357bp, containing the N-terminal segment of AChE-T as 
shown below: 
ý. oe t1 
lkb 
500bp 
300bp -357bp 
Figure 2.5 PCR production of N-terminal 
region of AChE with BgIII and KpNI 
compatible termini 
Following PCR reaction with BgIII and 
KpNI primers with Taq polymerase a 
product of 357bp was produced, and 
separated on a 1% TBE gel. 100bp marker 
and product sizes are shown on the left hand 
side. 
Since the DNA had been subjected to PCR with Taq polymerase, the PCR fragment had 
deoxyadenosine (A)-overhangs at the 3' ends of the amplified fragments, so that they 
could be ligated into a pBluescript vector which has 3' deoxythymidine (T) overhangs 
at its insertion site. Electrocompetent DH5a cells were transformed with the ligated 
pBluescript/AChE-T fragment and spread on LBA plates to undergo selection. Colonies 
were picked and colony PCR carried using the above Bg1 H and KpNI primers in order 
to establish whether the colonies expressed the pBluescript/AChE-T fragment. Colonies 
producing a PCR fragment of the correct size (357bp) were grown overnight in LBA 
and mimpreps produced. The DNA was then subject to further diagnostic digestion and 
the presence of the AChE-T fragment confirmed by restriction digests with BgI H and 
KpNI enzymes. A large scale digestion of pBluescript/AChE-T with Bg1 H and KpNI 
enzymes was carried out and run on a 1% TBE gel. The required DNA was then 
excised, and purified using a Qiagen gel extraction kit. 
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In order to finish the construction of AChE-T. the remainder of the full coding region of 
AChE in pEF-BOS was digested with KpN1 and Xbal and run on a 0.8% TBE gel. This 
fragment (1757bp) was then excised and purified using a Qiagen gel extraction kit. 
according to the manufacturer's instructions. 
ýN 
x0-9 
x 
OC-11 VQ tPcý 
2.7.11.2 Ligation ofAChE-Tfragments into pcDNA3: 
Figure 2.6 Digestion of pEF- 
BOS AChE-T with KpNI and 
XbaI 
pEF-BOS AChE-T was 
cleaved with KpNI and Xbal, 
releasing a fragment of 
1757bp and separated on a 
0.8% TBE gel. I kb marker and 
product sizes are shown on the 
left hand side. 
Once the two fragments of the AChE-T coding sequence had been isolated and purified, 
these were ligated into a pcDNA3 vector in a three-way ligation. The pcDNA3 vector 
(kindly provided by Dr David Mann) was linearised with BamHI and XbaI. The sticky 
ended pcDNA3 vector was then ligated with the BgIII-KpNI and the KpNI-AbaI 
fragments. This ligation reaction was purified and then transformed into 
electrocompetent DH5alpha, spread on LBA plates, and colonies picked, grown in 
LBA, the DNA isolated by miniprep and the sequence and orientation of the fragments 
verified by sequencing with T7 and SP6 universal primers on the pcDNA3 vector. 
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2.7.12 Production of pSuper-Retro-GFP-AChE -1, -2 and -3 constructs: 
To downregulate endogenous ACHE mRNA transcripts in NIH 3T3 cells and primary 
human fibroblasts, the pSuper-Retro RNA interference (RNAi) system was employed. 
Three unique sequences with the lengths of 19 nucleotides (later referred to as RNAi 
sequences) from the coding region of AChE were chosen. Using the oligoengine design 
tool, two sequences were designed against the coding region of mouse AChE- To 
suppress AChE in primary human fibroblasts, a sequence previously shown to be 
capable of suppressing ACK in an human adenocarcinoma cell line (Park et al., 2004) 
was utilised. Based on these R. NAi target sequences three pairs of complementary 
oligonucleotides were commercially synthesised. The synthesised oligonucleotides are 
shown below with RNAi sequence highlighted in red: 
RNAi sequence 1 (mouse target): 
5'GATCCCCATGACCCTCGAGACTCCAATTCAAGAGAI'TGGAG'I'C'I'CGAGGG 
TCATTTTTTA 
3'GGGTACTGGGAGCTCTGAGGTTAAGTTCTCTAACCTCAGAGCTCCCAGTA 
AAAAATTCGA 
R-NAi sequence 2 (mouse target): 
5'GATCCCCATGAATCTCTCATCAGCCGTTCAAGAGACGGCTGATGAGAGAT 
TCATTTTTTA 
3'GGGTACTTAGAGAGTAGTCGGCAAGTTCTCTGCCGACTACTCTCTAAGTA 
AAAAATTCGA 
RNAi sequence 3 (human target): 
5'GATCCCCGAGTGTCTGCTACCAATATTTCAAGAGAATATTGGTAGC, -A, GAC 
ACTCTTTTTA 
3'GGGCTCACAGACGATGGTTATAAAGTTCTCTTATAACC, ATCGTC-I-(J]-(J., -\(j 
AAAAATTCGA 
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The oligonucleotides for RNA mediated interference were synthesised by Sigma 
Genosys. The oligonucleotides were diluted in distilled nuclease free water to a 
concentration of 3mg. ml-1. The annealing reaction was carried out in a 50PI reaction 
containing 2pg of each sense and anti-sense oligonucleotide in a buffer of 50mM Tris- 
HCI pH8.0, I OMM MgC12, I OOmM NaCl and I mM dithioerythritol (DTE). The mixture 
was incubated at 940c for 5 minutes and allowed to cool down to room temperature, over 
the course of approximately 1hr. 
Once the oligonucleotides were annealed, they were ligated into the Bg1 IIIHindIII sites 
of pSuper-Retro-GFP, yielding pSuper-Retro-GFP-AChE -1, -2, and -3. In order to 
decrease background resulting from the annealing of partially nicked parental vectors, 
the ligations were treated for lhour at 370C with Bg1H. This site is destroyed by the 
annealing of the synthesised oligonucleotides, while it still exists in any parental vectors 
which reanneal. The ligation reaction was then cleaned using a Qiagen Gel extraction 
column in order to increase the transformation efficiency. This ligation reaction was 
transformed into electrocompetent DH5cc, spread on LBA plates, colonies picked and 
minipreped. In order to determine whether the insert had ligated successfully into the 
vector, a diagnostic EcoRIIHindIff digestion was carried out. Cleavage of the parental 
vector without insert results in a stuffer fragment of II 00bp, whilst in successfully 
ligated constructs digestion produced a fragment of 28 1 bp (as illustrated in Figure 2.7). 
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Figure 2.7 Production of RNAi constructs with pSuperRetro Neo GFP 
(A) pSuperRetro Neo GFP was digested with HindIII and BglII. Synthesised and annealed 
oligonucleotides with complementary ends were ligated into the linearised vector. (B) 
Diagnostic digestion with HindII and EcoRL Parental vectors contain aII 00bp stuffer sequence 
which is not present in vectors with successfully ligated oligonucleotides, which produce a 
fragment of 28 1 bp. I kb ladder and product sizes are shown on the left. 
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3 Expression, activity and localisation of AChE in neuronal 
and non-neuronal cells 
3.1 Introduction: 
AChE has long fascinated biochemists, neuroscientists and cell biologists. As an 
extracellular enzyme located at central synapses and neuromuscular junctions, it is most 
widely known for its regulation of cholinergic neurotransmission. AChE is a 
particularly fast enzyme, operating close to the diffusion limit to terminate ACh 
synaptic signalling. However, over the last two decades AChE has been revealed to be 
more than an exceptional enzyme. Indeed, neurochemists are taught early in their 
studies that unlike the ACh synthesizing enzyme ChAT, AChE is not restricted to 
cholinergic neurons. A plethora of studies have implicated AChE in having a wider role, 
firstly in the nervous system in control of neurite outgrowth ( Layer et al., 1993; Karpel 
et al., 1996; Koenigsberger et al., 1997; Olivera et al., 2003b; Whyte and Greenfield, 
2003), stress responses, and neurodegeneration (Greenfield, 2005). Additionally, AChE 
is implicated in haematopoiesis, proliferation (Munoz et al., 1999), osteoblast adhesion 
(Genever et al., 1999; Inkson et al., 2004), cancer (Stephenson et al., 1996) and 
apoptosis (Zhang et al., 2002), 
A hallmark of AChE is its specific catalytic activity, and this is most commonly used to 
localise the protein above other methods of detection. The presence or absence of AChE 
in tissues or cells is therefore typically determined by a spectrophotometric method 
called the Ellman assay (Ellman et al., 1961) or by cytochemical methods, including 
those described by Roots and Karnovsky (Karnovsky and Roots, 1964) or Koelle 
(Koelle and Friedenwald, 1950). Tissues and cell lines that show negligible activity are 
generally considered negative for AChE protein expression, (Zhang et al., 2002), in 
particular since it is difficult to eliminate all trace residue from cell culture media which 
can contain high levels of both AChE (Saxena et al., 2003) and BChE (Weitnauer et al., 
1998). In light of this, recent studies using other methods of detection, namely 
immunocytochemistry and western blotting have revealed that AChE is expressed in 
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cell types that had not previously been considered (Deng et al.. 2006; Thullbery et al., 
2005). 
3.2 Aims of this study: 
Although there have been several investigations into the role of AChE in neurones, 
several central questions remain unanswered regarding the mechanisms underlying 
AChE's effects, in particular since it is not a transmembrane protein and thus has no 
cytosolic region from which to signal. In non-neuronal cells even less is known 
regarding the role of AChE. This chapter will focus on gaining an insight into the 
potential morphoregulatory function of AChE, by characterizing the expression levels, 
catalytic activity, and cellular localisation of AChE in a panel of primary and immortal 
cells, of both neuronal and non-neuronal derivations. These include primary neuronal 
cells from the cerebellum (used for western blotting, activity and immunocytochemistry 
assays), the hippocampus and the cortex (used for immunocytochemistry). Non- 
neuronal cells include primary human skin fibroblasts which are an accessible source of 
phenotypically and karyotypically normal human cells, NIH 3T3 cells (a standard cell 
line), and primary cortical astrocytes. 
3.3 AChE antibodies: 
In order to establish the expression levels and immunocytochemical localisation of 
AChE several antibodies were utilized. Four different commercially available antibodies 
were used to determine expression levels by western blotting and immunolocalisation. 
The first antibody is a polyclonal antibody H-134 (Santa Cruz) raised towards a large 
immunogen encompassing amino acids 481-614 at the C-terminus of the synaptic form 
of human AChE (AChE-T). Though this region encompasses the specific C-terminal 
extension the synaptic AChE-T isoform, it also includes the region between 481 and 
575 amino acids (human numbering including the N-terminal signal sequence at 
residues 1-3 1) that is common to all forms of AChE and therefore is predicted to 
recognize all the AChE isoforms (Grisaru et al., 1999b; Carvalho et al., 2005). The 
second antibody is a monoclonal antibody MAB304 (Chemicon) raised against full 
length human erythrocyte AChE, recognises all isoforms, does not inhibit enzymatic 
activity (Olivera et al.. 2003b) and has been previously found to have functional effects 
on both dorsal root ganglion and hippocampal neurons (Olivera et al., 2003b; Sharma 
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and Bigbee, 1998). The epitope of MAB304 is suggested to be the PAS of AChE 
(Olivera et al., 2003b). The third antibody was a monoclonal anti-human AChE 
monoclonal antibody; Clone 46 (BD Biosciences) also raised against a large 
immunogen that encompasses the last 198 amino acids, from amino acid 411-609 of the 
human AChE-T isoform. This antibody has been extensively used in recent years, both 
for localisation by immunofluorescence ( Meshorer et al., 2002; Inkson et al., 2004; 
Dong et al 2004; Thullbery et al., 2005) and for immunoblotting on a variety of cell 
types (Dong et al.. ) 2004; Inkson et al., 2004; Thullbery et al., 2005; Deng et al., 2006). 
As a monoclonal antibody directed to the C-terminal third of AChE-T, it is potentially 
an AChE-T specific probe, or may have its epitope in the common domain (similar to 
H-134). However, the manufacturers, BD biosciences were unable to confirm whether 
the epitope if the antibody is within C-tenninal extension specific for AChE-T and thus 
splice variant specific or not [personal communication between author and 
manufacturer]. The final antibody used in the panel was a polyclonal antibody 
recognising a peptide from the N-terminus of mouse AChE; E-19 (Santa Cruz). The 
respective immunogens of the antibodies are shown below in Figure 3.1. 
Clone 46 
1 
-- 614 
100 200 300 400 500 600 Nc 
AChE 
C-terminal splicing 
Figure 3.1 The regions of AChE recognised by the antibodies E-19, MAB304, H-134 and 
Clone 46. Schematic representation of AChE shows that the goat polyclonal E- 19 is directed to 
N-ten-ninal amino acids (of mouse AChE); the immunogen of MAB304 is erythrocyte ACK 
and therefore the entire common domain is shown, (the pale blue denotes the different C- 
terminus of erythrocyte AChE); the immunogen of mouse monoclonal antibody Clone 46 
encompasses amino acids 411-609 of human synaptic AChE-T; the immunogen of polyclonal 
antibody H-134 encompasses amino acids 481-614 of human synaptic AChE-T. The site of C- 
terminal splicing at amino acid 575 (human numbering) is highlighted, amino acids 1-575 are 
common to all AChE isoforms, amino acids after this site are only found in the AChE-T 
isoforrn. Numbering derived from swiss prot entry P22303 for the unprocessed AChE precursor 
including arnino acids 1-31 of the signal sequence. 
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3.4 Expression levels of AChE in primary, immortal, neuronal and 
non-neuronal cells: 
The relative level of AChE in the different cell types was first established by 
immunoblot. A comparison of the relative level of AChE in cultured cerebellar neurons, 
the neuronal PC12 cell line,, fibroblasts and astrocytes by equal protein loading on 
reducing PAGE using the monoclonal antibody Clone 46 revealed the principal species 
present in all cells is a 65kDa doublet corresponding to AChE monomers as illustrated 
in Figure 3.2 (The relative prominence of the upper and lower bands varies from blot to 
blot and the doublet is not often not resolved, as illustrated in later chapters). This major 
AChE band corresponds in size to the synaptic form of AChE. An additional less 
abundant, lower AChE band was observed specifically at approximately 50kDa in 
whole cell lysates of 3T3 cells, primary human fibroblasts and astrocytes grown under 
normal conditions. This lower band has also been observed in other non-neuronal cells 
examined for AChE expression, including osteoblasts and human umbilical endothelial 
cells (Inkson et al., 2004; Carvalho et al., 2005). This lower band could result from 
differences in glycosylation of the non-neuronal cell types or may reflect the expression 
of different splice variants. Indeed recently, Meshorer et al. reported the existence of the 
novel N-AChE protein(s) containing N-terminal extensions hypothesised to result in 
production of a transmembrane domain. Such N-terminally extended transcripts have 
been demonstrated in monocytes, granulocytes and lymphocytes (Meshorer et al., 
2004). 
75- 
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Figure 3.2 Neuronal and non-neuronal cells express equivalent levels of AChE protein. 
Representative western blots (7.5% reducing SDS-PAGE) showing AChE In equal 
concentrations of lysates of 3T3 fibroblasts (3T3), cerebellar granule neurons after 2 and 7 days 
in vitro (CGN2, CGN7), NGF-differentiated PC12 cells, primary fibroblasts (Fib), rat brain 
membrane (13M) and astrocytes (Astro). Tubulin is shown as a loading control. White arrow 
indicates 65 kDa doublet; black arrow indicates 50 k-Da species. Positions of molecular weight 
markers are shown on the left in kDa. 
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3.5 AChE catalytic activity in neuronal and non-neuronal cells. 
The Ellman assay is a sensitive assay capable of detecting small amounts of ACK 
activity. Ellman assays were designed to determine how much total ACh hydrolysis 
activity the neuronal and non-neuronal cells express. As can be seen in Figure 3.3, 
despite their equivalence in protein level, there is a large difference in catalytic activity 
between neuronal and non-neuronal cells. Primary cerebellar granule cellular lysates 
show significant levels of enzymatic activity, as does the neuronal PC12 cell line, when 
induced to differentiate into a more neuronal phenotype (by addition of nerve growth 
factor). In comparison, the non-neuronal cells including NIH 3T3, primary human 
fibroblasts and astrocytes show significantly less ChE activity; 3T3 cells, fibroblasts 
and astrocytes contain 12-, 4- and 5-fold less ChE activity respectively than neurons in 
the Ellman AChE assay (Figure 3.3). 
60 
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Figure 3.3 Relative levels of ChE activity in neuronal and non-neuronal cells. 
Ellman assay of ACh hydrolysis activity in cell lines and primary cells. Ellman assays were 
performed on crude protein lysates. ACh hydrolysis activity is expressed as relative AChE 
activity 60 min after substrate addition to primary fibroblast (Fib), 3T3 fibroblast (3T3), NGF- 
differentiated PC 12 cells, cerebellar granule neuron (CGN) and astrocyte lysates, containing 10 
pg protein. Individual samples were analyzed in triplicate or quadruplicate and results shown 
are average activity with standard error of the mean pooled from 3-5 separate experiments 
(except PC 12s where n=2). 
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3.6 Cytochemical Localisation of AChE: 
In order to confirm the results of the Ellman enzyme assay, AChE cytochemical staining 
using the method of Karnovsky and Roots (Karnovsky and Roots, 1964) was carried 
out. This method reveals AChE activity by the presence of dark brown precipitates 
resulting from AChE cleavage of acetylthiocholine. Reduction of ferricyanide by the 
sulphydryl group of thiocholine produces copper ferrocyanide, which forms brownish 
precipitates at the sites of enzyme activity. As can be seen in Figure 3.4, under normal 
circumstances, little AChE activity can be seen in 3T3s fibroblasts while clear regions 
of activity are seen in both naYve PC12 cell aggregates and CGNs, confirming the 
results of the Ellman assay. Not all CGNs are cytochemically positive, showing 
heterogeneity in the neuronal population. No staining for AChE was observed when 
BW284c5l,, a known specific AChE inhibitor was added to the incubation medium 
illustrating that the reaction product is specific. 
AChE Cytochernical Staining: 
Cerebellar Granule cells: 
3T3 fibroblasts: 
A 
+BW284c5l 
E 
+BW284c5l 
C 
Figure 3.4 AChE activity detected in 3T3 fibroblasts, PC12 cells and CGN by the method 
of Karnovsky and Roots. (A) In 3T3 fibroblasts no AChE cytochemical staining is observed. 
(139 D) ACK cytochemical staining is observed in cerebellar neuronal cultures and aggregates 
of na*fve PC I 2s. (C, E) ACK cytochemical staining is specific as treatment of the cultures with 
AChE specific inhibitor, BW284c5l at 50ýM prevents the ACK cytochemical reaction. Scale 
bar 20ýtm 
Control 
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Together the immunoblotting, Ellman assays and cytochernical staining results reveal 
that neuronal and non-neuronal cells express equivalent levels of AChE protein, yet 
non-equivalent levels of catalytically active AChE. Historically AChE detection has 
relied on catalytic activity (Ellman and Roots assays), which may explain why high 
levels of AChE in non-neuronal cell types are only recently being revealed. 
3.7 Glycosylation of AChE. 
Glycosylation is one of the most common post-translational modifications of proteins in 
eukaryotic cells. During glycosylation, carbohydrate groups are attached to the side 
chains of asparagine, serine or threonine, and this is important in the synthesis of many 
cell surface glycoproteins. Mammalian glycoproteins contain two major types of 
oligosaccharides (glycan); known as N- and 0- linked oligosaccharides. N-linked 
glycosylation occurs in the ER where large preformed mannose/oligosaccharide core 
structures containing 14 sugar residues; GlC3Man9GlcNAC2, (where Glc is glucose, Man 
is mannose and NAc is N-acetylglucosamine) are transferred from a lipid precursor to 
the asparagine residue of the protein by the enzyme oligosaccharyltransferase. The 
target asparagine is usually within part of the glycosylation sequence Asn-X-Ser/Thr, 
where X represents any amino acid other than proline (Kornfeld and Korrifeld, 1985). 
AChE has several potential N-glycosylated sites and previous work has revealed that 
this glycosylation is important in the biosynthesis, stability and secretion of AChE 
(Velan et al., 1993). Therefore, in order to gain an insight into whether differences in 
AChE activity and the lower AChE band notable in non-neuronal cells were related to 
AChE glycosylation, 3T3 fibroblast lysates were treated with N-glycosidase F in order 
to remove N-linked glycans. Band shifts for N-glycosylated prion protein were 
investigated as a positive control for N-glycosidase activity. Prion protein runs on SDS- 
PAGE as two halves, an N-terminal as well as a C-terminal half and the fall length. The 
C-terminus is glycosylated and therefore runs at the same molecular weight as the full 
length until it is deglycosylated, when it then runs at approximately 25kDa. Whilst the 
treatment did change the pattern of prion protein in 3T3 cellular lysates, unmasking the 
presence of a 25kDa band, it did not affect that of AChE (Figure 3.5). 
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Figure 3.5 Deglycosylation 
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3.8 Expression of multimeric complexes of AChE in 3T3 fibroblasts. 
In order to gain further information on the AChE forms present in 3T3 fibroblasts, non- 
reducing PAGE was carried out on cellular lysates (Figure 3.6). This revealed that 
several multimeric AChE complexes were present in 3T3 fibroblast homogenates. 
Immunoblotting with both the polyclonal antibody H- 134 and the monoclonal antibody 
Clone 46 both revealed higher molecular weight protein bands, running at the same 
positions, suggesting that these are likely to correspond to true AChE complexes rather 
than the being the result of non-specific interactions. This was further supported when 
the relative running positions of the immunopositive bands was compared to that of 
recombinant human AChE, and were shown to align with those of the pure protein. 
Recombinant AChE was used as a positive marker for the H- 134 antibody and yielded a 
heavy molecular weight form corresponding to tetramers at just over 250kDa (on 7.5% 
SDS-PAGE separation), the intermediate dimeric isoform. at approximately 130kDa and 
a broad light band with a MW close to the 65-and 70-kDa resulting from monomeric 
isoforms. Similar multimeric complexes have previously been seen in non-reducing 
PAGE of homogenates of human brain (Darreh-Shori et al., 2004) and mouse thymus 
(Nieto-Ceron et al., 2005). 
In 3T3 homogenates, the bands observed in the 3T3 fibroblast cellular lysates included a 
band at just above 250kDa and runs at the same relative position as tetramers of pure 
AChE, suggesting that these are also tetramers or may reflect heteromeric AChE 
complexes. Total 3T3 lysates probed with H-134 also detect a very faint, barely visible 
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band which runs at the same position as dimers of pure protein, though this was not seen 
with Clone 46, potentially due to its low abundance. Three bands were then detected 
between 75-5OkDa, one band at approximately 751cDa, one at approximately 65kDa and 
one at 50kDa, the 65kDa band comigrating with pure monomers of AChE. These three 
lower molecular weight bands may reflect different AChE splice variants, differences in 
post-translational modifications or differences in protein associations, such as the 
presence or absence of a membrane anchor like PRiMA. Indeed, the lower 50 kDa band 
has also been noted in brain and been suggested to correspond to soluble AChE-R 
monomers (Darreh-Shori et al., 2004). Subcellular fractionation to isolate the Triton X- 
100 soluble membrane fraction of the 3T3 lysates (Figure 3.6 lane 4) additionally 
revealed that the highest molecular weight complex, a potential AChE tetramer, is 
detectable in this fraction and thus associated with cellular membranes. 
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Figure 3.6 Expression of 
multimeric AChE complexes in 
non-reduced 3T3 homogenates. 
Representative western blots 
(7.5% non-reducing SDS-PAGE) 
probed for AChE in human 
recombinant AChE (rhuAChE) 
and total 3T3 lysates detected 
with polyclonal rabbit antibody 
H-134 (1: 500) and in total 3T3 
lysates and 3T3 triton soluble 
membrane fraction detected with 
monoclonal mouse antibody 
Clone 46 (1: 2500). Black arrows 
indicate running positions of pure 
ACK isoforms. Positions of 
molecular weight markers are 
shown on the left in kDa. 
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3.9 Localisation of AChE. 
Immunoblotting provided information regarding the levels of AChE expression, and 
activity in the cells under investigation, however in order to gain insight into the role of 
AChE in these cells, its localisation was determined. Since the AChE of fibroblasts and 
astrocytes showed only relatively low levels of enzymatic activity, the surface and 
intracellular distribution of endogenous ACK in these cells was observed by indirect 
immunofluorescence microscopy using the four AChE antibodies previously described. 
This section will particularly focus on the localisation of AChE in non-neuronal cells 
including NIH 3T3s, primary human fibroblasts and astrocytes as the distribution of 
AChE in neuronal cells has been characterized by several other groups, (Dong et al., 
2004; Olivera et al., 2003b). 
3.9.1 AChE in fibroblasts and astrocytes localises to discrete regions on the 
cell surface: 
For immunolocalisation in fixed cultures, cells were fixed briefly for 7mins in 4% 
paraformaldehyde for surface, or fixed and Triton X-100 permeabilised for intracellular 
labelling. On the surface of 3T3s, primary human fibroblasts and astrocytes, 
representative images in Figure 3.7 show that cell surface AChE is strikingly distributed 
in discrete patches or rings (especially noticeable on the surface of 3T3 fibroblasts), 
particularly, but not exclusively around the cell periphery, occasionally with drifts at the 
front edge of the cell (observed particularly in Figure 3.7C on the surface of human 
fibroblasts). On 3T3 fibroblasts, AChE staining is focused at the distal tips and 
processes as illustrated in Figure 3.7. 
Comparison of the surface AChE distribution detected by the four different antibodies 
was found to be very similar with all the different antibodies used, with the exception of 
E-19 which in addition to being distributed at the distal tips was also found to have a 
somewhat streaky distribution on the surface of some cells, particularly 3T3 fibroblasts 
(Figure 3.8). Due to the similarity of the distribution detected by H-134, Clone 46 and 
MAB304, the antibodies have been used interchangeably throughout the rest of this 
chapter, with the majority of labelling carried out using H-134 due to relative cost 
efficiency and availability. This surface AChE distribution is extremely unlikely to be a 
result of a serum contaminant or adherence of serum AChE to the cell membrane, since 
vigorous washing and maintaining the cultures for several hours or even days in a serum 
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free medium did not affect this pattern of immunofluorescence. Furthen-nore. this 
striking surface distribution is not the result of partial permeabilisation, since 
permeabilisation with Triton X-100 (Figure 3.9) or methanol (data not shown) and 
AChE detection with either polyclonal antibody H-134 or monoclonal antibody Clone 
46 reveals a different distribution, with the immunoreactivity predominately located in 
the perinuclear region, as demonstrated in previous studies (Genever et al., 1999; Jin et 
al., 2004; Thullbery et al., 2005). The monoclonal antibody Clone 46 gave particularly 
bright immunofluorescence of intracellular AChE, with relatively low levels of 
immunofluorescence on the cell surface compared to the other antibodies. 
3.9.2 AChE can be recognised on the surface of live 3T3 fibroblast cultures: 
In order to further characterise the distribution of AChE, the ability of the antibodies to 
bind to live cultures of 3T3 fibroblasts was determined. Both MAB304 and E-19 were 
found to be able to detect AChE on the surface of unfixed cultures of 3T3 fibroblasts, 
and MAB304 could also detect AChE on the surface of human fibroblasts. H-134 and 
Clone 46, both of which recognise the C-terminal third of AChE, did not appear to be 
able to bind to live 3T3 cultures, even though all the antibodies give a similar 
distribution on fixed cultures. This suggests that the C-terminal region of AChE may be 
less accessible, very mobile or interacting with other components on live cultures and 
thus only available for antibody binding upon paraformaldehyde fixation. The 
distribution of AChE on the surface of live fibroblasts was compared to that of Neural 
Cell Adhesion Molecule (NCAM) on the surface of 3T3 fibroblasts stably expressing 
the 140kDa isoform. of NCAM (Doherty et al., 1990). Comparable live staining of 
AChE and NCAM was carried out at 4'C in 2%BSA/DMEM in order eliminate any 
serum contaminant and is shown in Figure 3.10. NCAM is a homophilic binding 
glycoprotein expressed on the surface of neurones, glia and skeletal muscle and plays a 
role in cell-cell adhesion, neurite outgrowth, synaptic plasticity, and learning and 
memory (Doherty et al., 1990). In 3T3s engineered to express the 140kDa form of 
NCAM, the NCAM immunoreactivity visualised by N16 monoclonal antibody staining 
in these cells was distributed in a fine punctate pattern over the whole surface of the 
cells and is particularly evident at regions of cell-cell interactions. In comparison, 
neither MAB304 not E-19 showed focused AChE immunofluorescence at sites of cell- 
cell contact. Live staining of AChE with MAB304 or E-19 (at 4'C in order to prevent 
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any endocytosis or AChE redistribution) showed a slightly different distribution to that 
in fixed cultures with broader staining over the cell surface, but with the staining still 
focused at the cell periphery and along the edges of the 3T3 fibroblasts, while MAB304 
staining of the human fibroblasts was concentrated at the leading edge of the cell. The 
differences between the live and fixed staining patterns are likely to result from the 
difference in the availability of AChE under these two conditions. 
This contradicts the study of Thullbery et al, which suggested that AChE is expressed 
the surface of neuronal but not non-neuronal cells (Thullbery et al., 2005). However, the 
consistent surface immunofluorescent pattern of four antibodies recognising different 
epitopes, together with the AChE immunoreactive bands in the Triton X-100 soluble 
membrane fraction of 3T3 homogenates and ability of two antibodies to bind to "live" 
AChE suggests that an AChE form is present on the cell surface. Such differences may 
result from the reliance of the study by Thulberry et al on immunofluorescence detected 
by Clone 46, which as mentioned gives particularly bright intracellular staining, with 
only a low level of surface staining, raising the possibility that surface AChE may be 
masked by the bright intracellular staining on permeabilised cultures. 
3.9.3 Correlation of surface AChE with elements of the cellular 
cytoskeleton: 
The cytoplasm of eukaryotic cells is structured by a scaffolding of microfilaments (MF), 
microtubules (MT) and intermediate filaments (IF). MF and MT are constituted by actin 
and tubulin, respectively, in all types of cells, while IFs include vimentin in fibroblasts 
and GFAP in astrocytes. In order gain further information on the localisation of AChE 
in fibroblasts and astrocytes, its surface distribution in fixed cultures detected by H-134 
was examined in relation to these structural elements. Cells were briefly (7 minutes) 
fixed in 4% paraformaldehyde and stained for AChE before permeabilisation and 
detection of actin (fixed in formaldehyde), tubulin or vimentin/GFAP. Figure 3.11 a 
shows that there is no definite association between the surface AChE patches and the 
termination of the cytoskeletal elements, unlike the distribution of vinculin (Figure 
3.11 b) which is clearly located at the termination of actin stress fibres. Of the three 
cytoskeletal fibres. MTs appeared to have the closest relationship with AChE 
immunostained regions. 
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Distribution of AChE on the surface of fibroblasts and astrocytes 
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Figure 3.7 Surface AChE distribution on fibroblasts and astrocytes. 
(A-1) Detection of surface AChE on 3T3 fibroblasts, primary fibroblasts and astrocyte cultures 
fixed in 4% paraformaldehyde with rabbit polyclonal antibody H- 134 (1: 75) and secondary anti- 
rabbit Alexa Fluor A488 (1: 8000) (A-H) Cells were Triton X-100 permeabilised and counter- 
labelled for tubulin (A, D, G) with monoclonal anti-tubulin antibody (1: 50) (gift Dr Mann) and 
anti-mouse Alexa Fluor A488 (1: 8000) secondary antibody (A, G), or anti-mouse Alexa Fluor 
A555 (1: 8000) (D). (C) Permeabilised cells were labelled for vimentin with mouse monoclonal 
IgM LN-6 (1: 5000) and anti-mouse IgM Alexa Fluor A488 (1: 8000). (H) Triton X-100 
penneabilised cells were counter labelled with GFAP with mouse monoclonal clone I antibody 
(1: 2000) and secondary anti-mouse Alexa Fluor A488 (1: 8000). Scale Bar 20ýtm. 
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AChE Surface Labelling 
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I Figure 3.8 AChE surface distribution is similar in 3T3s, Human fibroblasts and Astrocytes using 4 different antibodies. 
(A-K) Detection of surface AChE on 3T3 fibroblasts, primary fibroblasts and astrocyte cultures 
fixed in 4% formaldehyde. (A, E, H) AChE detected with rabbit polyclonal antibody H-134 
(1: 75) and secondary anti-rabbit Alexa Fluor A488 (1: 8000). (B, F, 1) AChE detected with 
mouse monoclonal antibody MAB304 (1: 200) and secondary anti-mouse Alexa Fluor A488 
(1: 8000). (C, G, J) ACK detected by monoclonal antibody clone 46 (1: 100) and secondary 
anti-mouse Alexa Fluor A488 (1: 8000). (D, K) ACK detected with goat polyclonal antibody E- 
19 (1: 100) and secondary anti-goat FITC conjugate (1: 100). (A-K) After surface AChE 
detection, Cells were triton permeabilised and labelled for actin with TRITC-phalloidin 
(1: 5000). Scale Bar 20Vim. 
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Figure 3.9 AChE intracellular distribution is similar in 3T3s, human fibroblasts and 
Astrocytes using two different antibodies. 
(A-1) Detection of intracellular AChE on 3T3 fibroblasts, primary fibroblasts and astrocyte 
cultures fixed in 4% paraformaldehyde and permeabilised with Triton X-100. (A, C, E) AChE 
was detected with rabbit polyclonal antibody H-134 (1: 75) and secondary anti-rabbit Alexa 
Fluor A555 (1: 8000). (B, D, F) AChE detected by monoclonal antibody clone 46 (1: 100) and 
secondary anti-mouse Alexa Fluor A555 (1: 8000). Images captured using a confocal Zeiss 
Axioplan 2 microscope and X 100 objective. Scale Bar 20ýtm. 
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Figure 3.10 AChE can be detected on the surface of live, unfixed 3T3 cultures 
(A-B) AChE detected on the surface of unfixed 3T3 fibroblasts. (A) Mouse monoclonal antibody 
MAB304 (1: 200) was applied to 3T3 fibroblasts at VC for lhr followed by application of 
secondary anti-mouse Alexa Fluor A488 antibody (1: 8000). (B) E-19 (1: 100) was applied to 
fibroblasts at4'C for 1hr followed by application of its secondary anti-goat FITC conjugate (1: 100). 
(C) NCAM detected on the surface of unfixed 3T3 fibroblasts expressing a transgene for the 
NCAM 140kDa isoform. N16 antibody (1: 5000) was applied to fibroblasts at VC for I hr followed 
by application of its secondary anti-mouse Alexa Fluor A488 antibody (1: 8000). (D) MAB304 
(1: 200) was applied to human primary fibroblasts at VC for 1hr followed by application of its 
secondary anti-mouse Alexa Fluor A488 antibody, tracing shows cell outline (1: 8000). (E) 
Immunofluorescence upon application of anti-mouse Alexa Fluor A488 (1: 8000) at same exposure 
time and conditions. (F) Immunofluorescence seen upon application of DAKO anti-goat FITC 
conjugate (1: 100) at same exposure time and conditions. All cells were then fixed in 4% 
paraformaldehyde and mounted with mowoil. Scale Bar 20ýtm. 
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AChE distribution compared to cytoskeletal elements 
Figure 3.11a Surface AChE distribution in relation to the cellular cytoskeleton. 
Surface ACK staining using H-134 was compared to the cytoskeletal elements actin, MTs and 
intermediate filaments. (A-1) Detection of surface AChE on 3T3 fibroblasts, primary fibroblasts 
and astrocyte cultures fixed in 4% paraformaldehyde (or formaldehdye for actin costains) with 
rabbit polyclonal antibody H-134 (1: 75) and secondary anti-rabbit Alexa Fluor A488 (1: 8000) 
(A, D, G) or Alexa Fluor A555 (1: 8000) (B, C, E, F, H, 1). Cells were Triton X-100 
permeabilised and labelled for actin (A, D, G), with TRITC-phalloidin (1: 5000), counter- 
labelled for tubulin (13, E, H) with monoclonal anti-tubulin antibody (1: 50) (gift Dr Mann) and 
anti-mouse Alexa Fluor A488 (1: 8000) secondary antibody or (C, F) Triton X-100 
permeabilised and counter labelled with monoclonal IgM anti-vimentin antibody LN-6 (1: 5000) 
and secondary antibody anti-mouse IgM Alexa Fluor A488 (1: 8000) (1) Triton X-100 
permeabilised cells were counter labelled for GFAP with mouse monoclonal clone I antibody 
(1: 2000) and secondary anti-mouse Alexa Fluor A488 (1: 8000). (C, F, 1) show merged images. 
Images were captured using an upright Zeiss Axioplan 2 microscope with a X100 objective. 
Scale Bar 20ýtm- 
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Vinculin distribution compared to actin stress fibres 
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Figure 3.11 b Vinculin is located at the ends of actin stress fibres. 
Primary human fibroblasts were 4% formaldehyde fixed, Triton X-100 permeabilised and 
immunolabelled for vinculin (J) with the monoclonal antibody Clone hVINC-1 (1: 400) and 
secondary anti-mouse Alexa Fluor A488 (1: 8000). Fibroblasts were then labelled for actin with 
TRITC-phalloidin (K) (1: 5000). (L) Merged image of vinculin and actin. Scale Bar 20ýtm. 
3.9.4 AChE colocalisation with perlecan: 
The ability of the antibodies to bind to AChE on the cell surface raises the intriguing 
question of how it is positioned there. AChE is generally regarded to have no 
transmembrane domain and therefore is localised in the CNS and muscle by two 
anchoring units; the hydrophobic membrane anchor PRiMA which anchors ACK in the 
CNS and the collagen tailed CoIQ which anchors it at the NMJ. The localisation of 
AChE has been most studied in the NMJ, however until recently even the protein 
interactions important for AChE anchoring in this region were not known. In 1999, 
genetic analyses in mice and protein biochemistry revealed two potentially important 
players in the precise localisation of AChE in this region; perlecan and a-dystroglycan 
(aDG), an important component of the dystrophin complex (Peng et al., 1999; Steen and 
Froehner, 2003) (see section 1.4.3). 
Perlecan is a HSPG which is secreted but remains in close association with the cell 
surface and is an abundant component of most basement membranes (Iozzo et al., 1994; 
Iozzo and San Antonio, 2001). As a secreted HSPG, perlecan in the NMJ binds both 
AChE (via its CoIQ tail) and aDG (See Introduction section 1.4.3) and is required for 
the correct distribution of AChE at the NMJ as shown by perlecan knockout studies 
(Peng et al., 1999; Arikawa-Hirasawa et al., 2002). At the neuromuscular junction of 
perlecan deficient mice, skeletal muscle development occurs normally and the 
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expression level of AChE is unaffected. However, immunostaining for CoIQ and the 
catalytic subunit of AChE reveals their complete absence from the NMJ. Thus, proper 
localisation of AChE to the neuromuscular junction appears to require perlecan 
(Arikawa-Hirasawa et al., 2002). Furthermore, it has been shown that the dystroglycan- 
perlecan complex serves as a cell surface acceptor for asymmetric AChE in Xenopus 
myotubes, where it concentrates AChE at the synapse by lateral migration at the plane 
of the membrane (Peng et al., 1999). 
In order to gain an understanding of the localisation and potential interactions of AChE 
in fibroblasts and astrocytes, coirnmunostaining for AChE and perlecan was carried out. 
Perlecan is known to be expressed in 3T3s (Aviezer et al., 1997), human fibroblasts 
(Winkler et al., 2002) and astrocytes (Winkler et al., 2002) and this was also confirmed 
in this study (Figure 3.12), where surface perlecan distribution is shown with an actin 
costain to visualise cellular morphology. This revealed perlecan on the cell surface of 
fibroblasts and astrocytes, with discrete regions of staining and some patchy distribution 
particularly evident on the surface of 3T3 fibroblasts. Cultures were then costained for 
AChE and Perlecan. As can be seen in Figure 3.13 there does appear to be some 
colocalisation, particularly between AChE and perlecan in primary human fibroblasts 
and astrocytes. In 3T3s, the perlecan has a wider distribution, including some fibrous 
staining or streaky distribution that shows partial overlap with AChE. 
3.9.5 AChE shows no colocalisation with cc-dystroglycan: 
As mentioned, another component recently found to be involved in the correct 
distribution of AChE at the NMJ is aDG. DG is a central element of the dystrophin- 
associated protein complex, and is involved in the pathogenesis of brain and retinal 
dysfunctions associated with many forms of muscular dystrophy (Endo, 2005; Moore et 
al., 2002). ccDG is a receptor for several extracellular matrix (ECM) molecules, such 
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Perlecan expression on the surface of fibroblasts and astrocytes 
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Figure 3.12 Perlecan can be detected on the surface of 3T3 fibroblasts, primary human 
fibroblasts and cortical astrocytes. 
(A-1) Detection of surface perlecan and intracellular actin on 3T3 fibroblasts, primary fibroblasts 
and astrocyte cultures fixed in 3.7 % formaldehyde. (B, E, H) Perlecan was detected with rabbit 
polyclonal antibody R63 (1: 200) and anti-rabbit Alexa Fluor A488 (1: 8000) secondary antibody. 
(A, D, G) Actin was detected with TRITC-phalloidin (1: 5000) after Triton X-100 permeabilisation. 
(C, F, 1) Merged images of Perlecan and Actin from (A, D, G), and (B, E, H). Scale bar 20[tm. 
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AChE and perlecan distribution on the surface of fibroblasts and astrocytes 
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Figure 3.13 AChE shows partial colocalisation with perlecan in 3T3 fibroblasts, Primary 
Human fibroblasts and cortical astrocytes. 
(A-1) Detection of surface AChE and perlecan on 3T3 fibroblasts, primary fibroblasts and astrocyte 
cultures fixed in 4% paraformaldehyde. (A, D, G) AChE was detected with mouse monoclonal 
antibody MAB304 (1: 200) and anti-mouse Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, 
H) Perlecan was detected with polyclonal R63 (1: 200) primary antibody and anti-rabbit IgG Alexa 
Fluor A488 (1: 8000) secondary antibody. (C, F, 1) Merged images of AChE and Perlecan. Scale 
Bar 20ýLrn. 
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as laminin, and perlecan, and links the ECM to the actin cytoskeleton (Kanagawa et al., 
2005). At the NMJ, (xDG binding the transmembrane (xDG anchors perlecan via CoIQ 
to AChE at the post-synaptic membrane (Jacobson et al., 2001; Peng et al., 1999). In the 
absence of aDG, perlecan and AChE are normally expressed but do not correctly 
distribute and colocalise with AChRs, illustrating the requirement for the dystroglycan 
complex in correct AChE clustering (Peng et al., 1999). 
Since AChE is associated with aDG in the neuromuscular junction, its distribution 
relative to AChE in NIH 3T3. human fibroblasts and astrocytic cultures, in which it is 
expressed (Belkin and Smalheiser, 1996; Guadagno and Moukhles, 2004) was 
investigated by immunofluorescence. In all three cell types, most aDG 
immunoreactivity is distributed in a fine punctate pattern over the whole surface of the 
cell (Figure 3.14), similar to the pattern seen in Muller cells (Noel et al., 2005), although 
in primary fibroblasts the level of aDG surface expression appears to be lower than in 
3T3 fibroblasts and astrocytes. In comparison, as previously stated, the AChE 
immunoreactivity is localised in discrete regions, particularly at the distal processes of 
3T3s. These regions of AChE immunostaining are within the area where aDG is 
expressed, however there is little colocalisation between the two proteins, implying that 
aDG is not involved in AChE clustering in these cells. 
3.9.6 AChE on the surface of fibroblasts and astrocytes does not colocalise 
with focal contacts or PI-integrins. 
The distribution of AChE at discrete regions on the cell surface, together with evidence 
of AChE involvement in neurite outgrowth and osteoblast adhesion suggests that it 
could play a role in cell-substratwn interactions in fibroblasts and astrocytes. In order to 
further elucidate the role of AChE in 3T3s and human fibroblasts, its distribution was 
compared to that of proteins known to be involved in cell adhesion. One well 
characterized family of molecules involved in cell adhesion is the integrins. These 
molecules act as heterodimeric cell adhesion receptors that mediate attachment of cells 
to the ECK and in signal transduction from the ECM to the cell to regulate the cell- 
matrix interactions required for cell proliferation, differentiation, and migration 
(Boudreau and Jones, 1999; Moissoglu and Schwartz, 2006). Integrin cell surface 
receptors attach to the underlying substrate by focal contacts and link there to the actin 
cytoskeleton. A large number of specific proteins are known to be concentrated at focal 
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contacts, particularly structural and cytoskeletal proteins including vinculin (Ziegler et 
al., 2006). Using vinculin as a marker of focal contacts and co-immunolabelling with 
surface AChE revealed that although there is some marginal overlap between the two 
proteins, in general the AChE patches on 3T3s, human fibroblasts and astrocytes are 
larger, less numerous and differently distributed than vinculin foci (Figure 3.15A-C). 
The localisation of surface AChE in relation to 01 integrins detected by the functional 
PI integrin antibody AIIB2 (Bohnsack et al., 1990) was examined in human fibroblasts. 
As can be seen in Figure 3.15D, there does not appear to be significant colocalisation 
between AChE and the foci of 01 integrins labelling in these cells, suggesting that these 
two proteins are unlikely to interact in these static cultures. 
3.9.7 AChE codistributes with amyloid precursor protein in fibroblasts and 
astrocytes: 
Amyloid precursor protein (APP) is a transmembrane glycoprotein with a large N- 
terminal extracellular domain, a transmembrane region and a short cytoplasmic tail 
(Kabadere et al., 2001). Several isoforms of APP containing 695 (APP695), 751 
(APP751), and 770 (APP770) amino acid residues can be generated by the alternative 
splicing of a single gene (Weidemann et al., 1989). This protein is most widely known 
for its expression in the central nervous system where proteolytic cleavage by two 
secretases (y and P) produces a peptide, known as the AP peptide which undergoes 
fibrillogenesis to produce the amyloid plaques characteristic of AD (Selkoe, 1989a; 
Selkoe, 1989b). APP is expressed by a large variety of cell types, including neurones, 
astrocytes, and microglial cells (Adlerz et al., 2003; Monning et al., 1995). However, 
the normal function of APP in cells is unknown. In addition to its expression in the 
nervous system it has recently been shown both in this laboratory and by other groups 
(Sabo et al., 2001) that APP is highly expressed in several non-neuronal cells including 
NIH 3T3 cells, human fibroblasts, astrocytes and Madin-Darby canine kidney (MDCK) 
cells (Sabo et al 2001; Kenny and Saffell unpublished observations). 
There are several pieces of evidence linking AChE and APP, in particular suggestions 
that AChE may have a role in AD. The characteristic neuropatho logical lesions of AD 
include senile plaques and neurofibrillary tangles, both of which are abundant in regions 
enriched for cholinergic synapses (Geula and Mesulam, 1989). Indeed, AChE is found 
123 
Chapter 3: Expression, Activity and Localisation of AChE in neuronal and non- 
neuronalcells 
associated in senile plaques, and in vitro can promote the generation of amyloid 
aggregates by accelerating fibrillogenesis of the AP peptide (Inestrosa et al.. 1996a). 
Furthermore, cholinesterase inhibitors have been shown to modulate APP processing 
(Lahiri et al., 1994; Mori et al., 1995; Lahiri et al., 1997; Pakaski et al., 2001), while the 
C-terminal region of APP and AP can induce AChE expression. In 2002, Greenfield and 
Vaux. identified a short region in the C-terminal domain of AChE which is homologous 
to a region of AP (Greenfield and Vaux, 2002), and this peptide itself has been found to 
have both trophic and toxic effects on neurones (Day and Greenfield, 2004; Emmett and 
Greenfield, 2004; Greenfield, 2005; Zbarsky et al., 2004). In addition, at the NMJ, APP 
is known to colocalise with AChRs (Askanas et al., 1992), which are juxtaposed to 
AChE. Thus, a number of associations exist between the two proteins in the brain and 
neuronal cells, which triggered examination of their relationship in 3T3 fibroblasts, 
primary human fibroblasts and astrocytes by immunofluorescence. 
Three antibodies recognizing different epitopes on APP were available to characterize 
its localisation. These included, firstly the monoclonal antibody MAB22C II which 
recognises an epitope between residues 66 and 81 in the N-terminal part of APP 
(Hilbich et al., 1993; Weidemann et al., 1989). The location of this epitope means that 
22C II should recognise both full length and C-tenninal truncated soluble APP 
isoforms. 22C II has also been reported to recognise amyloid precursor like protein -2 
(APLP2) (Slunt et al., 1994) and has been used extensively for localisation studies in 
the nervous system (Clarris et al., 1995; Young et al., 1999). The second antibody used 
was the monoclonal antibody 6EIO, which recognises amino acids 1-17 of the human 
AP domain between the alpha secretase and beta-secretase cleavage sites, and therefore 
recognises full length APP, the AP peptide and soluble alpha cleaved APP, but not 
soluble beta cleaved APP nor APLPI/APLP2. Finally, a third antibody used was a 
polyclonal antibody (denoted pAPP hereafter) directed to the N-terminus of APP 
(immunogen confirmed through communication with Manufacturer), which should have 
a similar recognition spectrum to 22C 11. The relative positions recognised by the APP 
antibodies are shown Figure 3.16 
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Figure 3.14 AChE and (xDG do not colocalise in fibroblasts and astrocytes. 
(A-1) Detection of surface AChE and ccDG on 3T3 fibroblasts, primary fibroblasts and astrocyte 
cultures fixed in 4% paraformaldehyde. (A, D, G) AChE was detected with rabbit polyclonal 
antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, H) 
aDG was detected with monoclonal IgM antibody IIH6 (1: 200) and anti-mouse IgM Alexa Fluor 
A488 (1: 8000) secondary antibody. (C, F, 1) Merged images of AChE and (xDG. Scale Bar 20ýtm. 
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Primary Fibroblasts 
Figure 3.15 Surface AChE does not colocalise with focal contacts or bl-integrin. 
Surface AChE staining on paraformaldehyde fixed cultures of 3T3 fibroblasts, primary human 
fibroblasts and astrocytes using H- 134 was compared to vinculin staining of focal contacts and PI- 
integrin staining. (A-C) Surface ACK was detected with rabbit polyclonal antibody H-134 (1: 75) 
and anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody followed by 0.2% Triton X-100 
permeabilisation and detection of vinculin with monoclonal antibody Clone hVfNC-1 (1: 400) and 
secondary anti-mouse Alexa Fluor A488 (1: 8000) antibody. (D) AChE was detected with rabbit 
polyclonal antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A488 (1: 8000) followed by detection 
of PI-integrins with rat monoclonal A11132 antibody (1: 200) and secondary anti-rat Alexa Fluor 
A568 (1: 2000). Scale bar 20um. 
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Figure 3.16 Schematic representation of A-PP and location of the regions recognised by the 
polyclonal N-terminal antibody, the monoclonal 22C11 antibody and the monoclonal 
antibody 6EI0.22C II recognises residues 66-81 of the N-terminus of APP, while the 6E 10 
epitope is located at residues 1-17 of the AP region. Also indicated are the regions cleaved by 
three secretases a, P and 7, the most well known cleavage product being that arising from 
cleavage by the 7 and P secretases to produce the AP peptide. 
The surface and intracellular pattern of APP immunolocalisation on 3T3 fibroblasts was 
first investigated using the three different APP antibodies. As can be seen in Figure 
3.17. 
) all three antibodies show a very similar surface distribution of focused 
immunoreactivity in the distal processes and patches on the cell surface of 3T3 
fibroblasts, which appears strikingly similar to the pattern of AChE staining in these 
cells,, as shown by the comparative surface immunostained 3T3 images of AChE (H- 
134) and APP (pAPP), costained with MTs (Figure 3.17). Interestingly, the different 
antibodies revealed very different intracellular APP distribution. Both 22C II and 6E 10 
antibodies revealed that endogenous APP is present intracellularly in the cytoplasm, in 
both cases the most intense labelling being in the perinuclear region, sometimes with a 
clear circle of labelling around the nucleus. However, while 22C II gave a fibrous 
staining within the cytoplasm, 6E 10 detected a cytoplasmic granular pattern of APP and 
also stained in the nucleus. The intracellular APP pattern detected by the N-terminal 
pAPP antibody showed a third distribution, with a striking punctate immunoreactivity 
particularly in the nucleus. This implies that although all three antibodies detect the 
same species on the cell surface; different epitopes appear to be recognised within the 
cell, possibly reflecting the different abilities of the antibodies to detect APP, the AP 
peptide and APLP2, or differences in the availability of the different epitopes. The 
possibility that there is non-specific staining of another protein also cannot be excluded. 
Further characterisation of the different APP species detected intracellularly was not 
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undertaken. The common pattern of immunofluorescence shown by the different APP 
antibodies at the cell surface implies that the species being detected is a true APP form 
rather than the Ap peptide or APLP2. 
Using the pAPP antibody to further examine the localisation of APP on the surface of 
human fibroblasts revealed that APP on the cell surface is focused in discrete patches or 
drifts in primary fibroblasts and that like AChE there appears to be a closer correlation 
with MTs than other cytoskeletal elements (Figure 3.18a). This striking distribution has 
previously been noted on the surface of astrocytes using 22C 11, but is a novel finding 
on the surface of fibroblasts (Young et al., 1999). When APP on the surface of human 
fibroblasts is stained before permeabilisation for MTs or vimentin filament staining, and 
an enlarged view examined, a clear alignment of APP with lamellipodial microtubules 
can be seen (Figure 3.18b). Association of APP with the intermediate filament vimentin 
is less evident and APP rich projections do not contain vimentin filaments (Figure 
3.18b). The possibility that the apparent localisation of APP at the edges of 
microtubules could result from partial the cell permeabilisation which can result from 
paraformaldehyde fixation can be discounted, since as previously mentioned Triton X- 
100 permeabilisation of the cells and immunodetection with this antibody reveals 
prominent immunofluorescence in the nucleus, but not the cell cytoplasm (Figure 3.17). 
Colocalisation studies were then carried out using pAPP antibody in combination with 
MAB304 to detect AChE and APP (Figure 3.19). Additionally 22C II was used to 
detect APP and H-134 to detect AChE, and an example costain on astrocytic cultures is 
also shown. Both combinations of antibodies show almost complete colocalisation 
between AChE and APP on the surface of 3T3 fibroblasts, primary human fibroblasts 
(pAPP and MAB304) and cortical astrocytes (pAPP/NIAB304 and 22CI I/H-134). The 
association of surface expressed APP with microtubules is particularly significant since 
there is a closer alignment of surface AChE with the MT network than either 
intermediate filaments (such as vimentin) or the actin cytoskeleton (see Figure 3.11). 
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APP distribution in 3T3 fibroblasts 
Figure 3.17 The distribution of surface AIPP detected on 3T3 fibroblasts by three antibodies is 
very similar to AChE. 
(A-C) Surface APP staining on 4% paraformaldehyde fixed cultures of 3T3 fibroblasts. (D-F) 
Intracellular APP staining on Triton X-100 permeabilised 3T3 fibroblasts. (A, D) monoclonal APP 
antibody 6EIO (1: 100) and (C, F) monoclonal 22CII antibody (1: 800), both visualised using 
secondary anti-mouse Alexa Fluor A488 (1: 8000). (B, E) APP detected with rabbit polyclonal APP 
antibody (1: 100) and anti-rabbit Alexa Fluor A488 (1: 8000). (G) Surface AChE detected with 
rabbit polyclonal antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) followed by 
permeabilisation and detection of tubulin with monoclonal antibody (1: 50) (gift Dr Mann) and 
Alexa Fluor A488 secondary antibody (1: 8000). (H) Surface APP detected with pAPP (1: 100) and 
anti-rabbit Alexa Fluor A555 (1: 8000) followed by Triton X-100 permeabilisation and detection of 
tubulin as for (G). Scale bar 20[im. 
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APP and cytoskeletal elements on primary human fibroblasts: 
Figure 3.18a Surface APP distribution correlates most closely with microtubules. 
(A-1) The surface APP distribution detected by pAPP was compared to that of actin, tubulin and 
vimentin. (A, D, G) Detection of surface pAPP on primary fibroblasts fixed in 4% fon-naidehyde. 
APP was detected with rabbit polyclonal antibody pAPP (1: 100) and anti-rabbit Alexa Fluor A488 
(A) or A555 (D, G) (1: 8000) secondary antibody. (B, E, H) Actin, Tubulin and Vimentin were 
detected after permeabilisation with 0.2% Triton X-100. (B) Actin was detected with TRITC- 
phalloidin (1: 5000), (E) Tubulin was detected with monoclonal rat ab6161 antibody and anti-rat 
Alexa Fluor A488 secondary antibody (1: 2000). (H) Vimentin was detected with monoclonal 
mouse antibody LN-6 and anti-mouse IgM Alexa Fluor A488 (1: 8000) secondary antibody. (C, F, 
1) Merged images of APP with actin (C), Tubulin (D) and Vimentin (1). Images were captured on 
an upright Zeiss Axioplan 2 microscope with aX 100 objective. Scale bar 20ýtm. 
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Enlarged view of surface APP and the cytoskeletal elements Tubulin and 
Vimentin 
Figure 3.18b Surface APP on human fibroblasts is most closely associated with the 
microtubule network. 
(A-F) The surface APP distribution on primary human fibroblasts as detected by pAPP was 
compared to that of tubulin and vimentin. (A, D, G) Detection of surface pAPP on primary 
fibroblasts fixed in 4% paraformaidehyde. APP was detected with rabbit polyclonal antibody pAPP 
(1: 100) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E) Tubulin and 
Vimentin were detected after permeabilisation with 0.2% Triton X-100. (B) Tubulin was detected 
with monoclonal rat ab6161 antibody (1: 1000) and anti-rat Alexa Fluor A488 secondary antibody 
(1: 2000). (E) Vimentin was detected with monoclonal mouse antibody LN-6 primary antibody 
(1: 5000) and anti-mouse IgM Alexa Fluor A488 (1: 8000) secondary antibody. (C, F) Merged 
images of APP with Tubulin (C) and Vimentin (E). Scale bar 20um. 
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Figure 3.19 AChE and A_PP colocalise on the surface of fibroblasts and astrocytes. 
(A-1) Cultures of 3T3s, primary fibroblasts and cortical astrocytes were stained for detection of 
surface ACK and APP. (A, D, G) Detection of surface AChE on 3T3 fibroblasts, primary 
fibroblasts and astrocyte cultures fixed in 4% paraformaldehyde. ACK was detected with 
mouse monoclonal antibody MAB304 (1: 200) and anti-mouse Alexa Fluor A555 (1: 8000) 
secondary antibody. (B, E, H) APP was detected with pAPP (1: 100) primary antibody and anti- 
rabbit Alexa Fluor A488 (1: 8000) secondary antibody. (J) Surface AChE detected with rabbit 
polyclonal antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary 
antibody. (K) APP was detected with mouse monoclonal 22C 11 (1: 800) primary antibody and 
anti-mouse Alexa Fluor A488 (1: 8000) secondary antibody. (C, F, 1, L) Merged images of 
AChE and APP. Images A-1 were captured using a confocal upright Zeiss Axioplan 2 
microscope with an X 100 objective. Scale bar 20ýtm. 
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3.9.8 Disruption of microtubules does not remove APP or AChE from the 
fibroblast cell surface. 
As AChE appeared more associated with MTs, and APP actually appear congruent "-ith 
them, the effect of disrupting microtubles on their distribution was characterised. 3T3 
fibroblasts were treated with the drug nocodazole, which binds to P-tubulin subunits to 
prevent their polymerization, so that following the normal depolymerisation of dynamic 
MTs the subunits cannot then reassemble to form the MT network (Samson et al., 
1979). 3T3 fibroblasts were treated 0.2[tM nocodazole for 15mins, then fixed briefly 
with 4% fon-naldehyde for 7mins and labelled for either surface AChE with H-134 or 
surface APP with 22C 11, followed by permeabilisation and immunolabelling with a 
tubulin antibody that labels all MTs. In control untreated cultures, AChE was as 
previously located at the fibroblasts distal tips, and APP had a similar distribution, but 
with a more obvious fibrous surface distribution. Upon treatment with nocodazole, and 
clear disruption of virtually all the MTs, discrete regions of AChE and APP were still 
visible on the cell surface and some regions of APP staining still appeared fibrous 
(Figure 3.20). Therefore, though both APP and AChE may be secreted along MTs, they 
do not appear to be indirectly associated with them. 
3.9.9 AChE localises to the leading edge in migrating fibroblasts and 
astrocytes 
For cells in culture, it is difficult to identify the front and rear of cell. Therefore, in order 
to further characterise the distribution of AChE, its localisation in cells induced to 
migrate by in vitro wounding or during the post-plating spreading stage was examined. 
Microscopy was carried out on 85-95% confluent monolayers of 3T3 fibroblasts, human 
fibroblasts and astrocytes which had been wounded with a blunted 21G needle to 
produce an initial wound of approximately 600[tm. Cells were allowed to migrate into 
the wound for 6hrs and then fixed and immunolabelled with the polyclonal AChE 
antibody H- 134, before permeabilisation of immunostaining of intermediate filaments to 
show the cell morphology. This revealed that AChE localises to the extending 
lamellipodia in all three cell types, particularly near the lamellipodial edge (Figure 3.2 1) 
and suggests a potential role for AChE in cell adhesion and polarised migration in non- 
neuronal cells. Interestingly, not all of the lamellipodia induced by wounding were 
labelled with an AChE antibody, particularly seen in the migrating astrocytic cultures. 
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suggesting that it is specifically found in lamellipodia in a particular functional state. 
Coirnmunolocalisation of AChE and APP revealed that the codistribution seen in resting 
fibroblasts is maintained in migrating cells (Figure 3.22). In an in i, itro wound of human 
fibroblasts, APP also localises to the extending lamellipodia where it showed precise 
localisation with AChE. The localisation of APP at the leading edge of migrating cells 
has previously been described in MDCK cells (Sabo et al., 2001), where APP was 
shown to colocalise with the cytosolic adaptor protein FE65. 
3.9.10 AChE localises to specific peripheral patches in spreading cells: 
Human fibroblasts, 3T3 fibroblasts and astrocytes were plated and allowed to begin 
adhering and spreading for three hours before fixation. AChE distribution in these cells 
was then determined using surface H-134 immunolabelling, before permeabilisation and 
tubulin immunostaining. In these spreading cells, AChE was found located at the cell 
periphery in discrete regions (Figure 3.23a). Localising AChE and vinculin in spreading 
cultures of astrocytes (Figure 3.23b) revealed that though both molecules were focused 
at the periphery of the cell, there did not appear to be a relationship between their 
distributions, implying that if AChE is involved in attachment of these cells it is not 
doing so via focal adhesions. The distribution of AChE in semi-spreading astrocytes, 
immunolabelled 12hrs post-plating was also compared with labelling of adhesion sites 
with an anti-phosphotyro sine antibody. Tyrosine-phosphorylated proteins accumulate in 
adhesion sites in both dynamic and static membranes, making phosphotyrosine a good 
marker for both focal adhesions and focal complexes (Sabo et al., 2001). Labelling of 
phosphotyrosine proteins with the monoclonal antibody 4G 10 showed tick-like staining 
reminiscent of vinculin labelling of focal adhesions, as well as larger evenly spaced 
regions of immunofluorescence at the cell periphery. AChE colocalised with these 
larger regions of phosphotyrosine labelling in these peripheral membrane regions, 
which had a ruffled appearance and may have been lamellipodia. In addition, co- 
immunodetection with MAB22c II to detect APP revealed that in these spreading cells. 
APP distribution colocalises tightly with AChE (Figure 3.24). Such a pattern of discrete 
patches of immunofluorescence at the cell periphery has previously shown for APP in 
spreading astrocytic cultures, where APP was found to colocalise with active PI 
integrin (Storey et al., 1996). 
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Surface AChE and APP distribution before and after treatment with 
nocodazole: 
Figure 3.20 Disruption of microtubules with nocodazole does not disrupt AChE or AIPP 
from the 3T3 fibroblast cell surface. 
Surface AChE and APP were detected on 4% parafon-naldehyde fixed control cultures (A, Q or 
3T3 fibroblasts were treated with 0.2ýM nocodazole (B, D) for 15mins to disrupt microtubules. (A, 
B) AChE was detected with H-134 (1: 75) and anti-rabbit Alexa Fluor A555 followed by 0.2% 
Triton X-100 permeabilisation and detection of tubulin with mouse monoclonal anti-tubulin 
antibody (1: 50) and ant-mouse Alexa Fluor A488 (1: 8000). (C, D) APP was detected with 
monoclonal 22CII (1: 800) and anti-mouse Alexa Fluor A488 followed by 0.2% Triton X-100 
permeabilisation and detection of tubulin with rat monoclonal ab6161 (1: 1000) and ant-rat Alexa 
Fluor A568 (1: 2000). DAPI positive nuclei are shown in blue. Scale bar 20ýLrn 
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Figure 3.21 AChE is expressed at the leading edge of migrating cells 
(A-1) Cultures of 3T3s, primary fibroblasts and cortical astrocytes were grown to 85-95% 
confluency and an in vitro wound created with a blunted 21G needle and allowed to migrate for 
6hrs. (A, D, G) Detection of surface AChE on 3T3 fibroblasts, primary fibroblasts and astrocyte 
cultures fixed in 4% paraformaidehyde. AChE was detected with rabbit polyclonal antibody H- 
134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, D) Vimentin was 
detected after permeabilisation with 0.2% Triton X-100 with monoclonal IgM antibody LN-6 
(1: 5000) and anti-mouse IgM Alexa Fluor A488 (1: 8000). (H) GFAP was detected after 
permeabilisation with 0.2% Triton X-100 with monoclonal IgG antibody Clone-I (1: 5000) and 
anti-mouse IgG Alexa Fluor A488 (1: 8000). (C, F) Merged images of labelled AChE and 
Vimentin. (1) Merged image of labelled AChE and GFAP. Scale bar 20[tm. Arrows show 
direction of migration. 
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AChE and APP detection on migrating Human Fibroblasts 
Figure 3.22 AChE and APP colocalise at the leading edge of migrating cells. 
(A-C) Cultures of primary fibroblasts were grown to 85-95% confluency prior to wounding and 
detection of surface expressed ACK and APP after 6hrs migration. (A) Detection of surface 
AChE on, primary fibroblasts fixed in 4% paraformaldehyde. ACK was detected with rabbit 
polyclonal antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary 
antibody. (B) APP was detected with monoclonal 6EIO (1: 100) primary antibody and anti- 
mouse IgG Alexa Fluor A488 (1: 8000) secondary antibody. (C) Merged image of AChE and 
APP labelled in (A) and (B). Direction of migration indicated by white arrows and tracing of 
cell outline shown in white. Scale bar 20ptm. 
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Figure 3.23 AChE is distributed at discrete regions at the periphery of spreading cells. 
(A-1) Cultures of 3T3s, primary fibroblasts and cortical astrocytes were allowed to attach and 
spread on plastic for 3hrs (spreading stage) prior to detection of AChE and Tubulin. (A, D, G) 
Detection of surface ACK on 3T3 fibroblasts, primary fibroblasts and astrocyte cultures fixed in 
4% paraformaldehyde. AChE was detected with rabbit polyclonal antibody H-134 (1: 75) and anti- 
rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, H) Tubulin was detected with (1: 50) 
primary antibody (gift Dr Mann) and anti-mouse IgG Alexa Fluor A488 (1: 8000) secondary 
antibody after Triton X-100 permeabilisation. (C, F, 1) Merged images of AChE and tubulin. 
Images were captured using a confocal Zeiss Axioplan 2 microscope with a X100 objective. Scale 
bar 20[tm. 
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AChE on spreading primary astrocytes 
Figure 3.23b AChE on spreading astrocytes does not colocalise with vinculin but does show 
some colocalisation with phosphotyrosine. 
(A-F) Cultures of cortical astrocytes were allowed to attach and spread on plastic for 3hrs (A-C) or 
12hrs (D-F). (A, D) AChE detected on surface of astrocyte cultures fixed in 4% paraformaidehyde 
with rabbit polyclonal antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary 
antibody. (B) Cultures were Triton X-100 permeabilised and immunolabelled for vinculin with 
monoclonal antibody clone hVINC-1 (1: 400) and anti-mouse IgG Alexa Fluor A488 (1: 8000) 
secondary antibody. (E) Cultures were permeabilised and immunolabelled for phosphotyrosine with 
monoclonal antibody 4GIO (1: 500) and anti-mouse IgG Alexa Fluor A488 (1: 8000) secondary 
antibody. (C, F) Merged images of (A, D) with (B, E). Scale bar 20ýtm. 
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Figure 3.24 AChE and APP colocalise at the periphery of spreading cells. 
(A-1) Cultures of 3T3s, primary fibroblasts and cortical astrocytes were allowed to attach and 
spread on plastic for 3hrs (spreading stage) prior to detection of AChE and APP. (A, D, G) 
Detection of surface AChE on 3T3 fibroblasts, primary fibroblasts and astrocyte cultures fixed in 
4% paraformaldehyde. AChE was detected with rabbit polyclonal antibody H-134 (1: 75) and anti- 
rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, H) APP was detected with 22C 11 
(1: 800) primary antibody and anti-mouse IgG Alexa Fluor A488 (1: 8000) secondary antibody. (C, 
F, 1) Merged images of AChE and APP. Images were captured using a confocal Zeiss Axioplan 2 
microscope and aX 100 objective. Scale bar 20ýtm. 
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3.10 Distribution of AChE in primary neuronal cultures and neuronal 
cell lines. 
Accumulated evidence suggests that AChE plays a role in the regulation of the 
cytoarchitecture of developing neurones; (Griffnan et al., 1998; Koenigsberger et al.. 
1997; (Bigbee et al., 2000; De Jaco et al., 2002; Jacobsen, 2002). Although the 
immunofluorescent distribution of AChE has been examined in several other studies 
(Dong et al., 2004; Olivera et al., 2003b; Thullbery et al., 2005), in order to gain 
information regarding the potential morphogenic role of AChE in neuronal cells, the 
cellular and subcellular localisation of AChE was characterized by 
immunocytochernistry in both primary disassociated neuronal cultures and in neuronal 
cell lines. 
3.10.1 Primary neuronal cultures express surface AChE in a segmental 
pattern and at growth cones. 
Immunolocalisation with the AChE polyclonal antibody H- 134 revealed that embryonic 
hippocampal, and cortical and post-natal cerebellar cultured neurones all express 
endogenous AChE. As shown in Figure 3.25, from early time points (DIV 2-4) the cells 
express surface AChE. In these young cultures, AChE is highly expressed on both the 
soma and segmentally along neuronal processes, particularly found in some, but not all 
growth cones, the highly motile structure at the growing end of neuronal processes. 
AChE immunofluorescence was also observed at some branch points, where neurites 
changed direction (particularly evident in cerebellar cultures in Figure 3.25). The 
presence of AChE at neurite branch points indicates a potential role in stabilising 
adhesion of a potentially fragile region or in the branching process itself. Elevating 
AChE expression in DRG neurones increases distal. branching, (Bigbee et al., 2000) 
supporting this possibility. 
The segmented pattern was not a result of disruption of neurite continuity during 
fixation and staining, nor did it represent the 'footprints' of detached cells, since 
costaining with tubulin (Figure 3.25), or actin (not shown) showed continuous neurites. 
Moreover, there was a marked difference in AChE immunostaining when cells were 
penneabilised with Triton X-100 (Figure 3.26) or methanol (not shown) before being 
exposed to the primary antibody. In the absence of permeabilisation, some neurones do 
not stain for AChE and those that do, have the afore-mentioned segmental pattern. In 
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Triton X-100 permeabilised cultures, the vast majority of the cells become 
immunofluorescent, with more diffuse staining throughout the neurone, similar to the 
intracellular distribution seen in non-neuronal cells, except that in the small neuronal 
cell soma, the perinuclear region is less visible (Figure 3.26). 
The discrete segmental and focused distribution of AChE at growth cones supports the 
premise that AChE plays a role in neurite outgrowth of developing neurones, as 
suggested by previous studies (Dong et al., 2004; Olivera et al., 2003b). However, 
AChE is only variably present on the surface of growth cones, in a manner similar to the 
variability seen regarding the localisation of AChE at the leading edge of migrating 
fibroblasts. The specific segmental pattern of AChE expression of the neuronal surface 
has previously been demonstrated in hippocampal cultures (Dong et al., 2004; Olivera et 
al., 2003b), however this is the first demonstration that this distribution appears to be 
consistent in neurones isolated from different regions of the brain and that it is present 
at branch points (Figure 3.25). 
3.10.2 AChE shows some colocalisation with ccDG in primary neuronal 
cultures. 
(xDG is critical for correct neural cell migration in the CNS, as illustrated by the 
disordered migration in the cerebral cortex and cerebellum produced by deletion of 
brain dystroglycan (Moore et al., 2002). ccDG is broadly expressed in late embryonic 
and early postnatal cerebellar neurones, before being largely downregulated during 
maturation (Henion et al., 2003). Colocalisation studies for AChE and ccDG were 
performed on primary cerebellar, hippocampal and cortical neurones. On these young 
cultures, ccDG has a broad, punctate staining pattern on the neurite surface, whilst 
AChE is as previous concentrated in discrete regions (Figure 3.27). While AChE does 
not follow the same distribution as (xDG, they often both coincided at areas of bright 
concentration. Previous reports have shown that only low levels of perlecan at present in 
the central nervous system, and thus the colocalisation of AChE and perlecan in 
neurones was not investigated. 
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AChE distribution on the surface of primary neurons 
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Figure 3.25 AChE is expressed at discrete regions on the surface of primary neurones, 
particularly branch points and growth cones. 
(A-C) PND4 cerebellar neurones, (D-F) E18 hippocampal neurones, (G-1) E18 cortical neurones. 
In all cases, neuronal cultures were plated and processed for imaging after 2-3 days in culture. (A, 
D, G) Neurones were fixed in 4% paraformaldehyde, and immunolabelled for AChE with 
polyclonal H-134 (1: 75) and secondary antibody, anti-rabbit Alexa Fluor A555 (1: 8000). (13, E, H) 
Neurons were permeabilised with 0.2% Triton X-100 and immunolabelled for tubulin with 
monoclonal mouse anti-tubulin (1: 50, gift Dr D. Mann) and anti-mouse Alexa Fluor A488 secondary 
antibody (1: 8000). (C, F, 1) Merged images of AChE and tubulin. Hollow arrows highlight branch 
points of neurones, filled arrows highlight neurite tips and growth cones. Images captured with a 
confocal Zeiss Axioplan 2 microscope and aX 100 objective. Scale bars 20Vtm. 
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Intracellular Localisation of AChE in neuronal cultures 
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Figure 3.26 Intracellular AChE detected by H-134 shows a continuous distribution. 
(A-C) PND4 cerebellar neurones, (D-F) E18 hippocampal neurones, (G-1) E18 cortical neurones. 
In all cases, neurones cultures were plated and processed for imaging after 2-3 days in culture. (A, 
D, G) Neurones were fixed in 4% paraformaidehyde, permeabilised with 0.2% Triton X-100 and 
immunolabelled for AChE with polyclonal H-134 (1: 75) and secondary antibody, anti-rabbit Alexa 
Fluor A555. (B, E, H) Tubulin was detected with monoclonal mouse anti-tubulin (1: 50, gift Dr D. 
Mann) and anti-mouse Alexa Fluor A488 secondary antibody (1: 8000). (C, F, 1) Merged images of 
AChE and Tubulin. Scale bar 20[trn 
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AChE and aDG distribution on the surface of neuronal cultures 
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Figure 3.27 AChE and ccDG show limited colocalisation on the surface of primary neuronal 
cultures. 
(A-1) Detection of surface AChE and aDG on primary neuronal cultures fixed in 4% 
paraformaldehyde. (A, G) AChE was detected with rabbit polyclonal antibody H-134 (1: 75) and 
anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, H) aDG was detected with 
mouse monoclonal IgM antibody IIH6 (1: 200) and anti-mouse IgM Alexa Fluor A488 (1: 8000) 
secondary antibody. (C, F, 1) Merged images of AChE and aDG. Hollow arrows show areas of 
colocalisation. Scale bar 20ýtm. 
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3.10.3 AChE in neuronal cultures codistributes with APP. 
Given that AChE in fibroblasts and astrocytes colocalises with APP, the distribution of 
each was examined in neuronal cultures. As can be seen in Figure 3.28 APP in primary 
neuronal cultures of embryonic hippocampal or postnatal cerebellar cultures labelled 
with either 22C II or pAPP, is expressed in a segmental pattern, reminiscent of the 
distribution of AChE. Stretches of brightly labelled neurites interrupted by APP- 
negative regions are common. This segmental distribution of APP has been noted by 
several other studies (Allinquant et al., 1994; Yamazaki et al., 1997), and like that of 
AChE, is destroyed by Triton X-100 permeabilisation (Figure 3.29), which produces 
continuous immunofluorescence throughout the soma and neurites (in the case of 
22C 11). Colocalisation studies revealed that these segments of APP staining showed 
almost complete colocalisation with cell surface AChE (Figure 3.30) in all the neuronal 
populations examined. Though both AChE and APP are reported to be present in serum 
(Saxena et al., 2003); the association between AChE and APP cannot be due to 
components originating from serum since all neuronal populations were maintained in 
defined serum free media. Furthermore, the association between AChE and APP is 
specific and not generalized to other proteins since immunofluorescent localisation of 
ccDG demonstrated a diffuse distribution indicating that the distribution is not an 
artefact of fixation or sample preparation. 
3.11 AChE is located close to the substratum: 
In order to gain a greater understanding of the potential function of AChE from its 
localisation a fluorescence microscopy technique known as total internal reflection 
fluorescence microscopy (TIRFM) was used. This technique exploits the unique 
properties of an induced evanescent wave in a limited specimen region immediately 
adjacent to the interface between two media having different refractive indices. In this 
case the interface in the application of TIRFM is the contact area between a specimen 
and a glass coverslip of thickness 1.5. If AChE does contribute to adhesion and 
migration of cells it would be expected to be at the cell-substratum interface. Using 
TIRFM to detect only the fluorescence emitted within 100nm of the glass coverslip 
revealed AChE rings and patches at the leading edge of migrating and spreading 
primary fibroblasts, astrocytes and the tips of 3T3 cell processes, in addition to the 
segmental staining of neurites (Figure 3.3 1). 
146 
Chapter 3: Expression, Activity and Localisation of AChE in neuronal and non- 
neuronalcells 
APP (22C11 / pAPP) distribution on the surface of neuronal cultures 
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Figure 3.28 APP is expressed at discrete regions on the surface of primary neurones, 
particularly branch points. 
(A, B) PND4 cerebellar neurones, (C, D) E18 hippocampal neurones. In all cases, neuronal cultures 
were plated and processed for imaging after 2-3 days in culture. (A, Q Merged image of neurones 
fixed in 4% paraformaldehyde, and immunolabelled for APP with monoclonal antibody 22C 11 
(1: 800) and secondary antibody, anti-mouse Alexa Fluor A488 (1: 8000), then permeabilised with 
0.2% Triton X-100 and immunolabelled with tubulin with monoclonal rat anti-tubulin ab6161 
(1: 1000) and anti-rat Alexa Fluor A568 secondary antibody (1: 2000). (B, D) Merged images of 
neurons fixed in 4% paraformaldehyde, and immunolabelled for APP with rabbit polyclonal 
antibody pAPP (1: 100) and secondary antibody, anti-rabbit Alexa Fluor A555 (1: 8000), then 
permeabilised with 0.2% Triton X-100 and immunolabelled with tubulin with monoclonal mouse 
anti-tubulin antibody (1: 50, gift Dr D. Mann) and anti-mouse Alexa Fluor A488 secondary antibody 
(1: 8000). Hollow arrows highlight branch points of neurons, filled arrows highlight neurite tips. 
Scale bars 20ýtm. 
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Intracellular Localisation of APP in neuronal cultures 
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Figure 3.29 Intracellular APP detected by 22C11 shows a continuous distribution. 
(A-C) PND4 cerebellar neurones, (D-F) E 18 cortical neurones. In all cases, neurones cultures were 
plated and processed for imaging after 2-3 days in culture. (A, D) Neurones were fixed in 4% 
paraformaldehyde, permeabilised with 0.2% Triton X-100 and immunolabelled for APP with mouse 
monoclonal antibody 22C 11 (1: 800) and secondary antibody, anti-mouse Alexa Fluor A488. (B, E) 
Tubulin was detected with monoclonal rat anti-tubulin ab6161 and anti-rat Alexa Fluor A568 
secondary antibody (1: 2000). (C, F) Merged images of APP and tubulin. Scale bar 20ýtm 
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Surface localisation of AChE and APP on primary neuronal cultures 
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Figure 3.30 AChE colocalises with APP on the surface of primary neuronal cultures. 
(A-C) PND4 cerebellar neurones, (D-F) E18 hippocampal neurones, (G-1) E18 cortical neurones. 
In all cases, neurones cultures were plated and processed for imaging after 2-3 days in culture. (A, 
D, G) Neurones were fixed in 4% paraformaldehyde, and immunolabelled for AChE with rabbit 
polyclonal H-134 (1: 75) and secondary antibody, anti-rabbit Alexa Fluor A555 (1: 8000). (B, E, H) 
Neurones were immunolabelled with monoclonal APP antibody 22C 11 (1: 800) and anti-mouse 
Alexa Fluor A488 secondary antibody (1: 8000). (C, F, 1) Merged images of AChE and APP. 
Hollow arrows denote areas of colocalisation at branch points. Images captured using a confocal 
Zeiss Axioplan 2 microscope with aX 100 objective. Scale bars 20ýtm. 
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AChE localisation by TIRF 
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Figure 3.31 TIRF microscopy reveals that AChE is localised close to the substratum. 
Cultures of 3T3 fibroblasts, primary fibroblasts, astrocytes and cerebellar neurons were plated as 
described in the materials and methods on coverslips of 1.5mm thickness for TIRF imaging. (A, C, 
E, G and H) Cultures were fixed in 4% paraformaldehyde and stained for AChE with rabbit 
polyclonal antibody H-134 (1: 75) followed by secondary antibody anti-rabbit Alexa Fluor A488 
(1: 8000). ACK immunofluorescence was visualised on a microscope adjusted for TIRF 
microscopy so that only labelling 100nm from the glass coverslip could be visualised. (B, D, F) 
Phase images of cells imaged by TIRF in (A, C, E). Hollow arrows denote branch points on 
neurones. Scale bar 20ýtm. 
Phase Image 
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3.12 AChE interactions on the surface of 3T3 fibroblasts: 
The colocalisation of AChE with APP and perlecan suggests that it may have functional 
interactions with these elements on the cell surface. In order to obtain further 
information on how AChE may be having a morphoregulatory role, these potential 
interactions and other potential AChE binding partners in fibroblasts were investigated. 
3.12.1 AChE antibody mediated clustering induced redistribution of 
perlecan but not aDG or APP: 
As previously noted, AChE can be detected by MAB304 on unfixed cell cultures. 
Application of MAB304, together with its secondary antibody to 3T3 fibroblast cultures 
at 37'C was found to cross-link AChE at the fibroblast surface (Figure 3.32D). This 
clustering/patching phenomenon is also seen upon application of antibodies to other cell 
surface molecules, particularly those involved in adhesion such as NCAM. Indeed, 
application of an NCAM antibody to live cultures of 3T3s engineering to express the 
human 140kDa form NCAM clusters it in a manner similar to that seen with AChE 
(Figure 3.32B). 
In fixed 3T3 fibroblasts, perlecan has a streaky distribution which shows some 
colocalisation with AChE. In order to determine whether these two proteins were able to 
interact on the cell surface, AChE was clustered by live application of MAB304 and its 
secondary antibody at 37'C, the cells fixed and the localisation of perlecan subsequently 
determined. Significantly, following AChE clustering, perlecan shows some 
redistribution with AChE (Figure 3.33), suggesting that the two proteins interact 
directly or indirectly in the cell surface. Although, AChE does not appear to show any 
particular colocalisation with aDG, a potential interaction between the two proteins was 
investigated. Due to the species of antibodies available which can be used for live 
staining, the effect of clustering aDG on the distribution of ACK, detected in fixed 
cultures by H-134 was determined. This combination of antibodies for clustering was 
carried out as the only available aDG antibody IIH6 is a mouse IgM antibody and thus 
there is the potential for cross-reactivity between the secondary anti-mouse IgM and the 
secondary anti-mouse IgG if MAB304 clustering was carried out followed by aDG 
immunodetection. Clustering aDG with the functional monoclonal antibody IIH6 and 
then probing the localisation of AChE with the polyclonal antibody H-134 reveals that 
although aDG itself can be clustered by this antibody. AChE does not co-redistribute 
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(Figure 3.34). This suggests that aDG and AChE do not appear to have any functional 
interaction on the cell surface, as had previously been implied by their disparate staining 
in fixed cultures. 
The similar localisation of AChE and APP suggested that these two proteins could form 
a complex on the cell surface. To investigate this, AChE was again cross-linked at the 
fibroblast surface with MAB304, and its secondary anti-mouse antibody at 370C. 
However, unlike perlecan, following antibody mediated clustering of AChE on the 
surface of 3T3 cells, APP remains at the cell periphery and does not redistribute with 
AChE (Figure 3.35) suggesting that APP is unlikely to link clustered AChE to the 
plasma membrane. However, the mobility of APP on the cell surface in response to 
antibody clustering was not able to be tested since it cannot be visualized by live 
staining (Allinquant et al., 1994). Therefore, the possibility cannot be excluded that APP 
and AChE maybe linked directly or indirectly by a low affinity interaction that cannot 
overcome APP cytoskeletal anchoring (Allinquant et al., 1994), preventing APP 
mobility during AChE clustering. 
3.13 Characterisation of potential AChE binding partners: 
AChE is classically thought to have no transmembrane domain capable of initiating 
downstream signalling [although recent work has suggested that alternative N-terminal 
splicing many result in a potential transmembrane domain (Meshorer et al., 2004)]. 
Therefore,, AChE must interact with other molecules in order to induce any 
morphoregulatory effects. It could potentially act as a trans-interacting partner, that is, 
an interaction between the cell surface of one cell and a molecule from the ECM or from 
the cell surface of an adjacent cell. The binding partner for AChE at the neuronal cell 
surface has, however, remained elusive. Manipulating AChE levels has been shown to 
influence neurexin and neuroligin levels (Andres et al., 1997; Grifman et al., 1998; 
Dong et al., 2004). Indeed as discussed previously, AChE shares significant homology 
to neuroligin and both a classified within the same family of cell adhesion proteins. The 
binding partners of neuroligin-1 is P-neurexin, which has been considered a potential 
AChE ligand. 
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NCAM and AChE can be clustered on the cell surface 
Fixed immunofluorescence 
Figure 3.32 Application of antibodies to NCAM or AChE can cluster them on the cell surface. 
(A) 3T3 fibroblasts expressing the 140kDa NCAM transgene were fixed in 4% paraformaldehyde 
and labelled for surface NCAM with mouse monoclonal antibody N 16 (1: 10,000) and anti-mouse 
Alex Fluor A488. Cell morphology was revealed by subsequent permeabilisation and labelling for 
tubulin using rat monoclonal A6161 (1: 1000) and anti-rat Alexa Fluor A568 (1: 2000). (B) Surface 
NCAM was clustered by applying N16 (1: 5000) for lhr at 37'C followed by anti-mouse Alexa 
Fluor A488 (1: 8000) for I hr at 37'C. Cell morphology was revealed as in (A) after fixation with 4% 
paraformaidehyde. (C) 3T3 fibroblasts were fixed in 4% paraformaldehyde and labelled for surface 
AChE with mouse monoclonal antibody MAB304 (1: 200) and anti-mouse Alex Fluor A488 
(1: 8000). Cell morphology was revealed by subsequent pen-neabilisation and labelling for tubulin 
using rat monoclonal A6161 (1: 1000) and anti-rat Alexa Fluor A568 (1: 2000). (D) Surface ACK 
was clustered by applying MAB304 (1: 200) for lhr at 37'C followed by anti-mouse Alexa Fluor 
A488 (1: 8000) for lhr at 37'C. Cell morphology was revealed as in (C) after fixation with 4% 
paraformaldehyde. Scale bar 20um. 
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Perlecan distribution upon AChE clustering 
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Figure 3.33. AChE clustering partially redistributes perlecan in 3T3 fibroblasts. 
(A) 3T3 fibroblasts fixed in 4% paraformaldehyde and surface AChE detected with monoclonal 
mouse MAB304 (1: 200) and anti-mouse Alexa Fluor A488 (1: 8000). (B) Perlecan was detected 
with rabbit polyclonal R63 antibody (1: 200) and anti-rabbit Alexa Fluor A555 (1: 8000). (C) 
Merged image of AChE and Perlecan. (D) MAB304 was applied to live cultures of 3T3 fibroblasts 
(1: 200) in 2%BSA/DMEM/HEPES for 1hr at 37'C, followed by incubation with anti-mouse Alexa 
Fluor A488 (1: 8000) at 37'C for 1hr. (E) Perlecan was labelled as for (B) after fixation in 4% 
paraformaldehyde. (F) Merged image of AChE and Perlecan labelled in (D) and (E). Scale bar 
20[tm 
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AChE distribution upon aDG clustering 
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Figure 3.34 a-DG clustering does not redistribute AChE. 
(A) 3T3 fibroblasts fixed in 4% paraformaldehyde and surface ctDG was detected with mouse 
monoclonal IIH6 antibody (1: 200) and anti-mouse IgM Alexa Fluor A488 (1: 8000). (B) AChE 
detected with polyclonal H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000). (C) Merge of 
fixed cultures of ctDG and AChE labelled in (A) and (B). 
(D) IIH6 was applied to live cultures of 3T3 fibroblasts (1: 200) in 2%BSA/DMEM/HEPES for I hr 
at 37'C, followed by incubation with anti-mouse IgNI Alexa Fluor A488 (1: 8000) at 37'C for lhr. 
(E) AChE was labelled as for (B) after fixation in 4% paraformaldehyde. (F) Merge of aDG and 
AChE labelled in (E) and (D). Scale Bar 20um. 
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APP distribution upon AChE clustering 
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Figure 3.35 AChE clustering does not redistribute APP. 
(A) 3T3 fibroblasts fixed in 4% paraformaldehyde and surface AChE detected with mouse 
monoclonal MAB304 (1: 200) and anti-mouse Alexa Fluor A488 (1: 8000). (B) APP detected with 
rabbit polyclonal pAPP antibody (1: 100) and anti-rabbit Alexa Fluor A555 (1: 8000). (C) Merge of 
AChE and APP on fixed cultures. (D) MAB304 applied to live cultures of 3T3 fibroblasts (1: 200) in 
2%BSA/DMEM/HEPES for lhr at 37'C, followed by incubation with anti-mouse Alexa Fluor 
A488 (1: 8000) at 37'C for lhr. (E) APP was labelled as for (B) after fixation in 4% 
paraformaldehyde. (F) Merge of AChE and APP on AChE clustered cells. Scale bar 20urn 
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However,, although neuroligin-I to neurexin-IP binding is detectable by surface 
plasmon resonance, such an interaction between AChE and neurexin is not evident 
(Comoletti et al., 2003). Therefore, the endogenous binding partner for AChE even in 
neurones is still under investigation. 
Another possibility that has been suggested is that AChE can act as a homophilic 
binding molecule and can bind to other AChE molecules present either on different cells 
or in the matrix using a mechanism similar to oligomerisation of multiple AChE 
molecules (Botti et al., 1998). The localisation of AChE does not appear reminiscent of 
a homophilic binding molecule, neither in fixed cultures, nor when detected on live 
cells. Indeed direct comparison with the distribution of the well known homophilic 
adhesion molecule NCAM (Figure 3.10) showed that AChE exhibited a different pattern 
of localisation. In addition, no functional AChE-AChE interactions have been 
demonstrated in cells engineered to express AChE (Guenneugues et al., 1996). 
Therefore, AChE is likely to bind to an as yet unknown partner, either when it is 
anchored on the surface or upon being secreted to become matrix-bound, where it can 
interact with other molecules that may be found on the cell surfaces in a manner similar 
to neuroligin-neurexin interactions at synaptic sites. 
In non-neuronal cells far less is known regarding the morphoregulatory function of 
AChE. In bone, AChE has recently been suggested to play a role as a novel bone matrix 
molecule by secretion into the ECM, however, the interactions mediating these effects 
have not been characterised (Genever et al., 1999; Inkson et al., 2004). Recent studies 
suggest that laminin is a likely candidate for an AChE ligand as AChE laminin binding 
can be demonstrated in vitro (Bigbee and Sharma, 2004; Johnson and Moore, 2003; 
Paraoanu and Layer, 2004; Paraoanu and Layer, 2005). Indeed, AChE interacts with 
laminin in a yeast two-hybrid screen and has been recently shown to co- 
immunoprecipitate with AChE (Paraoanu and Layer, 2004; Paraoanu and Layer, 2005). 
In order to elucidate the function of AChE in fibroblasts, the effects of addition of 
several potential ligands on the distribution of AChE on the fibroblast cell surface has 
been examined. 
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3.13.1 Laminin addition clusters (xDG but not AChE on the surface of 
fibroblasts: 
To determine whether laminin induces a reorganization of AChE on the fibroblast cell 
surface, the distribution of AChE as well as that of aDG in 3T3 cells, and primary 
human fibroblasts treated with or without 50ýigml-' laminin-I was examined. 
Localisation of AChE with the polyclonal antibody H-134, revealed very similar 
distribution of AChE in both treated and untreated cells. In comparison, the localisation 
of aDG on the cell surface was markedly altered upon laminin addition as shown in 
Figures 3.36a. aDG is known to be a receptor for several extracellular matrix (ECM) 
molecules, including laminin, agrin and perlecan, and links the ECM to the actin 
cytoskeleton. In the absence of laminin, aDG immunoreactivity was distributed in a fine 
punctate pattern uniformly over the surface of the cells with virtually no aggregates. 
Upon overnight treatment with 50ýtgml-' laminin-1 (alplyl), aDG clusters formed, 
varying in size, shape and fluorescence intensity. The induction of (xDG clusters by 
laminin was dose dependent; with a significant increase in the number of (xDG clusters 
at concentrations of laminin-I from 5ýtgml-' onwards (data not shown). This laminin- 
induced rearrangement in aDG assembly has been previously reported in muscle cells 
(Montanaro et al., 1999) and more recently in Schwann cells (Tsiper and Yurchenco, 
2002) and retinal Miffler cells (Noel et al., 2005). 
In addition, the effect of addition of laminin- I on the distribution of another laminin 
receptor, 01-integrin was examined on human fibroblasts. In contrast to aDG, 01- 
integrin on the surface of human fibroblasts did not cluster upon treatment with laminin- 
I and remained distributed evenly over the surface of the cells as shown in Figure 
3.36b, even though it is a known larninin receptor. Based on this lack of clustering of 
AChE, larninin is unlikely to be the endogenous ligand for AChE in these cells, but a 
role in other cells cannot be excluded. 
3.13.2 Addition of collagen IV or fibronectin does not affect the distribution 
of AChE on the surface of fibroblasts: 
The effects of other components of the extracellular matrix were also investigated. 
Addition of collagen IV, another ECM molecule shown to be able to bind to AChE in 
i, itro (Johnson and Moore, 2003) did not affect the distribution of AChE on the cell 
surface of fibroblasts, as shown in figure 3.37. This was also true for addition of 
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fibronectin at a variety of concentrations, an example of which is shown in Figure 3.37. 
Therefore, in fibroblasts, laminin, collagen IV and fibronectin do not appear to mediate 
interactions with AChE. Indeed, though laminin and collagen IV are prevalent in the 
peripheral nervous system, they have a limited distribution in the central nervous 
system, also suggesting the existence of other AChE binding proteins (Bigbee and 
Sharma,, 2004). 
3.14 Immunolocalisation specificity: 
In order to verify the specificity of the antibodies, for each antibody, and for each cell 
type examined, secondary antibody only controls were carried out. These controls are 
shown in figure 3.38. The nucleus is clearly labelled by DAPI; however application of 
the secondary antibodies alone does not result in any significant binding, indicating that 
the staining shown is specific. Where costains were carried out, similar controls were 
performed, where the second primary antibody was omitted to ascertain no cross- 
reactivity of the second secondary antibody with the first primary antibody. All 
immunofluorescence was eliminated by omission of primary antibody. In multiple label 
experiments, labelling patterns were identical to those seen with single labelling, and 
channels were imaged sequentially to avoid bleed-through. 
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AChE and ccDG distribution upon treatment with laminin 
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Figure 3.36a. Overnight culture with Laminin clusters ccDG but not AChE in 3T3s and 
Human fibroblasts. 
(A-F) Detection of surface ccDG and AChE on 3T3 fibroblasts and (G-J) primary fibroblast 
cultures fixed in 4% parafon-naldehyde. (A, D, G, J) AChE was detected with rabbit polyclonal 
antibody H-134 (1: 75) and anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, H, 
K) (xDG was detected with mouse monoclonal IgM antibody IIH6 (1: 200) primary antibody and 
anti-mouse IgM Alexa Fluor A488 (1: 8000) secondary antibody. (C, F, 1, L) Merge of AChE and 
ctDG labelled in (A, D, G, J), and (B, E, H, K). Images captured on a confocal Zeiss Axioplan 2 
microscope with aX 100 objective lens. Scale bar 20[im. 
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Figure 3.36b Overnight addition of larninin clusters aDG but not Pl-integrin. 
(A-F) Detection of surface ctDG and PI-integrin on primary fibroblast cultures fixed in 4% 
paraformaldehyde. (A, D) PI-integrin was detected with rat monoclonal antibody A11132 (1: 200) 
and anti-rat Alexa Fluor A568 (1: 8000) secondary antibody. (B, E) (XDG was detected with mouse 
monoclonal IgM IIH6 (1: 200) primary antibody and anti-mouse IgM Alexa Fluor A488 (1: 8000) 
secondary antibody. (C, F) Merged images of PI -integrin and (XDG. Images captured on a confocal 
Zeiss Axioplan 2 microscope with aX 100 objective lens. Scale Bar 20um. 
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AChE and aDG distribution on the surface of 3T3 fibroblasts upon 
treatment with collagen IV or Fibronectin 
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Figure 3.37 Addition of Collagen IV and Fibronectin fails to redistribute AChE or (xDG. 
(A-1) Detection of surface AChE and ccDG on 3T3 fibroblast cultures fixed in 4% 
paraformaidehyde. (A, D, G) AChE was detected with rabbit polyclonal antibody H- 134 (1: 75) and 
anti-rabbit Alexa Fluor A555 (1: 8000) secondary antibody. (B, E, H) GCDG was detected with 
mouse monoclonal IIH6 (1: 200) primary antibody and anti-mouse IgM Alexa Fluor A488 (1: 8000) 
secondary antibody. (C, F, 1) Merged images of ACIiE and aDG. Images were captured using a 
confocal Zeiss Axioplan 2 microscope with aX 100 objective lens. Scale bar 20ýtm. 
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MAB304 + anti-rabbit MAB304 + anti-mouse Anti-mouse IgG Alexa Fluor A555 Alexa Fluor A488 Alexa Fluor A555 
A 
Clone 46 + anti-rabbit Clone 46 + anti-mouse 
Anti-mouse IgG Alexa Fluor A488 Alexa Fluor A555 Alexa Fluor A488 
pAPP + anti-mouse pAPP + anti-rabbit 
Anti-rabbit IgG Alexa Fluor A488 Alexa Fluor A488 Alexa Fluor A555 
H-I 34 +anti mouse H-1 34 +anti-rabbit 
Anti-rabbit IgG Alexa Fluor A555 Alexa Fluor A555 Alexa Fluor A488 
Figure 3.38a Immunolocalisation specificity 
(A-P) 3T3 fibroblasts were 4% paraformaldehyde fixed (A, B, E, F, 1, J, M, N) Instead 
of primary antibody, fibroblasts were incubated with PBS followed by secondary 
antibodies (A, B) Anti-mouse IgG Alexa Fluor A555. (E, F) Anti-mouse IgG Alexa Fluor 
A488. (1, J) Anti-rabbit IgG Alexa Fluor A555. (M, N) Anti-rabbit Alexa Fluor A555. In 
costains there are no non-specific interactions of the secondary antibodies. Surface 
MAB304 is detected with anti-mouse Alexa Fluor A555 (D) but not anti-rabbit Alexa 
A488 (Q. Surface Clone 46 is detected with anti-mouse IgG Alexa Fluor A488 (H) but 
not anti-rabbit Alexa A555 (G). Surface pAPP is detected with anti-rabbit IgG Alexa 
Fluor A555 (L) but not anti-mouse IgG Alexa A488 (K). Surface H- 134 is detected with 
anti-rabbit IgG Alexa Fluor A488 (P) but not anti-mouse Alexa A555 (0). Scale bar 
20ýtm 
163 
Chapter 3: Expression, Activity and Localisation of AChE in neuronal and non- 
neuronalcells 
Human Fibroblasts MAB304 + anti-rabbit MAB304 + anti-mouse 
Anti-mouse IgG Alexa Fluor A488 (green) Alexa Fluor A555 Alexa Fluor A488 
Clone 46 + anti-rabbit Clone 46 + anti-mouse 
Anti-mouse IgG Alexa Fluor A555 (red) Alexa Fluor A488 Alexa Fluor A555 
H-134 + anti-mouse H-134 + anti-rabbit 
Anti-rabbit IgG Alexa Fluor A555 (red) Alexa Fluor A488 Alexa Fluor A555 
Astrocytes MAB304 + anti-rabbit MAB304 + anti-mouse 
Anti-mouse IgG Alexa Fluor A555 (red) Alexa Fluor A488 Alexa Fluor A555 
22CIl + anti-rabbit 22C1 I+ anti-mouse 
Anti-rabbit IgG Alexa Fluor A555 (red) Alexa Fluor A555 Alexa Fluor A488 
H-134 + anti-mouse H-134 + anti-rabbit 
Anti-mouse IgG Alexa Fluor A488 (green) Alexa Fluor A488 Alexa Fluor A555 
3.38b Immunolocalisation specificity 
(A-X) Human fibroblasts and astrocytes were 4% paraformaldehyde fixed (A, B, E, F, 1, J, M, N, 
Q, R, U, V) Instead of primary antibody, fibroblasts were incubated with PBS followed by 
secondary antibodies as designated. In costains there are no non-specific interactions of the 
secondary antibodies. Surface MAB304 is detected with anti-mouse Alexa Fluor A555 (D, P) but 
not anti-rabbit Alexa A488 (C, 0). Surface H-134 detected with anti-rabbit IgG Alexa Fluor 
A555 (L, X) but not anti-mouse IgG Alexa A488 (K, W). 22C II and Clone 46 are detected by 
anti-mouse IgG Alexa A488 (H, T) but not by anti-rabbit IgG Alexa A555 (G, S). Scale bar 
20ýirn 
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3.15 Discussion: 
Characterisation of the relative expression levels, enzymatic activity and subcellular 
localisation of AChE described in this chapter has revealed several novel findings. 
Firstly it appears that regardless of the amount of AChE specific catalytic activity, all 
the cells under investigation expressed the AChE protein by immunoblot and 
immunofluorescence analysis. Neuronal cells express significantly more enzymatic 
activity compared to non-neuronal cells; however the protein levels are equivalent, in 
agreement with recent previous studies (Thullbery et al., 2005). Characterisation of the 
surface localisation of AChE revealed that it distributed in discrete regions of the cell 
surface and shows precise colocalisation with APP and some overlap with perlecan. In 
migrating cells, AChE is distributed at the leading edge of the cells, while in young 
neuronal cultures, AChE is found specifically in the growth cone and at branch points, 
where its colocalisation with APP is maintained. In spreading cells AChE is distributed 
in discrete regions of the cell periphery, again showing precise colocalisation with APP, 
but not with the focal adhesion marker vinculin. Using the technique of TIRF 
microscopy, these regions of AChE immunofluorescence were shown to be close to the 
substratum, suggestive of a role in adhesion. Application of the monoclonal AChE 
antibody MAB304 and its secondary antibody to live fibroblast cultures at 37'C 
redistributed AChE away from the cell periphery, towards the centre of the cells. This 
clustering action also caused some redistribution of perlecan, but had no effect on the 
localisation of APP, implying a functional interaction between AChE and perlecan on 
the fibroblast cell surface. Characterisation of potential interacting partners on the cell 
surface of fibroblasts revealed that while addition of laminin could cluster and 
redistribute ccDG, it had no effect on the surface localisation of AChE, nor did addition 
of collagen IV or fibronectin. The relevance and potential implications of these novel 
findings are discussed below. 
3.15.1 Do fibroblasts and astrocytes express AChE? 
The expression and function of AChE outside the nervous system is an area of research 
that is still in its infancy. Though this is not the first study to show the expression of 
AChE with seemingly low catalytic activity in non-neuronal cells (See Thulberry et al 
2005), it has found several novel pieces of information, much of which relies upon the 
use of antibodies directed against AChE. Therefore, an obvious area of concern is the 
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specificity of the antibodies; is what they are detecting truly AChE? This is particularlý' 
important since the catalytic activity is much lower than that in neuronal cells. Several 
key pieces of evidence support AChE as the species being detected and will be briefly 
addressed before further discussion of the implications of this data. Firstly, on reducing 
western blots the major AChE band in fibroblasts and astrocytes co-migrates with that 
detected in cerebellar granule cells and PC12 cells, two cell types established to express 
AChE (Grifman et al., 1998; Meshorer et al., 2002). Secondly on non-reducing western 
blots the species detected by two separate AChE antibodies, one a monoclonal (Clone 
46) and one a polyclonal (H-134) are the same with no other major bands being 
detected, and importantly migrate at the same relative position as human recombinant 
AChE detected by H-134. In chapter 4, where an AChE-T transgene is expressed in 
fibroblasts, Figure 4.8 shows that this results in the increased intensity of a band 
identical to that in parental cells detected by Clone 46, and is accompanied by an 
increase in AChE specific activity in Figure 4.9. Moreover, in chapter 5, Figures 5.1 
shows an apoptosis induced increase in AChE specific activity that is accompanied by 
increased density of the band detected by Clone 46 on western blots (Figure 5.2). In 
addition, in Chapter 5, initial studies using RNA mediated interference showed a 
suppression of AChE expression on human fibroblasts detected by intracellular AChE 
immunofluorescence with Clone 46 (5.1 1B). 
Both antibodies used for western blotting have been extensively used in recent years for 
this purpose in well respected j ournals in including the Journal of neuroscience (Dong et 
al., 2004), Bone (Inkson et al., 2004) and Oncogene (Deng et al., 2006). With respect to 
the detection of the species on the cell surface, subcellular fractionation showed by 
western blotting (and correlating with pure AChE protein in Figure 3.5) that 
immunopositive species were detected in the Triton X-100 soluble membrane fraction. 
Moreover, four antibodies raised against different immunogens of the protein produced 
similar staining patterns on non-permeabilised cells. Indeed, AChE has already been 
shown to be transcribed in NIH 3T3 fibroblasts as highly as in C2 myoblasts and 
myotubes (Mutero et al., 1995). Together all these pieces of evidence suggest that the 
species under detection has a high probability of being AChE rather than a non-specific 
artefact, though ultimate confirmation could be carried out by mass spectrometry. If this 
species was not AChE it would have to comigrate specifically at the molecular weight 
of neuronal and recombinant AChE, form oligomeric forms under non-reducing 
166 
Chapter 3: Expression, Activity and Localisation of AChE in neuronal and non- 
neuronalcells 
conditions that run at the same position to recombinant AChE. be recognised by four 
different AChE antibodies raised against different immunogens, (two polyclonal and 
two monoclonal), be increased by AChE overexpression and reduced by RNAi 
mediated knockdown. 
3.15.2 AChE, a role beyond the enzymatic? 
A notable outcome of both this study and that of Thullbery et al is the comparable 
levels of expression of AChE protein in neuronal and non-neuronal cells, but the 
disparity in their levels of enzymatic activity (Thullbery et al., 2005). While a low level 
of enzymatic activity is quite logical in non-neuronal cells which do not need to 
terminate ACh mediated neurotransmission, the comparable level of protein expression 
is more difficult to explain unless AChE has additional functions not dependent upon 
catalytic activity in these cells. 
How the non-neuronal cells have lower levels of enzymatic activity is an intriguing 
question. It could represent a lower activity of the whole pool, or there may be a small 
proportion of fully active AChE within a larger inactive pool. AChE is generally 
considered catalytically active when expressed, but this is not this first time that AChE 
species of relatively little activity have been observed, as inactive AChE has previously 
been demonstrated in chicken brain and in apoptotic lung fibroblasts (Chatel et al., 
1993a; Jin et al., 2002; Rotundo, 1988). In chicken brain, where 70-80% of newly 
synthesized AChE is rapidly degraded in the endoplasmic reticulum (Rotundo, 1988) 
antibodies differentially recognising either total or catalytically active forms of AChE 
have shown inactive AChE constitutes 30% of the total present in chick brain (Chatel et 
al., 1993b). Moreover, addition of the neuropeptid e calcitonin gene related peptide to 
cultured chick myotubes has also been shown to induce an increase in AChE mRNA 
and protein, without any increase in activity, suggesting the production of inactive 
AChE forms (Choi et al., 1998). Thus, significant amounts of non-catalytically active 
AChE are already known to be expressed and the results of this chapter show that a 
higher proportion of these inactive/less active forms are expressed in non-neuronal 
versus neuronal cells. 
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Reducing PAGE showed a lower molecular weight species of approximately 50kDa that 
was selectively expressed in non-neuronal cells, and whose expression has previously 
been noted in osteoblasts (Inkson et al., 2004). Although its identity as AChE has not 
been confirmed, (for example by mass spectrometry), its specific expression in non- 
neuronal cells with relatively low levels of enzymatic activity makes it tempting to 
consider whether this band is a less active/inactive species. Alternatively, this band may 
represent a higher proportion in these cells of a particular splice variant, such as the 
classical C-terminal soluble R splice variant, or one of the recently described novel N- 
terminal splice variants (Meshorer et al., 2004). This would need to be resolved using 
reverse-transcriptase polymerase chain reaction (RT-PCR) on the mRNA being 
transcribed by the different cell types. This was not carried out due to time constraints, 
but would prove to be a vital step towards identifying the lower AChE band and 
potentially the origins of the differences in enzymatic activity. 
3.15.3 AChE on the surface of neuronal and non-neuronal cells; a function 
at regions of membrane protrusion? 
Though neuronal and non-neuronal cells differed in activity levels, all the cells 
examined showed a parallel surface AChE distribution with immunolabelling 
concentrated at regions of membrane motility; the growth cones of neurones and the 
leading edge of migrating fibroblasts and astrocytes. AChE was expressed on the 
surface of neurones isolated from three different brain regions and although its presence 
on these cells can be in part be attributed to an ACh hydrolysis, its distribution at branch 
points and growth cones is also suggestive of a morphoregulatory role. Though 
hippocampal neurones are heavily innervated by cholinergic axons from the basal 
forebrain (Frotscher and Leranth, 1985; Amavour et al., 2002), relatively few neurones 
in the hippocampus are cholinergic (Amavour et al., 2002), while the cerebellum 
receives very little cholinergic input, being mainly glutarnatergic (Appleyard et al., 
1988). Therefore, the expression of AChE in cultures of young cerebellar, hippocampal 
and cortical neurones supports suggestions that AChE may be initially universally 
expressed by projecting neurones regardless of their final neurotransmitter identity 
(Robertson, 1987). The segmental distribution and localisation at growth cones was 
only examined in young cultures of neurones (DIV3-4) and there is evidence in vitro 
that this expression pattern is transient (Dong et al., 2004). In vivo studies have shown 
the expression level of AChE in the cortex (Geula et al., 1995), hippocampus (Forloni et 
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al., 1989) and cerebellum (Olschowka and Vijayan, 1980) declines with brain 
maturation, also supporting a role in initial pathfinding. Indeed avian neural crest cells 
transiently express AChE during their migration (Layer and Kaulich, 199 1 ). 
The localisation of AChE at growth cones in hippocampal neurones has been previously 
shown by several other groups (Dong et al., 2004; Olivera et al., 2003b; Thompson et 
al., 1996) and the discontinuous segmental distribution has also been noted in chick 
sympathetic neurones (Rotundo and Carbonetto, 1987), however this is the first report 
of a consistent distribution of AChE at the leading edge of migrating non-neuronal cells. 
Since the cellular processes governing cell migration are also those crucial in growth 
cone motility, the parallel distribution of AChE at motile growth cones in neurones and 
leading larnellipodia of non-neuronal cells makes it tempting to hypothese that AChE 
plays conserved role inherent in these processes. Both cell migration and neurite 
outgrowth are governed by the ability of the cell to extend, retract and stabilize 
membrane protrusions in a defined direction. The protrusive force is provided by actin 
via a ruffling leading lamellipodium from which radiate filopodial spikes. Filopodia 
extending from advancing growth cones consist of densely bundled F-actin, which acts 
like antennae by transducing environmental signals into cellular responses through the 
rapid reorganization of the actin cytoskeleton (Challacombe et al., 1996). 
Similarly during fibroblast motility, the leading edge extends an actin-polymerisation 
mediated protrusion at its front with addition of new membrane from internal stores, and 
attachment to the substratum via integrins. Actomyosin contraction then moves the cell 
body forwards, towards the protrusion, with release of attachments at the cell rear and 
retraction of the tailing end. Localisation of vinculin in primary fibroblasts clearly 
showed it in adhesion sites leading from F-actin stress fibres, in comparison AChE in 
fibroblasts did not appear particularly localised at proximal endings of F-actin filaments, 
but appeared more closely associated with MTs (though its surface distribution was not 
altered upon MTs disruption with nocodazole). MTs are also pivotally involved in cell 
migration, though it appears in a more cell-type specific manner and their perturbation 
has been shown to inhibit lamellipodia formation in fibroblasts, astrocytes and neurones 
(Liao et al., 1995. Etienne-Manneville and Hall, 2001; Gibney and Zheng, 2003). 
Directed migration requires cells to polarise, which relies on MTs orientating along the 
migration axis, so that the golgi apparatus and microtubule organizing centre are 
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directed towards the leading edge, a process that involves the cytosolic tumour 
suppressors APC and Dlg (Etienne-Manneville et al., 2005). MTs are also Involved in 
cell contraction during migration and induce focal adhesion disassembly via dynamin 
and focal adhesion kinase (Ezratty et al., 2005). Cell migration therefore depends upon 
coordination between these two cytoskeletal elements (their relative positions and 
associations during protrusion are shown in Figure 3.39) and ACK interacting with 
MTs could allow it to play a role in cell motility. 
The arrangement of the cytoskeletal elements during cell protrusion is illustrated below: 
lamellipodia 
ruffles 
actin-rich 
region 
actin , 
hkjlldleý; 
filopodia 
actin - 
niesýw ork 
focal adhesion 
stress fibers 
4- protrusion 
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lamella 
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rN 
microtubule-rich 
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Figure 3.39 Cytoskeletal elements 
contributing to cellular protrusion 
In cellular protrusions, there are actin rich 
regions shown in red which form filopodia 
by actin bundles, a dense actin meshwork 
forming a ruffling lamellipodia and only a 
few pioneer microtubules; and a 
microtubule-rich region shown in green, 
where microtubules radiate from the 
centrosome (dark preeil star) with their 
plus-ends directed towards the plasma 
membrane and where actin structures are 
essentially limited to stress fibers (thick red 
lines), anchored to the substrate via focal 
adhesions (blue dots). In the neuronal 
axon, the actin-rich region is limited to the 
peripheral zone of the growth cone, while 
microtubules extend from the cell body 
into the central region of the growth cone. 
Taken from Etienne-Manneville 2004 
Another element which AChE could be associated with at these regions is the exocyst 
complex. This complex of proteins was originally described in yeast and has now been 
implicated in several aspects of exocytosis and vesicle trafficking in mammalian cells. 
The exocyst is specifically localised to sites of active exocytosis and polarized cell 
growth, for example, in developing neurones, the exocyst is localised to the tips of 
growing neurites (Kee et al., 1997) and at branch points (Lalli and Hall 2005). Indeed 
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immunofluorescent localisation of elements of the exocyst complex in young cultured 
hippocampal neurones shows a segmental distribution along neurites, and concentrated 
labelling at branch points and growth cones, reminiscent of AChE (Hazuka et al., 1999). 
These segments have recently been suggested to be sites where synaptic vesicle protein 
transport vesicles pause during formation of presynaptic terminals (Sabo et al., 2006). 
The exocyst complex is a downstream effector of the small GTPases including Rab, 
Rho, and Ral, allowing them to regulate exocytosis and membrane morphology. Recent 
studies have shown that the exocyst component Exo70 interacts with the Arp2/3 
complex, which stimulates actin polymerization by nucleating actin filaments (Zuo et 
al.,, 2006). Indeed in scratch assays, endogenous Exo70 is recruited from intracellular 
membranes to the leading edge as cells moved into the wound (Zuo et al., 2006). Thus, 
AChE in regions of membrane motility could additionally be interacting with 
components of the exocyst complex, a hypothesis which could be characterised by 
further colocalisation studies using antibodies directed to members of the exocyst 
complex. The localisation of AChE at these motile regions makes it perfectly placed to 
play a morphoregulatory role, though further studies are needed to determine whether it 
is coordinating with known migratory elements; MTs, actin, the exocyst complex, or 
whether it may be part of a novel macromolecular cell surface complex involved in 
modulating cell protrusion and thus motility. The functional role of AChE in the 
processes of outgrowth and migration will be examined in Chapter 4. 
Intriguingly, initial studies using polyclonal anti-AChE antibody H-134 in wounded 
mouse skin kindly carried out by Dr Ryoichi Mori in Dr Paul Martin's group in Bristol 
has revealed that akin to the localisation of AChE at the leading edge of in vitro 
wounded monolayer, in wounded mice a high level of AChE is detected in the leading 
epidermis at the wound edge I day after wounding (Figure 3.40, where AChE staining 
is shown in red). This level has decreased by 3 days, when only a weak positive signal 
was detected in the nascent epidermis, while after 7 days there is only a very weak 
positive signal in the nascent epidermis, but an additional infiltration of AChE positive 
cells into the wound site. This suggests that the striking localisation of AChE in 
migrating cells in vitro also occurs in vivo and that AChE may play a role in the initial 
stage of in vivo wound healing in mice. 
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AChE 
Normal 
skin 
Day 1 
Day 3 
Day 7 
V: wound edge E: Epidermis 
4: leading edge NE: Nascent Epidermis 
HF: Hair Follicles 
MdH: Modulla of Hairs 
CtH: Cortex of Hairs 
D: Dermis 
S: Scab 
WS: Wound Site 
MsL: Muscle Layer 
Figure 3.40 AChE localises to the leading epidermis at early time points during in vivo 
wound healing. Sections of wounded mice were fixed in paraformaldehyde and 
immunohistochernical localisation of AChE carried out with H-134 (1: 100) and anti-rabbit 
TRITC (1: 400) in unwounded skin or in the skin at Day 1,3, or 7 post-wounding. AChE 
expression of cells of the nascent epidermis at the wound margin was elevated on Day I post- 
wounding. Kindly carried out by Dr Ryoichi Mori, University of Bristol. 
3.15.4 AChE and APP; common distribution and function? 
A notable outcome of the localisation study was the precise colocalisation between 
AChE and APP in both neuronal and non-neuronal cells. The physiological role of APP 
has not yet been elucidated, but it is most well known for the involvement of its 
cleavage product, the AP peptide in AD. In the mature nervous system, APP has been 
localised to both peripheral and central synaptic sites (Schubert et al., 1991), where it 
has potential roles in cell-cell and cell-substrate adhesion (Breen et al., 1991; Schubert 
et al., 1989). Like AChE, a number of studies over the past decade have suggested a role 
for APP in the promotion of neurite outgrowth, cellular migration and adhesion (Sabo et 
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al., 2001; Sabo et al., 2003; Storey et al., 1996). AChE activity is lower in most regions 
of the AD brain, but it is increased within and around amylold plaques, where it 
colocalises with AP within the plaques (Wright et al., 1993). AChE promotes amylold 
fibre assembly (Inestrosa et al., 1996a). Moreover, AChE-AP complexes are more 
neurotoxic than the AP peptide alone on in vitro hippocampal cultures and in vivo upon 
injection into the dorsal hippocampus (Alvarez et al., 1998; Reyes et al., 2004), thought 
to be partially mediated by decreasing the cytoplasmic level of P-catenin, a key 
component of Writ signalling (Inestrosa et al., 2005; Inestrosa et al., 2000; Inestrosa et 
al., 2004). 
In addition to the correlations between AChE and APP related to AD,, there are many 
other parallels between these two proteins. Like AChE, APP expression increases to 
coincide with the period of brain development when neurite outgrowth and 
synaptogenesis is maximal (Moya et al., 1994) and APP expression increases during 
neuronal differentiation (Hung et al., 1992). Reminiscent of AChE, APP is expressed 
highly within growing neurites and in growth cones and in vitro studies have shown that 
APP can promote cell adhesion (Breen et al., 1991; LeBlanc et al., 1992; Schubert et al., 
1989), cell survival, and neurite outgrowth of PC 12 cells and primary cultures of central 
and peripheral neurones (Araki et al., 1991; Milward et al., 1992). Keratinocytes 
derived from APP knockout mice show reduced migration and adhesion (Siemes et al., 
2006) and like AChE, APP is proposed to bind to laminin and collagen IV (Kibbey et 
al., 1993; Caceres and Brandan, 1997; Johnson and Moore, 2003; Paraoanu and Layer, 
2004; Paraoanu and Layer, 2005). Similar to AChE, the mechanism and components 
interacting with APP interacts to mediate these effects have not been resolved. 
The significant segmental distribution of both AChE (in hippocampal neurones) and 
APP (in cortical neurones) in neurites and growth cones has been individually noted by 
previous studies (Allinquant et al., 1994; Olivera et al., 2003b; Dong et al., 2004). 
However this is the first time that a precise colocalisation between these proteins has 
been shown in both neuronal and non-neuronal cultures. Indeed, like AChE relatively 
few studies have examined a role for APP outside the nervous system. Comparison of 
the surface distribution of APP with elements of the cellular cytoskeleton showed a 
clear alignment of APP with lamellipodial microtubules. This is interesting since 
secretion of neuronal AChE tetramers is microtubule dependent (Lucas and Kreutzberg, 
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1985) and APP is known to play a role in intracellular transport (Gunawardena and 
Goldstein, 2001; Salehi et al., 2006), though seemingly not as a kInesin receptor 
(Lazarov et al., 2005). Therefore, it is possible that APP is delivered with AChE to sites 
of active membrane protrusion which are required for cell migration. Supporting an 
interaction between AChE and APP is a study carried out by Bigbee and Sharma in 
2004, examining potential binding partners for AChE. They found that pure AChE 
could bind to a protein of a molecular weight of II OkDa, the molecular weight of APP 
(Bigbee and Sharma, 2004). 
Interestingly, the expression of APP has also recently been considered during wound 
healing in mice and shown to increase in expression in the epidermis at the wound 
margin, in a manner temporally similar to AChE (Kummer et al., 2002). Examination of 
APP mRNA levels revealed that APP expression initially increases, peaking I day after 
wounding, with a decline after 3 days, followed by an increase at day 13, when wound 
closure is achieved (Kummer et al., 2002). This expression pattern would appear similar 
to the AChE expression seen in Figure 3.40 where an initial increase in AChE staining 
is seen in the new epidermis at the wound edge, followed by a reduction and subsequent 
increase in AChE expression in cells infiltrating into the wound. Thus, it is possible that 
in vivo AChE and APP may codistribute in an analogous manner to in vitro and this is 
currently being addressed by collaborative studies with Dr Paul Martin's group. 
Clustering of ACK did not redistribute APP, suggesting either that these are not 
directly interacting on the cell surface or that their interaction is too weak to overcome 
the anchoring interactions holding APP in place. Alternatively, AChE and APP may be 
directed to the same location on the cell surface by binding to a common interacting 
partner. Intriguingly, a region of APP located within the AP sequence has been found to 
have seven residues in common with the 12-25 fragment of the human AChE-T peptide, 
potentially suggesting that these regions of both proteins may interact with a common 
target (Greenfield and Vaux, 2002). 
The colocalisation between AChE and perlecan is particularly pertinent since APP has 
been shown to associate with components of the extracellular matrix, including perlecan 
(Narindrasorasak et al., 1991). Indeed, perlecan is implicated in the pathogenesis of AD 
as it localises with AP in senile plaques, and like AChE can accelerate AP fibril 
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formation, and maintain AP fibril stability (Castillo et al., 1997; Narindrasorasak et al.. 
1995). In addition, the adhesion of vascular smooth muscle cells to perlecan can be 
inhibited by addition of the AP peptide (Mok et al., 2006). Since AChE shows 
significant colocalisation with APP and perlecan, it seems likely that these two proteins 
would also show colocalisation with each other, though this would need to be 
confirmed. Thus, on the cell surface one could hypothesise that a complex may exist 
between MTs, AChE, APP and perlecan, potentially providing a mechanical link 
between the internal cytoskeletal network via the cytoplasmic domain of APP and 
extracellular matrix proteins to modulate cell protrusion. Indeed perlecan has been 
shown to play a role in the metastatic migration, adhesion, and invasion of tumour cells. 
Increased perlecan expression is observed in breast cancer and highly metastatic murine 
melanoma cells, and its suppression by antisense can reduce metastatic potential, 
migration and proliferation (Marchisone et al., 2000). Transgenic mice expressing a 
mutated perlecan gene have also been shown to have reduced wound repair (Zhou et al., 
2004). 
The interactions of the integrin family of receptors with ECM are critically important 
for substratum adhesion and migration. Comparison of the distribution of AChE with 
Pl-integrin and vinculin revealed that AChE staining did not correspond to the general 
integrin distribution or focal adhesions in fibroblasts and astrocytes. Despite this 
apparent lack of correlation it is possible that AChE co-distributes with a sub- 
population, potentially of active integrin receptors not distinguished by this Pl-integrin 
antibody. Indeed, in migrating MDCK cells APP has been shown to colocalise with 
active Pl-integrins but only in unstable focal complexes, not at the more stable focal 
contacts characterised by vinculin (Sabo et al., 2001). Moreover, the distinct peripheral 
segments of APP immunolabelling observed in spreading astrocytes have previously 
been shown to colocalise with Pl-integrins (Yamazaki et al., 1997). Interestingly, 
within the AP domain of APP there is an RHDS tetrapeptide motif (at residues 5-8 of 
the AP sequence) (Ghiso et al., 1992; Saporito-Irwin and Van Nostrand, 1995). The 
similarity of this motif to the RGDS binding motif recognized by many integrin 
receptors has led to suggestions that AP can affect adhesion via integrin-like receptors 
(Sabo et al., 1995). The colocalisation of AChE and APP would imply that AChE may 
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also be located at these sites and could be further characterised with antibodies directed 
against active PI -integrins. 
3.15.5 AChE distribution on the surface of non-neuronal cells; a role for 
perlecan but not ccDG? 
Colocalisation studies with aDG and perlecan, known players in anchoring AChE at the 
NMJ revealed that AChE did show some co-distribution with perlecan, while aDG 
showed a far wider general cell surface distribution. AChE clustering also induced some 
redistribution of perlecan suggesting that these two proteins show a functional 
interaction on the cell surface, while aDG clustering had no effect on AChE 
distribution. However, even in the NMJ, aDG, like other members of the dystrophin 
complex, localises not only to the postsynaptic membrane but also along the general 
sarcolemma and yet is involved in the specific clustering of AChE via perlecan (Peng et 
al., 1999). Thus, there may be another layer of specificity which is not immediately 
discernable. Glycosylation is vitally important in the interactions of aDG with laminin 
for example. Therefore, perhaps differentially glycosylated forms of aDG provide 
specificity to its interactions, both in the neuronal and non-neurons systems. In such a 
case a differentially glycosylated form, not specifically recognised by the antibody used 
here may be specifically localised in the regions rich in AChE. Further localisation 
studies using antibodies directed to the different glycoepitopes of aDG would clarify 
this. 
At the NMJ, perlecan is linked to AChE via its CoIQ tail, and therefore an obvious 
question raised by the partial codistribution of AChE and perlecan in fibroblasts and 
astrocytes is whether AChE in these cells interacts with a CoIQ anchor (which could 
then bind to perlecan). This could be determined with CoIQ antibodies, several of which 
have recently become commercially available, or by RT-PCR. AChE could alternatively 
be anchored to the cell membrane via WAT-PRAD interactions (see introduction) with 
PRiMA, particularly since subcellular fractions reveals AChE immunoreactive bands in 
the Triton X-100-soluble membrane fraction. RT-PCR studies would be essential to 
confirm the identity of the AChE isoforms expressed in these cells. However the 
presence of multimeric AChE-immunoreactive complexes co-migrating with 
recombinant tetrameric AChE suggests that at least the AChE-T form is expressed in 
3T3 fibroblasts, and that this multimeric complex is associated with cell membranes. 
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3.15.6 Conclusions and Summary 
Comparative levels of AChE are expressed by both neuronal and non-neuronal cells; 
however the enzymatic activity does not correlate with protein expression, being 
significantly lower in non-neuronal cells. This shows that the level of ACh hydrolysis of 
a particular cell type cannot be used as an indicator of the level of AChE protein 
expression. Immunofluorescent studies localised AChE to the leading edge of migrating 
fibroblasts and astrocytes, the periphery of spreading cells and to branch points and the 
growth cones of neurones, which were shown by TIRF microscopy to be close to the 
substratum. The specific localisation of ACK to regions of membrane motility in vitro, 
at early stages of wound healing in mice in vivo together with previous studies showing 
AChE is expressed by migrating neural crest cells and neuronal stem cells suggests it 
may have a universal role in modulating migration which is likely to not be dependent 
upon enzyme activity. The functional role of AChE in outgrowth and migration in the 
cell types examined in this chapter will be the focus of Chapter 4. 
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4 AChE and its ligands modulate outgrowth, migration and 
adhesion in neuronal and non-neuronal cells 
4.1 Introduction 
The actions of AChE and selected AChE-ligands suggest that it may play a role in 
neurite outgrowth and cell adhesion. However, the mechanism underlying these effects 
has not yet been characterised and significant variability is seen between different 
studies and different neuronal populations. The striking localisation of AChE shown in 
Chapter 3 at the leading edge of fibroblasts and astrocytes and on the growth cones of 
neurones suggests it may play a common role in protrusion in both neuronal and non- 
neuronal cells. This was systematically investigated by examining the actions of ACK 
and ligands binding at different sites on the molecules on the outgrowth of neurones 
isolated from three regions of the rodent brain and on fibroblast migration. 
Though a role for AChE is emerging outside the nervous system, the majority of work 
examining a putative morphoregulatory role for AChE up to now has focused on the 
actions of AChE and its ligands in neuronal cells. A role for AChE in neurite outgrowth 
was first suggested by morphological studies which revealed that in vivo there is a close 
spatiotemporal correlation between transient AChE expression and areas of axon tract 
formation, even in areas that do not go on to become cholinergic (Anderson and Key, 
1999). Indeed, even in Drosophila photoreceptor cells, AChE is present during axonal 
outgrowth, before the formation of functional connections within the developing optic 
lobes (Wolfgang and Forte, 1989). By manipulating the levels of AChE in 
neuroblastoma cells or DRG neurones, Koenigsberger et al. and Bigbee et al., 
demonstrated that the extent of neurite outgrowth in these cells directly correlated with 
their levels of AChE expression (Koenigsberger et al., 1997; Bigbee et al., 1999; Bigbee 
et al., 2000). Increased outgrowth is also seen upon increasing AChE-T levels in C6 
glioma and PC12 neuronal cells (Karpel et al., 1996; Grifman et al., 1998). In these 
studies AChE is suggested to promote neurite extension by modulating the adhesion 
capacity of neurites. In addition, AChE is suggested to have a synaptogenic property, 
and can for example enhance NMJ development (Sternfeld et al., 1998) and this 
property does appear to be dependent upon the hydrolytic capability of AChE 
Sterrifeld et al., 1998. Olivera et al., 2003b; Dong et al., 2004). 
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Although multiple reports support a role for AChE in neuronal outgrowth and adhesion 
(Bigbee et al., 2000; Day and Greenfield, 2002; Olivera et al., 2003b; Dong et al., 
2004), the mechanism underlying this neuritogenic role is not fully understood, nor 
universally accepted by all those within the AChE field. AChE has several regions that 
have been considered candidates for mediating morphoregulation. The HNK-I epitope 
on AChE was early on considered as a mediator of adhesion since this carbohydrate 
epitope is characteristically expressed on a series of cell adhesion molecules including 
integrins, proteoglycans, and glycolipids where it is involved in both cell-cell and cell- 
matrix interactions, including the migration of neural crest cells (Bronner-Fraser, 1987). 
An HNK-I epitope has been shown to be expressed on isoforms of electrophorus, 
bovine and human AChE (Bon et al., 1987; Johnson and Moore, 2001). However, since 
BChE forms can also possess this epitope, a function for HNK-I in AChE specific 
effects is less likely (Weikert and Layer, 1994). 
AChE shows homology with a group of cell adhesion molecules including neurotactin, 
glutactin, gliotactin and neuroligin (Olson et al., 1990; Barthalay et al., 1990; Auld et 
al., 1995; Ichtchenko et al., 1995; Darboux et al., 1996; Andres et al., 1997; Grifman et 
al.. ) 1998) all of which possess an AChE-like extracellular 
domain, but lack the critical 
serine residue required for a functional enzymatically active site. Comparative 
modelling of these proteins with AChE has led to the identification of a region of 
negative electrostatic charge on homologous regions of their surface (Botti et al., 1998). 
This conserved domain has been denoted an electrotactin domain and has been 
suggested to be of functional importance in cell adhesion (Botti et al., 1998). 
Crystallographic and biochemical studies have also revealed two other features 
conserved between all cholinesterase-domain proteins; the presence of a calcium 
binding EF-hand motif, and the ability to form oligomers via a four-helix bundle and the 
PAS. The ligands of neuroligin, and neurotactin (P-neurexin and amalgam respectively) 
interact with this cholinesterase-homologous electrotactin domain and both these 
molecules show the characteristics of heterophilic cell adhesion proteins in cell 
aggregation assays (Nguyen and Sudhof, 1997; Fremion et al., 2000). Furthermore, 
AChE shows functional redundancy with both neurotactin and neuroligin. Replacement 
of the cholinesterase domain of neurotactin with that of AChE, still allowed the 
chimeric protein to retain its adhesive properties (Darboux et al., 1996). while 
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neuroligin shows redundancy with AChE in the ability to support neurite outgrowth in 
vitro (Grifman et al., 1998). 
A significant amount of evidence has suggested that the key region of AChE in neurite 
outgrowth is the PAS (Bataille et al., 1998; Bigbee et al., 1999; Blasina et al., 2000. 
Olivera et al., 2003b). This is based on both its presence in the region of homology 
shared by members of the cholinesterase domain family and several in vitro studies 
which have shown that neurite outgrowth is affected by ligands that modulate the PAS, 
but not by ligands that solely affect the active site (Bataille et al., 1998; Bigbee et al., 
1999; Day and Greenfield, 2002; Olivera et al., 2003b). This was first shown by the 
seminal paper of Layer et al in 1993, when treatment of chick retinal cells with 
BW284c5I which binds at both the PAS and the active site was shown to be able to 
modulate outgrowth, while echothiophate which acts at the active site had no effect 
(Layer et al., 1993). Ligands binding at the PAS have since been shown to modulate 
neurite outgrowth of hippocampal neurones (Olivera et al., 2003b), motor neurones 
(Bataille et al., 1998) and chick retinal cultures (Blasina et al., 2000). In vitro studies 
have shown that AChE can bind to both laminin and collagen IV via a PAS mediated 
mechanism (Johnson and Moore, 2003), supporting suggestions that AChE mediates 
effects on outgrowth effects via an adhesive function involving the PAS. 
The neuritogenic function of AChE has also been suggested to be dependent upon the 
C-terminal extension of AChE (Sternfeld et al., 1998). Expression of different AChE 
constructs in Xenopus spinal neurones showed that increasing the levels of both 
wildtype and an inactive AChE-T mutant could increase neurite outgrowth, but that this 
action was not shared by constructs producing soluble AChE fonns (Sternfeld et al., 
1998). Though the PAS domain is common to all AChE isoforms, this study indicated 
that the ability of AChE to increase neurite outgrowth relied upon it being able to 
associate with the membrane. Conversely, other studies have shown that alternative, 
soluble and GPI-anchored AChE isoforms were equally as capable of stimulating 
neurite outgrowth as the AChE-T synaptic isoform. (De Jaco et al., 2002), while addition 
of soluble AChE isoforms have also been shown to increase neurite outgrowth in 
dopaminergic, hippocampal and spinal cord motor neurones (Jones et al., 1995; Holmes 
et al., 1997; Bataille et al., 1998; Day and Greenfield, 2002; Olivera et al.. 2003b). 
Therefore. the contribution of the C-terminus is unclear. 
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In addition, the outgrowth modulating activity of AChE becomes more complex when 
taking into account that neurite outgrowth from cultured neurones can also be affected 
by acetylcholine (ACh) or its agonists (Lipton et al., 1988; Small et al., 1995). Thus, 
AChE exerting its enzymatic activity to hydrolyse ACh secreted from growth cones, 
may create an ACh sink, which would also influence the neurite growth. Therefore, 
AChE may affect neurite outgrowth directly by means of a neuritogenic role and 
indirectly by mediating ACh hydrolysis. 
Recent studies have shown that AChE is extensively expressed outside of the central 
nervous system and initial studies suggest that AChE may play a morphoregulatory role 
in these non-neuronal cells. In bone, AChE is suggested to act as a novel bone matrix 
protein, based on its presence at cement lines, increase during osteoblast differentiation 
and the ability of AChE inhibitors to reduce osteoblast adhesion (Genever et al., 1999; 
Inkson et al.,, 2004). In addition, a role has recently emerged for AChE in the 
endothelium (Carvalho et al., 2005). ACh itself is also widely expressed outside the 
nervous system (Grando et al., 2003; Kirkpatrick et al., 2003; Wessler et al., 2003), 
where it has been shown to modulate cell-cell adhesion of keratinocytes (Nguyen et al., 
2003). Thus, the actions of AChE on neurite outgrowth and adhesion are complex and 
multifaceted, with much debate still existing within the literature regarding the 
underlying mechanism and protein domains involved and far less is known regarding its 
role in non-neuronal cells. 
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4.1.1 Aims of this study 
The localisation of AChE at the leading edge of migrating fibroblasts and astrocytes and 
the growth cones of neurones make it ideally placed to play a role in cellular migration. 
In this chapter the aim was to test whether AChE could play a common role in 
protrusion at the leading edge of neurites and all adherent cells. The effects of 
modulating AChE interactions using commercially available AChE inhibitors, an AChE 
antibody, eel AChE and overexpression of AChE-T in 3T3 fibroblasts was examined in 
several paradigms, namely neuronal outgrowth and fibroblast migration and adhesion. 
One hypothesis to explain the actions of AChE is that it mediates its effects by binding 
to an as yet unidentified endogenous ligand. Thus, application of ACK or AChE 
ligands could potentially have two effects; mimicking an endogenous ligand to 
potentiate migration and outgrowth, or competition/ perturbation of the interactions of 
ACK and its endogenous ligand to reduce outgrowth and migration. This was 
investigated using a comprehensive panel of ACK ligands binding to different sites on 
the molecule. These agents were; the monoclonal antibody MAB304 shown in Chapter 
3 to be capable of binding to live cultures of fibroblasts, BW284c5l and fasciculin two 
inhibitors known to bind to the PAS of AChE, and two inhibitors considered to bind 
primarily to the active site of AChE; tacrine, and edrophonium. In addition, the effects 
of increasing ACK levels by application of exogenous eel AChE and co-culture with 
AChE overexpressing fibroblasts was tested. The actions of these AChE ligands on 
neurite outgrowth were determined and compared in three types of primary rodent 
neurones; those isolated from PND4 cerebellar granule neurones (CGNs), E18-19 
hippocampal and E18-19 cortical neurones. These developmental ages were examined 
as they represent the time at which post-natal cerebellar and embryonic hippocampal 
and cortical development occurs; the neurones have been newly generated, but it is prior 
to major axonal outgrowth. The process of neurite outgrowth is analogous to cellular 
migration in motile cells and the actions of AChE ligands and ACK overexpression 
were examined on fibroblasts. 
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4.2 AChE Morphoregulation in neurones 
4.2.1 Commercially available AChE ligands inhibit AChE activity: 
Several AChE ligands are commercially available and are known to be capable of 
inhibiting AChE activity. In order to examine the effects of the inhibitory AChE ligands 
on neurones and fibroblasts,, the relative inhibitory activity of a panel of ligands on 
commercially available eel AChE was first established, as shown in figure 4.1. The eel 
AChE was incubated with the inhibitors for 30mins on ice, prior to analysis of the 
activity being carried out. As can be seen in Figure 4.1, activity is significantly inhibited 
by addition of 1-100ýtM BW284c5l, 100ýiM-ImM edrophonium, 10-100ýtM tacrine 
and WnM-IýM fasciculin. The AChE inhibitors have been used within these 
concentration ranges in subsequent neurite outgrowth and migration assays. 
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Figure 4.1 Action of AChE inhibitors on AChE activity 
Effects of AChE inhibitors BW284c5 1, Tacrine, Fasciculin and Edrophonium on enzymatic 
activity of commercially available eel AChE. Pure enzyme was incubated for 30 min with 
increasing concentration of each inhibitor. AChE activities are shown as percentage of controls. 
Representative experiment in triplicate ± sem. 
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4.2.2 Selected AChE ligands retard neurite outgrowth in primary neuronal 
cultures and cell lines: 
The actions of AChE ligands on endogenous AChE on primary cultures of embryonic 
hippocampal, cortical and postnatal cerebellar neurones were investigated using agents 
that bind to both the active and the peripheral anionic site of AChE. These agents 
included BW284c5l which binds primarily to the peripheral anionic site of AChE 
(Barak et al., 1994). MAB304, which is an AChE-scavenging monoclonal antibody 
raised against human erythrocyte AChE. It is thought to recognise the peripheral anionic 
site and does not inhibit the catalytic activity of AChE (Olivera et al., 2003b). 
Additionally, fasciculin was used which is a potent AChE inhibitor isolated from the 
venom of the green mamba, and binds to the PAS with extremely high affinity. 
Selective inhibitors of the catalytic site of AChE edrophonium chloride and tacrine were 
used in order to ascertain the influence of the enzymatic activity on neurite outgrowth. 
Embryonic cultured hippocampal, cortical (E 18) or postnatal cerebellar neurones were 
plated at low density (5,000 cells per well on poly-L-lysine coated tissue cultures plates 
or coverslips) in F12/DMEM with B27 supplement. 16hrs post-plating (DIVI) the 
cultures were treated with a single application of one of the following; 5-50PM 
BW284c5l, 20pg ml-1 MAB304 (or IgG control), I OOnM- I pM fasciculin, I OpM tacrine 
or IOOpM edrophonium, once again in F12/DMEM with B27 supplement. Two days 
post ACK ligand addition, cultures were fixed, and neurones visualised using an 
antibody against GAP-43 (labelled neurones were detected using an anti-rabbit antibody 
conjugated to Alexa Fluor A555 and analysed using fluorescent microscopy). GAP-43 
is a useftil marker of neuronal morphology in vitro as its synthesis and transport occurs 
at high rates during periods of axonal extension and associates with the actin 
cytoskeleton (Skene and Virag, 1989). The length of the longest primary neurite 
extending from each cell body in a field of view at X40 was measured; representative 
neurones are shown in Figure 4.2C, 4.3C and 4AC for cerebellar, hippocampal and 
cortical neurones respectively. These experiments were then repeated a minimum of 
three times for both cerebellar (Figure 4.2) and hippocampal (Figure 4.3) neurones, 
while the results for cortical neurones (Figure 4.4) are a single representative 
experiment (additional experiments were carried out with cortical neurones and gave 
similar results to those presented, however due to the limited availability of fasciculin, 
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the effects of this ligand were only tested once on this neuronal. Population, the results 
of which are shown). 
Lower concentrations of BW284c5l (5ýM) showed a general trend of retarding neurite 
outgrowth in both cerebellar, and hippocampal. neurones, while higher concentrations of 
BW284c5l (50ýtM) severely inhibited outgrowth in all three neuronal populations 
(P<0.01-0.001). In hippocampal and cortical neurones 100nM fasciculin significantly 
retarded outgrowth, while this effect was only significant in cerebellar neurones at I ýM 
The single concentration of MAB304 (20[tgml-') used significantly reduced primary 
neurite outgrowth in all three neuronal populations relative to control cultures and those 
treated with an IgG control. Such results are consistent with previous work on 
hippocampal neurones (Day and Greenfield, 2002; Olivera et al., 2003b) and DRG 
explants (Sharma and Bigbee, 1998). The single concentration of tacrine tested (10ýM) 
did not have any significant effect on the neurite outgrowth of cerebellar, hippocampal 
or cortical neurones. 
However,, interestingly, though edrophoniurn had no effect on outgrowth from cortical 
(Figure 4.4) and hippocampal (Figure 4.3) neurones at the concentrations tested, it did 
induce a slight, though significant reduction in cerebellar outgrowth (Figure 4.2,82.8% 
± 3.9 of control outgrowth, results as pooled from three independent experiments), 
potentially suggesting differences in the susceptibility of the neurones to the different 
agents. Interestingly outgrowth from chick sympathetic neurones was also reduced by 
addition of edrophoniurn (Small et al., 1995). Comparison of the reduction of outgrowth 
in response to the different factors revealed that in general hippocampal neurones show 
the most retardation of neurite outgrowth in response to MA3 04 (with 48.1 % of control 
response), then 50ýM BW284c5l (51.3% of control outgrowth), and 100nM Fasciculin 
(79.1 % of control), while both cerebellar and cortical neurones were more susceptible to 
the actions of BW284c5l (45.5% of control for cerebellar and 38.3 % of control for 
cortical outgrowth) than MAB304 (53.8% of cerebellar and 68.5% of cortical control 
response) and lOOnM fasciculin (76.6% of cerebellar and 65.8% of cortical control 
outgrowth). 
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Figure 4.2 Selected AChE ligands retard cerebellar neurite outgrowth. 
CGNs at PND4 were plated at low density, 16hrs post-plating, AChE inhibitors, antibodies or 
negative controls were added for a ftirther 48hrs. (A) Histogram pooled from 3-6 independent 
experiments shows the mean neurite length in each condition ± s. e. m, 150 neurite scored in each 
experiment. Number in brackets denotes number of experiments. (B) The mean number of neurones 
per field compared in 20 fields of view were compared between the different conditions. Results are 
mean neuron number ± s. e. m. Significance determined by unpaired -students T-test. *denotes 
P<0.05, "denotes P<0.001. (C) The representative electronically captured images (using a X63 
objective lens) show the reduced neurite lengths of PND4-5 cerebellar neurones, treated for 48hrs, 
16hrs post-plating with AChE inhibitors, antibodies or negative controls. Neurons were visuallsed 
by fixing with 4% parafonnaldehyde, permeabilised with 100% ice-cold methanol and labelled with 
rabbit anfi-GAP-43 primary antibody (1: 1000) followed by anti-rabbit Alexa Fluor A555 secondary 
antibody (1: 8000). BW denotes BW284c5 1. Scale bar 20ýtm 
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gure 4.3 Selected AChE ligands retard hippocampal neurite outgrowth. 
HI pocampal neurons at E 18 were plated at low density, 16hrs post-plating, AChE ligands were p 
added for a further 48hrs. (A) Histogram pooled from 3-6 independent experiments shows the mean 
neurite length in each condition ± s. e. m., 150-200 neurite lengths measured in each experiment. 
Number in brackets denotes number of independent experiments (B) The mean number of neurones 
per field compared between the different conditions, neuron number in 20 fields of view was scored 
per condition. Statistical significance was calculated using unpaired student T-test. "denotes 
P<0.001, *denotes P<0.05. (C) The representative electronically captured images (using a X63 
objective lens) show the reduced neurite lengths of E18 hippocampal neurones, treated for 48hrs, 
16hrs post-plating with AChE inhibitors, antibodies or negative controls. Neurons were visuallsed 
by fixing with 4% paraformaldehyde, permeabilised with 100% ice-cold methanol and labelled with 
rabbit anti-GAP-43 primary antibody (1: 1000) followed by anti-rabbit Alexa Fluor A555 secondary 
antibody (1: 8000). Scale bar 20pm 
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Figure 4.4 Selected AChE ligands retard cortical neurite outgrowth. 
Cortical neurones at E18 were plated at low density, 16hrs post-platIng, AChE ligands were added 
for a further 48hrs. (A) Histogram showing mean neurite length in each condition ± s. e. m' 150-200 
neurite lengths measured in a single experiment (B) The mean number of neurones per field 
compared between the different conditions ± s. e. m. *denotes P<0.05, "denotes P<0.001 (C) The 
representative electronically captured images (using a X63 objective lens) show the reduced neunte 
lengths of E18 cortical neurones, treated for 48hrs, 16hrs post-plating with ACK inhibitors, 
antibodies or negative controls. Neurons were visualised by fixing with 4% paraformaldehyde, 
permeabilised with 100% ice-cold methanol and labelled with rabbit anti-GAP-43 primary antibody 
(1: 1000) followed by anti-rabbit Alexa Fluor A555 secondary antibody (I - 8000). Scale bar 20pm 
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In order to ensure that the reduction in neurite outgrowth is not simply due to a non- 
specific neurotoxic action of the compounds added, the effect of the different AChE 
ligands on neuronal survival was estimated by counting the number of neuronal cell 
bodies of 20 fields of view, in the control cultures compared to those treated with each 
inhibitor, at each different concentration. The histograms in Figures 4.2B, 4.313 and 
4.413 show the effects of the ligands on neuronal cell number in cerebellar, hippocampal 
and cortical cultures respectively. As can be seen, treatment with control IgG, MAB304, 
tacrine, edrophonium, fasciculin and 5ýtM BW284c5l did not significantly decrease cell 
number in any of the neuronal cultures. At higher concentrations of BW284c5l (50[tM), 
there was a slight but statistically significant (P<0.05) reduction in cell number in 
hippocampal and cortical cultures, though not in cerebellar neurones, suggesting that the 
reduction in outgrowth cannot be accounted for solely due to neurotoxic effects. 
Since MAB304 consistently reduced outgrowth without toxicity, its action on neurite 
outgrowth of NB2a cells with serum deprivation induced process extension was also 
assessed. Figure 4.5 shows that addition of 20ýtgml-' MAB304 to differentiating N132a 
cells retards neurite outgrowth to 37.5% of the control outgrowth level, in a manner 
similar to that seen in the primary neuronal cultures and in other neuroblastoma cell 
lines (Koenisberger et al 1997). 
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Figure 4.5 MAB304 retards neuroblastoma neurite outgrowth. 
NB2a cells were induced to differentiate by 24hrs serum deprivation. Cultures were then 
exposed to 20ýigml-' MAB304 or control conditions for 48hrs. (A) Neurite outgrowth of NB2a 
cells exposed to MAB304 or control conditions, histogram is representative of mean of 200 
neurites per condition in a single experiment. (B) Representative images of control and 
MAB304 treated cultures. After 48hrs exposure, cells were fixed, permeabilised with ice-cold 
methanol and neurites visualised with anti-tubulin antibody and anti-mouse Alexa Fluor A488. 
Scale bar 20ýtm 
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Together, these results show that AChE ligands can specifically retard neurite 
outgrowth in populations of neurones isolated from diverse regions of the brain and that 
this action is not dependent upon suppression of enzymatic activity per se, but rather 
perturbation of interactions on the surface of the molecule, likely associated with the 
PAS. The conserved action of the PAS ligands on the different neuronal populations 
suggests that AChE may be required for normal development of hippocampal, cortical 
and cerebellar neurones in culture. 
4.2.3 AChE increases neurite outgrowth of primary neuronal cultures: 
Addition of exogenous eel AChE has been shown to increase neurite length in 
embryonic hippocampal and embryonic ventral mesencephalic neurones (Day and 
Greenfield, 2002; Holmes et al., 1997; Olivera et al., 2003b; Whyte and Greenfield, 
2003), however addition of human recombinant AChE has been shown to inhibit 
glutamatergic transmission in hippocampal cultures (Dong et al., 2004). In order to 
resolve whether increasing AChE levels can play a neuritogenic or inhibitory role and 
whether such effect varies between neuronal populations, and developmental age, 
experiments were carried out using two methods of presenting AChE to neurones 
isolated from the cerebellum, hippocampus and cortex. Initial experiments carried out 
on poly-L-lysine characterised the effect on neurite length of exposure to soluble eel 
AChE for 48hrs in an analogous manner to characterisation of the actions of AChE 
ligands on neurite outgrowth. Additionally, cellular monolayers overexpressing AChE- 
T were used as a substratum in neurite outgrowth assays to also examine the effect on 
neurite outgrowth. This type of coculture outgrowth experiment has been employed 
several times in the study of NCAM and APP (Doherty et al., 1992, Saffell, and Kenny 
unpublished observations; Meiri et al., 1998; Saffell et al., 1994). 
Initial experiments (Figure 4.6A, n=l, mean neurite length from 150-200 neurones) on 
cerebellar, hippocampal. and cortical neurones revealed that addition of soluble eel 
AChE did appear to increase neurite length in all these cultures, particularly notable in 
the hippocampal cultures. Compared to control cultures, addition of 10ýtgml-' (IOUml-1) 
stimulated a 1.2-fold increase in neurite length in cerebellar and cortical neurones, and a 
1.4-fold increase in hiPpocampal neurite length. 
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Monolayers of control fibroblasts and fibroblasts stably expressing the rat AChE-T form 
(see Chapter 2 and Section 4.3), fibroblasts stably expressing APP or NCAM (140-kDa 
isoform) were established on poly-L-lysine and fibronectin coated wells. 24hrs later the 
growth medium was removed and dissociated cerebellar or hippocampal neurones were 
plated onto the fibroblast monolayers at low density (5000 neurones per well) in 
F12/DMEM with B27 supplement for 16hrs. As can be seen, in Figure 4.6B culturing 
cerebellar and hippocampal neurones on monolayer of fibroblasts overexpressing 
AChE-T (Clone T-1, see section 4.3) resulted in a significant increase in neurite length. 
CGNs on control untransfected fibroblasts had neurite lengths of 58.8 ± 1.4 ýtm, while 
those cultured on AChE-T expressing fibroblasts had a mean primary neurite length of 
91.0 ± 4.7 [tm, a 1.5 fold increase in outgrowth. Basal hippocampal outgrowth was 
increased from 60.1 ± 2.1 on control fibroblasts to 97.2 ± 1.3 on AChE-T expressing 
fibroblasts, representing a 1.6-fold increase in outgrowth (results pooled from 3 
independent experiments). The increase in neurite outgrowth seen under these 
conditions is comparable to that seen in fibroblasts engineered to overexpress either the 
neuronal 695 amino acid isoform of APP or the 140kDa isoforms of NCAM (Figure 
4.6Q. Representative images of neurite exposed to increased levels of AChE are shown 
in Figure 4.7. 
Based on these results it appears that increasing the level of AChE presented to the 
neuronal cultures either by exogenous application or by coculture has a neuritogenic 
effect on cerebellar, hippocampal and cortical neurones, supporting previous studies in 
hippocampal, doparninergic and spinal cord motor neurones (Day and Greenfield, 2002; 
Holmes et al., 1997, Bataille et al 1998; Olivera et al., 2003b). Thus, AChE appears to 
be important for the normal outgrowth of both primary neurones from several distinct 
regions of the brain and a neuronal cell line. Based on these results, it appears that 
irrespective of the neurotransmitter which the neurones eventually differentiate to use, 
AChE is expressed (Figure 3.25) and contributes to neurite outgrowth. 
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Figure 4.6 AChE increases neurite outgrowth. 
(A) PND4 CGN, E18 Hippocampal and Cortical neurones were isolated, plated at low density 
on PLL, and 16hrs post-plating, ACK at I Omgml-1 added for a further 48hrs. The length of the 
longest primary neurite per cell was measured using image analysis and the mean process length 
calculated. Results are shown as mean ± sem of a single experiment where 150-200 primary 
neurites were analysed (B) PND4 CGN and E 18 hippocampal neurones were isolated and plated 
onto monolayers of fibroblasts transfected with AChE-T or control untransfected fibroblasts. 
The length of the longest primary neurite per cell after 16hrs culture was measured using image 
analysis and the mean process length calculated. Results are shown as mean ± sem of 3 
independent experiments and a minimum of 150-200 cells were analysed per experiment. (C) 
Comparison of mean primary neurite outgrowth of PND4 CGN on fibroblast monolayers 
expressing AChE, APP695 or NCAM and untransfected fibroblasts. Results are mean ± sem of 
a single representative experiment. Significant difference compared to controls was assessed by 
unpaired Student's t-test. 
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Figure 4.7 Neuronal morphology after exposure to AChE 
The representative electronically captured images (using a X63 objective lens) show (A) 
The increased neunte lengths of dissociated cerebellar, hippocampal and cortical neurons 
cultured with 10 ýtgml-' eel AChE. (B) Increased neurite lengths of hippocampal and 
cerebellar neurons cultured on monolayer expressing AChE-T, APP or NCAM Neurones 
were visuallsed by fixing with 4% paraformaldehyde, permeabilised with 100% ice-cold 
methanol and labelled with rabbit anti-GAP-43 priman, antibody (I -1000) followed by anti- 
rabbit Alexa Fluor A555 secondary antibody (1.8000). Scale bar 20ýtm 
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4.3 The morphoregulatory role of AChE in non-neuronal cells 
As described in Chapter 3, AChE is highly expressed in the non-neuronal 3T3s and 
primary human fibroblasts. Particularly interesting is the AChE distribution In fixed 
cultures of migrating and spreading cells, which is suggestive of a role in migration and 
adhesion. Its colocalisation in the leading edge with APP, a protein which itself has an 
emerging role in outgrowth and migration (Sabo et al., 2001; Sabo et al., 2003) also 
supports this suggestion. In order to evaluate role of AChE in these cells, the actions of 
the well characterised AChE inhibitors and antibody, previously used on neuronal cells 
were tested. The effect of a gain of function of AChE on 3T3s was also examined by 
overexpressing the synaptic AChE-T isoform. 
4.3.1 AChE-T overexpression alters the morphology of 3T3 fibroblasts: 
AChE-T-expressing fibroblasts clones expressing the synaptic form of AChE (AChE-T) 
were constructed as described in Chapter 2, where the cDNA of AChE-T (a kind gift 
from Professor Massoulie, Laboratoire de Neurobiologie Cellulaire et Moleculaire, 
Ecole Normale Superieure, Paris, France) was subcloned into pcDNA3 (Invitrogen) and 
its nucleotide sequence confirmed in an automated sequencer. Fibroblasts are an 
appropriate cell type to use as they are a well characterised model in which to study 
morphoregulatory changes and indeed much work on characterising the molecules 
involved in migration and adhesion has been carried out in these cells (Ridley and Hall, 
1992; Ridley et al., 1992; Anton et al., 2003). Clones were screened for expression by 
western blotting with Clone 46 directed against the C-terminal third of AChE. Stable 
expression of AChE-T in 3T3 cells resulted in increased levels of the AChE-T transgene 
and three clones shown by western blotting to have increased levels of AChE protein 
were characterised; T-1. T-4, T-5 (Figure 4.8). 
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Expression of AChE in AChE-T transfected fibroblasts 
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Figure 4.8 Expression of cellular AChE in AChE-T expressing fibroblast clones. 
Western blots showing AChE expression in control (C) fibroblasts and 8 stable AChE-T 
expressing clones (T 1-8) expressing different levels of the rat AChE-T transgene. The cells 
were lysed 2 days after plating and were loaded according to protein content. The monoclonal 
antibody Clone 46 was used to probe 7.5% SDS-PAGE gels. The gel was subsequently stripped 
and reprobed for tubulin. Increased levels of ACK were seen at approximately 65-kDa by the 
monoclonal Clone 46 antibody, which reacts to the C-terminus of AChE. Tubulin was detected 
by the monoclonal ab6161 antibody in control fibroblasts and AChE-T expressing clones. 
Positions of molecular weight markers are indicated on the left-hand side in kDa. 
Overexpression of AChE changed the cellular morphology, so that the majority of cells 
within each clonal population no longer exhibited the typical fibroblast shape. Among 
the most noticeable changes were cell body enlargement and extension of long 
processes, which traversed over nearby cells, particularly notable in higher density 
cultures (as illustrated in Figure 4.9Q. This is consistent with overexpression studies in 
other cell types; in gliomas AChE-T overexpression resulted in massive process 
extension (Karpel et al., 1996), while overexpression in retinal Muller cells modifies the 
cytoskeleton, increasing vimentin expression, resulting in thicker, longer processes 
(Keller et al., 2001b). AChE-T overexpression in neuroblastoma cells also increased 
process extension (Bigbee et al., 2000; De Jaco et al., 2002). 
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Visualising the clonal morphology with (x-tubulin (Figure 4.9C) or actin (using TRITC- 
phalloidin binding in Figure 4.10) clearly shows that the AChE-T overexpressing T-1. 
T-4 and T-5 fibroblasts are significantly larger in cell area and longer processes. 
Costaining for AChE expression shows that the expression pattern appears to be broadly 
similar to the parental distribution, although the discrete regions of AChE 
immunoreactivity are generally wider and more expansive, in line with the larger cell 
shape (Figure 4.10). Since AChE is most notable for its enzymatic activity, the effect 
that AChE-T overexpression had on the low basal level of AChE activity in 3T3s was 
investigated. The limited reports so far characterising effect of AChE overexpression 
have provided disparate results with regard to changes in enzymatic activity. Karpel et 
al and Sharma et al showed that in cultured glioma cells and neuroblastoma 
respectively, AChE overexpression resulted in significant increases in cellular activity 
(Karpel et al., 1996; Sharma et al., 2001), whilst for Keller et al in 2001 overexpressing 
the entire rabbit AChE gene and Jin et al, overexpressing the rat AChE-T form showed 
no significant increase in activity, though protein levels were increased (Keller et al., 
2001b; Jin et al., 2004). This appears to indicate that in some cells there is a post- 
translational regulation of overall AChE activity (Keller et al., 2001b; Jin et al., 2004). 
As shown in figure 4.9A, Ellman assays pooled from three independent experiments 
carried out specifically on clone T-I revealed that there was a significant increase in 
ACh hydrolysis, and is attributable to AChE since it was fully inhibited by 50pM 
BW284c5l (Figure 4.9B). The increase in specific AChE activity also provides further 
evidence that the clones isolated post-selection are indeed expressing increased AChE 
levels and not simply the result of expansion of particular cell variants within the 3T3 
fibroblast population, since this was not clonal pre-selection. 
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Figure 4.9 AChE-T expressing fibroblasts have increased AChE specific activity. 
(A) Overexpressing AChE-T clones have increased AChE activity. Ellman assays performed on 
equal protein concentrations of cellular lysates of untransfected and clone T-I show increased 
AChE activity. Data is representative of three experiments performed in triplicate. (B) 
Overexpressing AChE-T clones have increased AChE specific activity. Ellman assays 
performed on equal protein concentrations of cellular lysates of untransfected and clone T-1 
show increased AChE activity that is completely inhibited by the AChE specific inhibitor 
BW284c5l at 50ýM. Data is the mean of a single Ellman assay performed in quadruplicate ± 
s. e. m. Data is normalised to control activity. Statistical significance compared to controls, was 
assessed by unpaired Student's t-test. 
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Figure 4.9C AChE-T expressing fibroblasts have altered morphologies 
The AChE-T expressing fibroblasts have larger cell bodies and longer processes that extend 
over other cells. This can be seen in (A-L) representative electronically captured phase images 
of equal density. fn (A, B, D, E, G, H, J and K) fibroblasts were fixed with 4% 
paraformaldehyde and pen-neabilised with 0.2% Triton XIOO. The microtubule network was 
then visualised with the mouse monoclonal antibody (1: 50) and the secondary anti-i-mouse 
Alexa Fluor 488 (1: 2000), mounted with DAPI containing mowoil and representative images 
captured electronically using a X63 objective lens. (C, F, I and L) show representative images 
of fibroblasts prior to fixation. images were captured using a X40 objective lens. Scale bar 
204m 
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Surface AChE distribution on control and AChE-T expressing clones: 
Control fibroblasts 
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Figure 4.10 AChE distribution is similar in control and AChE-T expressing clones. 
(A-H) Surface ACK distribution on parental 3T3 and AChE-T overex-pressing fibroblasts 
was examined. Cells were set up at equal densitý, T, fixed in paraformaldehyde and AChE 
distribution determined using AChE rabbit polyclonal H-134 antibody (1 -75) and anti-rabbit 
Alexa Fluor A555 (1: 8000). Cell morphology was revealed by subsequent penneabilisation 
with 0.2% Triton X-100 and detection of F-actin using TRITC-phalloidin toxin (1.5000). 
Representative images captured using X63 objective lens. Scale bar 20ýtm. 
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The mean cell areas were measured for control and AChE-T expressing T- 1, T-4 and T- 
5 fibroblasts and were found to be significantly increased in the AChE-T expressing 
clones as shown in Figure 4.11. The histogram in Figure 4.11 shows the mean cell area 
of 100 cells measured each time in 4-10 independent experiments and illustrates that the 
AChE-T expressing clones show a 2.7-, 1.9- and 2.1 fold increases in cell area for 
clones T- Iý T-4 and T-5 respectively. 
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4.3.2 AChE is involved in migration in fibroblasts: 
Figure 4.11 AChE-T 
expressing fibroblasts have 
increased cell areas. 
Overexpression of AChE 
increases cell area relative to 
untransfected cells. Results are 
mean cell area of 100 cells 
measured in 4-10 independent 
experiments ± s. e. m. 
The results presented in the section 4.2 together with several earlier studies strongly 
implicate a role for AChE in cell adhesion and outgrowth in neuronal cells. Little is 
known about whether AChE in non-neuronal cells has a comparable function. An 
analogous process to neurite outgrowth in motile non-neuronal cells is cellular 
migration. Indeed, axonal growth can be conceived as an alternative program for a cell 
whose migratory activity is inhibited. Thus the process of neurite growth is 
mechanistically related to the of cell migration as discussed in Chapter 3. In fibroblasts 
and astrocytes, AChE localises to the leading edge and colocalises with APP. This is 
particularly relevant since APP itself has previously been shown to play a role in 
cellular migration (Sabo et al., 2001) and lends credence to AChE also having such a 
role. In order to assess the functional importance of ACK in fibroblast migration the 
effect of both perturbing AChE using inhibitors and antibodies in 3T3 and primary 
human fibroblasts and increasing AChE levels by overexpression in 3T3 cells was 
examined in vitro would healing assays. 
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4.3.3 Acceleration of wound healing by overexpression of AChE-T in 3T3 
fibroblasts 
Wound healing is one method that has been previously used as a measure of the rate of 
cell migration or movement (Rosen and Misfeldt, 1980; Green et al., 2004). In response 
to wounding, the cells along the edge of the wound first send out lamellipodia then 
eventually migrate into the wound. As an assay for the possible role of AChE in cell 
movement/protrusion suggested by its striking distribution, the rate of wound closure of 
sub-confluent (-85-95% confluent) monolayers of wild-type 3T3 fibroblast cells, and 
3T3 fibroblasts stably transfected with AChE-T (clones T-1 and T-5), as well as the 
migration rate of a G418 resistant clone which had not been found to express higher 
levels of AChE (T-2), was determined. Over 24hrs, AChE overexpression in T-1 and T- 
5 increased the rate at which the cells travelled to achieve wound closure when 
compared with both the parental cells, and with the non-overexpressing clone T-2. The 
migration rate of T-2 was identical to that of parental 3T3s, while T-1 showed an 87% 
increase in wound closure rate (P<0.05), and T-5 showed a 64% increase (mean ± sem 
of 3 independent experiments) over control cells (Figure 4.12A). Comparing the actual 
wound width reduction over time for control 3 T3 fibroblasts and T- I in a smaller wound 
(-250[tm), Figure 4.12B shows over an 8hr time period, T-I migrated at 22.6pm/hr, 
while the migration rate of the parental 3T3s was only 10.3pm/hr (mean width ± SEM 
for 3 wounds, 40 data points pooled at each time point of each wound). Thus, increasing 
the endogenous AChE level in 3T3 cells appears to increase the rate of migration of 
cells at the wound edge, analogous to the increased neurite outgrowth seen in Figure 
4.7. Since these AChE clones have significantly increased AChE activity, it is possible 
this may account for their increase in the migratory capability. To determine whether 
this was the case, a further wound healing assay was carried out comparing the 
migratory capability of T- I in the presence and absence of BW284c5 1. As can be seen 
in Figure 4.12C, addition of 50pM BW284C51, which fully inhibits T-1 enzyme 
activity in ellman assays (Figure 4.1) did not reduce migration, (the slight increase 
observed was not statistically significant), suggesting that the increased rate of 
migration seen in T- I is not dependent upon the increased activity. 
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Figure 4.12 AChE expressing fibroblasts show a faster rate of wound closure in an in in 
vitro wound. 
(A) 3T3 fibroblasts overexpressing AChE-T have a faster rate of wound closure than parental 
cells. 85% confluent fibroblast cultures were wounded and rate of closure over 24hrs 
determined for parental control (C) cells and clones T- 1, T-2, T-5. Results are the means ± s. e. m 
of three independent experiments, where each wound was measured at 40 points along the 
wound length. (B) Comparison wound width of parental and Clone T- I over time. Wounds were 
measured at 40 points along wound length at each time point and results are mean of triplicate 
wounds ± s. e. m. (C) Comparison of closure rate of control fibroblasts and Clone T-1 in the 
presence and absence of AChE specific inhibitor BW284c5l (50ýM). Wounds were measured 
at 40 points along wound length at each time point and results are mean of duplicate wounds 
s. e. m in a single experiment. 
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Since increasing AChE levels was capable of increasing the migratory capability of the 
cells, the actions of the inhibitors and antibody tested in the neurite outgrowth paradigm 
were also examined for their effect on fibroblast migration. Although wildtype 
fibroblasts showed little AChE activity it is possible that functional involvement in 
migration may be dependent on a small pool of active AChE, particularly since ACh is 
ubiquitously expressed (Wessler et al., 2003), and has been shown to enhance cell-cell 
adhesion of keratinocytes (Nguyen et al., 2003) and inhibit neurite outgrowth (Small et 
al., 1995). In order to determine whether migration was affected by inhibition of 
enzyme activity or changes in ACh levels, 3T3 migration rates were determined in the 
presence of the previously used AChE inhibitors; fasciculin, and BW284c5 1, as well as 
ACh, soluble eel AChE, MAB304 and control IgG. Antibodies or inhibitors were added 
immediately after wounding and wound width was measured at Ohr and 24hrs post 
wounding. As can be seen in Figure 4.13A, only MAB304 could inhibit the wound 
closure, by 48% (though this did not reach statistical significance), whilst ACh, eel 
AChE and the AChE inhibitors did not have any significant effect. The polyclonal 
antibody E-19 can also bind to the surface of unfixed fibroblasts, as shown in Figure 
3.10. This antibody was acquired relatively late in the preparation of this thesis and thus 
has not been thoroughly characterised. An initial experiment examining the effects of E- 
19 on wound healing was carried out in a single wound healing assay performed in 
triplicate wells (Figure 4.16B). As can be seen in Figure 4.1613, E-19 at 20ýtgml_' did 
appear to reduce wound closure over 24hrs compared to an IgG control. This antibody 
preparation is relatively dilute (200ýtgml-') and thus some effect is seen on migration 
upon application of an IgG control in the same carrier solution and protein 
concentration (though this was not statistically different from the control). 
The effect of MAB304 on migration was then assessed on the rate of wound healing of 
primary human fibroblasts and compared to the effect seen upon addition of a functional 
PI-integrin antibody (AIIB2) which has previously been used to inhibit adhesion of 
human neutrophils and migration of human bladder carcinoma cells (Bohnsack et al., 
1990; Dorfleutner et al., 2004). Hurnan fibroblasts were found to have a slightly faster 
basal rate of migration and thus, the wound width was measured immediately after 
wounding and 12hrs post wounding. Figure 4.13C (mean ± SEM from 3 independent 
experiments) illustrates that in the absence of antibodies fibroblasts migrated at a rate of 
14.4 ± 1.7pm/hr and addition of a control IgG had no effect on migration, but this was 
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reduced by application of the 01-integrin antibody (AlIB2) to 8.2 ± 1.6pm/hr (P<0.02) 
and by MAB304 to 8.5 ± 1.4[tm/hr (P<0.02), a reduction in migration rate of 43% and 
41% respectively. Neither AIIB2 nor MAB304 were capable of entirely retarding 
migration however as closure was achieved in each case by 24-36hrs post wounding 
(data not shown). These migration data in combination with the changes in neurite 
outgrowth in neuronal cells, suggest that AChE may have a common role in regulation 
of movement or cellular protrusion in both neuronal and non-neuronal cells. 
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Figure 4.13 AChE antibodies 
reduce wound closure in an in 
vitro wound. 
(A) Effect of AChE inhibitors 
BW284c5l (50 ýikl) and Fasciculin 
(I [M), ACh (I mgml-'), eel AChE 
(10 [igmi-1), and MAB304 (20 
[tgml-') on 3T3 wound closure. 85% 
confluent 3T3 cultures were 
wounded and rate of closure 
determined after 24hrs Results are 
expressed as % of 3T3 control rate, 
pooled from 3 independent 
experiments ± s. e. m, where each 
wound was measured at 40 points 
along the wound length. (B) Effect 
of addition of the polyclonal 
antibody E-19 (20 [tgml-') on 3T3 
fibroblast wound closure. Results 
are expressed as % of 3T3 control 
rate of wound closure over 24hrs in 
a single experiment carried out in 
triplicate wounds ± s. e. m, where 
each wound was measured at 40 
points along the wound length. (C) 
Rate of wound closure ([tm/hr) from 
0-12 hr for primary fibroblasts alone 
(Control), or with control IgG, PI 
integrin AlIB2 or AChE MAB304 
Abs. Results are mean closure rate 
pooled from 3 independent 
experiments ± s. e. m. Significance 
determined using Student unpaired 
T-test. 
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4.3.4 An AChE antibody reduces fibroblast adhesion 
There are several ways in which AChE could modulate migration, including altering 
adhesion, altering actin dynamics or both. In neuroblastomas, AChE expression has 
been shown to correlate with substratum adhesion and this is postulated to mediate the 
increased outgrowth seen upon overexpression of AChE in these cells (Shanna et al., 
2001). In order to examine whether changes in fibroblast migration in response to 
application of MAB304 could result from modulation of cell adhesion, the effect of 
MAB304 on adhesion was determined using a single cell adhesion measurement 
analysis (developed by Professor Djamgoz's research group, Imperial College and 
previously used to assess single cell adhesion by Mycielska et al 2006). Low density 
cultures of 3T3 fibroblasts were incubated overnight with MAB304 and control IgG, 
before the suction pressure required to detach individual cells from the plate 
('detachment negative pressure', DNP kPa per cell) was determined for 100-200 cells in 
each plate. The results from 3 independent experiments revealed that the AChE 
antibody consistently reduced the negative pressure (kPa/cell) required to detach 3T3 
cells compared to an IgG control. The results from one representative experiment are 
shown in Figure 4.14, where addition of MAB304 reduced adhesion to 57.9% compared 
to incubation with an IgG control. Thus, MAB304, an antibody that can redistribute 
AChE away from the cell periphery can reduce also migration, potentially due to a 
reduction in cell-substratum adhesion, suggesting that like integrins, AChE may have a 
morphoregulatory function in substratum adhesion and polarised migration. 
25 
20 
15 
10 
5 
0 
Control IgG MAB304 
Figure 4.14 3T3 fibroblast adhesion is reduced 
by incubation with an AChE antibody. 
Low density cultures of 3T3 fibroblasts were 
plated and 24hrs later incubated for 16hrs with 
20 ýtgml-l IgG control, or anti-AChE antibody 
MAB304. The detachment negative pressure 
required to detach 3T3 fibroblasts was then 
established for 150-200 cells under each 
condition. Results are a single representative 
experiment., three further experiments gave 
similar results. 
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4.3.5 PAS treatment increases AChE levels in neurones but not fibroblasts 
In order to attempt to resolve the actions of AChE inhibitors on both neurones and 
fibroblasts, particularly given the differences in cellular responses to the inhibitors, an 
initial investigation was carried out into the effect of BW284c5I and edrophoniurn on 
AChE levels in both cell types. Previous in vitro studies have suggested that AChE 
ligands acting at the PAS can cause a feedback upregulation of AChE under in vitro 
conditions (Dong et al., 2004; Keller et al., 2001b). Specific anti-AChE treatments can 
also cause feedback upregulation of AChE expression i. n vivo in the brain of humans 
(Darreh-Shori et al., 2004) and mice (Kaufer et al., 1998). 
The AChE expression level was compared in control, BW284c5l, and edrophonium- 
treated cerebellar neurones and fibroblasts using Western blot analysis. In both cases, 
the cultures were plated and 16hrs later treated for 48hrs with a single dose of the AChE 
inhibitor. In this way, the treatment conditions were analogous to those of the neurite 
outgrowth assays (although 24 hrs longer than the exposure time for 3T3 migration 
assays). Obstruction of the PAS with 5-50ýM BW284c5l induced an enhancement of 
AChE expression in cultured cerebellar neurones (Figure 4.15A), while treatment with 
the active site inhibitor edrophonium had no such effect. This feedback mechanism has 
previously been noted in hippocampal neurones, where the enhancement of AChE 
expression has been shown to impair glutamatergic signalling (Dong et al., 2004), and 
in chick retinal cultures (Keller et al., 2001a; Keller et al., 2001b). The AChE inhibitor 
treated cerebellar lysates were also probed for PARP cleavage in order to ascertain 
whether the increase in AChE levels was due to apoptosis (a phenomenon further 
discussed and examined in chapter 5). The extent of PARP cleavage was similar in both 
the treated and untreated cultures, indicating that under these conditions, the increase in 
AChE levels in not a result of apoptosis as detected by this marker. In comparison, 
treatment of 3T3 cells with BW284c5l for three days in the presence of 10% 
FCS/DMEM, did not appear to have any effect on the AChE levels (Figure 4.1513). This 
may be due to the reported presence of high levels of AChE in serum, which could also 
interact with these agents (Saxena et al., 2003), thus attenuating their effect of the 3T3 
associated AChE. 
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BW284C51 Edrophonium 
A 
Control 5ýN 50[im 1mm 
75 
50 
AChE - Clone 46 
Cerebellar Granule cells: 
1 4pý. - 40 
PARP - H-250 
B 
75 
50-1ýýýýý 
"'Owý mww""] 3T3 fibroblasts: 
AChE - Clone 46 
Figure 4.15 Chronic treatment with PAS inhibitors increases AChE levels in neurones but 
not in 3T3 fibroblasts. (A-B) Cerebellar neurones and 3T3 cells were plated at 5x 105 cells and 
16hrs post-plating exposed to 5-50 ýtNl BW284C51 or I mM Edrophonium for 48hrs. Treated 
and untreated samples were lysed in X2 sample buffer and 10 4g loaded onto 7.5% SDS-PAGE 
and transferred onto nitrocellulose. Membranes were incubated with anti-AChE antibody Clone 
46 (1: 2500) followed by anti-mouse HRP (1: 3000). Cerebellar granule cell membrane was 
additionally stripped and reprobed for PARP with polyclonal H-250 (1200) and anti-rabbit 
HRP (1 -5000) Molecular weight markers are indicated on the left hand side in kDa. 
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4.4 Discussion: 
In order to characterise whether AChE has a morphoregulatory function in both 
neuronal and non-neuronal cells, the action of AChE, pharmacological inhibitors and an 
antibody were examined in several paradigms; outgrowth, migration and adhesion in 
neurones and fibroblasts. This has revealed three significant findings. Firstly. 
application of AChE ligands or AChE itself can modulate neurite outgrowth in a 
manner not dependent on enzymatic activity. For the first time, a direct comparison was 
carried out on the effects of a panel of AChE ligands on neurones isolated from three 
regions of the brain, the cerebellum, the hippocampus and the cortex. Only ligands that 
bind to the PAS of AChE or are able to bind to the surface of AChE (like MAB304) 
were capable of significantly retarding neurite outgrowth, while those inhibiting activity 
by binding the active site of the enzyme could not consistently modulate outgrowth 
across the three neuronal populations. Increasing the AChE available to neurones by 
exogenous application of eel AChE at 10 [igml- 1 (equivalent to 10 Uml- 1) or for the first 
time by co-culturing cerebellar and hippocampal neurones with fibroblasts expressing a 
rat AChE-T transgene was shown to be capable of increasing neurite length. Secondly 
in the analogous process of migration in non-neuronal fibroblasts, overexpression of 
AChE increased the migratory capability of the cells, while antibodies that can bind to 
live AChE on the surface of the cells retarded cellular migration. This suggests a 
conserved role for AChE in cell motility and pathfinding. Thirdly, initial studies suggest 
a blockade of the AChE PAS by BW284c5l induced overexpression of AChE in 
neurones, but had no effect on AChE levels in fibroblasts, indicating differences in the 
responsiveness of the two cell types. The mechanisms underlying these AChE mediated 
responses and approaches to determine possible signalling pathways and receptors will 
be considered below. 
4.4.1 AChE plays a common role in outgrowth and migration 
A role for AChE in adhesion and outgrowth in developing neural cells was first 
indicated by its transient expression during periods of neural differentiation and 
neuritogenesis, prior to synaptogenesis, (Layer, 1990; Layer and Kaulich, 1991), which 
then gradually declines with maturation (Dong et al., 2004). More recently, there have 
been indications that such a morphoregulatory role for AChE may extend outside the 
nervous system. The study by Inkson et al in 2004 showed that during osteoblast 
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differentiation there was an increase in AChE levels and revealed that AChE inhibitors 
could reduce osteoblast adhesion (Inkson et al., 2004), while a role for AChE is also 
emerging in the endothelium (Carvalho et al., 2005) and epithelium (Plageman et al.. 
2002). 
Though considerable work suggests that AChE has a role in neurite outgrowth including 
studies on chick retinal cells (Layer et al., 1993), hippocampal neurones (Day and 
Greenfield, 2002; Olivera et al., 2003b), embryonic ventral mesencephalic neurones 
(Whyte and Greenfield, 2003), dorsal root ganglion neurones (Sharma and Bigbee, 
1998) and neuroblastomas (Koenigsberger et al., 1997; Sharma et al., 2001), the effects 
of AChE inhibitors on neurite outgrowth are somewhat confusing. Most studies have 
shown that only PAS specific ligands can affect outgrowth (Day and Greenfield, 2002; 
Olivera et al., 2003b), however there have also been reports that some active site 
inhibitors (e. g., edrophonium, tacrine, and chlorpyrifos) can also affect cellular 
morphology (Small et al., 1995; De Ferrari et al., 1998; Das and Barone, 1999). This 
study screened for the effects of a comprehensive panel of both PAS and active site 
inhibitors on outgrowth from three neuronal populations at both embryonic and early 
postnatal stages. The results presented in this chapter support the neuritogenic region of 
AChE being distinct from active site and likely associated with the PAS due to the 
conserved retarding action of PAS specific inhibitors on all the neuronal populations, 
and the lack of effect a significant effect by active site inhibitor tacrine. Edrophonium 
had no effect on outgrowth from hippocampal and cortical cultures, but did show a 
slight inhibition in cerebellar cultures. Interestingly addition of edrophonium has been 
shown to slightly reduce the neurite outgrowth of chick sympathetic neurones (Small et 
al., 1995) suggesting that different neuronal populations show somewhat different 
susceptibilities to the AChE inhibitors. 
In this study, addition of Electrophorus electricus AChE, Type V-S AChE (10 Uml-1) to 
the neuronal cultures or co-culture with AChE-T expressing fibroblasts both resulted in 
increased neurite outgrowth, an effect conserved throughout the different neuronal 
populations. In the past, significant variability has been seen in the responsiveness of 
different preparations of neuronal populations to addition of AChE, even within the 
same research group. Addition of a purified tetrameric form of the same AChE as that 
added here has previously been shown to increase the length of tyrosine hydroxylase 
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positive em ryonic neurones at 0.3-3 Uml-1 (Whyte and Greenfield, 2003). However, in 
an earlier study in 2002, Susan Greenfield's group had shown that addition of the same 
purified tetrameric Electrophorus electricus eel AChE was unable to affect outgrowth 
of postnatal organotypic hippocampal. cultures treated for 14 days, though addition of 3- 
10 Uml-1 monomeric recombinant AChE was capable of increasing outgrowth (Day and 
Greenfield, 2002). In 1998 Bataille et al showed that eel AChE at 4 Uml-1 could 
increase the length of spinal cord motor neurones (Bataille et al., 1998), while in 2003 
Olivera et al showed that application of 0.01-0.05 Uml-1 eel AChE to dissociated 
embryonic hippocampal neurones significantly increased outgrowth, expression of the 
synaptic marker SV2a (a synaptic vesicle protein) and the surface expression of the 
glutamate receptor subunit AMPA (Olivera et al., 2003a, b). In comparison, addition of 
0.5-3.0 Uml-1 human recombinant AChE specifically reduced the amplitude of 
glutamate currents, leaving GABArgic currents unaffected, suggesting that excess 
extracellular AChE interferes with glutamatergic functions. Therefore, there appear to 
be significant differences between the effects of AChE depending upon the neuronal 
preparation, the concentration of AChE applied and potentially the species of AChE 
(mouse, human or eel). In this study, the eel AChE was not purified therefore, the 
possibility exists that outgrowth could result from an additional contaminating 
substances in the preparation. 
Non-specific effects of protein addition also cannot be discounted since a protein 
control such as BSA was not included, though BSA addition has previously been shown 
to have no effect on outgrowth (Whyte and Greenfield, 2003). However, the similarity 
of the outgrowth response seen upon culturing neurones on an AChE-T monolayer 
suggests that this is likely to be a specific effect of AChE. The ability of both soluble 
and substratum AChE to increase outgrowth builds on the work of Sternfeld et al, 
Sharma et al, and De Jaco et al in supporting a neuritogenic role for AChE (De Jaco et 
al., 2002; Sharma et al., 2001; Sternfeld et al., 1998). However, further experiments 
involving direct comparison of the actions of human recombinant AChE and eel AChE 
on neuronal outgrowth of the different neuronal population at a variety of 
concentrations are required to resolve whether these different species are capable of 
stimulating neurotrophic and inhibitory neuromodulatory responses. 
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In an analogous manner to the stimulation of outgrowth in neuronal cultures, increasing 
the levels of AChE in fibroblasts was found to increase their migratory capability. while 
application of MAB304 (and E-19 in a single experiment) could retard migration. These 
results together with those of chapter 3 revealing the striking localisation of AChE at the 
leading edge of fibroblasts, astrocytes and growth cones of neurones suggests that 
ACK could play a conserved role in regulation of cell motility. Initial examination of 
the effect of MAB304 on adhesion suggests that the effects of this antibody on 
migration may result from perturbation of an adhesive mechanism. As discussed in 
chapter 3, the mechanisms governing neurite outgrowth and cellular migration are 
fundamentally similar. The conserved increase seen upon increasing AChE levels and 
the retardation in both process upon AChE pertubation therefore suggests that it could 
play a conserved role in both outgrowth and migration. Expression studies in Swiss 3T3 
fibroblasts have shown that the Rho-like GTPase family, including Cdc42, Racl, and 
RhoA,, are key regulators of the signal transduction pathways that mediate the actin 
cytoskeleton changes required for cell migration (Hall, 1998). Rho activation assembles 
stress fibres and focal contacts (Ridley and Hall, 1992), while activation of Cdc42 
results in the formation of filopodia, and Rac activation results in the formation of 
lamellipodia. Cdc42 and Rac also induce the formation of focal complexes (Ridley et 
al., 1992; Kozma et al., 1995; Nobes and Hall, 1995). 
The effects of Rho GTPases on the organization of the actin cytosk-cleton are best 
characterized in fibroblasts, however they appear to also have similar roles in all cells 
including neurones. Activation of Rac in the neuroblastoma cell line NI E-1 15 promotes 
formation of larnellipodia, while Cdc42 activation prornotes filopodia formation 
(Kozi-na et al., 1997). Activation of Rho in neuronal cells induces formation of 
contractile actin-rnyosin filaments. Howe-ver, while in response to this activation 
fibroblasts maintain a flattened shape through the formation of strong focal adhesion 
attachment sites. in neurones this induces neUrite retraction and cell rounding. 
Dissection of the molecular mechanisms underlyino the migratorv action of AChE \vIII ý Z-7 
therefore involve examination of whether AChE can modulate the activation of these 
GTPases. 
The lack of effect of AChE ligands fasciculin and BW284c5l on fibroblast migration 
may seem surprising, given that they are capable of retarding neurite outgrowth. 
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However, there are several possible reasons for the differences in the responsi": eness of 
the different cell types; although AChE does appear to be expressed at the cell surface, 
by fixed and live immunofluorescence, and subcellular fractionation (shown in Chapter 
3), the form of AChE accessible on the surface has not been characterised. There have 
been reports in AD brains of AChE forms that show reduced substrate inhibition and 
responsiveness to BW284c5l (Geula and Mesulam, 1989), while as prevlouslý' 
mentioned in chick brain inactive AChE forms are produced (Chatel et al., 1993a) and 
thus the AChE form expressed on the surface of 3T3s may also be a modified form, to 
which small inhibitors such as fasciculin or BW284c51 cannot specifically bind, but to 
which a larger antibody complex, such as MAB304 can still attach. Alternatively, 
specific binding of MAB304 to AChE on the fibroblast cell surface may perturb an 
interaction with an AChE binding partner, which is not affected by binding of AChE 
inhibitors. Indeed, although MAB304 is suggested to bind to the PAS (Olivera et al., 
2003b), this has not been independently confirmed. Several additional controls would 
need to be carried out to verify the validity of this effect. For example, further studies on 
migration and adhesion with antibodies recognising surface proteins uninvolved in cell 
migration, such as the transferrin receptor would need to be carried out to rule out the 
possibility that changes in migration could simply result from the binding of any surface 
expressed protein. The increase in migration shown upon AChE-T overexpression 
would suggest that the actions of AChE are less likely to be non-specific. Moreover, this 
is not the first time that an antibody has been shown to have more potent morphological 
effect than other AChE ligands. In 1997, Koenigsberger et al found that a polyclonal 
antibody raised against human erthythrocyte AChE (like MAB304) was able to retard 
murine neuroblastoma outgrowth far more consistently than BW284c5l, whose main 
effect at 100 ýtM was to reduce the percentage of long neurites (Koenigsberger et al., 
1997). Alternatively, though the action of AChE on migration and outgrowth appears to 
be conserved in both neurones and fibroblasts, the interacting components may differ 
between the two cells types, resulting in differing responsiveness. 
Interpretation of the effects of AChE inhibitors on neurite outgrowth must also take into 
consideration the action of some ligands on other elements of the cholinergic system. 
For example tacrine, and BW284c5l markedly block torpedo nicotinic acety1choline 
receptors (AChRs) when they are expressed in Xenopus (Olivera et al., 2005; Olivera- 
Bravo et al., 2005). These AChE inhibitors were shown to antagonise nicotinic AChRs 
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in a non-competitive way, likely to be due to an open channel block (Olivera et al.. 
2005). The BW284c5l blocking effect was more potent than that of tacrine, and similar 
to that of the true AChR antagonist d-tubocurarine. Although tacrine had no significant 
effect on neurite outgrowth, an effect of BW284c5l on nicotinic AChRs cannot be 
completely discounted, particularly since it was a more potent AChR antagonist than 
tacrine. Furthermore, the concentrations of BW284c5l and fasciculin needed to inhibit 
neurite outgrowth were very high (micromolar-nanomolar). In contrast, nanomolar- 
picomolar concentrations are required to block cholinesterase activity. Indeed in the rat 
retina, BW284c5l has been shown to have an IC50 of 5.2 nM (Sastry et al., 1995), 
while effects on neurite outgrowth were only observed at concentrations above 5 ýM 
Some of the reduced outgrowth effects seen in this study at 50 ýLM can be attributed to a 
neurotoxic effect, as indicated by the reduction in neurone number (Figure 4.3C and 
4.4C), and demonstrated previously in hippocampal cultures (Day and Greenfield, 2002; 
Olivera et al., 2003b). Indeed, controversy exists in the literature regarding the 
concentrations of AChE ligands required to retard neurite outgrowth. The results of 
Koenigsberger et al. (Koenigsberger et al., 1997) demonstrated that neurite outgrowth 
is proportionally related to levels of AChE expression, whereas Posturna et al. found 
neurite outgrowth was only retarded in the presence of toxic levels of AChE inhibitors 
(Postuma et al., 1999). Some of the differences between these two studies may be due to 
differences in the systems under investigation, neuroblastoma cells in the case of 
Koenigsberger and chick retinal neurones in Posturna et al. Fasciculin is known to 
inhibit mammalian AChE in the picomolar range, while it can only inhibit 50% of the 
avian enzyme activity at concentrations as high as 10 gM (Radic et al., 1994), due to 
sequence differences in the PAS limiting the contacts that it can make with AChE 
(Duran et al., 1996). 
The preliminary data revealing that BW284c51 inhibition induced AChE 
overexpression in cerebellar neurones and the lack of effect of BW284c5l on AChE 
levels in fibroblasts is also suggestive of differences in the interactions and availability 
of AChE in these cells and thus the differences in their cellular responsiveness. Though 
this action is intriguing, it was an initial study and ftirther characterisation would need 
to be carried out. In addition it becomes somewhat coriftising to interpret since addition 
of soluble AChE increased neurite length, whilst BW284c5I potently retarded 
outgrowth. This would suggest that the feedback induced AChE is likely to be a 
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different form, such as AChE-R. Indeed, recent work by Soreq's group in 2004 
suggested that PAS blockade increased the levels of both the AChE-R and AChE-T 
molecules (Dong et al., 2004). However, whether only PAS specific ligands can induce 
such as effect is ambiguous, since recent studies have shown that organophosphates 
were also able to increase AChE-T and AChE-R levels in treated PC12 cells (Jameson 
et al.,, 2007). This initial study suggests that this feedback mechanism is not conserved 
across all cell types, but it remains pertinent in neurones due to the use of AChE 
inhibitors in the treatment of AD and indeed the effects of the anti-AChE agents used as 
pesticides and in warfare, since any that affect the PAS of AChE will have more 
complex effects than previously thought. 
4.4.2 Possible mechanisms of action of AChE 
The actions of AChE ligands such as MAB304 are fairly easy to reconcile, their binding 
to surface AChE is likely to perturb its normal interactions and thereby reducing 
neuronal outgrowth and fibroblast migration. However, the mechanisms underlying the 
effects of addition of AChE on neurones are more difficult to resolve. How can 
presenting increased levels of AChE result in increased outgrowth? One possibility is 
that AChE on the cell surface can interact with a putative ligand to stimulate outgrowth, 
or alternatively matrix bound AChE may bind to a putative receptor on the cell surface, 
thereby also inducing signalling cascades which would in turn stimulate outgrowth. 
Either of these scenarios would be perturbed by addition of AChE inhibitors binding 
and thus preventing the interactions of AChE with its endogenous ligand. If a receptor 
for AChE were present on the cell surface, application of AChE either as a soluble 
molecule or presented in the substratum could induce the signalling cascade responsible 
for outgrowth. On the other hand, increased AChE on the cell surface could potentially 
bind to a ligand in the ECM, such as perlecan, to stimulate membrane protrusion by an 
unknown mechanism. Previous work on neuroblastomas overexpressing AChE revealed 
that these cells have increased neurite outgrowth compared to wildtype cells and this 
was attributed to increased adherence to a variety of substrata including plastic, PLL, 
and collagen IV, though interestingly no increase in adherence to laminin was observed 
(Sharma et al., 2001). Applying this theory to fibroblasts, the increase in migration 
could be due to a modulation of the adhesiveness of these cells, supported by the finding 
that MAB304, which retarded migration, also reduced substratum adhesion. The 
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mechanisms involved in cell adhesion are well known to be essential f'or cell imoration. 
in particular to establish contact between the newly formed lamellipodia and i-natrix 
constituents to allow traction to drive the cell forward. Again this would need to be 
further characterised by assessing the effects of antibodies to other membrane targets. as 
well as investigation into whether the AChE ligands BW-184c5l Could Jim e an,, - actiolllý' 
on adhesion. In addition, the mechanism underlying the increased migration of the 
AChE-T expressing clones could be characterised using the single cell adhesion 
apparatus utilised in section 4.3.4 (Figure 4.14) to compare the adhesion to that of 
wildtype 3T3 fibroblasts, however differences in the surface area of the wildtype and 
AChE-T expressing cells (Figure 4.11 shows that there is a 2.7-fold increase in cell area 
for clone T-1 versus wildtype 3T3s), which may make interpretation of the adhesion 
results difficult. 
Since AChE is generally considered not to have a transmembrane domain (though 
recently characterised N-terminal splice variant may have an N-terminal transmembrane 
extension, see introduction section 1.2.5), it must mediate its actions on outgrowth and 
migration by interactions with a binding partner. The identity of the binding partner of 
AChE mediating these effects on neuronal and fibroblast motility is a fundamental 
question that remains unsolved. AChE is reported not to bind to itself to promote 
homophilic adhesion (Guenneugues et al., 1996). Indeed, none of the other members of 
the cholinesterase homology domain family mediate their actions by a homophilic 
binding mechanism (Barthalay et al., 1990; Nguyen and Sudhof, 1997), implying that 
AChE interactions are also likely to be heterophilic in nature. In vitro studies showed 
that human recombinant AChE could bind to a substratum of coated down laminin or 
collagen IV (Johnson and Moore, 2003). Laminin has also been implicated by a yeast 
two-hybrid screen and immunoprecipitations (Paraoanu and Layer, 2004; Paraoanu and 
Layer, 2005). However, in chapter 3 the addition of potential AChE ligands including 
laminin, collagen IV and fibronectin did not alter the surface distribution of AChE 
(Figure 3.35-3.37), suggesting that none of these is the endogenous binding partner of 
AChE on the surface of fibroblasts. These cannot be ruled out as binding partners in 
neurones, particularly since fibroblasts and neurones show some differences in their 
responsiveness to AChE ligands, possibly indicating that they may have different 
binding partners or mediate responses via multiple interactions. 
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Previous work has suggested several mediators for AChE's effects in neurones. One 
possible signalling pathway AChE may influence is the neuroligin-neurexin junction. 
Neuroligins, (members of the cholinesterase domain homology family) are specificallý 
located in the postsynaptic membrane of brain excitatory synapses (Song et al., 1999) 
where they interact intracellularly with PSD-95, and help regulate targeting of 
NMDARs and AMPA receptors (Chetkovich et al., 2002). Overexpression of AChE-T 
in mice suppresses neurexin- IP production in embryonic spinal motor neurones (Andres 
et al., 1997), while in hippocampal neurones, chronic BW284c5I treatment induces 
AChE-overexpression and reduction of the expression of neurexin-IP, indicating that 
modulating AChE levels affects the expression of neurexins (Dong et al., 2004). Since 
neurexins are not known to be expressed outside the nervous systems these are unlikely 
to be the binding partners of AChE in non-neuronal cells but may mediate its effects in 
neurones. AChE has also been shown to increase neurite length in embryonic ventral 
mesencephalic, cultures (Whyte and Greenfield, 2003). This is suggested to be via an 
inhibition of voltage-dependent calcium currents (VDCQ since incubation of these 
neurones with selective VDCC antagonists, can mimic an AChE-mediated increase in 
the outgrowth of tyrosine hydroxylase positive neurones (Whyte and Greenfield, 2003). 
Thus, it is possible that AChE mediates an increase in outgrowth in neuronal cultures by 
inhibition of calcium currents (Whyte and Greenfield, 2003). However, many cell 
adhesion molecules including NCAM, LI, and laminin have multiple means of 
interaction and this may also prove to be the case for AChE. 
Though addition of soluble AChE did not significantly increase fibroblast migration 
when pooled from three independent experiments, in individual experiments there was a 
slight increase above control levels (Figure 4.13A) and this should be further 
characterised at a range of concentrations. In addition, it would be interesting to 
determine whether fibroblast migration could be enhanced by coating down a 
substratum of AChE or APP in the presence or absence of perlecan, in an analogous 
manner to that previously tested on neurones (Small et al., 1995) 
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4.4.3 Implications of AChE mediated cell protrusion 
The finding that an increase in AChE correlates with increased migration and outgrowth 
has potential implications for several cellular processes and pathologies. The ability of 
even the simplest organism to respond to the extracellular environment by directional 
migration is fundamental to life. Cell movement during development, inflammation, 
wound healing all rely on cell crawling and aberrations in the signalling pathways 
involved have been shown to contribute to tumour invasion and metastasis. Indeed, 
changes in AChE forms and glycosylation have already been observed during metastatic 
breast cancer and astrocytomas (Ruiz-Espero et al 2003; Plick et al 2003). The findings 
presented in this chapter that AChE plays a role in cell movement and that this extends 
outside the nervous system provides further insight into the mechanisms that regulate 
cell migration and will contribute not only to our understanding of basic cellular 
processes, but will also lead to the development of new therapeutic approaches for a 
wide variety of medical conditions. 
The results of the neurite outgrowth and migration assays would suggest that AChE 
plays a common role in cell protrusion. The current data available from knockout mice 
does not fully support this since they have been shown to survive and develop up to a 
year postnatally, with most deficits attributable to lack of AChE enzymatic activity 
(Duysen et al., 2002; Mesularn et al., 2002; Cousin et al., 2005). However, in vivo 
experiments manipulating AChE levels were also found to modulate levels of neurexins 
(Andres et al., 1997). Therefore, during development of knockout animals 
compensatory mechanisms are likely to be set in motion which may mask effects of 
AChE knockdown on migration and pathfinding. Indeed, adaptive responses to a 
genetic modification have already been shown to confound the interpretation of 
phenotypes of several knockout animals. An example of this principle was shown in 
mice in which the myoglobin gene had been disrupted. Pharmacological inhibitors of 
oxymyoglobin formation had previously indicted that myoglobin was essential to 
maintain energy metabolism and contractile function of the myocardium, analogous to 
the implications arising from the actions of AChE ligands. Surprisingly, myoglobin 
knockout mice were found to have normal cardiac function (Garry et al., 1998), which 
would suggest that myoglobin is unimportant for oxygen transfer in the myocardium, 
just as the viability of the AChE knockout mouse implies that AChE is not critical for 
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normal cellular pathfinding. However, subsequent work determined that survival in the 
absence of myoglobin was possible due to significant compensatory adaptive responses 
(Williams and Wagner, 2000), and this could well be the case for AChE. Therefore. the 
interpretation of data from AChE knockouts is not unambiguous. Even with such 
compensatory actions occurring, it would be interesting to examine whether wound 
healing of AChE deficient mice and their fibroblast migration were changed relative to 
wildtype mice, particularly since changes in keratinocyte migration have been noted 
from mice deficient in APP, which colocalises with AChE at the leading edge of 
migrating cells (Siemes et al., 2006). 
4.4.4 Conclusions and Summary 
The data provided by both the neurite outgrowth and migration experiments suggests 
that AChE does indeed have a morphoregulatory function in both neuronal and non- 
neuronal cells and that this appears to be as a regulator of membrane dynamics in the 
lamellipodia of migrating cells and in growth cones. This is likely to be via a 
mechanism involving mediation of cell substratum adhesion but appears independent of 
catalytic activity. Some differences in the responsiveness of the neurones and fibroblasts 
to AChE ligands was observed and may reflect differences in the interactions of AChE 
on the different cell types. The underlying mechanism by which AChE mediates this 
morphoregulatory function remains to be determined, in particular the identity of its 
binding partners, (potential candidates being APP and perlecan) in neurones and 
fibroblasts and its relationship to known adhesion/polarization mediators such as the 
small GTPases. 
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5 The involvement of AChE in apoptosis, survival and proliferation 
5.1 Introduction: 
In recent years, evidence has begun to suggest that AChE may play a role in the control 
of cellular apoptosis, survival and proliferation (Calderon et al., 1999; Calderon et al., 
1998; Munoz et al., 1999; Park et al., 2004; Zhang et al., 2002) and see introduction 
sections 1.7.8-1.7.11. However, the consistency of this involvement in different cell 
types, the underlying mechanism and the involvement of the enzymatic activity remains 
unclear. This chapter will aim to further dissect the involvement of AChE in apoptosis 
and survival, in particular the contribution of the catalytic activity by comparing the 
effects of AChE ligands binding to both the active and peripheral anionic sites, and 
overexpression of AChE itself in a range of cellular apoptosis, survival, and 
proliferation assays on 3T3 fibroblasts and neurones. 
As early as 1976, aI 00-fold increase in AChE activity was noted in WRL- I OA 
fibroblasts (though not in other fibroblasts examined), when growth was arrested, 
suggesting a link between the cholinergic system and non-neuronal cell growth (Bartos 
and Glinos, 1976). Indeed, modulation of AChE levels have been shown to correlate 
with both increased proliferation and increased apoptosis. For example, exposure of 
rodents to the AChE inhibitor pesticide malathion can induce breast turnours (Cabello et 
al., 2001), while treating the breast cancer cell line MCF-7 with the organophosphate 
pesticides monocrotophos and omethoate increases cell proliferation (Isoda et al., 2005). 
Farm workers and others exposed to anti-cholinesterase pesticides show an increased 
risk of leukaemia and gliomas (Brown et al., 1990; Aschner, 2000). Modifications in the 
ACHE gene are common in leukemic patients (Lapidot-Lifson et al., 1989) and in 
several myeloproliferative disorders (Ehrlich et al., 1992). Based on such findings, 
AChE has been postulated to function as a myeloid tumour suppressor gene 
(Stephenson et al., 1996). However, an overview of the available literature reveals that 
the situation is much more complex than a straightforward decrease in ACK function 
resulting in an increase in cell division. Firstly, exposure to anti -chol inesterases can 
induce a feedback mechanism resulting in overexpression of AChE (as shown by Dong 
et al 2004 and in Figure 4.15). In addition, though some cancers such as colon cancer 
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and within malignant lymph nodes show reduced AChE (Montenegro et al.. 2006: Ruiz- 
Espejo et al., 2003), others such as breast cancer show increased AChE activity (Ruiz- 
Espejo et al., 2002; Ruiz-Espejo et al., 2003), while in lung tumours, the level of AChE 
varies depending on the type of tumour (Martinez-Moreno et al., 2006). Moreover, 
while some AChE inhibitory pesticides have been observed to induce aberrant 
proliferation, others have the opposite action; donepezil, an AChE inhibitor licensed to 
treat AD inhibits neuroblastoma proliferation and promotes differentiation instead 
(Sortino et al., 2004). In addition, application of AChE to neuroblastomas can be toxic 
(Calderon et al., 1998), but its application to PC12 cells can induce their proliferation 
(Munoz et al., 1999). Thus, there is no clear correlation between reduction of AChE and 
induction of proliferation. 
While the effect of modulation of AChE levels appears inconsistent, a small but 
significant body of work over recent years have shown that increasing AChE levels may 
play a role in cellular apoptosis. The term apoptosis originates from the greek meaning 
"apo" (falling) "ptosis" (off), in analogy to leaves falling off trees. When a cell receives 
an apoptotic stimulus, be it an internal or external signal, such as changes in gene 
regulation, ligation of distinct receptors, or irreversible cellular or nuclear damage, there 
begins an active and defined mode of cell death. Apoptotic stimuli result in activation of 
a group of cysteine proteases called caspases, the homologues of which were first 
identified in Celegans (Yuan et al., 1993). These enzymes are activated in a sequential 
manner to initiate and execute controlled cell death. In the mitochondria, apoptotic 
stimuli alter the balance between proapoptotic proteins such as BAX versus anti- 
apoptotic proteins such as Bcl-2, increasing the proportion of pro-apoptotic proteins in 
the mitochondrial outer membrane. These pro-apoptotic proteins are thought to 
homodimerise and produce pores making the mitochondrial membrane permeable 
(Gross et al., 1998). This allows the escape of the inner membrane space proteins such 
as cytochrome C, which usually functions as an electron carrier to shuttle electrons 
during oxidative phosphorylation (Musser and Chan, 1998). Upon mitochondrial 
membrane disruption cytochrome C leaks out of the intermembrane space and binds to 
Apaf-l and adenosine triphosphate (ATP). This complex then binds to pro-caspase-9 
creating a multi-protein complex known as the apoptosome (Park et al.. 2004). The 
apoptosome induces cleavage of the pro-caspase-9, producing active caspase 9, which 
in turn activates effector caspase-3. Caspase 3 is known to cleave a nuclear enzyme 
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known as Poly Adenosine Diphosphate (ADP) ribose polymerase (PARP). which is 
highly conserved in higher eukaryotes. PARP functions as a DNA binding protein to 
recognise DNA strand breaks and poly ADP-ribosylate nuclear proteins. PARP is 
cleaved by caspase 3 from its 116kDa form into signature fragments of 89kDa and 
24kDa. The 24 kDa fragment then irreversibly binds to the broken ends of D, \A. 
blocking the access of repair enzymes to the damaged DNA and ensurilig that the 
apoptotic pathway proceeds. The cleavage of PARP into the 89kDa and 24kDa 
fragments is often used as a measure of apoptosis as it can appear as early as 3 hours 
post apoptosis inducing event, and precedes the ability to detect actual DNA 
fragmentation. Indeed, DNA fragmentation is a relatively late event in the apoptotic 
pathway, occurring once endonucleases have become activated to degrade the genomic 
DNA at internucleosomal linker regions producing 180- to 200- base pair DNA 
fragments. 
Early work showed that treatment of erythroleukemic K562 cells with high doses of 
gamma irradiation increased AChE activity, which correlated with the cessation of their 
proliferation (Schwenke et al., 1995). Robitzki et al also showed in 1998 that upon 
BChE antisense transfection in retinospheroids, both AChE and apoptosis increased 
(Robitzki et al., 1998). A direct role for AChE in apoptosis was inferred by a pivotal 
paper in 2002 by Zhang et al which revealed that during apoptosis induced in a variety 
of non-neuronal cells including HeLa cells, DAMI cells and human lung fibroblasts, 
there was an increase in AChE-specific activity. Treatments of these apoptosing cells 
with either AChE inhibitors or an anti-sense construct reduced cell death suggesting 
AChE directly influenced the apoptotic pathway (Zhang et al., 2002). Since 2002, a 
number of other studies have shown an increase in either AChE activity or protein in a 
number of cell types including osteoblasts (Gu et al., 2002), human lung fibroblasts (Jin 
et al., 2002), neuroblastomas (Yang et al., 2002; Zhang et al., 2003) and cortical 
neurones (Xiao et al., 2006). Examination of mRNA levels during apoptosis suggested 
that the increase in AChE observed was due to a selective increase in the AChE-T splice 
variant (Yang et al., 2002; Zhang et al., 2002; Deng et al., 2006), as opposed to the 
selective increase in the AChE-R variant seen upon exposure to physical, chemical or 
psychological stressors (Kaufer et al., 1998). 
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Though these studies suggested AChE was involved in the apoptotic process. the point 
at which AChE acted and what its role was remained unclear. In 2004, an intriguing 
study by Park et al found that silencing the AChE gene by RNA-mediated interference 
protected colon adenocarcinorna cells from apoptosis. Examination of the cleavage 
patterns of PARP and caspase-9, immunoprecipitation of Apaf-1 and localisation of 
cytochrome C in etoposide treated control and AChE suppressed cultures revealed that 
silencing AChE did not prevent cytochrome c release from the mitochondria, but did 
prevent the interaction of Apaf-1 with cytochrome C. This was suggested to indicate 
that AChE plays a fundamental role in formation of the apoptosome by Apaf-1 and 
cytochrome C, since AChE suppression prevented the subsequent cleavage and 
activation of caspase-3 and PARP (Park et al., 2004). Though this study suggested 
where AChE may act in the apoptotic pathway, the how remains unknown. The specific 
increase in AChE activity upon apoptosis suggests that this has some function during 
the process, however what this role may be is unclear. In addition, the prevention of 
apoptosis afforded by AChE inhibitors does not appear to be consistent, neither between 
different inhibitors nor between different cell types. For example, BW284c5l was able 
to attenuate tumour necrosis factor stimulated apoptosis in Dami and human lung 
fibroblasts (Zhang et al., 2002), but unable to prevent apoptosis in topotecan treated 
Jurkat cells (Huang et al., 2005), evidence for a fundamental role for AChE activity in 
apoptosis being therefore equivocal. Thus, whether the increase in AChE activity and/or 
protein is a critical player in apoptosis is a fundamental question that remains 
unanswered. 
A recent study (Deng et al., 2006) has suggested that the increase in AChE levels 
observed during apoptosis is mediated by c-Jun NF12-terminal kinases (JNK), known 
players activated in response to chemical and physical stressors (Cerezo-Guisado et al., 
2006; Khelifi et al., 2005; Kurinna et al., 2004; Willaime-Morawek et al., 2003). In this 
recent study, exposure to etoposide and excisanin A, two anticancer agents, induced 
apoptosis in a colon cancer cell line SW620, unregulated AChE-T, activated JNK and 
increased the expression and phosphorylation of c-Jun (Deng et al., 2006). JNK 
inhibitors and small interfering RNA directed to JNK prevented the increase in AChE 
mRNA and protein levels indicating AChE expression may be mediated by the 
activation of the JNK pathway during apoptosis through a c-Jun-dependent mechanism. 
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However, this study did not go on to establish the effect that blocking the JNK mediated 
increase in AChE had on cellular apoptosis. 
5.2 Aims of this study 
As outlined above, the involvement of AChE in apoptosis, cellular survival and 
proliferation is ambiguous, with several conflicting reports. In addition, the results of 
chapter 4 show that application of exogenous or substratum AChE to neurones can be 
neuritogenic, while expression of AChE-T in fibroblasts increases migration. Such 
trophic actions would seem to be at odds with a fundamental role for AChE in apoptotic 
cell death. Therefore, this study aimed to answer two questions, firstly whether AChE 
increased in both neuronal cells which already have high levels of activity, as well as 
non-neuronal cells. Secondly if AChE levels were found to show a conserved increase 
across cell types, whether the increase in AChE protein and activity represented a 
fundamental component during apoptosis, or whether these two processes could be 
uncoupled? These were tested by examining the effect of apoptotic induction on non- 
neuronal and neuronal AChE levels and attempting to dissect the involvement of the 
catalytic activity using a panel of AChE ligands. Building on the study of Deng et al, 
the signalling mechanisms underlying the increase in AChE were tested using 
pharmacological inhibitors. Dissection of the involvement of AChE in cellular 
apoptosis, survival and proliferation is particularly relevant since not only are the only 
currently licensed drugs to treat Alzheimer's AChE inhibitors, but the widespread use of 
pesticides means that the population is continually being exposed to cholinesterase 
inhibitors and thus a through understanding of the actions of AChE will provide 
information on which to base new drug designs. 
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5.3 AChE activity in 3T3 fibroblasts and astrocytes increases upon 
apoptosis 
In contrast to the results presented in this thesis, Zhang et al 2002 implied, based on 
enzymatic activity, that AChE was not normally expressed by NIH 3T3 fibroblasts 
unless the cells were induced to undergo apoptosis (Zhang et al., 2002). This disparity is 
explained by considering the results revealed in Chapter 3, where the expression level of 
AChE in 3T3s is found to be comparable to that of primary cerebellar neuronal cultures; 
despite the level of activity in fibroblasts being many fold lower. The work of Zhang et 
al did however indicate that the AChE activity may be modulated in 3T3 cells in 
response to apoptosis. In order to investigate the role of AChE in apoptosis, the first 
step was to determine conditions under which 3T3s (and other cell types) could be 
induced to apoptose. Two well -characterized inducers of apoptosis in 3T3 cells are 
prolonged serum deprivation (Garcia-Maya et al., 2006) and treatment with 
staurosporine, a protein kinase and topoisomerase 11 inhibitor (Tamaoki et al., 1986). 
Using the Ellman assay, a significant increase in the AChE activity of 3T3 whole cell 
lysates was revealed in cells treated by serum deprivation (72hrs) or staurosporine 
(24hrs) (Figure 5.1). Data from three independent experiments revealed that 72hr serum 
deprivation (5.1A) or treatment with I ýM staurosporine for 24hrs (5.113) both 
increased AChE activity over 60minutes approximately 4-fold. Exposing astrocytic 
cultures to I ýM staurosporine for 6hrs revealed that there is a 2-fold increase in activity 
upon apoptosis of these cells (5.1Q. In inhibition experiments, the AChE specific 
inhibitor BW284c5l (Figure 5.113 lower, showing single experiment) was able to fully 
inhibit the staurosporine induced apoptosis activity, indicating that it resulted from true 
AChE activity. In addition, cytochemical staining of serum deprived 3T3 fibroblasts 
using the Roots and Karnovsky method (Karnovsky and Roots, 1964) reveals AChE 
specific activity in these apoptotic cells, where the activity appears to be concentrated in 
the nucleus after 72hr of serum deprivation. Again this activity is fully inhibited by the 
AChE specific inhibitor BW284c5l (Figure 5.1 D). 
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AChE Activity by Ellman assay: 
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Figure 5.1: Apoptosis induced by serum deprivation and staurosporine increases AChE 
specific activity in 3T3 fibroblasts and astrocytes. (A) Representative Ellman assay showing 
% increase in AChE activity in 5 gg 3T3 fibroblast lysate upon 72 hrs serum deprivation. (B) 
Ellman assay pooled from three independent experiments showing % increase in AChE activity 
in 5 ýtg 3T3 fibroblast lysate upon 24 hrs treatment with Staurosporine (STS). Lower histogram 
shows single ellman assay showing % increase in AChE activity in 5 ýtg 3T3 fibroblast lysate 
upon 24 hrs treatment with Staurosporine in the presence or absence of the AChE specific 
inhibitor BW284c5l (BW) ± s. e. m of triplicate wells. (C) Single ellman assay showing % 
increase in AChE activity in 5 ptg astrocyte lysate upon 6hrs treatment with Staurosporine (STS) 
(D) Cytochemical staining for AChE activity using the methods of Roots and Kamovsky on 
control, and 72 hr serum deprived 3T3 fibroblast cultures in the presence or absence of the 
AChE specific inhibitor BW284c5 1. Scale bar 20gm 
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AChE protein levels during apoptosis: 
3T3 fibroblasts: 
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Figure 5.2 AChE protein levels increase upon apoptosis. 
(A) Western blot of time course of serum deprivation from 0-72 hrs showing AChE levels by 
probing with Clone 46 (1: 2500), PARP cleavage with H-250 (1: 200) and tubulin levels 
(1: 1000). (B) Western blots of ACK levels (Clone 46 1: 2500) and PARP cleavage (H-250 
1: 200) on PC 12, NB2a and 3T3 cell lysates in the presence and absence of Staurosporine (I ýtM 
treatment of 3T3 cells and 100 nM treatment of PC12 and N132a cells). All lysates were 
separated on 7.5% SDS-PAGE. Molecular weight markers are indicated on right hand side in 
kDa. 
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5.4 AChE protein levels increase in apoptotic fibroblasts and 
neuronal cell lines, but expression is not apoptosis dependent. 
Having established that AChE activity in apoptotic 3T3 fibroblasts does indeed increase 
in response to serum deprivation- or staurosporine-induced apoptosis, the protein level 
of ACK was characterised in these cells and also in neuronal cell lines undergoing 
apoptosis. Studies examining the role of AChE in apoptosis have tended to focus on 
non-neuronal cells since the increase in activity is more dramatically revealed in cells 
with low levels of basal activity (Zhang et al., 2002). The involvement of AChE in 
apoptosis in neuronal cells is important to determine given the use of AChE inhibitors 
to treat AD. In order to assess induction of apoptosis in these cells, the cleavage of Poly 
(ADP-ribose) polymerase (PARP) was assessed. Examining AChE levels during a time 
course of serum deprivation revealed that AChE levels increase in serum-starved 3T3 
fibroblasts to a maximal 1.7-fold increase after 24 h (Figure 5.2A), concomitant 
apoptosis being shown by PARP cleavage. However, as shown in the untreated lysates 
and in Chapter 3, Figure 3.2, AChE expression in fibroblasts is not dependent upon 
apoptosis. Staurosporine-induced apoptosis similarly increased AChE levels in 3T3 
fibroblasts and neuronal PC12 and N132a cells (Fig. 5.213), suggesting that increased 
AChE levels in response to apoptosis is a conserved mechanism in both neuronal and 
non-neuronal cells. 
Using the diagnostic TUNEL (Terminal deoxynucleotidyl Transferase fluorescein- 
dUTP Nick End Labelling) reaction to identify apoptotic cells also shows that the 
increase in AChE correlates with apoptosis, but apoptosis is not required for expression 
(as shown in Chapter 3). The TUNEL method identifies apoptotic cells in situ by using 
terminal deoxynucleotidyl transferase (TdT) to transfer fluorescein-dUTP to strand 
breaks of cleaved DNA. Under conditions of normal culture, intracellular AChE in 3T3 
cells as detected by anti-AChE antibody Clone 46 is concentrated in perinuclear region. 
Upon apoptosis induction by serum deprivation, co-immunolocalisation with the 
TUNEL reaction reveals that AChE aggregated into the nuclei of apoptotic 3T3 cells as 
revealed in Figure 5.3 
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Figure 5.3 Localisation of AChE in apoptotic 3T3 fibroblasts. 
Control or serum deprived 3T3 fibroblast cultures were fixed in 4% methanol free formaldehyde 
and Triton X-100 permeabilised. (A, D) Representative images of intracellular AChE detected 
by monoclonal antibody Clone 46 (1: 200) and anti-mouse IgG Alexa Fluor A555. (B, E) 
Apoptotic cells detected by TUNEL reaction. (C, F) Merge of cells processed for AChE 
immunofluorescence and TUNEL reactivity. Images captured on X63 objective. Scale bar 
20ýtm. 
As previously shown in chapter 3 by immunoblotting and immunofluorescence, 3T3 
fibroblasts express significant amounts of AChE during normal culture conditions in 
both surface and intracellular compartments. In order to examine whether both surface 
and intracellular AChE pools (surface versus total) were contributing to this apoptosis 
mediated increase,, the AChE levels in apoptosing fibroblasts were determined by 
sandwich ELISA on apoptotic (serum deprived or staurosporine treated) fibroblasts, on 
paraformaldehyde fixed or Triton X- 100 permeabilised cultures. As shown in figure 5.4, 
the major increase of 3.7-fold in AChE levels is shown on permeabillsed cultures 
(correlating with the 4-fold increase in AChE activity upon 72hr serum deprivation), 
which would detect both intracellular and surface pools, but a slight increase (1.7-fold) 
is also detected on fixed but not permeabilised cultures. This pattern was also seen on 
ELISAs performed on staurosporine treated cultures (data not shown). Though it cannot 
be ruled out that this is due to a slight permeabilisation of the membrane during 
paraformaldehyde fixation, and thus allowing the intracellular pool to be detected, this 
may suggest that increased AChE is also trafficked to the surface during apoptosis. 
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Surface and Total AChE levels during serum deprivation induced apoptosis: 
Figure 5.4 AChE levels increase upon apoptosis 
in 3T3 fibroblasts. 
Surface and intracellular AChE levels were 
400 measured by ELISA using anti-AChE antibody H- Control 134 on control or serum deprived cultures. 2x 104 
2 
. 4- Serum 
cells were plated per well of 96-well ELISA plates. 
C: 300 0 
24hrs post-plating cells were switched to serum- deprived free media for 72hrs. AChE levels were determined 
by probing with anti-AChE polyclonal antibody H- 
200 
a) 134 (1: 500) on either 4% paraformaidehyde fixed 
(n M cultures (surface) or fixed and 0.2% Triton X-100 W 
L_ permeabilised cultures (total). Detection was 100 
L i 
completed by subsequent incubation with anti- 
it 
rabbit-HRP secondary antibody followed by 
0 incubation with the HRP substrate K-blue. Tubulin 
Surface Total 
detection was carried out in parallel on triton 
permeabilised cultures in order to account for cell 
loss during apoptotic induction and AChE levels 
were adjusted accordingly. Data are the mean ± SD 
of two independent experiments, each of 
quadruplicate wells. Data is expressed as a 
percentage of control (no serum deprivation) for 
surface or total AChE after adjusting for tubulin 
content. 
5.5 Actions of AChE ligands on fibroblast survival and proliferation. 
The consistent increase in AChE activity upon induction of fibroblast and astrocyte 
apoptosis might suggest that it is important in the apoptotic pathway. If this is the case, 
the application of agents inhibiting the enzymatic activity may have the ability to 
interfere with this; alternatively if interactions of the protein rather than the catalytic 
activity are important, addition of agents that bind to but do not inhibit AChE such as 
the monoclonal antibody MAB304 may be capable of affecting apoptosis. 
In order to assess the actions of AChE ligands on 3T3 fibroblasts, both a survival assay 
and a proliferation assay were developed using these cells and fibroblast growth factor 2 
(FGF2). Though most commonly known as a mitogen for fibroblasts, FGF2 has been 
shown in this laboratory to be capable of supporting cell survival (Anderson et al., 2005; 
Garcia-Maya et al., 2006). Sur-vival coiWitions ý, vcre obtaiiied b\ Ltsiiw, the lo\\ cell 
miiiiber of 7x 10' cells per NA-ell of a 96 well plate and striii(yent media coiiditions. 
Fibroblasts Nvere plated in 0.5% FCS/'DNIEM and 16-2241irs post-plating this \vas 
reiiioved and replaced witli seruni-free DMEM alone or stipplelileilted wall different 
concentrations of FGF2' for 72hrs. In order to determine the IlUniber of cells preseilt 
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before serum withdrawal (hereafter termed the initial cell miniber). 20 pL of MTS 
CeIITiter96 AQUEOUS One Solution reagent was added to each well of a quadruplicate. 
After incubation at 37'C for a further 3h,, the absorbance at 490 nrn was detennined. The 
quantity of formazan product as measured by the amount of 490-nm absorbance is 
directly proportional to the number of living cells in culture. 20 ýIL of MTS CeIlTiter96 
AQUEOUS One Solution was added to tile treated Cultures after 7-1 1-irs iii order to 
determine the final cell number. This revealed that while 337% of cells survived in tile 
absence of serum, low concentrations of FGF2 (0.1 ngml-1) increased cell sur\ival to 
53%, while exposure to higher concentrations of FGF2 (1-100 numl-1) reduced cell 
survival to below baseline (Figure 5.5). This response is very similar to the pre\iousk 
reported neurite outgrowth response of cerebellar granule neurons to FGF2 (Williams et 
al., 1994), suggesting that the underlying signalling mechanisms governing Z: ý L- Cý 
responsiveness to FGF2 may be common to cells of differing origi I 
L- L-111. 
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Figure 5.5: FGF-2 causes a 
peak of survival at low 
concentrations. Representative 
curve illustrating effect of FGF2 
on 3T3 cell survival over 3 days 
in DMEM (Ong/ml) or 
supplemented with FGF2. Final 
cell number was determined from 
eight wells in a colorimetric MTS 
assay and expressed as % starting 
cell number. 7,000 cells were 
plated per ELISA well. 
FGF concentration ngml-l 
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In order to assess the potential proliferative effects ot'AC: hL liuand,, on 3 1") fibroblasts. 
a proliferation assa-,.,, on this case using FGF2 as a m1togen was defined. In contrast to 
the survival assay. proliferation was examined by using a more permissive media and a 
higher cell density. ')T-)' fibroblasts were set up at 1.4 x 103 CelS/well of 96-kNell plates 
in DMEM/0.5% FCS. 24hrs later an initial number of cells was determined with MTS 
(as described) and increasing concentrations of FGF2 were added in DMEM. giving a 
basal media of 0.25% FCS/DMEM. The effect of increasing concentrations of FGF-" 
(0.01-100 ngml- on the proliferation of -3)T-33 
fibroblasts was examined after 72111-s 
exposure. In the absence of FGF2. the initial cell number was maintained over the 7-2111- 
assay period, but there was no increase in cell number indicative of proliferation. Upon 
supplementation with FGF2, there was a dose dependent increase in cell number 
peaking at a 60% increase at intermediate (1-10 n(yrnl-1) concentrations of FGF2. At 1-1 
higher concentrations (100 ngmi-1), FGF2 was on1v able to Stimulate a 20% increase in 
cell number (Figure 5.6). 
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Figure 5.6: FGF-2 causes a 
peak of proliferation at 
intermediate concentrations. 
Representative curve 
illustrating effect of FGF2 on 
3T3 cell proliferation over 3 
days in DMEM/0.5% FCS 
alone (0 ng/ml) or 
supplemented with FGF2. Final 
cell number was determined 
from quadruplicate wells in a 
colorimetric NITS assay and 
expressed as % starting cell 
number. The starting cell 
number is shown as a dotted 
line. 14,000 cells were plated 
per ELISA well. 
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Upon establishment of these assays, the actions of AChE ligands under sui-N-I\al and 
proliferation conditions ýý, ere examined and compared to that of FGF2. FrstlN-. the 
effects of the AChE inhibitors, tacrine, BW284c5l, fasciculin, edrophonium. and 
galanthamine acting at both the active and peripheral anionic sites were examined under 
these survival conditions and compared to the action of FGF-" at 0.1 rignil-1. Under 
conditions of serum deprivation for 72hrs there was an approximate a 50% reduction in 
the number of cells present compared to initial cell number (Figure 5.7A). Results 
representative of 3-20 experiments reveals that addition of 10 pM tacrine, and 10 ýtgml-' 
galantharnine were capable of supporting cell survival as effectively as FGF2 with up to 
80% of the cells remaining after 72hrs. 
The effects of galanthamine are less significant when the data is presented as a 
percentage of control (Figure 5.7B), but tacrine clearly still supports cell survival. 
Addition of BW284c5 I. fasciculin and edrophonium at a variety of concentrations was 
not able to consistently increase cell survival, though fewer repetitions with these 
factors were carried out (Figure 5.7). Thus, it appears that though some AChE ligands 
can increase cell survival, inhibition of AChE enzyme activity per se is not sufficient to 
prevent apoptosis. The effects of the monoclonal antibody MAB304 were also 
investigated on cell survival and this also appeared to increase the number of cells 
remaining. However, addition of an IgG control also appeared to provide some survival 
effect and therefore further work is required to resolve the validity of this action. 
However, the survival promoting actions of tacrine and galanthamine are particularly 
intriguing given the use of AChE inhibitors in the treatment of Alzheimer's disease and 
such a survival promoting effect on non-neuronal cells may contribute to their activity. 
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Figure 5.7 Tacrine and Galanthamine increase 3T3 fibroblast cell survival. 
(A) Data pooled from 33 to 20 experimerits. 7x 10- cells were plated per ELISA ýNell, '141irs later 
mitial startmo riumber was determiried usiria MTS assav arid AChE irihibitors added at 
desiortated coil ceiiti'at toils. Relative cell rturilber was determiiied usim-, MTS three davs after 
additiori. Histooram shows data expressed as % startim, cell iiumber ± s. e. m. Siumificaiice 
deterri-imed by studerits T-test compared to coiltrol uritreated cultures (B) Data from (A) 
expressed as a percei-itage of coritrol (rio supplemerit, DMEM alorie) for each coriditimi. Number 
iii brackets dei-iotes mimber of mdepeiiderit experimerits from xN hich data is pooled. 
As Tacrine. consistently appeared to increase cell number. and given that some AChf, ", 
figands. partICUlarly pesticides have been reported to be capable of tumongenesis and 
LHIC011trOlled proliferation (See Chapter 5 introduction). the actions of the ACIT ligands I 
on fibroblast proliferation . vere also examined in order to determine whether the 
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apparent survival effects could be due to proliferative actioiis. The effect of addition of 
the AChE inhibitors tacrine,, fasciculin, BW248c51, edrophonium, and FGF-2 for 72hrs 
was examined in the presence of 0.25% serum, employed as for the FGF2 proliferation 
assay (Figure 5.6). Data representative of 3 experiments revealed that addition of 10 
ngml- I FGF-2 increased the number of cells two-fold above the initial cell number; 
however addition of the AChE inhibitors did not increase cell number significantly 
(Figure 5.8). Addition of 10 ýM tacrine and 100 nM fasciculin did consistently induce a 
slight increase in cell number, but this did not reach statistical significance (similar 
results were obtained for the addition of galanthamine, data not shown). This suggests 
that the survival actions of tacrine are a true survival action rather than a result of 
proliferation and that the biological effects of AChE inhibitors at these concentrations 
on 3T3 fibroblast proliferation are limited. 
AChE inhibitor proliferation: 
250 
a- 
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0 
Day 0 
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Figure 5.8: AChE inhibitors do not stimulate 3T3 fibroblast proliferation. 
1.4 x 104 cells were plated per ELISA well, 24hrs later initial starting number was 
determined using NITS assay and AChE inhibitors added at designated concentrations. 
Relative cell number was determined using NITS three days after addition. Histogram 
shows data expressed as percentage starting cell number +/- s. e. m. and is representative of 
3 experiments. Dotted line shows initial cell number. 
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5.6 Effect of AChE-T overexpression on cell growth: 
The inconsistent ability of AChE ligands both in this study and others to increase cell 
survival suggests that the activity of AChE is not fundamental to apoptosis in these 
cells. However, this does not rule out the ability of AChE itself to be involved in 
apoptosis in a manner independent of activity. Indeed, addition of AChE to Neuro2A 
cells has been found to induce toxicity even when heat inactivated and treated with 
BW284c5l suggesting that such an action is independent of the catalytic activity 
(Calderon et al., 1998). In order to establish whether increasing AChE levels could 
affect fibroblast cell growth, the effects of increasing AChE expression on 3T3 
fibroblasts was examined using the AChE-T clones characterised in Chapter 4. Parental 
3T3s and the AChE-T overexpressing clone T-1 were set up at 2x 103 cells per well on 
96-well plates and the relative growth rate compared initially over 3 days. 
Results pooled from 3 independent experiments revealed that cell number increased 
comparatively in the parental and AChE-T expressing Clone T-I over 3 days (Figure 
5.9A, B). However, initial experiments examining proliferation at later time points 
suggests that a difference does appear after 4 and 5 days (Figure 5.9 Q. Examining the 
cellular morphology suggested that this reduction in the growth rate of the 3T3 
fibroblasts overexpressing AChE-T did not reflect enhanced apoptosis as the fibroblasts 
do not exhibit features of apoptosis such as cell and nuclear shrinkage. Rather since 
Clone T-I cells have a significantly larger cell area than the control cells (Chapter 4, 
Figure 4.11) it is likely that the cells simply become quiescent and cease to proliferate 
due to confluency earlier than control cells. Therefore, though this would need to be 
examined ftirther,, it appears that increasing the AChE expression levels certainly at 
early time points does not inhibit proliferation nor drive the cells towards apoptosis. 
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AChE-T clone proliferation: 
A 
160 
140 
120 
100 
bu 
60 
40 a- 
20 
0 
Control 
TI 
12 
Culture Time (Days) 
C 
- 250 C: ) m 
öe 200 
0 
c: 150 
100 
50 
0 
012345 
Culture Time (Days) 
B 
(D 
2 140 
cu Control 
c 120 T- 1 
100 
0 
c: 80 
0.2 
L) CU 60 
-0 40 
= -0 a) _0 
20 
a) 
0 
(o 
Figure 5.9: AChE-T expressing fibroblasts 
have a normal rate of proliferation over 3 
days. 
2x 101 3T3s were cultured in triplicate in 
10%FCS/DMEM and assayed using NITS to 
determine the relative number of fibroblasts ± 
sem at indicated times post plating. (A, B) Data 
pooled from 3 independent experiments (A) 
Cell proliferation for control and AChE-T 
expressing Clone T-1, data is presented as raw 
OD490nmvalues (B) Cell proliferation adjusted 
by subtracting the day 0 reading from every 
value for control and AChE-T expressing 
fibroblasts. (C) Single experiment carried out 
over 5 days, data is presented as raw OD 490nin 
values ± s. e. m of quadruplicate wells. 
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5.7 Increased AChE is not required for staurosporine induced 
fibroblast apoptosis: 
From both the actions of AChE inhibitors and the effects of AChE overexpression on 
cellular growth, AChE does not appear to be a driving factor in apoptosis in fibroblasts. 
Nevertheless, the conserved increase in both protein levels and activity suggests that 
AChE may play some function during the apoptotic pathway. In order to further clarify 
this initial investigations were carried out examining the signalling pathway underlying 
the increase in AChE. Though several studies have now implicated AChE involvement 
in apoptosis, there has been little characterisation of the mechanisms underlying the 
observed increase in AChE expression and activity. A recent study in the SW620 colon 
cancer cell line suggested the apoptosis induced increase in AChE protein is JNK 
dependent, however the effect of blocking the increase in AChE on apoptosis was not 
characterised (Deng et al., 2006). To examine first whether the increase in AChE 
expression in apoptotic fibroblasts was dependent upon JNK activity, 3T3 fibroblasts 
were driven to apoptose by 24 hr treatment with staurosporine, in the presence or 
absence of the commercial JNK inhibitor SP600125. 
Figure 5.10 shows that while staurosporine induced an increase in AChE activity 
(5.1 OA), this was significantly inhibited by co-treatment with SP600125. Next the effect 
of SP600125 on 3T3 cell apoptosis was determined by PARP cleavage in the treated 
cells. This revealed that SP600125 treated fibroblasts in which the increase in AChE 
level and activity was significantly reduced still exhibited the characteristic apoptotic 
morphology of cell and nuclear shrinkage (Figure 5.10Q, and PARP cleavage was not 
reduced (5.10D). The increase in AChE levels upon staurosporine stimulation is not 
very marked, however, the parallel blot probed for PARP clearly shows similar levels of 
cleavage in the staurosporine and SP600125-StaurosPrine treated cultures (Figure 
5.10D). Furthen-nore, using CellTiter96 AQUEOUSOne Solution to measure relative cell 
number, survival assays were carried out to determine the effect on 3T3 cell survival of 
adding staurosporine in the presence or absence of SP600125. In brief, 3T3s (14 x 103 
cells per well in 96-well plates) were incubated 16-24hr post-plating in the presence or 
absence of staurosporine and/or SP600125 in a final volume of 100ý11 for 24hrs, before 
20 ýtL of MTS CeIlTiter96 AQUEOUS One Solution reagent was added to each well. After 
incubation at 37'C for a ftirther 3 h, the absorbance at 490 rim, was determined. This 
revealed that the reduction in cell number induced by staurosporine treatment was not 
239 
Chapter 5: The involvement of AChE in apoptosis, survival and proliferation 
significantly reversed upon inhibition of JNK by SP600125. However, some reduction 
in basal activity was observed upon addition of SP600125 (though not statistically 
significantly), which masks any increase in survival upon SP600125 addition.. so JNK 
inhibition may have a slight survival promoting effect. Thus, it appears that while an 
increase in AChE levels and activity do correlate with apoptosis, significantly inhibiting 
this with a JNK inhibitor still allows the apoptotic process to occur in fibroblasts 
5.8 Use of RNA-mediated interference to examine the role of AChE in 
fibroblasts: 
Over the past decade one of the most exciting and powerful research tools to come to 
the fore has been RNA-mediated interference (RNAi). RNAi-based therapeutics harness 
an endogenous cellular regulatory mechanism in which small double-stranded RNA 
molecules, or small interfering RNAs, bind to and mediate the destruction of specific 
mRNA molecules, preventing their translation into protein. In order to elucidate more 
fully the role of endogenous AChE in fibroblasts, the potential of RNAi was 
investigated. In 2004, Park et al identified a suitable RNAi target within the human 
sequence (Park et al., 2004), however no targets had so far been established for the 
mouse sequence. Using the oligoengine RNAi vector based system, which has the 
advantage of GFP expression to allow identification of transfected cells and a 
specialised design tool two targets were identified in the mouse sequence. However, 
analysis of both 3T3 fibroblasts and N132a neuroblastomas expressing the RNAi 
sequence I (5'ATGACCCTCGAGACTCCAA 3') or sequence 2 (5' 
ATGAATCTCTCATCAGCCG 3') by immunofluorescence for AChE (using Clone 46) 
revealed that there did not appear to be any discernable AChE knockdown, either within 
a 24-72hr period (Figure 5.11 A, B showing expression of RNAi sequence I at 24,48 
and 72hrs post-transfection) or upon generation of stable RNAi expressing clones (not 
shown). The sequence utilised by Park et al in 2004,5'-GAGTGTCTGCTACCAATAT- 
3' was also inserted into the oligoengine system and its effects examined in primary 
human fibroblasts. As can be seen in Figure 5.1113, by immunofluorescent analysis 
there does appear to be knockdown of AChE expression in cells expressing the RNAi 
construct 48hrs post-transfection, while no effect was seen upon transfection of the cells 
with an empty vector control (data not shown). However, the difficulty in efficiently 
transfecting primary human fibroblasts with exogenous DNA (Fountain et al., 1988), in 
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addition to time constraints, prevented the effects of this knockdown from being further 
characterised. 
AChE activity 
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Figure 5.10 JNK activation is required for increased AChE levels and activity, but not 
apoptosis. (A) Ellman assay on 5 ptg 3T3 lysate treated for 24 hrs with JNK inhibitor 20 ýtM 
SP600125, staurosporine I [tM or both factors. Values shown are relative % of control values ± 
s. e. m of quadruplicate wells of a single experiment. (B) NITS survival assay cells were treated 
with 20 ptM SP600125, staurosporine I gM or both factors. Results are expressed as % of 
control untreated cell value ± s. e. m of quadruplicate wells of representative experiment. (C) 
Representative phase contrast pictures captured under X40 of cells treated with 20 ýLM 
SP600125, staurosporine I ýtNl or both factors, scale bar 20 ýtm (D) Western blot of cellular 
lysates used in (A) and probed for ACK using Clone 46 (1: 2500) and PARP cleavage using H- 
250 (1: 200). Molecular weight markers sizes are indicated on right hand side in kDa. 
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Initial characterisation of potential for RNAi mediated knockdown of AChE in 
mouse 3T3 fibroblasts: 
04 
Figure 5.11a RNA interference mediated knockdown of AChE in 3T3 fibroblasts. 
3T3 fibroblasts were plated at 2x 104 cells per well of 24 well plates. 16hrs post-plating 
they were transfected with the pSuperRetro RNAi system using calcium phosphate 
transfection and assessed for knockdown at time points between 24-72hrs. Cells were 
assessed for knockdown by AChE immunofluorescence. (A, D, G). Cells were fixed in 4% 
paraformaldehyde, permeabilised with 0.2% Triton X-100 and assessed for ACK 
expression using clone 46 (1: 200). (B, E, H) RNAi vector transfected cells were identified 
by GFP expression. (C, F, 1) Merged images of AChE immunofluorescence and GFP 
expression. Scale bar 20ýtm. 
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Initial characterisation of potential for RNAi mediated knockdown of AChE in 
neuroblastomas and primary human fibroblasts : 
Primary Human Fibroblasts: 
Figure 5.11b RNA interference mediated knockdown of AChE in neuroblastomas and 
human fibroblasts. 
N132a neuroblastomas and primary human fibroblasts were plated at 2x 104 cells per well of 
24 well plates. 16hrs post-plating they were transfected with the pSuperRetro RNAi system 
using Fugene (human fibroblasts) or calcium phosphate transfection (neuroblastomas) and 
assessed for knockdown at time points between 24-72hrs. Cells were assessed for 
knockdown by AChE immunofluorescence. (J, M, P, S) Cells were fixed in 4% 
paraformaldehyde, permeabilised with 0.2% Triton X-100 and assessed for intracellular 
ACK expression using clone 46 (1: 200). (K, N, Q, T) RNAi vector transfected cells were 
identified by GFP expression. (L, 0, R, U) Merged images of ACK immunofluorescence 
and GFP expression. Scale bar 20ýtm. 
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5.9 Discussion 
The results presented in this chapter reveal several novel findings on the involvement of 
AChE in survival and apoptosis. Induction of apoptosis (by two different stimuli in the 
case of fibroblasts) was able to increase AChE activity and/or protein levels in 
fibroblasts, astrocytes and neuronal cell lines. This suggests that an increase in AChE is 
a conserved response to apoptosis across both neuronal and non-neuronal cells and 
different inducers of apoptosis. Though addition of the AChE ligands tacrine, and 
galanthamine was capable of supporting some 3T3 fibroblast survival under conditions 
of serum deprivation, this effect was not consistent in all the ligands tested. 
Characterisation of the signalling pathway underlying the increase in AChE protein and 
activity revealed that this was dependent on JNK activity in fibroblasts, as previously 
demonstrated in colon cancer cells, and significantly, inhibition of JNK activity 
significantly reduced the increase in AChE levels and activity but did not prevent 
apoptosis. From these data it appears that the increase in protein level and enzymatic 
activity of AChE is unlikely to play a fundamental role in apoptosis in 3T3 fibroblasts. 
The implications and clinical relevance of these findings are considered below. 
5.9.1 Increased AChE is a marker of apoptosis in neuronal and non- 
neuronalcells 
The induction of apoptosis in neuronal cell lines, astrocytes and fibroblasts was found to 
increase AChE levels/activity in all the cell types, revealing that this is a conserved 
mechanism both in non-neuronal cells which have only low basal levels of ACK 
activity, and also in neuronal cells, which already have higher levels of basal activity 
(See Figure 3.3). The origin of this increase in ACK protein and activity is intriguing. 
In principle, it could result from either an increase in newly synthesised, more active 
AChE, or from the reduced turnover of endogenous AChE and its release from an 
inactive / less active conformation. Evidence from previous studies suggests that the 
increase is due to increased transcription, specifically of the AChE-T isoform, with no 
effect on the AChE-H, or AChE-R isoforms (Deng et al., 2006; Zhang et al., 2002). The 
results from this study would also support this scenario in fibroblasts since inhibition of 
JNK, a kinase which activates transcription factors, significantly reduced the increase in 
ACK activity. In addition, the increase in ACK levels in 3T3 fibroblasts detected by 
ELISA (Figure 5-4) correlated with the increase in AChE activity (Figure 5.1). 
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However, turnover studies in neuroblastomas undergoing AP peptide induced apoptosis 
found that AChE levels in these cells increased by reducing enzyme degradation rather 
than increased synthesis (Hu et al., 2003). Since neuroblastomas are of neuronal 
derivation, and thus express a higher basal level of AChE activity (Thullbery et al., 
2005), it is possible that different mechanisms exist to increase AChE levels in the 
different cell types. Alternatively, further examination may reveal that enhancement in 
protein synthesis, and reduced degradation have a shared contribution to the final AChE 
increase, in particular since in the studies of Zhang et al and Deng et al, the potential 
contribution of changes in degradation and turnover were not examined (Zhang et al., 
2002; Deng et al., 2006). The mechanism underlying the increased protein levels in 3T3 
fibroblasts could be resolved by the differential use of transcription blockers such as 
actinomycin D, translation inhibitors such as cycloheximide and proteosome inhibitors 
such as lactacystin. 
5.9.2 Increased AChE is not fundamental to apoptosis 
The conserved increase in AChE level and activity across cell types and different 
apoptotic stimuli shown both in the study by Zhang et al and in this study is noteworthy, 
and such results together with the findings of Park et al who showed that RNAi 
mediated AChE suppression could prevent etoposide stimulated apoptosis, have been 
previously interpreted as suggesting that AChE may be a critical element in apoptosis 
(Zhang et al., 2002; Park et al., 2004). However, the inconsistent ability of all the AChE 
inhibitors examined to impede apoptosis both in this study and previously (Huang et al., 
2005), suggested that AChE activity per se is not a requirement for apoptosis across all 
cell types. In addition, a fundamental role for AChE in apoptosis would seem at odds 
with its postulated neuritogenic role, shown both in Chapter 4, Figure 4.5-4.6 and in 
previous studies on several neuronal populations (Holmes et al., 1997; Day and 
Greenfield, 2002; Olivera et al., 2003b). This study has further elucidated the 
mechanisms governing the AChE involvement in apoptosis by showing that JNK 
inhibition can significantly reduce this increase in both protein levels and activity in 
fibroblasts, without the prevention of apoptosis. This would seem to suggest either that 
the small increase in AChE activity remaining upon JNK inhibition is enough to allow 
apoptosis or that AChE is not fundamental to apoptosis. This would appear in 
contradiction to the finding of Park et al, who in 2004 showed that suppression of 
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AChE expression prevented PARP cleavage and subsequent etoposide induced cell 
death (Park et al., 2004). However, such differences may be reconciled "-hen 
considering that in this study the endogenous basal level of AChE protein was not 
changed, while in the study of Park et al the basal level was suppressed. If the results of 
Park et al and this study are both valid, then this may suggest that this endogenous pool 
of AChE plays a role in apoptosis, and since this pool of AChE has little activity in 
fibroblasts (Chapter 3, Figure 3.3), that the enzymatic activity may not be important. 
Alternatively, although staurosporine is known to induce cytochrome C release from the 
mitochondria (Duan et al., 2003), it may also induce apoptosis independent of 
apoptosome formation and thus bypass a requirement for AChE. At this stage, therefore 
the only conclusion that can be drawn is that though staurosporine induced apoptosis 
increases AChE activity and protein, this increase is not required for apoptosis to occur. 
Though the results of this chapter suggest that AChE activity is not required for 
staurosporine induced apoptosis, it may still play a non-fundamental but contributing 
role. The enzymatic activity of ACK has been implicated in a variety of processes apart 
from hydrolysis of ACh, including, hydrolysis of heroin to morphine (Salmon et al., 
1999) and acrylarnindase activity (Checler et al., 1994) and such actions may also have 
a influence on cell survival. This would explain why tacrine, and galantharnine were 
consistently capable of increasing cell survival. Both tacrine and galanthamine have 
been shown to be able to increase PC 12 cell survival in previous studies (Zhang and 
Tang, 2000). Galanthamine has also been shown to be able to attenuate glutamate-Ap 
induced apoptosis of cortical neurones (Kihara et al., 2004) and glutamate induced 
apoptosis of motor neurones (Nakarnizo et al., 2005). The survival effect does not seem 
to be associated with any interactions at the PAS since neither BW284c5l nor fasciculin 
both of which bind at the PAS could consistently increase cell survival. In Chapter 3 
regions of AChE immunofluorescence on the surface were found to have some regions 
of colocalisation with regions of intracellular phosphotyrosine staining, revealing that 
signalling is occurring in these regions of the cell, though how ligand interactions on the 
cell surface would be transmitted to the interior of the cell is unclear. Both galanthamine 
and tacrine are known to be able to modulate nicotinic acetylcholine receptors and thus 
any neuroprotective effects of these AChE inhibitors could in part be attributable to this 
action (Nakamizo et al., 2005). Tacrine has additionally been shown to inhibit a variety 
of potassium channels, including the fast transient potassium current in rat hippocampal 
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neurones (Rogawski, 1987) and the delayed rectifier potassium current in the larval 
muscle of Drosophila (Kraliz and Singh, 1997). Though these are not likely to be 
expressed on fibroblasts, it is possible that these inhibitors mediate their effects by 
acting on targets other than AChE. Alternatively these inhibitors may mediate their 
actions by specifically mimicking the interactions of a putative endogenous ligand for 
AChE, though once again how such a signal could be transduced remains unclear. 
Even though the increase in AChE does not seem fundamental in apoptosis, it is still an 
intriguing conserved effect and is likely to play some role in the cell. Since in Chapter 4 
(Figures 4.2-4.6,4.12-4.14), AChE was shown to have a potential role in cell migration 
and adhesion,, it is possible that the increase in AChE in these cells upon apoptosis 
could be related to this role and may represent an attempted to alter the cellular- 
substratum interactions during apoptosis, particularly since ELISAs suggest that the 
surface AChE pool may increase slightly upon apoptosis, though this would require 
further investigation. 
5.9.3 AChE-T expression has negligible effect on proliferation over 3 days 
As with many aspects within the cholinesterase field, the effects of increasing AChE 
levels on cell division reported within the literature is contradictory. Transfection with 
an AChE-T vector into the human glioblastorna U87MG cells produced a 10% increase 
in proliferation, though this was not statistically significant (Perry et al., 2002), while 
overexpression with an AChE-R construct induced a 40% increase in glioblastorna 
proliferation (Perry et al., 2002). Overexpression of an AChE-T construct in normal rat 
kidney cells was reported to significantly reduce the level of cellular proliferation after 
4 days when compared to wildtype cells, ascribed to a sensitization of the cells to 
apoptosis (Jin et al., 2004). In the current study, 3T3 fibroblasts overexpressing AChE-T 
had a similar initial growth rate over 3 days compared to parental cells. Examining later 
time points suggested that there was a reduction in proliferation of the overexpressing 
clone, but this would need to be characterised more thoroughly since the AChE-T 
expressing cells were significantly larger than the wildtype cells (as shown in Figure 
4.11). It is possible that the cells simply became quiescent prior to the wildtype 3T3 
cells due to lack of space, thereby reducing their apparent proliferation rate. In the study 
by Jin et al, a similar method of determining cell number over time was carried out, but 
no mention is made of the relative size of the AChE-T expressing clones compared to 
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the wildtype cells, raising the possibility that the reduced proliferation seen it that stud), 
may also have resulted from changes cell area (Jin et al., 2004). Furthermore, careful 
examination of that study revealed that the difference in proliferation rate between the 
wildtype and AChE-T expressing cells is very subtle even at 4 days, and suggests that 
the effects of AChE-T expression on proliferation are negligible. The effects of AChE-T 
expression on fibroblast proliferation are also pertinent to the migration results of 
Chapter 4.3.2, Figure 4.12 since they show that increased cell proliferation was unlikely 
to contribute to the increased rate of wound closure over 24 hours. 
5.9.4 Implications for AChE and apoptosis 
The conserved increase in AChE upon apoptosis, together with the ability of apoptosis 
to proceed if this increase is significantly reduced suggests that while increased AChE 
functions as a marker of apoptosis, this pool does not play a driving role in the process. 
This has several implications for AD. In the AD brain, particularly within plaque rich 
regions both the neurones and astrocytes undergo apoptosis (Mouser et al., 2006). If the 
in vitro findings in this chapter that AChE levels and activity in astrocytes and neurones 
increases upon apoptosis is also true in vivo, it could initiate a destructive cycle of 
toxicity in these regions. AChE is known not only to complex with, and increase the 
fibrillogenesis of AP, but also to increase its toxicity (Alvarez et al., 1995; Alvarez et 
al., 1997). In addition exogenous application of AChE has been shown to increase APP 
levels in glia (von Bernhardi et al., 2003). Therefore, a pernicious scenario could be 
imagined whereby apoptosing neurones and astrocytes in plaque regions would have 
increased levels of AChE, which in turn would increase expression of APP and AP, 
accelerate AP fibril formation, and increase the toxicity of the fibrils, thereby inducing 
further apoptosis. Since inhibition of JNK can reduce the apoptosis-induced increase in 
AChE, and thus potentially reduce the toxicity of AChE- AP complexes, JNK inhibition 
could prove beneficial in AD. Though such drugs would not prevent the initial apoptotic 
trigger, they could potentially reduce the plaque burden and the cycle of toxicity 
accompanying increased AChE levels. 
248 
Chapter 5: The involvement of AChE in apoptosis, survival and proliferation 
5.9.5 Conclusions and Summary 
Increased AChE levels serve as a marker of apoptosis in both neuronal and non- 
neuronal cells, but do not seem to be required for staurosporine induced apoptosis in 
fibroblasts, explaining the inconsistent actions of AChE inhibitors to promote cell 
survival. The function of the increase in AChE during apoptosis remains unclear; 
however, further characterisation using RNAi mediated interference could provide 
further information. 
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General Discussion 
Every movement of muscle, every thought requires nerve transmission. As a supremely 
efficient enzyme, AChE is critical in allowing such fundamental processes to occur and 
functions as an almost perfect terminator of ACh mediated neurotransmission. Why 
then should AChE have any additional functions? The enzymatic activity of AChE is 
remarkable in itself, but its expression in non-cholinergic regions of the brain and 
outside the nervous system has lead to suggestions that AChE could function in cellular 
morphoregulation. Over the past twenty years, there has been an exponential increase in 
interest in AChE such that it is now implicated in many major cellular processes and 
pathologies including neurite outgrowth, synaptogenesis, apoptosis, neurodegeneration, 
cell adhesion, cancer and gulf war syndrome. As fascinating and therapeutically 
important as the implied novel functions of AChE are, debate still continues as to the 
specificity, mechanism of action and contribution of the enzymatic activity to these 
activities. The experiments conducted for this thesis were designed to systematically 
examine whether AChE could play a morphoregulatory role in both neuronal and non- 
neuronal cells. As a result of these investigations, several novel findings have been 
obtained on the localisation and involvement of AChE in the processes of outgrowth, 
migration and apoptosis of neurones and fibroblasts, which have implications for 
general cellular migration and neurodegeneration. 
6.1 Expression and localisation 
As the first foray of this researcher and indeed this laboratory into the cholinesterase 
field, the project was begun by an initial examination into the expression levels of 
AChE,, whereupon to our surprise the expression level of AChE in 3T3 fibroblasts was 
found to be equivalent to that found in neuronal cells. Further examination revealed that 
though the protein expression levels appeared similar, very different levels of activity 
are observed, with far lower found in the non-neuronal cells. This comparative level of 
AChE expression in both neuronal and non-neuronal cells, with very disparate levels of 
activity, has recently been observed by other groups (Thullbery et al., 2005), supporting 
these findings. Characterisation of location of expressed AChE by immunofluorescence 
and subcellular fractionation of fibroblasts revealed expression on the cell surface, 
where it showed precise colocalisation with APP and some codistribution with perlecan. 
251 
Chapter 6: General discussion 
On the surface of migrating or spreading fibroblasts and young neuronal cultures, AChE 
localised to regions of membrane protrusion, including the leading edge of migrating 
cells and the growth cones of neurones. Though AChE has previously been observed in 
growth cones (Olivera et al 2003; Dong et al 2004), the localisation of AChE at regions 
of membrane protrusion in non-neuronal cells is novel and occurs not only in in vitro 
wounds, but also in vivo, where AChE localises to the leading epithelium at the wound 
edge of mouse skin (Figure 3.40). The colocalisation of AChE and APP was maintained 
in an in vitro wound where they both distributed specifically to the leading edge of the 
wound and to discrete segmental regions of neuronal cultures. Though previous studies 
have shown an interaction between AP peptide of APP and the PAS of AChE in vitro 
(Inestrosa et al 1996), this is the first demonstration of a colocalisation between the full 
length APP and AChE, particularly in non-neuronal cells. Indeed, this localisation raises 
the question of whether the interaction between AChE and AP seen in senile plaques in 
AD could represent a deregulation of the normal interaction between AChE and APP, or 
competition of the AP peptide for direct/indirect interactions with AChE. 
6.2 Apoptosis 
This study also showed a conserved increase in AChE level and activity during 
apoptosis of both neuronal and non-neuronal cells, highlighting the multifunctionality of 
this protein. This study has built on the work of Deng et al, in showing that the increase 
in AChE activity is dependent upon JNK activity (Deng et al., 2006). Though this 
increase in AChE specific activity and protein has been suggested to play a fundamental 
role in apoptosis (Zhang et al 2002; Park et al 2004) a significant reduction in AChE 
activity and levels by the use of a JNK inhibitor did not prevent apoptosis nor could 
AChE inhibitors consistently prevent serum deprivation induced cell death. This 
suggests that either there is a threshold effect whereby even a low level increase in 
AChE activity and protein can contribute to apoptosis, or that this increase in AChE is 
not required for the apoptotic pathway. Interestingly, fNK signalling is already 
proposed to play a critical role in the development of neurodegenerative disorders such 
as AD, since AP is known to induce cell death by a JNK mediated pathway (Morishima 
et al, 2001). The C-terminal domain of APP has been shown to bind to the adaptor 
protein JIP- I b, a scaffolding protein for JNK. This interaction between APP and JIP- Ib 
is disrupted upon the cleavage of APP by caspases during apoptosis (Schenfield et al 
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2002). Thus, AChE and APP may also be linked during apoptosis. where cleavage of 
APP releases JIP- Ib allowing it to bring together JNK with its activating kinase: MAPK 
Kinase. Activation of JNK could then subsequently lead to increased transcription of 
AChE (Schenfield et al., 2002). Though the results of this thesis suggest apoptosis can 
occur without significant increases in AChE levels, its involvement could be further 
characterised using RNAi mediated suppression of endogenous AChE in primary 
human fibroblasts. Further investigation of AChE up-regulation, its targets and 
functions during apoptosis, would be important not only to elucidate the apoptotic 
mechanism of action as well as facilitate the development of therapeutic approaches that 
selectively target AChE expression pathways in the treatment of AD. A role for AChE 
in cell death would seem somewhat at odds with its postulated adhesive role, however 
since the function of AChE in apoptosis is still unclear these two actions may actually 
be inter-related. It is possible that the increase in AChE activity and protein upon 
apoptosis may even represent a cellular response to alter their adhesiveness, similar to 
the upregulation of AChE-R upon stressful stimuli. 
6.3 Modulation of outgrowth and migration by AChE ligands 
Though far from being the first study to examine the effects of AChE and its ligands on 
neurite outgrowth, this study was comprehensive in examining a panel of ligands 
binding at different sites on AChE and directly comparing their actions on different 
neuronal populations. BW284c5l, fasciculin and MAB304 were all found capable of 
reducing the mean length of the longest neurite in three different populations of 
neurones, and this action did not depend solely upon inhibition of enzymatic activity 
since the inhibitors tacrine and edrophoniurn did not consistently affect outgrowth in the 
three neuronal populations under examination. The finding that these particular 
inhibitors could retard neurite outgrowth is in agreement with other groups, who also 
found that MAB304 (Sharma and Bigbee 1998; Olivera et al 2003), BW284c5l 
(Koneisberger et al 1997; Olivera et al 2003) and fasciculin (Bataille et al 1998; Blasina 
et al 2000) could retard neurite outgrowth and/or adhesion. These results are consistent 
with work indicating that in neurones, ligand binding on the molecule surface, 
potentially at the PAS, but not at the active site can modulate neurite outgrowth. 
Increasing AChE levels either by addition of electric eel AChE or culturing neurones on 
fibroblasts overexpressing AChE-T significantly increased neurite length, an action that 
has also been shown upon addition of eel AChE to embryonic hippocampal (Olivera et 
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al 2003) and ventral mesencephalic neurones (Whyte and Greenfield 2003). The 
analogous increase in fibroblast migration upon expression of AChE-T and the 
retardation upon incubation with anti-AChE antibodies shown here suggests that ACK 
may play a common morphoregulatory role in all cells, both neuronal and non-neuronal. 
6.4 What might be the role of AChE in polarised migration ? 
Though these actions are potentially very intriguing, how AChE may be mediating such 
effects is still not clear. The functional data together with the localisation of AChE at 
growth cones and the leading edge of migrating cells suggests that it may play a role in 
polarised cell migration, a process requiring polarisation of the cell, its adhesion to the 
substratum and membrane protrusion. Most components contributing to cellular polarity 
such as Cdc42, Dlg-l, APC and Rap-I are cytosolic (Osmani et al., 2006). Thus, it is 
difficult to reconcile a role for surface AChE in this process. Based on its localisation, 
AChE would appear more likely to mediate membrane protrusion since its distribution 
is reminiscent of that of the exocyst complex which is mobilised to the leading edge 
(Zuo et al., 2006). Alternatively, AChE could be functioning via an adhesive 
mechanism, in particular since AChE mediated neurite outgrowth has been shown to 
correlate with adhesion (Sharma et al., 2001). An AChE mediated adhesive role in 
fibroblasts is supported by the tentative observation that incubation with an AChE 
antibody which binds to the surface of unfixed AChE cultures can reduce the negative 
pressure required to de-adhere fibroblasts (Figure 4.14). Since adhesion and protrusion 
are intimately linked, AChE may play a role in both processes. For example, during cell 
migration, there is protrusion of the leading edge, followed by adhesion to the 
substratum, whilst during cell spreading there is first adhesion to the substratum and 
then extension of protrusions. Thus, AChE mediated adhesion could be hypothesised to 
stimulate protrusion by a mechanism similar to that of integrin mediated adhesion to an 
extracellular matrix. The absence of colocalisation of AChE with vinculin at focal 
contact sites argues against AChE functioning in combination with integrins and its 
associated signal transduction. However, the codistribution of AChE with patches of 
phosphotyrosine staining suggests that surface AChE is located close to regions of 
intracellular signalling. 
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6.5 How is AChE associated with the cell surface ? 
In order to be able to mediate such morphoregulatory actions, AChE must be able to 
transduce signals to the cell interior. As AChE is traditionally thought to have no 
transmembrane domain [though N-terminal splicing predicts potential N-terminally 
extended transmembrane forms (Meshorer et al 2004)], it must mediate 
morphoregulation by interacting with other signalling components. Key to elucidating 
the mechanisms underlying AChE mediated actions is how AChE is anchored, and in 
fibroblasts this remains unanswered. Could it be anchored by PRiMA as it is in central 
synapses, or by CoIQ as in the neuromuscular junction basal lamina? The partial 
codistribution of AChE and perlecan and the redistribution of perlecan upon AChE 
antibody mediated clustering would suggest an interaction between the two, potentially 
via CoIQ in analogous manner to the NMJ (Figure 6.1A). However, against such a 
suggestion is the limited colocalisation with (xDG, which would also be involved in 
such a scenario. The presence of multimeric, (possible tetrameric) fonns in the Triton 
X-100 soluble membrane fraction of 3T3 fibroblasts seen upon non-reducing but not 
reducing SDS-PAGE (Figure 3.6) suggests that AChE may by disulphide linked to an 
integral membrane protein, such as MMA or an equivalent anchor as illustrated in 
Figure 6.113. A third possibility that AChE can associate with an as yet unidentified 
membrane receptor, a candidate for this being APP 
A Possible modes of AChE anchoring: 
P-dystroglycan 
Hydrophobic tethering 
protein (PRiMA? ) 
Figure 6.1 Schematic diagrammatic representations of possible modes of anchoring of 
AChE on the surface of fibroblasts. AChE could be anchored either via perlecan and CoIQ as 
in the NMJ (A) or potentially via a transmembrane tethering unit such as PRiMA or its 
equivalent (B). 
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6.6 AChE: receptor or ligand? 
In addition to appearing to act as a receptor on the cell surface of neurones and 
fibroblasts, AChE also appears to be capable of acting as a ligand when it is either 
added exogenously or in coculture to stimulate neurite outgrowth, as shown previously 
(Holmes et al 1997, Day and Greenfield 2002, Olivera et al 2003) and in Figure 4.6. 
Under these conditions, AChE could be binding directly to a cell surface receptor, or 
could bind to elements in the ECM in addition to a cell surface receptor in order to 
transduce signals into the cell interior. Thus, AChE appears to be capable of functioning 
both as a putative receptor and a putative ligand whose interactions can be blocked by 
antibodies and/or inhibitors. Obviously, the key question that arises from this is what is 
AChE interacting with in order to have these effects? And indeed could its putative 
receptor and ligand be one and the same molecule? An initial examination into whether 
any of the suggested interacting partners of AChE; namely laminin and collagen IV, 
reported to bind to AChE in vitro via its PAS (Johnson and Moore et al 2003) could 
affect AChE distribution on the fibroblast surface suggested that neither can act as a 
ligand for cell surface AChE in fibroblasts (Figure 3.35-3.37). These may still function 
as a ligand for neuronal AChE, as additionally suggested by the recent co- 
immunoprecipitation of AChE together with laminin (Paranou and Layer 2004), though 
this interaction is more likely to occur in the peripheral nervous system where these 
ECM components are prevalent, rather than in the CNS where they have a more limited 
distribution (Paranou and Layer 2004). Though neurexin has been proposed as an AChE 
interacting protein dues the changes in its levels seen upon manipulation of AChE levels 
(Andres et al 1997; Grifinan et al 1998), binding of AChE to neurexin cannot be 
detected by surface plasmon resonance, unlike the interaction of neurexin I P. with its 
true binding partner neuroligin (Comoletti et al 2003). 
6.7 Purpose of AChE/APP/perlecan colocalisation ? 
The colocalisation of AChE with perlecan (in fibroblasts and astrocytes) and APP (in all 
neuronal and non-neuronal cells examined) suggests that these may be involved 
together in AChE mediated morphoregulation. The next question is, therefore, what is 
the nature of their role? The partial redistribution of perlecan in response to AChE 
clustering (Figure 3.33) suggested that these two interact directly or indirectly. Though 
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APP did not redistribute, a direct interaction between the two molecules cannot be ruled 
out. Indeed, AChE and APP share many characteristics; both can stimulate neurite 
outgrowth of a wide variety of neuronal populations, and both are implicated in cell 
adhesion, and migration (Sabo et al 2001,2003). An APP fragment and AChE also 
increase in parallel when neuroblastomas become confluent (Brofinan et al., 1996). 
Moreover, APP, like AChE has been shown to be able to induce outgrowth of E12 chick 
sympathetic neurones when coated as a substratum, but in both cases outgrowth 
required the presence of a HSPG, such as perlecan (Small et al., 1994, Small et al., 
1995). If AChE, APP and perlecan are interacting, once again the question becomes 
how? Is the role of perlecan to cluster AChE at the cell surface as at the NMP, which 
would then place AChE in ECM, or is perlecan playing a functional role similar to its 
involvement with FGF signalling ? 
As a transmembrane protein APP could function directly or within a larger complex as a 
receptor for secreted AChE and provide the downstream signalling pathway via its 
cytosolic domain to stimulate neurite outgrowth or migration, potentially in 
combination with perlecan. However, since APP is found both on the cell surface and 
secreted from fibroblasts and neurones (Racchi et al 2003; Kenny and Saffell 
unpublished data), it could act as either as a ligand for membrane-anchored AChE 
(Figure 6.2Q, a receptor for soluble AChE (Figure 6.2A) or indeed interact with AChE 
in cis, (Figure 6.2B), potentially in a tripartite complex with perlecan. Thus as 
postulated in Chapter 3, AChE, APP and perlecan may interact directly or indirectly to 
function as a complex at regions of membrane protrusion and such possible schemes of 
interactions are illustrated overleaf- 
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Cell Protrusion ??? 
AB 
Membrane 
Tethered AChE 
AChE 
C 
AChE Receptor 
-Tyrosine Kinase? 
Figure 6.2 Schematic representations of potential interactions of AChE, APP and perlecan 
Further support for APP as a candidate binding partner for AChE also comes from a 
study carried out by Bigbee and Sharma in 2004, characterising AChE binding proteins 
in the embryonic spinal cord and astrocytes. This revealed soluble AChE binding to 4 
proteins of molecular weights, 33,3 5,110 and 200 kDa, whose expression in the spinal 
cord diminished during development. Though the 200kDa band was shown to comigrate 
with that of laminin gamma-1, the identity of the other bands was not deten-nined. This 
is particularly relevant to this study since APP has a molecular weight of I 10 kDa and is 
expressed in both astrocytes and the spinal cord, where its expression decreases with 
maturity in a temporally similar manner to that of the postulated AChE binding partner 
(Kawarabayashi et al 1991; Arai et al 1994; Young et al 1999), making APP a good 
candidate for the identity of this protein. 
If AChE and APP are proved to have functional interactions, then AChE may bind 
either directly or indirectly to APP to mediate migration via signalling from its 
intracellular domain to cytosolic intermediates. In both the leading edge of migrating 
non-neuronal MDCK cells and the growth cones of embryonic cortical neurones, APP 
colocalises and binds to the cytosolic adaptor protein FE65, which in turn colocalises 
with and is known to bind to Mena (Gertler et al., 1996; Sabo et al., 2001,2003). Mena 
has been shown to negatively regulate cell motility in fibroblasts and growth cones 
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(Bear et al., 2000), and thus FE65 binding to Mena has been postulated to release its 
negative action on migration (Sabo et al., 2001). AChE could thus mediate cell 
protrusion via APP in a similar manner. 
An alternative hypothesis which could explain why AChE and APP show such 
colocalisation is that as mentioned in introductory section 1.7.11, both a 14 amino acid 
sequence located at the C-terminus of AChE-T (residues 587-598 in human AChE) and 
the amino acids 598-609 human APP (residues 2-15 of the AP peptide sequence) show 
significant homology to each other. In APP this region is upstream of the alpha 
secretase cleavage site and thus located at the end of soluble alpha cleaved APP. Based 
on this it could be hypothesised that these regions of each molecule interact with a 
common target which could be located either on the cell surface or in the extracellular 
matrix, thereby closely localising the two molecules are shown in Figure 6.3. 
Figure 6.3 Colocalisation of 
soluble AChE and soluble APP 
by interactions with a common 
binding partner interacting with 
their homologous C-termini 
APP AChE 
Future experiments could test the importance of AChE by examining the effects of 
RNAi-mediated AChE suppression in primary human fibroblasts. Though time 
constraints prevented characterisation of the effects of AChE suppression, initial studies 
suggested that expression of human AChE could be successfully suppressed, and this 
tool could potentially answer several pertinent questions. Examination of wounded 
primary fibroblasts transfected with AChE RNAi would provide further evidence as to 
the importance of AChE in cellular migration. In addition, suppression of AChE 
expression would reveal if it played a role in clustering APP and perlecan on the surface 
of fibroblasts. Constructs for the RNAi-mediated suppression of mouse APP have also 
been produced and could be used to examine the contribution of APP in maintaining the 
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distribution of AChE on 3T3 fibroblasts and its role in AChE stimulated outgrowth and 
migration. Experiments to ascertain the signalling pathways underlying the neurite 
outgrowth and migration responses could be approached by testing the effect of 
pharmacological inhibitors of known signalling proteins on the AChE mediated 
response. 
In addition, it would be interesting to determine if a substratum of AChE and HSPG, 
particularly perlecan could enhance migration of fibroblasts in a manner analogous to 
that seen with neurones (Small et al., 1995). Though initial studies suggested that the 
increased rate of cellular migration seen upon transfection of fibroblasts with AChE-T 
was not due to the increase in their activity, this would need to further studied. Indeed, 
the in vivo wound healing results could be interpreted as AChE being upregulated 
during wounding and this may occur in vitro, with a concurrent increase in activity, 
similar to the increase seen upon apoptosis. Such a scenario is particularly likely since 
previous studies have shown that AChE levels are increased upon culture on less 
permissive substrata (Gupta and Bigbee 1992), suggesting increased AChE levels occur 
to increase cellular adhesion and an analogous reaction may occur in response to 
wounding. 
6.8 Concluding remarks 
Almost a century of research into the AChE field has brought with it many advances in 
our understanding of its structure and activity. As the first synaptic component to be 
purified, and crystallised for structural and functional studies (Sussman et al.. 1991) 
historically it has been pivotal in our understanding of synaptic development and 
function. The research carried out during this thesis highlights the possible wider 
morphoregulatory role of AChE as a conserved mediator of cell adhesion and protrusion 
in both neuronal and non-neuronal cells. The consistent localisation of AChE with APP 
at protruding regions of membranes and its ability to modulate fibroblast migration and 
neurite outgrowth suggests that these molecules may present a novel signalling complex 
at regions of membrane protrusion. Further work is necessary to establish the exact role 
of AChE in polarised migration, the underlying interactions, signalling and the 
significance of the colocalisation with APP and perlecan. Thus, AChE exemplifies a 
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multifunctional protein, a near perfect terminator of neurotransmission and a mediator 
of morphoregulation in both neuronal and non-neuronal cells. 
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